GAL O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cortex O
, O
basal O
ganglia O
, O
septum O
and O
hippocampus) O
and O
the O
hypophysis O
, O
and O
that O
of O
butyrylcholinesterase O
(BuChE) O
in O
plasma O
and O
liver O
. O
RESULTS O
: O
Following O
administration O
of O
the O
highest O
of O
the O
GAL O
doses O
used O
(2.5; O
5; O
10 O
mg/kg O
i.m.) O
, O
AChE B
activity O
decreased O
mainly O
in O
the O
frontal O
cortex O
, O
hippocampus O
and O
hypophysis O
. O
In O
the O
interaction O
of O
GAL O
and O
CAR O
, O
AChE O
inhibition O
was O
stronger O
but O
without O
any O
statistical O
significance O
. O
The O
peripheral O
inhibition O
of O
BuChE O
was O
found O
to O
be O
dose-dependent O
. O
Premedication O
by O
CAR O
led O
to O
a O
slight O
change O
in O
the O
values O
of O
the O
activities O
monitored O
. O
CONCLUSIONS O
: O
CAR O
in O
terms O
of O
positive O
modulation O
of O
GAL O
targeting O
to O
the O
central O

galantamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
galantamine O
on O
acetylcholinesterase O
and O
butyrylcholinesterase O
activities O
in O
the O
presence O
of O
L-carnitine O
in O
rat O
selected O
brain O
and O
peripheral O
tissues.OBJECTIVES O
: O
The O
alkaloid O
galantamine O
(GAL) O
, O
which O
exhibits O
a O
combined O
anticholinesterase B
and O
direct O
parasympathomimetic O
mechanism O
of O
action O
, O
is O
employed O
in O
conjunction O
with O
therapeutic O
interventions O
in O
the O
stimulation O
of O
central O
cholinergic O
transfer O
in O
cognitive O
diseases O
. O
We O
attempted O
to O
achieve O
pharmacologically-induced O
enhancement O
of O
the O
parasympathomimetic O
activity O
of O
GAL O
in O
the O
key O
areas O
of O
rat O
brain O
, O
using O

GAL O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
galantamine O
on O
acetylcholinesterase O
and O
butyrylcholinesterase O
activities O
in O
the O
presence O
of O
L-carnitine O
in O
rat O
selected O
brain O
and O
peripheral O
tissues.OBJECTIVES O
: O
The O
alkaloid O
galantamine O
( O
GAL O
 O
, O
which O
exhibits O
a O
combined O
anticholinesterase B
and O
direct O
parasympathomimetic O
mechanism O
of O
action O
, O
is O
employed O
in O
conjunction O
with O
therapeutic O
interventions O
in O
the O
stimulation O
of O
central O
cholinergic O
transfer O
in O
cognitive O
diseases O
. O
We O
attempted O
to O
achieve O
pharmacologically-induced O
enhancement O
of O
the O
parasympathomimetic O
activity O
of O
GAL O
in O
the O
key O
areas O
of O
rat O
brain O
, O
using O

GAL O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
an O
interactive O
combination O
of O
the O
alkaloid O
with O
the O
transmembrane O
enhancer O
L-carnitine O
(CAR) O
. O
METHODS O
: O
We O
investigated O
activities O
of O
acetylcholinesterase O
(AChE) O
in O
brain O
areas O
(frontal O
cortex O
, O
basal O
ganglia O
, O
septum O
and O
hippocampus) O
and O
the O
hypophysis O
, O
and O
that O
of O
butyrylcholinesterase O
(BuChE) O
in O
plasma O
and O
liver O
. O
RESULTS O
: O
Following O
administration O
of O
the O
highest O
of O
the O
GAL O
doses O
used O
(2.5; O
5; O
10 O
mg/kg O
i.m.) O
, O
AChE B
activity O
decreased O
mainly O
in O
the O
frontal O
cortex O
, O
hippocampus O
and O
hypophysis O
. O
In O
the O
interaction O
of O
GAL O
and O
CAR O
, O
AChE O
inhibition O
was O
stronger O
but O
without O
any O
statistical O
significance O
. O
The O
peripheral O
inhibition O
of O
BuChE O
was O
found O
to O
be O
dose-dependent O
. O
Premedication O
by O
CAR O
led O
to O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 B
are O
associated O
with O
warfarin O
dose O
across O
the O
normal O
dose O
range O
. O
Haplotypes O
based O
on O
these O
SNPs O
explain O
a O
large O
fraction O
of O
the O
interindividual O
variation O
in O
warfarin O
dose O
, O
and O
VKORC1 O
has O
an O
approximately O
three-fold O
greater O
effect O
than O
CYP2C9 O
. O
Algorithms O
incorporating O
genetic O
(CYP2C9 O
and O
VKORC1) O
, O
demographic O
, O
and O
clinical O
factors O
to O
estimate O
the O
warfarin O
dosage O
, O
could O
potentially O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
than O
10-fold O
interindividual O
variability O
in O
the O
dose O
required O
to O
attain O
a O
therapeutic O
response O
. O
Information O
from O
pharmacogenomics O
, O
the O
study O
of O
the O
interaction O
of O
an O
individual's O
genotype O
and O
drug O
response O
, O
can O
help O
optimize O
drug O
efficacy O
while O
minimizing O
adverse O
drug O
reactions O
. O
Pharmacogenetic O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 O
and O
warfarin O
target O
enzyme O
, O
vitamin B
K I
epoxide I
reductase I
complex I
1 I
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 O
are O
associated O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
than O
10-fold O
interindividual O
variability O
in O
the O
dose O
required O
to O
attain O
a O
therapeutic O
response O
. O
Information O
from O
pharmacogenomics O
, O
the O
study O
of O
the O
interaction O
of O
an O
individual's O
genotype O
and O
drug O
response O
, O
can O
help O
optimize O
drug O
efficacy O
while O
minimizing O
adverse O
drug O
reactions O
. O
Pharmacogenetic O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 O
and O
warfarin O
target O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 B
are O
associated O

warfarin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
anticoagulant O
, O
but O
there O
is O
greater O
than O
10-fold O
interindividual O
variability O
in O
the O
dose O
required O
to O
attain O
a O
therapeutic O
response O
. O
Information O
from O
pharmacogenomics O
, O
the O
study O
of O
the O
interaction O
of O
an O
individual's O
genotype O
and O
drug O
response O
, O
can O
help O
optimize O
drug O
efficacy O
while O
minimizing O
adverse O
drug O
reactions O
. O
Pharmacogenetic O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 B
and O
warfarin O
target O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O

warfarin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 B
and O
warfarin O
target O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 O
are O
associated O
with O
warfarin O
dose O
across O
the O
normal O
dose O
range O
. O
Haplotypes O
based O
on O
these O
SNPs O
explain O
a O
large O
fraction O
of O
the O
interindividual O
variation O
in O
warfarin O
dose O
, O
and O
VKORC1 O
has O
an O
approximately O
three-fold O
greater O
effect O
than O
CYP2C9 O
. O
Algorithms O
incorporating O
genetic O
(CYP2C9 O
and O

warfarin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
analysis O
of O
two O
genes O
, O
the O
warfarin O
metabolic O
enzyme O
CYP2C9 B
and O
warfarin O
target O
enzyme O
, O
vitamin O
K O
epoxide O
reductase O
complex O
1 O
VKORC1 O
, O
confirmed O
their O
influence O
on O
warfarin O
maintenance O
dose O
. O
Possession O
of O
CYP2C9*2 O
or O
CYP2C9*3 O
variant O
alleles O
, O
which O
result O
in O
decreased O
enzyme O
activity O
, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin O
dose O
. O
Several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
VKORC1 O
are O
associated O
with O
warfarin O
dose O
across O
the O
normal O
dose O
range O
. O
Haplotypes O
based O
on O
these O
SNPs O
explain O
a O
large O
fraction O
of O
the O
interindividual O
variation O
in O
warfarin O
dose O
, O
and O
VKORC1 O
has O
an O
approximately O
three-fold O
greater O
effect O
than O
CYP2C9 O
. O
Algorithms O
incorporating O
genetic O
(CYP2C9 O
and O

succinate O
acts O
as O
AGONIST O
for O
what O
entity O
? O
expression O
in O
platelets O
and O
other O
blood O
cells O
we O
demonstrated O
that O
G6b O
, O
G6f O
, O
and O
LRRC32 O
are O
restricted O
to O
the O
platelet O
lineage O
, O
whereas O
LAT2 O
and O
SUCNR1 O
were O
also O
detected O
in O
other O
blood O
cells O
. O
The O
identification O
of O
the O
succinate B
receptor I
SUCNR1 O
in O
platelets O
is O
of O
particular O
interest O
, O
because O
physiologically O
relevant O
concentrations O
of O
succinate O
were O
shown O
to O
potentiate O
the O
effect O
of O
low O
doses O
of O
a O
variety O
of O
platelet O
agonists O
. O

succinate O
acts O
as O
AGONIST O
for O
what O
entity O
? O
expression O
in O
platelets O
and O
other O
blood O
cells O
we O
demonstrated O
that O
G6b O
, O
G6f O
, O
and O
LRRC32 O
are O
restricted O
to O
the O
platelet O
lineage O
, O
whereas O
LAT2 O
and O
SUCNR1 B
were O
also O
detected O
in O
other O
blood O
cells O
. O
The O
identification O
of O
the O
succinate O
receptor O
SUCNR1 O
in O
platelets O
is O
of O
particular O
interest O
, O
because O
physiologically O
relevant O
concentrations O
of O
succinate O
were O
shown O
to O
potentiate O
the O
effect O
of O
low O
doses O
of O
a O
variety O
of O
platelet O
agonists O
. O

foscarnet O
acts O
as O
NOT O
for O
what O
entity O
? O
were O
synthesised O
in O
vitro O
by O
expression O
of O
UL54 O
under O
the O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O

foscarnet O
acts O
as O
NOT O
for O
what O
entity O
? O
were O
synthesised O
in O
vitro O
by O
expression O
of O
UL54 O
under O
the O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A B
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O

foscarnet O
acts O
as O
NOT O
for O
what O
entity O
? O
were O
synthesised O
in O
vitro O
by O
expression O
of O
UL54 O
under O
the O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases B
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A B
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases O
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
control O
of O
the O
T7 O
promoter O
. O
Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 O
gene O
by O
site-directed O
mutagenesis O
. O
Mutated O
polymerases B
and O
polymerases O
from O
HCMV O
reference O
strains O
were O
studied O
. O
The O
activity O
of O
polymerases O
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet O
(V715M O
, O
T700A O
and O
N495K) O
was O
inhibited O
by O
concentrations O
of O
foscarnet O
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases O
. O
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible O
. O
It O
is O
also O
easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet O
in O
HCMV O
. O

foscarnet O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Development O
and O
validation O
of O
a O
non-radioactive O
DNA B
polymerase I
assay O
for O
studying O
cytomegalovirus O
resistance O
to O
foscarne O
.Phenotypic O
characterisation O
of O
the O
human O
cytomegalovirus O
(HCMV) O
pUL54 O
DNA O
polymerase O
is O
a O
useful O
tool O
for O
testing O
for O
mutations O
in O
the O
UL54 O
gene O
thought O
to O
render O
HCMV O
resistant O
to O
foscarnet O
. O
In O
this O
study O
, O
an O
in-house O
non-isotopic O
method O
for O
assessing O
polymerase O
enzymatic O
activity O
in O
the O
presence O
and O
absence O
of O
foscarnet O
was O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
recombinant O
human O
adenine O
phosphoribosyltransferase.Adenine O
phosphoribosyltransferase O
plays O
a O
role O
in O
purine O
salvage O
by O
catalyzing O
the O
direct O
conversion O
of O
adenine O
to O
adenosine O
monophosphate O
. O
The O
involvement O
of O
the O
purine O
salvage O
pathway O
in O
tumor O
proliferation O
and O
angiogenesis O
makes O
adenine O
phosphoribosyltransferase O
a O
potential O
target O
for O
oncology O
drug O
discovery O
. O
We O
have O
expressed O
and O
characterized O
recombinant O
, O
N O
terminally O
His-tagged O
human O
adenine O
phosphoribosyltransferase O
. O
Two O
assay O
formats O
were O
assessed O
for O
use O
in O
a O
high O
throughput O
screen O
: O
a O
spectrophotometric-based O
enzyme-coupled O
assay O
system O
and O
a O
radiometric O
ionic O
capture O
scintillation O
proximity O
bead O
assay O
format O
. O
Ultimately O
, O
the O
scintillation O
proximity O
assay O
format O
was O
chosen O
because O
of O
automated O
screening O
compatibility O
limitations O
of O
the O
coupled O

adenosine O
monophosphate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Configuration O
of O
a O
scintillation O
proximity O
assay O
for O
the O
activity O
assessment O
of O
recombinant O
human O
adenine O
phosphoribosyltransferase.Adenine O
phosphoribosyltransferase O
plays O
a O
role O
in O
purine O
salvage O
by O
catalyzing O
the O
direct O
conversion O
of O
adenine O
to O
adenosine O
monophosphate O
The O
involvement O
of O
the O
purine O
salvage O
pathway O
in O
tumor O
proliferation O
and O
angiogenesis O
makes O
adenine O
phosphoribosyltransferase O
a O
potential O
target O
for O
oncology O
drug O
discovery O
. O
We O
have O
expressed O
and O
characterized O
recombinant O
, O
N-terminally O
His-tagged O
human O
adenine O
phosphoribosyltransferase O
. O
Two O
assay O
formats O
were O
assessed O
for O
use O
in O
a O
high O
throughput O
screen O
: O
a O
spectrophotometric-based O
enzyme-coupled O
assay O

adenine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Configuration O
of O
a O
scintillation O
proximity O
assay O
for O
the O
activity O
assessment O
of O
recombinant O
human O
adenine O
phosphoribosyltransferase.Adenine O
phosphoribosyltransferase O
plays O
a O
role O
in O
purine O
salvage O
by O
catalyzing O
the O
direct O
conversion O
of O
adenine O
to O
adenosine O
monophosphate O
. O
The O
involvement O
of O
the O
purine O
salvage O
pathway O
in O
tumor O
proliferation O
and O
angiogenesis O
makes O
adenine O
phosphoribosyltransferase O
a O
potential O
target O
for O
oncology O
drug O
discovery O
. O
We O
have O
expressed O
and O
characterized O
recombinant O
, O
N-terminally O
His-tagged O
human O
adenine O
phosphoribosyltransferase O
. O
Two O
assay O
formats O
were O
assessed O
for O
use O
in O
a O
high O
throughput O
screen O
: O
a O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Antitumor O
activity O
of O
sorafeni O
in O
FLT3-driven O
leukemic O
cells.Activating O
internal O
tandem O
duplication O
(ITD) O
insertions O
in O
the O
juxtamembrane O
domain O
of O
the O
FLT3 B
tyrosine O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
MV4-11 O
and O
EOL-1 O
cells O
. O
The O
antitumor O
efficacy O
of O
sorafenib O
was O
evaluated O
against O
the O
MV4-11 O
leukemia O
grown O
subcutaneously O
in O
NCr O
nu/nu O
mice O
. O
Doses O
of O
3 O
and O
10 O
mg/kg O
administered O
orally O
for O
14 O
days O
resulted O
in O
six O
and O
nine O
out O
of O
10 O
animals O
with O
complete O
responses O
, O
respectively O
. O
The O
demonstration O
that O
sorafenib O
exhibits O
potent O
target O
inhibition O
and O
efficacy O
in O
FLT3-driven O
models O
suggests O
that O
this O
compound O
may O
have O
a O
therapeutic O
benefit O
for O
patients O
with O
FLT3-driven O
leukemias O
. O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
MV4-11 O
and O
EOL-1 O
cells O
. O
The O
antitumor O
efficacy O
of O
sorafenib O
was O
evaluated O
against O
the O
MV4-11 O
leukemia O
grown O
subcutaneously O
in O
NCr O
nu/nu O
mice O
. O
Doses O
of O
3 O
and O
10 O
mg/kg O
administered O
orally O
for O
14 O
days O
resulted O
in O
six O
and O
nine O
out O
of O
10 O
animals O
with O
complete O
responses O
, O
respectively O
. O
The O
demonstration O
that O
sorafenib O
exhibits O
potent O
target O
inhibition O
and O
efficacy O
in O
FLT3-driven O
models O
suggests O
that O
this O
compound O
may O
have O
a O
therapeutic O
benefit O
for O
patients O
with O
FLT3-driven O
leukemias O
. O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
activity O
of O
sorafenib O
in O
FLT3-driven O
leukemic O
cells.Activating O
internal O
tandem O
duplication O
(ITD) O
insertions O
in O
the O
juxtamembrane O
domain O
of O
the O
FLT3 B
tyrosine O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 O
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O

BAY O
43-9006 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
sorafenib O
in O
FLT3-driven O
leukemic O
cells.Activating O
internal O
tandem O
duplication O
(ITD) O
insertions O
in O
the O
juxtamembrane O
domain O
of O
the O
FLT3 B
tyrosine O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
( O
BAY O
43-9006 O
Nexavar) O
potently O
inhibits O
FLT3 O
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O

Nexavar O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
FLT3-driven O
leukemic O
cells.Activating O
internal O
tandem O
duplication O
(ITD) O
insertions O
in O
the O
juxtamembrane O
domain O
of O
the O
FLT3 B
tyrosine O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar O
potently O
inhibits O
FLT3 O
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 B
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 O
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 O
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular B
signal-regulated I
kinase1/2 I
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 O
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
kinase O
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 O
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 B
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 O
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
survival O
. O
We O
show O
that O
sorafenib O
(BAY O
43-9006 O
, O
Nexavar) O
potently O
inhibits O
FLT3 B
enzymatic O
and O
signaling O
activities O
. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT O
or O
FLT3-ITD O
, O
sorafenib O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 O
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O
sorafenib O
. O
Cell O
cycle O
arrest O
and O
induction O
of O
apoptosis O
were O
observed O
upon O
treatment O
with O
sorafenib O
in O
MV4-11 O
and O
EOL-1 O
cells O
. O
The O
antitumor O
efficacy O
of O
sorafenib O
was O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated O
tyrosine O
autophosphorylation O
as O
well O
as O
extracellular O
signal-regulated O
kinase1/2 O
and O
Stat5 O
phosphorylation O
. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1 O
, O
sorafenib O
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 B
signaling O
. O
The O
growth O
of O
the O
FLT3-independent O
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O
sorafenib O
Cell O
cycle O
arrest O
and O
induction O
of O
apoptosis O
were O
observed O
upon O
treatment O
with O
sorafenib O
in O
MV4-11 O
and O
EOL-1 O
cells O
. O
The O
antitumor O
efficacy O
of O
sorafenib O
was O
evaluated O
against O
the O
MV4-11 O
leukemia O
grown O
subcutaneously O
in O
NCr O
nu/nu O
mice O
. O
Doses O
of O
3 O
and O
10 O
mg/kg O
administered O
orally O
for O
14 O
days O
resulted O
in O
six O

citrulline O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
(rhArg) O
inhibits O
ASS-positive O
HCCs O
. O
All O
the O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg B
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine O
transcarbamylase O
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
, O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O
of O
ASS-positive O
HCC O
cells O

ornithine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
reported O
. O
Here O
, O
we O
provide O
direct O
evidence O
that O
recombinant O
human O
arginase O
(rhArg) O
inhibits O
ASS-positive O
HCCs O
. O
All O
the O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg O
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine B
transcarbamylase I
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
, O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O

ornithine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
reported O
. O
Here O
, O
we O
provide O
direct O
evidence O
that O
recombinant O
human O
arginase O
(rhArg) O
inhibits O
ASS-positive O
HCCs O
. O
All O
the O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg O
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine O
transcarbamylase O
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
, O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC B
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
that O
recombinant O
human O
arginase O
(rhArg) O
inhibits O
ASS-positive O
HCCs O
. O
All O
the O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg B
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine O
transcarbamylase O
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
, O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
, O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg O
but O
ADI O
had O
virtually O
no O
effect O
on O
these O
cells O
. O
They O
all O
expressed O
ASS O
, O
but O
not O
ornithine O
transcarbamylase O
(OTC) O
, O
the O
enzyme O
that O
converts O
ornithine O
, O
the O
product O
of O
degradation O
of O
arginine O
with O
rhArg O
, O
to O
citrulline O
, O
which O
is O
converted O
back O
to O
arginine O
via O
ASS O
. O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O
of O
ASS-positive O
HCC O
cells O
shows O
that O
OTC-deficient O
HCCs O
are O
sensitive O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HCC O
cells O
with O
OTC O
resulted O
in O
resistance O
to O
rhArg O
. O
Thus O
, O
OTC O
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg B
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O
of O
ASS-positive O
HCC O
cells O
shows O
that O
OTC-deficient O
HCCs O
are O
sensitive O
to O
rhArg-mediated O
arginine O
depletion O
. O
Therefore O
, O
pretreatment O
tumor O
gene O
expression O
profiling O
of O
ASS O
and O
OTC O
could O
aid O
in O
predicting O
tumor O
response O
to O
arginine O
depletion O
with O
arginine-depleting O
enzymes O
. O
We O
have O
also O
shown O
that O
the O
rhArg O
native O
enzyme O
and O
the O
pegylated O
rhArg O
(rhArg-peg(5,000mw)) O
gave O
similar O
anticancer O
efficacy O
in O
vitro O
. O
Furthermore O
, O
the O
growth O
of O
the O
OTC-deficient O

arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
induce O
rhArg O
resistance O
in O
ASS-positive O
HCC O
cells O
. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC O
expression O
and O
sensitivity O
of O
ASS-positive O
HCC O
cells O
shows O
that O
OTC-deficient O
HCCs O
are O
sensitive O
to O
rhArg-mediated O
arginine O
depletion O
. O
Therefore O
, O
pretreatment O
tumor O
gene O
expression O
profiling O
of O
ASS O
and O
OTC O
could O
aid O
in O
predicting O
tumor O
response O
to O
arginine O
depletion O
with O
arginine-depleting O
enzymes O
. O
We O
have O
also O
shown O
that O
the O
rhArg O
native O
enzyme O
and O
the O
pegylated O
rhArg O
(rhArg-peg(5,000mw)) O
gave O
similar O
anticancer O
efficacy O
in O
vitro O
. O
Furthermore O
, O
the O
growth O
of O
the O
OTC-deficient O
Hep3B O
tumor O
cells O
(ASS-positive O
and O
ADI-resistant) O
in O
mice O
was O
inhibited O
by O
treatment O
with O
rhArg-peg(5,000mw) O
, O
which O
is O
active O
alone O
and O

all-trans-retinol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
all-trans-13,14-dihydroretinol O
, O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O
Cyp26A1 O
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid O

all-trans-13,14-dihydroretinol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
, O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O
Cyp26A1 O
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid O
compounds O
, O

all-trans-7,8-dihydroretinol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O
was O
restricted O
to O
the O
liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish O
, O
whereas O
zRetSat O
B O
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages O
. O
Exogenous O
all-trans-retinol O
, O
all-trans-13,14-dihydroretinol O
, O
or O
all-trans-7,8-dihydroretinol O
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic O
acid-metabolizing O
enzyme O
, O
Cyp26A1 O
, O
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid O
metabolites O
in O
zebrafish O
. O
These O
findings O
point O
to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat O
in O
vertebrates O
, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid O
compounds O
, O
some O
of O

all-trans-retinoic O
acid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Specificity O
of O
zebrafish O
retinol O
saturase O
: O
formation O
of O
all-trans-13,14-dihydroretinol O
and O
all-trans-7,8- O
dihydroretinol.Metabolism O
of O
vitamin O
A O
, O
all-trans-retinol O
, O
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde O
, O
the O
visual O
chromophore O
, O
and O
all-trans-retinoic O
acid O
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O
a O
novel O
mammalian O
enzyme O
that O
saturates O
the O
13-14 O
double O
bond O
of O
all-trans-retinol O
to O
produce O
all-trans-13,14-dihydroretinol O
, O
which O
then O
follows O
the O

all-trans-13,14-dihydroretinol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Specificity O
of O
zebrafish O
retinol O
saturase O
: O
formation O
of O
all-trans-13,14-dihydroretino O
and O
all-trans-7,8- O
dihydroretinol.Metabolism O
of O
vitamin O
A O
, O
all-trans-retinol O
, O
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde O
, O
the O
visual O
chromophore O
, O
and O
all-trans-retinoic O
acid O
, O
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O

all-trans-7,8- O
dihydroretinol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Specificity O
of O
zebrafish O
retinol O
saturase O
: O
formation O
of O
all-trans-13,14-dihydroretinol O
and O
all-trans-7,8- O
dihydroretino O
.Metabolism O
of O
vitamin O
A O
, O
all-trans-retinol O
, O
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde O
, O
the O
visual O
chromophore O
, O
and O
all-trans-retinoic O
acid O
, O
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O
a O
novel O

all-trans-13,14-dihydroretinol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O

all-trans-7,8-dihydroretinol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O

all-trans-retinol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
putative O
RetSat O
homologues O
in O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O

all-trans-13,14-dihydroretinol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
expression O
through O
the O
retinoic O
acid O
receptor O
. O
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid O
metabolism O
are O
highly O
conserved O
across O
species O
. O
We O
previously O
described O
a O
novel O
mammalian O
enzyme O
that O
saturates O
the O
13-14 O
double O
bond O
of O
all-trans-retinol O
to O
produce O
all-trans-13,14-dihydroretinol O
, O
which O
then O
follows O
the O
same O
metabolic O
fate O
as O
that O
of O
all-trans-retinol O
. O
Specifically O
, O
all-trans-13,14-dihydroretinol O
is O
transiently O
oxidized O
to O
all-trans-13,14-dihydroretinoic O
acid O
before O
being O
oxidized O
further O
by O
Cyp26 B
enzymes O
. O
Here O
, O
we O
report O
the O
identification O
of O
two O
putative O
RetSat O
homologues O
in O
zebrafish O
, O
one O
of O
which O
, O
zebrafish O
RetSat O
A O
(zRetSat O
A) O
, O
also O
had O
retinol O
saturase O
activity O
, O
whereas O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O

all-trans-3,4-didehydroretinol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
zebrafish O
RetSat O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
(vitamin O
A2) O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O

vitamin O
A2 O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
B O
(zRetSat O
B) O
was O
inactive O
under O
similar O
conditions O
. O
Unlike O
mouse O
RetSat O
(mRetSat) O
, O
zRetSat B
A I
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol O
to O
produce O
either O
all-trans-13,14-dihydroretinol O
or O
all-trans-7,8-dihydroretinol O
, O
respectively O
. O
zRetSat O
A O
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol O
( O
vitamin O
A2 O
 O
, O
a O
second O
endogenous O
form O
of O
vitamin O
A O
in O
zebrafish O
. O
The O
dual O
enzymatic O
activity O
of O
zRetSat O
A O
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial O
phytoene O
desaturases O
and O
plant O
carotenoid O
isomerases O
. O
Expression O
of O
zRetSat O
A O

acetyl O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
we O
now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA B
is O
intrinsic O
to O
purified O
myelin O
membranes O
. O
This O
was O
supported O
by O
a O
novel O
TLC-based O
method O
for O
the O
assay O
of O
ASPA O
. O
That O
observation O
, O
together O
with O
previous O
demonstrations O
of O
numerous O
lipid-synthesizing O
enzymes O
in O
myelin O
, O
suggests O
utilization O
of O
acetyl O
groups O
liberated O
by O
myelin-localized O
ASPA O
for O
lipid O
synthesis O
within O
the O
myelin O
sheath O
. O
Such O
synthesis O
might O
be O
selective O
and O
could O
explain O
the O
deficit O
of O
myelin O
lipids O
in O
animals O
lacking O
ASPA O
. O

acetyl O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
considering O
the O
various O
physiological O
roles O
that O
have O
been O
proposed O
for O
this O
relatively O
abundant O
molecule O
one O
is O
obliged O
to O
take O
into O
account O
its O
unusual O
metabolic O
compartmentalization O
, O
according O
to O
which O
synthesis O
and O
storage O
occur O
in O
the O
neuron O
and O
hydrolytic O
cleavage O
in O
the O
oligodendrocyte O
. O
The O
latter O
reaction O
, O
catalyzed O
by O
aspartoacylase B
(ASPA) O
, O
produces O
acetyl O
groups O
plus O
aspartate O
and O
has O
been O
proposed O
to O
occur O
in O
both O
soluble O
and O
membranous O
subfractions O
of O
white O
matter O
. O
Our O
study O
supports O
such O
bimodal O
occurrence O
and O
we O
now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA O
is O
intrinsic O
to O
purified O
myelin O
membranes O
. O
This O
was O
supported O
by O

acetyl O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
considering O
the O
various O
physiological O
roles O
that O
have O
been O
proposed O
for O
this O
relatively O
abundant O
molecule O
one O
is O
obliged O
to O
take O
into O
account O
its O
unusual O
metabolic O
compartmentalization O
, O
according O
to O
which O
synthesis O
and O
storage O
occur O
in O
the O
neuron O
and O
hydrolytic O
cleavage O
in O
the O
oligodendrocyte O
. O
The O
latter O
reaction O
, O
catalyzed O
by O
aspartoacylase O
(ASPA) O
, O
produces O
acetyl O
groups O
plus O
aspartate O
and O
has O
been O
proposed O
to O
occur O
in O
both O
soluble O
and O
membranous O
subfractions O
of O
white O
matter O
. O
Our O
study O
supports O
such O
bimodal O
occurrence O
and O
we O
now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA B
is O
intrinsic O
to O
purified O
myelin O
membranes O
. O
This O
was O
supported O
by O

aspartate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
physiological O
roles O
that O
have O
been O
proposed O
for O
this O
relatively O
abundant O
molecule O
one O
is O
obliged O
to O
take O
into O
account O
its O
unusual O
metabolic O
compartmentalization O
, O
according O
to O
which O
synthesis O
and O
storage O
occur O
in O
the O
neuron O
and O
hydrolytic O
cleavage O
in O
the O
oligodendrocyte O
. O
The O
latter O
reaction O
, O
catalyzed O
by O
aspartoacylase B
(ASPA) O
, O
produces O
acetyl O
groups O
plus O
aspartate O
and O
has O
been O
proposed O
to O
occur O
in O
both O
soluble O
and O
membranous O
subfractions O
of O
white O
matter O
. O
Our O
study O
supports O
such O
bimodal O
occurrence O
and O
we O
now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA O
is O
intrinsic O
to O
purified O
myelin O
membranes O
. O
This O
was O
supported O
by O
a O
novel O
TLC-based O

aspartate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
physiological O
roles O
that O
have O
been O
proposed O
for O
this O
relatively O
abundant O
molecule O
one O
is O
obliged O
to O
take O
into O
account O
its O
unusual O
metabolic O
compartmentalization O
, O
according O
to O
which O
synthesis O
and O
storage O
occur O
in O
the O
neuron O
and O
hydrolytic O
cleavage O
in O
the O
oligodendrocyte O
. O
The O
latter O
reaction O
, O
catalyzed O
by O
aspartoacylase O
(ASPA) O
, O
produces O
acetyl O
groups O
plus O
aspartate O
and O
has O
been O
proposed O
to O
occur O
in O
both O
soluble O
and O
membranous O
subfractions O
of O
white O
matter O
. O
Our O
study O
supports O
such O
bimodal O
occurrence O
and O
we O
now O
present O
immunoblot O
, O
proteomic O
, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA B
is O
intrinsic O
to O
purified O
myelin O
membranes O
. O
This O
was O
supported O
by O
a O
novel O
TLC-based O

lactate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
activity O
and O
gene O
expression O
in O
placentas O
from O
preeclamptic O
pregnancies O
[Tsoi O
SCM O
, O
Zheng O
J O
, O
Xu O
F O
, O
Kay O
HH O
. O
Differential O
expression O
of O
lactate O
dehydrogenase O
isozymes O
(LDH) O
in O
human O
placenta O
with O
high O
expression O
of O
LDH-A(4) O
isozyme O
in O
the O
endothelial O
cells O
of O
pre-eclampsia O
villi O
. O
Placenta O
2001;22:317-22] O
. O
LDH B
is O
responsible O
for O
pyruvate O
conversion O
to O
lactate O
through O
glycolysis O
. O
In O
this O
study O
, O
we O
further O
investigated O
the O
role O
of O
hypoxia O
in O
primary O
trophoblast O
cells O
and O
a O
cultured O
cell O
line O
, O
JEG3 O
cells O
, O
to O
obtain O
a O
better O
understanding O
of O
how O
it O
affects O
the O
activities O
of O
lactate O
dehydrogenase O
, O
lactate O
production O
and O
regulatory O
genes O
, O
as O
a O
possible O
model O
for O
preeclampsia O
. O
Primary O

pyruvate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
(LDH) O
has O
increased O
activity O
and O
gene O
expression O
in O
placentas O
from O
preeclamptic O
pregnancies O
[Tsoi O
SCM O
, O
Zheng O
J O
, O
Xu O
F O
, O
Kay O
HH O
. O
Differential O
expression O
of O
lactate O
dehydrogenase O
isozymes O
(LDH) O
in O
human O
placenta O
with O
high O
expression O
of O
LDH-A(4) O
isozyme O
in O
the O
endothelial O
cells O
of O
pre-eclampsia O
villi O
. O
Placenta O
2001;22:317-22] O
. O
LDH B
is O
responsible O
for O
pyruvate O
conversion O
to O
lactate O
through O
glycolysis O
. O
In O
this O
study O
, O
we O
further O
investigated O
the O
role O
of O
hypoxia O
in O
primary O
trophoblast O
cells O
and O
a O
cultured O
cell O
line O
, O
JEG3 O
cells O
, O
to O
obtain O
a O
better O
understanding O
of O
how O
it O
affects O
the O
activities O
of O
lactate O
dehydrogenase O
, O
lactate O
production O
and O
regulatory O
genes O
, O
as O
a O
possible O
model O

PUFA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
alpha-Linolenic O
acid O
, O
Delta6-desaturase O
gene O
polymorphism O
, O
and O
the O
risk O
of O
nonfatal O
myocardial O
infarction.BACKGROUND O
: O
Delta(6)-Desaturase O
(FADS2) O
is O
the O
rate-limiting O
step O
in O
the O
polyunsaturated O
fatty O
acid O
(PUFA) O
biosynthetic O
pathway O
. O
OBJECTIVE O
: O
The O
aim O
was O
to O
test O
whether O
the O
common O
deletion O
[T/-] O
in O
the O
promoter O
of O
FADS2 B
affects O
the O
PUFA O
biosynthetic O
pathway O
and O
consequently O
modifies O
the O
effect O
of O
alpha-linolenic O
acid O
(ALA) O
on O
myocardial O
infarction O
(MI) O
. O
DESIGN O
: O
Case O
subjects O
(n O
=1694) O
with O
a O
first O
nonfatal O
acute O
MI O
were O
matched O
by O
age O
, O
sex O
, O
and O
area O
of O
residence O
to O
1694 O
population-based O
control O
subjects O
in O
Costa O
Rica O
. O
PUFAs O
were O
quantified O
by O
gas-liquid O
chromatography O

alpha-linolenic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
polymorphism O
, O
and O
the O
risk O
of O
nonfatal O
myocardial O
infarction.BACKGROUND O
: O
Delta(6)-Desaturase O
(FADS2) O
is O
the O
rate-limiting O
step O
in O
the O
polyunsaturated O
fatty O
acid O
(PUFA) O
biosynthetic O
pathway O
. O
OBJECTIVE O
: O
The O
aim O
was O
to O
test O
whether O
the O
common O
deletion O
[T/-] O
in O
the O
promoter O
of O
FADS2 B
affects O
the O
PUFA O
biosynthetic O
pathway O
and O
consequently O
modifies O
the O
effect O
of O
alpha-linolenic O
acid O
(ALA) O
on O
myocardial O
infarction O
(MI) O
. O
DESIGN O
: O
Case O
subjects O
(n O
=1694) O
with O
a O
first O
nonfatal O
acute O
MI O
were O
matched O
by O
age O
, O
sex O
, O
and O
area O
of O
residence O
to O
1694 O
population-based O
control O
subjects O
in O
Costa O
Rica O
. O
PUFAs O
were O
quantified O
by O
gas-liquid O
chromatography O
from O
plasma O
and O
adipose O
tissue O
samples O
. O
Least-squares O
means O
from O
generalized O

ALA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
risk O
of O
nonfatal O
myocardial O
infarction.BACKGROUND O
: O
Delta(6)-Desaturase O
(FADS2) O
is O
the O
rate-limiting O
step O
in O
the O
polyunsaturated O
fatty O
acid O
(PUFA) O
biosynthetic O
pathway O
. O
OBJECTIVE O
: O
The O
aim O
was O
to O
test O
whether O
the O
common O
deletion O
[T/-] O
in O
the O
promoter O
of O
FADS2 B
affects O
the O
PUFA O
biosynthetic O
pathway O
and O
consequently O
modifies O
the O
effect O
of O
alpha-linolenic O
acid O
( O
ALA O
on O
myocardial O
infarction O
(MI) O
. O
DESIGN O
: O
Case O
subjects O
(n O
=1694) O
with O
a O
first O
nonfatal O
acute O
MI O
were O
matched O
by O
age O
, O
sex O
, O
and O
area O
of O
residence O
to O
1694 O
population-based O
control O
subjects O
in O
Costa O
Rica O
. O
PUFAs O
were O
quantified O
by O
gas-liquid O
chromatography O
from O
plasma O
and O
adipose O
tissue O
samples O
. O
Least-squares O
means O
from O
generalized O
linear O

milrinone O
acts O
as O
NOT O
for O
what O
entity O
? O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase B
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
( O
milrinone O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O

8-methoxymethyl-3-isobutyl-1-methylxanthine O
acts O
as O
NOT O
for O
what O
entity O
? O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase B
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
( O
8-methoxymethyl-3-isobutyl-1-methylxanthine O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O

erythro-9-(2-hydroxy-3-nonyl)adenine O
acts O
as O
NOT O
for O
what O
entity O
? O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase B
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[ O
erythro-9-(2-hydroxy-3-nonyl)adenine O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O

4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one O
acts O
as O
NOT O
for O
what O
entity O
? O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase B
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[ O
4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one O
 O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O

zaprinast O
acts O
as O
NOT O
for O
what O
entity O
? O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
( O
zaprinast O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O

BRL-50481 O
acts O
as O
NOT O
for O
what O
entity O
? O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[ O
BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O

5-nitro-2,N,N-trimethylbenzenesulfonamide O
acts O
as O
NOT O
for O
what O
entity O
? O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
( O
5-nitro-2,N,N-trimethylbenzenesulfonamide O
 O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O

dipyridamole O
acts O
as O
NOT O
for O
what O
entity O
? O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 B
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O

dipyridamole O
acts O
as O
NOT O
for O
what O
entity O
? O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

1,3-isobutyl-1-methylxanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase B
(PDE) O
inhibitor O
( O
1,3-isobutyl-1-methylxanthine O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O

1,3-isobutyl-1-methylxanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
( O
1,3-isobutyl-1-methylxanthine O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O

milrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 B
( O
milrinone O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O

8-methoxymethyl-3-isobutyl-1-methylxanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 B
( O
8-methoxymethyl-3-isobutyl-1-methylxanthine O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O

erythro-9-(2-hydroxy-3-nonyl)adenine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 B
[ O
erythro-9-(2-hydroxy-3-nonyl)adenine O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O

4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 B
(Ro O
20-1724 O
[ O
4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one O
 O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O

zaprinast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 B
and O
PDE6 O
( O
zaprinast O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O

zaprinast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 B
( O
zaprinast O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O

BRL-50481 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 B
[ O
BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O

5-nitro-2,N,N-trimethylbenzenesulfonamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 B
[BRL-50481 O
( O
5-nitro-2,N,N-trimethylbenzenesulfonamide O
 O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 B
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O

dipyridamole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 O
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 B
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O

AMP O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O

adenosine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O

cAMP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O

AMP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O

IM O
acts O
as O
NOT O
for O
what O
entity O
? O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase B
domain I
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

IM O
acts O
as O
NOT O
for O
what O
entity O
? O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit B
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

IM O
acts O
as O
NOT O
for O
what O
entity O
? O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

IM O
acts O
as O
NOT O
for O
what O
entity O
? O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL B
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
- O
AXL B
- O
in O
a O
'kinase O
switch' O
. O
Further O
, O
the O
two O
IM O
resistant O
GIST O
patients O
express O
AXL O
and O
not O
c-Kit O
, O
seen O
by O
immunohistochemistry O
(IHC) O
. O
Real O
time O
reverse O
transcriptase-polymerase O
chain O
reaction O
and O
Western O
blotting O
of O
the O
GIST-S O
and O
GIST-R O
cells O
confirmed O
the O
switch O
from O
Kit O
to O
AXL O
. O
In O
GIST-R O
, O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
, O
a O
novel O

MP470 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase B
domain I
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

MP470 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit B
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

MP470 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

MP470 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
AXL B
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

imatinib O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
novel O
tyrosine B
kinase I
switch O
is O
a O
mechanism O
of O
imatini O
resistance O
in O
gastrointestinal O
stromal O
tumors.KIT O
or O
alpha-platelet-derived O
growth O
factor O
receptor O
(alpha-PDGFR) O
activating O
mutations O
are O
the O
pathogenic O
mechanisms O
that O
characterize O
gastrointestinal O
stromal O
tumors O
(GIST) O
. O
Despite O
excellent O
responses O
to O
imatinib O
mesylate O
(IM) O
, O
patients O
are O
relapsing O
. O
We O
developed O
an O
IM-resistant O
GIST O
cell O
line O
(GIST-R) O
from O
the O
IM-sensitive O
GIST882 O
cell O
line O
(GIST-S) O
by O

IM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
pathogenic O
mechanisms O
that O
characterize O
gastrointestinal O
stromal O
tumors O
(GIST) O
. O
Despite O
excellent O
responses O
to O
imatinib O
mesylate O
(IM) O
, O
patients O
are O
relapsing O
. O
We O
developed O
an O
IM-resistant O
GIST O
cell O
line O
(GIST-R) O
from O
the O
IM-sensitive O
GIST882 O
cell O
line O
(GIST-S) O
by O
growing O
these O
cells O
in O
IM O
. O
Gene O
expression O
profiling O
(GEP) O
of O
GIST-S O
, O
GIST-R O
cells O
and O
two O
IM O
resistant O
GIST O
patients O
demonstrated O
that O
KIT B
is O
downregulated O
implying O
a O
major O
role O
in O
IM O
resistance O
. O
Instead O
, O
GIST-R O
cells O
have O
acquired O
IM O
resistance O
by O
overexpressing O
the O
oncogenic O
receptor O
tyrosine O
kinase O
- O
AXL O
- O
in O
a O
'kinase O
switch' O
. O
Further O
, O
the O
two O
IM O
resistant O
GIST O
patients O
express O
AXL O
and O
not O
c-Kit O
, O
seen O

IM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(IM) O
, O
patients O
are O
relapsing O
. O
We O
developed O
an O
IM-resistant O
GIST O
cell O
line O
(GIST-R) O
from O
the O
IM-sensitive O
GIST882 O
cell O
line O
(GIST-S) O
by O
growing O
these O
cells O
in O
IM O
. O
Gene O
expression O
profiling O
(GEP) O
of O
GIST-S O
, O
GIST-R O
cells O
and O
two O
IM O
resistant O
GIST O
patients O
demonstrated O
that O
KIT B
is O
downregulated O
implying O
a O
major O
role O
in O
IM O
resistance O
. O
Instead O
, O
GIST-R O
cells O
have O
acquired O
IM O
resistance O
by O
overexpressing O
the O
oncogenic O
receptor O
tyrosine O
kinase O
- O
AXL O
- O
in O
a O
'kinase O
switch' O
. O
Further O
, O
the O
two O
IM O
resistant O
GIST O
patients O
express O
AXL O
and O
not O
c-Kit O
, O
seen O
by O
immunohistochemistry O
(IHC) O
. O
Real O
time O
reverse O
transcriptase-polymerase O
chain O
reaction O
and O
Western O
blotting O
of O
the O

MP470 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit B
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

MP470 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
AXL B
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase O
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

MP470 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
AXL O
is O
tyrosine O
phosphorylated O
and O
its O
ligand O
growth-arrest-specific O
gene O
6 O
is O
overexpressed O
implying O
autocrine O
activation O
. O
The O
kinase B
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid O
. O
Molecular O
modeling O
of O
the O
kinase O
domain O
of O
mutant O
c-Kit O
(V654A) O
and O
AXL O
showed O
no O
binding O
to O
IM O
but O
efficient O
binding O
to O
MP470 O
a O
novel O
c-Kit/AXL O
kinase O
inhibitor O
. O
MP470 O
synergizes O
with O
docetaxel O
(taxotere) O
and O
is O
cytotoxic O
to O
GIST O
cells O
. O

leflunomide O
acts O
as O
AGONIST O
for O
what O
entity O
? O
found O
to O
significantly O
induce O
Cyp1a1 O
in O
vivo O
but O
were O
not O
verified O
to O
bind O
or O
activate O
the O
AhR B
in O
vitro O
. O
Combining O
in O
vivo O
and O
in O
vitro O
findings O
, O
we O
identified O
nine O
AhR O
agonists O
, O
six O
of O
which O
are O
marketed O
therapeutics O
and O
have O
been O
approved O
by O
the O
U.S O
. O
Food O
and O
Drug O
Administration O
, O
including O
leflunomide O
flutamide O
, O
and O
nimodipine O
. O
These O
drugs O
do O
not O
produce O
dioxin-like O
toxicity O
in O
rats O
or O
in O
humans O
. O
These O
data O
demonstrate O
that O
induction O
of O
Cyp1a1 O
is O
a O
nonspecific O
biomarker O
of O
direct O
AhR O
affinity O
and O
activation O
and O
lend O
further O
support O
to O
the O
hypothesis O
that O
Cyp1a1 O
induction O
and/or O
AhR O
activation O
is O
not O
synonymous O
with O

flutamide O
acts O
as O
AGONIST O
for O
what O
entity O
? O
to O
significantly O
induce O
Cyp1a1 O
in O
vivo O
but O
were O
not O
verified O
to O
bind O
or O
activate O
the O
AhR B
in O
vitro O
. O
Combining O
in O
vivo O
and O
in O
vitro O
findings O
, O
we O
identified O
nine O
AhR O
agonists O
, O
six O
of O
which O
are O
marketed O
therapeutics O
and O
have O
been O
approved O
by O
the O
U.S O
. O
Food O
and O
Drug O
Administration O
, O
including O
leflunomide O
, O
flutamide O
and O
nimodipine O
. O
These O
drugs O
do O
not O
produce O
dioxin-like O
toxicity O
in O
rats O
or O
in O
humans O
. O
These O
data O
demonstrate O
that O
induction O
of O
Cyp1a1 O
is O
a O
nonspecific O
biomarker O
of O
direct O
AhR O
affinity O
and O
activation O
and O
lend O
further O
support O
to O
the O
hypothesis O
that O
Cyp1a1 O
induction O
and/or O
AhR O
activation O
is O
not O
synonymous O
with O
dioxin-like O

nimodipine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
induce O
Cyp1a1 O
in O
vivo O
but O
were O
not O
verified O
to O
bind O
or O
activate O
the O
AhR B
in O
vitro O
. O
Combining O
in O
vivo O
and O
in O
vitro O
findings O
, O
we O
identified O
nine O
AhR O
agonists O
, O
six O
of O
which O
are O
marketed O
therapeutics O
and O
have O
been O
approved O
by O
the O
U.S O
. O
Food O
and O
Drug O
Administration O
, O
including O
leflunomide O
, O
flutamide O
, O
and O
nimodipine O
These O
drugs O
do O
not O
produce O
dioxin-like O
toxicity O
in O
rats O
or O
in O
humans O
. O
These O
data O
demonstrate O
that O
induction O
of O
Cyp1a1 O
is O
a O
nonspecific O
biomarker O
of O
direct O
AhR O
affinity O
and O
activation O
and O
lend O
further O
support O
to O
the O
hypothesis O
that O
Cyp1a1 O
induction O
and/or O
AhR O
activation O
is O
not O
synonymous O
with O
dioxin-like O
toxicity O
. O

rolipram O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mice O
, O
rolipram O
dose-dependently O
suppressed O
CAR O
(ED(50) O
= O
2.4 O
mg/kg); O
however O
, O
in O
knockout O
mice O
, O
their O
sensitivity O
to O
rolipram O
at O
the O
higher O
doses O
(1.0 O
and O
3.2 O
mg/kg) O
was O
reduced O
, O
resulting O
in O
a O
threefold O
shift O
in O
the O
ED(50) O
(7.3 O
mg/kg) O
, O
suggesting O
PDE4B B
is O
involved O
, O
at O
least O
in O
part O
, O
with O
the O
activity O
of O
rolipram O
Only O
the O
highest O
dose O
of O
rolipram O
(3.2 O
mg/kg) O
produced O
a O
modest O
but O
significant O
degree O
of O
catalepsy O
. O
CONCLUSIONS O
: O
Rolipram O
has O
a O
pharmacologic O
profile O
similar O
to O
that O
of O
the O
atypical O
antipsychotics O
and O
has O
low O
extrapyramidal O
symptom O
liability O
. O
These O
results O
suggest O
that O
PDE4B O
mediates O
the O
antipsychotic O
effects O
of O
rolipram O
in O
CAR O
and O

rolipram O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
activity O
of O
rolipram O
. O
Only O
the O
highest O
dose O
of O
rolipram O
(3.2 O
mg/kg) O
produced O
a O
modest O
but O
significant O
degree O
of O
catalepsy O
. O
CONCLUSIONS O
: O
Rolipram O
has O
a O
pharmacologic O
profile O
similar O
to O
that O
of O
the O
atypical O
antipsychotics O
and O
has O
low O
extrapyramidal O
symptom O
liability O
. O
These O
results O
suggest O
that O
PDE4B B
mediates O
the O
antipsychotic O
effects O
of O
rolipram O
in O
CAR O
and O
that O
the O
PDE4B-regulated O
cyclic O
adenosine O
monophosphate O
signaling O
pathway O
may O
play O
a O
role O
in O
the O
pathophysiology O
and O
pharmacotherapy O
of O
psychosis O
. O

rolipram O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
studies O
provide O
evidence O
for O
reduced O
phosphodiesterase-4B O
(PDE4B) O
as O
a O
genetic O
susceptibility O
factor O
as O
well O
as O
suggesting O
an O
association O
of O
several O
single O
nucleotide O
polymorphisms O
(SNPs) O
in O
PDE4B O
that O
are O
associated O
with O
an O
increased O
incidence O
of O
schizophrenia O
. O
OBJECTIVES O
: O
The O
aim O
of O
the O
current O
study O
was O
to O
assess O
the O
activity O
of O
rolipram O
a O
nonsubtype-selective O
PDE4 B
inhibitor O
, O
in O
several O
animal O
models O
predictive O
of O
antipsychotic-like O
efficacy O
and O
side-effect O
liability O
and O
to O
use O
PDE4B O
wild-type O
and O
knockout O
mice O
to O
begin O
to O
understand O
the O
subtypes O
involved O
in O
the O
activity O
of O
rolipram O
. O
RESULTS O
: O
In O
rats O
, O
rolipram O
antagonized O
both O
phencyclidine O
hydrochloride- O
and O
D-amphetamine-induced O
hyperactivity O
and O
inhibited O
conditioned O

cyclic O
adenosine O
monophosphate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
rolipram O
(3.2 O
mg/kg) O
produced O
a O
modest O
but O
significant O
degree O
of O
catalepsy O
. O
CONCLUSIONS O
: O
Rolipram O
has O
a O
pharmacologic O
profile O
similar O
to O
that O
of O
the O
atypical O
antipsychotics O
and O
has O
low O
extrapyramidal O
symptom O
liability O
. O
These O
results O
suggest O
that O
PDE4B B
mediates O
the O
antipsychotic O
effects O
of O
rolipram O
in O
CAR O
and O
that O
the O
PDE4B-regulated O
cyclic O
adenosine O
monophosphate O
signaling O
pathway O
may O
play O
a O
role O
in O
the O
pathophysiology O
and O
pharmacotherapy O
of O
psychosis O
. O

threonine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
mutation O
in O
KYNU O
encoding O
kynureninase.Massive O
urinary O
excretion O
of O
xanthurenic O
acid O
, O
3-hydroxykynurenine O
and O
kynurenine O
, O
known O
as O
xanthurenic O
aciduria O
or O
hydroxykynureninuria O
, O
in O
a O
young O
Somali O
boy O
suggested O
kynureninase B
deficiency O
. O
Mutation O
analysis O
of O
KYNU O
encoding O
kynureninase O
of O
the O
index O
case O
revealed O
homozygosity O
for O
a O
c.593 O
A O
> O
G O
substitution O
leading O
to O
a O
threonine O
to-alanine O
(T198A) O
shift O
. O
A O
younger O
brother O
was O
found O
to O
have O
a O
similar O
excretion O
pattern O
and O
the O
same O
genotype O
. O
At O
present O
, O
neither O
of O
the O
two O
boys O
has O
symptoms O
of O
niacin O
deficiency O
. O
This O
is O
the O
first O
report O
linking O
xanthurenic O
aciduria O
to O
a O
mutation O
in O
the O
gene O
encoding O
kynureninase O
. O

alanine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
in O
KYNU O
encoding O
kynureninase.Massive O
urinary O
excretion O
of O
xanthurenic O
acid O
, O
3-hydroxykynurenine O
and O
kynurenine O
, O
known O
as O
xanthurenic O
aciduria O
or O
hydroxykynureninuria O
, O
in O
a O
young O
Somali O
boy O
suggested O
kynureninase B
deficiency O
. O
Mutation O
analysis O
of O
KYNU O
encoding O
kynureninase O
of O
the O
index O
case O
revealed O
homozygosity O
for O
a O
c.593 O
A O
> O
G O
substitution O
leading O
to O
a O
threonine-to- O
alanine O
(T198A) O
shift O
. O
A O
younger O
brother O
was O
found O
to O
have O
a O
similar O
excretion O
pattern O
and O
the O
same O
genotype O
. O
At O
present O
, O
neither O
of O
the O
two O
boys O
has O
symptoms O
of O
niacin O
deficiency O
. O
This O
is O
the O
first O
report O
linking O
xanthurenic O
aciduria O
to O
a O
mutation O
in O
the O
gene O
encoding O
kynureninase O
. O

sitagliptin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin B
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
, O
sitagliptin O
100 O
or O
200mg O
once O
daily O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
was O
associated O
with O
significant O
improvements O
relative O
to O
placebo O
in O
overall O
glycaemic O
control O
and O
indices O
for O
insulin O
response O
and O
beta-cell O
function O
. O
Improvements O
from O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O

glipizide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O
incidence O
of O
hypoglycaemia O
with O
sitagliptin O
was O
similar O
to O
that O
with O
placebo O
and O
, O
in O
combination O
with O
metformin O
, O
lower O
than O
that O
with O

sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
type O
2 O
diabetes O
mellitus O
, O
sitagliptin O
100 O
or O
200mg O
once O
daily O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
was O
associated O
with O
significant O
improvements O
relative O
to O
placebo O
in O
overall O
glycaemic O
control O
and O
indices O
for O
insulin O
response O
and O
beta-cell O
function O
. O
Improvements O
from O
baseline O
in O
mean O
glycosylated B
haemoglobin I
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) O
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O

sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
type O
2 O
diabetes O
mellitus O
, O
sitagliptin O
100 O
or O
200mg O
once O
daily O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
was O
associated O
with O
significant O
improvements O
relative O
to O
placebo O
in O
overall O
glycaemic O
control O
and O
indices O
for O
insulin O
response O
and O
beta-cell O
function O
. O
Improvements O
from O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O

sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
placebo O
in O
overall O
glycaemic O
control O
and O
indices O
for O
insulin O
response O
and O
beta-cell O
function O
. O
Improvements O
from O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O

Sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin B
hormones I
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

Sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like B
peptide-1 I
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

Sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

metformin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Improvements O
from O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O
incidence O
of O
hypoglycaemia O
with O
sitagliptin O
was O
similar O
to O
that O
with O
placebo O
and O
, O
in O

pioglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
baseline O
in O
mean O
glycosylated O
haemoglobin O
(HbA(1c)) O
were O
significantly O
greater O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
. O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O
incidence O
of O
hypoglycaemia O
with O
sitagliptin O
was O
similar O
to O
that O
with O
placebo O
and O
, O
in O
combination O
with O

metformin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
sitagliptin O
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes O
. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O
glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment O
, O
sitagliptin O
improved O
HbA(1c) B
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin O
or O
pioglitazone O
and O
was O
noninferior O
to O
glipizide O
when O
added O
to O
metformin O
Sitagliptin O
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo O
. O
The O
incidence O
of O
hypoglycaemia O
with O
sitagliptin O
was O
similar O
to O
that O
with O
placebo O
and O
, O
in O
combination O
with O
metformin O
, O
lower O
than O
that O
with O
glipizide O
. O
Sitagliptin O
had O
a O

Sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 B
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

Sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl B
peptidase-4 I
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 O
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

Sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sitagliptin O
. O
Sitagliptin O
an O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 B
inactivation O
of O
the O
incretin O
hormones O
glucagon-like O
peptide-1 O
and O
glucose-dependent O
insulinotropic O
polypeptide O
. O
This O
increases O
active O
incretin O
and O
insulin O
levels O
, O
and O
decreases O
glucagon O
levels O
and O
post-glucose-load O
glucose O
excursion O
. O
In O
large O
, O
well O
designed O
phase O
III O
trials O
in O
patients O
with O
type O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta B
catenin I
and O
mutant O
p53 O
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

parathion O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line O
, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation O
, O
anchorage O
independency O
and O
invasive O
capabilities O
. O
There O
was O
also O
an O
increase O
in O
c-kit O
, O
Trio O
, O
Rho-A O
, O
Rac-3 O
, O
EGFR O
, O
Notch-4 O
, O
Dvl-2 O
, O
Ezrin O
, O
beta O
catenin O
and O
mutant O
p53 B
protein O
expression O
in O
the O
parathion O
treated O
cells O
. O
However O
, O
atropine O
significantly O
inhibited O
this O
increase O
. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes O
, O
13 O
of O
them O
were O
altered O
by O
parathion O
treatment O
. O
Among O
the O
genes O
affected O
were O
the O
cyclins O
, O
such O
as O
cyclin O
D3 O
, O
the O
cyclin-dependent O
kinases O
(CDKs) O
such O
as O
CDK41 O
and O
the O
minichromosome O
maintenance O
deficient O
(MCM) O

Parathion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Gene O
expression O
signature O
of O
parathion-transformed O
human O
breast O
epithelial O
cells.Environmental O
substances O
seem O
to O
be O
involved O
in O
the O
etiology O
of O
breast O
cancers O
. O
Many O
studies O
have O
found O
an O
association O
between O
human O
cancer O
and O
exposure O
to O
agricultural O
pesticides O
such O
as O
the O
organophosphorous O
pesticides O
. O
Parathion O
is O
a O
cholinesterase B
inhibitor O
that O
induces O
the O
hydrolysis O
of O
body O
choline O
esters O
, O
including O
acetylcholine O
at O
cholinergic O
synapses O
. O
The O
primary O
target O
of O
action O
in O
insects O
is O
the O
nervous O
system O
whereby O
pesticides O
inhibit O
the O
release O
of O
the O
enzyme O
acetylcholinesterase O
at O
the O
synaptic O
junction O
. O
Atropine O
is O
a O
parasympatholytic O
alkaloid O
used O
as O
an O

celecoxib O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
drug O
(NSAID) O
amtolmetin O
guacyl O
, O
a O
pro-drug O
of O
the O
NSAID O
tolmetin O
, O
on O
lipid O
peroxidation O
, O
glutathione O
levels O
and O
activity O
of O
antioxidant O
enzymes O
(superoxide O
dismutase O
, O
catalase O
, O
glutathione O
peroxidase O
and O
glutathione O
reductase) O
in O
rat O
gastric O
mucosa O
, O
colon O
mucosa O
and O
liver O
, O
were O
compared O
with O
the O
effects O
of O
non-selective O
(indomethacin O
, O
diclofenac) O
and O
COX-2 B
selective O
( O
celecoxib O
NSAIDs O
. O
2 O
. O
Indomethacin O
treatment O
led O
to O
an O
increase O
in O
lipid O
peroxidation O
, O
glutathione O
peroxidase O
and O
glucose-6-phosphate O
dehydrogenase O
activities O
and O
to O
a O
decrease O
in O
catalase O
activity O
and O
glutathione O
levels O
in O
gastric O
mucosa O
. O
In O
contrast O
, O
amtolmetin O
guacyl O
treatment O
was O
without O
effects O
in O
gastric O
and O
colon O
mucosa O
, O
or O
liver O
from O
control O
animals O
. O
Like O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
amtolmetin O
guacyl O
, O
a O
pro-drug O
of O
the O
NSAID O
tolmetin O
, O
on O
lipid O
peroxidation O
, O
glutathione O
levels O
and O
activity O
of O
antioxidant O
enzymes O
(superoxide O
dismutase O
, O
catalase O
, O
glutathione B
peroxidase I
and O
glutathione O
reductase) O
in O
rat O
gastric O
mucosa O
, O
colon O
mucosa O
and O
liver O
, O
were O
compared O
with O
the O
effects O
of O
non-selective O
(indomethacin O
, O
diclofenac) O
and O
COX-2 O
selective O
(celecoxib) O
NSAIDs O
. O
2 O
. O
Indomethacin O
treatment O
led O
to O
an O
increase O
in O
lipid O
peroxidation O
, O
glutathione O
peroxidase O
and O
glucose-6-phosphate O
dehydrogenase O
activities O
and O
to O
a O
decrease O
in O
catalase O
activity O
and O
glutathione O
levels O
in O
gastric O
mucosa O
. O
In O
contrast O
, O
amtolmetin O
guacyl O
treatment O
was O
without O
effects O
in O
gastric O
and O
colon O
mucosa O
, O
or O
liver O
from O
control O
animals O
. O
Like O
amtolmetin O
guacyl O
, O
celecoxib O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
amtolmetin O
guacyl O
, O
a O
pro-drug O
of O
the O
NSAID O
tolmetin O
, O
on O
lipid O
peroxidation O
, O
glutathione O
levels O
and O
activity O
of O
antioxidant O
enzymes O
(superoxide O
dismutase O
, O
catalase O
, O
glutathione O
peroxidase O
and O
glutathione O
reductase) O
in O
rat O
gastric O
mucosa O
, O
colon O
mucosa O
and O
liver O
, O
were O
compared O
with O
the O
effects O
of O
non-selective O
(indomethacin O
, O
diclofenac) O
and O
COX-2 O
selective O
(celecoxib) O
NSAIDs O
. O
2 O
. O
Indomethacin O
treatment O
led O
to O
an O
increase O
in O
lipid O
peroxidation O
, O
glutathione O
peroxidase O
and O
glucose-6-phosphate B
dehydrogenase I
activities O
and O
to O
a O
decrease O
in O
catalase O
activity O
and O
glutathione O
levels O
in O
gastric O
mucosa O
. O
In O
contrast O
, O
amtolmetin O
guacyl O
treatment O
was O
without O
effects O
in O
gastric O
and O
colon O
mucosa O
, O
or O
liver O
from O
control O
animals O
. O
Like O
amtolmetin O
guacyl O
, O
celecoxib O

Indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
amtolmetin O
guacyl O
, O
a O
pro-drug O
of O
the O
NSAID O
tolmetin O
, O
on O
lipid O
peroxidation O
, O
glutathione O
levels O
and O
activity O
of O
antioxidant O
enzymes O
(superoxide O
dismutase O
, O
catalase O
, O
glutathione O
peroxidase O
and O
glutathione O
reductase) O
in O
rat O
gastric O
mucosa O
, O
colon O
mucosa O
and O
liver O
, O
were O
compared O
with O
the O
effects O
of O
non-selective O
(indomethacin O
, O
diclofenac) O
and O
COX-2 O
selective O
(celecoxib) O
NSAIDs O
. O
2 O
. O
Indomethacin O
treatment O
led O
to O
an O
increase O
in O
lipid O
peroxidation O
, O
glutathione O
peroxidase O
and O
glucose-6-phosphate O
dehydrogenase O
activities O
and O
to O
a O
decrease O
in O
catalase B
activity O
and O
glutathione O
levels O
in O
gastric O
mucosa O
. O
In O
contrast O
, O
amtolmetin O
guacyl O
treatment O
was O
without O
effects O
in O
gastric O
and O
colon O
mucosa O
, O
or O
liver O
from O
control O
animals O
. O
Like O
amtolmetin O
guacyl O
, O
celecoxib O

Cisapride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
initiation O
of O
cisapride O
treatment O
, O
increases O
in O
the O
dosage O
and O
the O
receipt O
of O
interacting O
medications O
. O
The O
relationships O
between O
the O
adverse O
events O
and O
the O
latter O
two O
factors O
exhibited O
biological O
gradients O
. O
Experimental O
evidence O
could O
be O
found O
from O
biological O
models O
, O
as O
well O
as O
reports O
of O
positive O
dechallenge O
and/or O
rechallenge O
found O
in O
individual O
patients O
. O
Cisapride O
was O
found O
to O
bind O
the O
human O
ether-a-go-go-related O
gene O
(HERG) O
potassium O
channel O
, O
which O
provides O
a O
plausible O
mechanism O
for O
QTc O
interval O
prolongation/arrhythmia O
. O
Other O
QTc O
interval-prolonging/arrhythmic O
drugs O
that O
also O
bind O
to O
HERG O
provided O
an O
analogy O
for O
cisapride O
causing O
QTc O
interval O
prolongation/arrhythmia O
via O
this O
mechanism O
. O
The O
evidence O
provided O
by O
clinical O
studies O
was O
inconsistent O
, O

cisapride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
biological O
models O
, O
as O
well O
as O
reports O
of O
positive O
dechallenge O
and/or O
rechallenge O
found O
in O
individual O
patients O
. O
Cisapride O
was O
found O
to O
bind O
the O
human O
ether-a-go-go-related O
gene O
(HERG) O
potassium O
channel O
, O
which O
provides O
a O
plausible O
mechanism O
for O
QTc O
interval O
prolongation/arrhythmia O
. O
Other O
QTc O
interval-prolonging/arrhythmic O
drugs O
that O
also O
bind O
to O
HERG B
provided O
an O
analogy O
for O
cisapride O
causing O
QTc O
interval O
prolongation/arrhythmia O
via O
this O
mechanism O
. O
The O
evidence O
provided O
by O
clinical O
studies O
was O
inconsistent O
, O
and O
epidemiological O
studies O
failed O
to O
demonstrate O
an O
association O
. O
Nevertheless O
, O
this O
did O
not O
prevent O
the O
assessment O
of O
causation O
. O
DISCUSSION O
: O
This O
study O
showed O
how O
different O
types O
of O
evidence O
found O
in O
pharmacovigilance O
can O
be O
evaluated O
using O
the O

sulindac O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
14-3-3epsilon B
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
. O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O
of O
14-3-3epsilon O
in O
HT-29 O
significantly O
protected O
cells O
from O
apoptosis O
. O
Our O
findings O
shed O
light O
on O
a O
novel O
mechanism O
by O
which O
NSAIDs O
induce O

indomethacin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
activity O
. O
As O
14-3-3epsilon B
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O
of O
14-3-3epsilon O
in O
HT-29 O
significantly O
protected O
cells O
from O
apoptosis O
. O
Our O
findings O
shed O
light O
on O
a O
novel O
mechanism O
by O
which O
NSAIDs O
induce O
colorectal O
cancer O

sulindac O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
induce O
colorectal O
cancer O
cell O
apoptosis O
by O
suppressing O
14-3-3epsilon.To O
determine O
the O
role O
of O
14-3-3 O
in O
colorectal O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon B
protein I
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O

Sulindac O
sulfide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta B
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
. O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O

Sulindac O
sulfide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta B
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
. O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O

Sulindac O
sulfide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
induce O
colorectal O
cancer O
cell O
apoptosis O
by O
suppressing O
14-3-3epsilon.To O
determine O
the O
role O
of O
14-3-3 O
in O
colorectal O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon B
proteins I
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O

Indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 B
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O

Indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O

SC-236 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
a O
selective O
cyclooxygenase-2 B
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O

SC-236 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
a O
selective O
cyclooxygenase-2 O
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O

N-ethylmaleimide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
cotransporter O
(KCC) O
isoform O
expression O
was O
characterized O
in O
corneal O
epithelial O
cells O
(CEC) O
. O
During O
exposure O
to O
a O
50% O
hypotonic O
challenge O
, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC) O
. O
A O
KCC B
inhibitor-[(dihydroindenyl)oxy] O
alkanoic O
acid O
(DIOA)-blocked O
RVD O
more O
in O
HCEC O
than O
RCEC O
. O
Under O
isotonic O
conditions O
, O
N-ethylmaleimide O
(NEM) O
produced O
KCC O
activation O
and O
transient O
cell O
shrinkage O
. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC O
. O
Immunoblot O
analysis O
of O
HCEC O
, O
RCEC O
, O
primary O
human O
CEC O
(pHCEC) O
, O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O
revealed O
KCC1 O
, O
KCC3 O
, O
and O
KCC4 O
isoform O
expression O
, O
whereas O
KCC2 O
was O
undetectable O
. O
During O

NEM O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
isoform O
expression O
was O
characterized O
in O
corneal O
epithelial O
cells O
(CEC) O
. O
During O
exposure O
to O
a O
50% O
hypotonic O
challenge O
, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC) O
. O
A O
KCC B
inhibitor-[(dihydroindenyl)oxy] O
alkanoic O
acid O
(DIOA)-blocked O
RVD O
more O
in O
HCEC O
than O
RCEC O
. O
Under O
isotonic O
conditions O
, O
N-ethylmaleimide O
( O
NEM O
produced O
KCC O
activation O
and O
transient O
cell O
shrinkage O
. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC O
. O
Immunoblot O
analysis O
of O
HCEC O
, O
RCEC O
, O
primary O
human O
CEC O
(pHCEC) O
, O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O
revealed O
KCC1 O
, O
KCC3 O
, O
and O
KCC4 O
isoform O
expression O
, O
whereas O
KCC2 O
was O
undetectable O
. O
During O
a O

[(dihydroindenyl)oxy] O
alkanoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
epithelial O
cells.The O
dependence O
of O
regulatory O
volume O
decrease O
(RVD) O
activity O
on O
potassium-chloride O
cotransporter O
(KCC) O
isoform O
expression O
was O
characterized O
in O
corneal O
epithelial O
cells O
(CEC) O
. O
During O
exposure O
to O
a O
50% O
hypotonic O
challenge O
, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC) O
. O
A O
KCC B
inhibitor- O
[(dihydroindenyl)oxy] O
alkanoic O
acid O
(DIOA)-blocked O
RVD O
more O
in O
HCEC O
than O
RCEC O
. O
Under O
isotonic O
conditions O
, O
N-ethylmaleimide O
(NEM) O
produced O
KCC O
activation O
and O
transient O
cell O
shrinkage O
. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC O
. O
Immunoblot O
analysis O
of O
HCEC O
, O
RCEC O
, O
primary O
human O
CEC O
(pHCEC) O
, O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O

DIOA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dependence O
of O
regulatory O
volume O
decrease O
(RVD) O
activity O
on O
potassium-chloride O
cotransporter O
(KCC) O
isoform O
expression O
was O
characterized O
in O
corneal O
epithelial O
cells O
(CEC) O
. O
During O
exposure O
to O
a O
50% O
hypotonic O
challenge O
, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC) O
. O
A O
KCC B
inhibitor-[(dihydroindenyl)oxy] O
alkanoic O
acid O
( O
DIOA O
-blocked O
RVD O
more O
in O
HCEC O
than O
RCEC O
. O
Under O
isotonic O
conditions O
, O
N-ethylmaleimide O
(NEM) O
produced O
KCC O
activation O
and O
transient O
cell O
shrinkage O
. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC O
. O
Immunoblot O
analysis O
of O
HCEC O
, O
RCEC O
, O
primary O
human O
CEC O
(pHCEC) O
, O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O
revealed O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase B
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC B
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

Dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatini O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase B
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatini O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC B
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatini O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatini O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-35482 O
) O
: O
a O
potent O
oral O
multi-targeted O
kinase B
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-35482 O
) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC B
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-35482 O
) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-35482 O
) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase B
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
( O
BMS-354825 O
 O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC B
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
( O
BMS-354825 O
 O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
( O
BMS-354825 O
 O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

BMS-354825 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL.PURPOSE O
: O
Dasatinib O
( O
BMS-354825 O
 O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O

lumiracoxib O
acts O
as O
NOT O
for O
what O
entity O
? O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 B
to I
Ala I
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O

lumiracoxib O
acts O
as O
NOT O
for O
what O
entity O
? O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 B
to I
Ala I
or I
Leu I
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O

lumiracoxib O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
with O
wild-type O
human O
COX-2 B
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib O
COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

aniline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 B
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O

2,6-dichloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 B
to I
Ile I
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro O
 O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O

2,6-dichloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human B
COX-2 I
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro O
 O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O

2,6-dimethyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 B
to I
Ile I
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl O
 O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O

2,6-dimethyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human B
COX-2 I
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl O
 O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O

2-chloro-6-methyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 B
to I
Ile I
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl O
substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

2-chloro-6-methyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human B
COX-2 I
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl O
substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 B
to I
Ile I
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human B
COX-2 I
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s B
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 O
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine B
COX-1 I
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O
COX-2 O
. O
The O
extent O
of O
COX-2 O
inhibition O
plateaued O
at O
around O
50% O
and O
suggested O
that O
the O
inhibitor O
may O
be O
reversibly O
bound O
to O
the O
enzyme O
. O
Kinetic O
studies O
with O
lumiracoxib O
demonstrated O
that O
it O
was O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 O
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine O
COX-1 O
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O
COX-2 O
. O
The O
extent O
of O
COX-2 O
inhibition O
plateaued O
at O
around O
50% O
and O
suggested O
that O
the O
inhibitor O
may O
be O
reversibly O
bound O
to O
the O
enzyme O
. O
Kinetic O
studies O
with O
lumiracoxib O
demonstrated O
that O
it O
was O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine O
COX-1 O
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O
COX-2 O
. O
The O
extent O
of O
COX-2 O
inhibition O
plateaued O
at O
around O
50% O
and O
suggested O
that O
the O
inhibitor O
may O
be O
reversibly O
bound O
to O
the O
enzyme O
. O
Kinetic O
studies O
with O
lumiracoxib O
demonstrated O
that O
it O
was O
a O
time-dependent O
and O
slowly O
reversible O
inhibitor O
of O
human B
COX-2 I
that O
exhibited O
at O
least O
two O
binding O
steps O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O

arylacetic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Molecular O
determinants O
for O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 B
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine O
COX-1 O
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O

Lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Molecular O
determinants O
for O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib O
. O
Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 B
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O

methyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
a O
time-dependent O
and O
slowly O
reversible O
inhibitor O
of O
human O
COX-2 B
that O
exhibited O
at O
least O
two O
binding O
steps O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O

phenylacetic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
slowly O
reversible O
inhibitor O
of O
human O
COX-2 B
that O
exhibited O
at O
least O
two O
binding O
steps O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Molecular O
determinants O
for O
the O
selective O
inhibition O
of O
cyclooxygenase-2 B
by O
lumiracoxi O
.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 O
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O

aniline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX B
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O

lumiracoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human B
COX-2 I
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 O
to O
Ile O
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O

Na(+) O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+) O
dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O

l-alanine O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O

Na(+) O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
differences O
in O
ASCT2 B
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+) O
dependent O
amino O
acid O
transporter O
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

amino O
acid O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
in O
ASCT2 B
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+)-dependent O
amino O
acid O
transporter O
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

alanine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O

serine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O

cysteine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O
SHR O
PTE O

l-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
SHR O
PTE O
cells O
and O
kidney O
cortices O
from O
WKY O
and O
SHR O
was O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O

amino O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O

l-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 B
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O

l-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+)-dependent O
amino O
acid O
transporter O
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

l-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 B
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+)-dependent O
amino O
acid O
transporter O
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

l-[(14)C]alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Underexpression O
of O
the O
Na+-dependent O
neutral O
amino O
acid O
transporter O
ASCT2 B
in O
the O
spontaneously O
hypertensive O
rat O
kidney.This O
study O
examined O
the O
inward O
transport O
of O
l-[(14)C]alanine O
an O
ASCT2 O
preferential O
substrate O
, O
in O
monolayers O
of O
immortalized O
renal O
proximal O
tubular O
epithelial O
(PTE) O
cells O
from O
Wistar-Kyoto O
(WKY) O
and O
spontaneously O
hypertensive O
(SHR) O
rats O
. O
The O
expression O
of O
ASCT2 O
in O
WKY O
and O
SHR O
PTE O
cells O
and O
kidney O
cortices O
from O
WKY O
and O
SHR O
was O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O

glucose O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
of O
glucose O
and O
glucagon O
secretion O
after O
intravenous O
arginine O
. O
Islet O
morphology O
was O
examined O
and O
insulin B
secretion O
and O
glucose O
oxidation O
were O
measured O
in O
isolated O
islets O
. O
RESULTS O
: O
Fasting O
plasma O
glucose O
levels O
were O
reduced O
by O
GRA O
(6.0 O
+/- O
0.2 O
vs O
7.4 O
+/- O
0.5 O
mmol/l; O
p O
= O
0.017) O
. O
The O
acute O
insulin O
response O
to O
intravenous O
glucose O
was O
augmented O
(1,300 O
+/- O
110 O
vs O
790 O
+/- O
64 O
pmol/l; O
p O
< O
0.001) O
. O
The O
early O
insulin O
response O
to O
oral O
glucose O
was O
reduced O
in O
mice O
on O
HFD O
+ O
GRA O
(1,890 O
+/- O
160 O
vs O
3,040 O
+/- O
420 O
pmol/l; O
p O
= O
0.012) O
, O
but O
glucose O
excursions O
were O
improved O
. O
Intravenous O
arginine O
significantly O
increased O
the O

glucose O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
isolated O
islets O
. O
RESULTS O
: O
Fasting O
plasma O
glucose O
levels O
were O
reduced O
by O
GRA O
(6.0 O
+/- O
0.2 O
vs O
7.4 O
+/- O
0.5 O
mmol/l; O
p O
= O
0.017) O
. O
The O
acute O
insulin B
response O
to O
intravenous O
glucose O
was O
augmented O
(1,300 O
+/- O
110 O
vs O
790 O
+/- O
64 O
pmol/l; O
p O
< O
0.001) O
. O
The O
early O
insulin O
response O
to O
oral O
glucose O
was O
reduced O
in O
mice O
on O
HFD O
+ O
GRA O
(1,890 O
+/- O
160 O
vs O
3,040 O
+/- O
420 O
pmol/l; O
p O
= O
0.012) O
, O
but O
glucose O
excursions O
were O
improved O
. O
Intravenous O
arginine O
significantly O
increased O
the O
acute O
glucagon O
response O
(129 O
+/- O
12 O
vs O
36 O
+/- O
6 O
ng/l O
in O
controls; O
p O
< O
0.01) O
, O
notably O
without O
affecting O
plasma O

arginine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
response O
to O
intravenous O
glucose O
was O
augmented O
(1,300 O
+/- O
110 O
vs O
790 O
+/- O
64 O
pmol/l; O
p O
< O
0.001) O
. O
The O
early O
insulin O
response O
to O
oral O
glucose O
was O
reduced O
in O
mice O
on O
HFD O
+ O
GRA O
(1,890 O
+/- O
160 O
vs O
3,040 O
+/- O
420 O
pmol/l; O
p O
= O
0.012) O
, O
but O
glucose O
excursions O
were O
improved O
. O
Intravenous O
arginine O
significantly O
increased O
the O
acute O
glucagon B
response O
(129 O
+/- O
12 O
vs O
36 O
+/- O
6 O
ng/l O
in O
controls; O
p O
< O
0.01) O
, O
notably O
without O
affecting O
plasma O
glucose O
. O
GRA O
caused O
a O
modest O
increase O
in O
alpha O
cell O
mass O
, O
while O
beta O
cell O
mass O
was O
similar O
to O
that O
in O
mice O
on O
HFD O
+ O
vehicle O
. O
Isolated O
islets O

glucose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
acute O
glucagon O
response O
(129 O
+/- O
12 O
vs O
36 O
+/- O
6 O
ng/l O
in O
controls; O
p O
< O
0.01) O
, O
notably O
without O
affecting O
plasma O
glucose O
. O
GRA O
caused O
a O
modest O
increase O
in O
alpha O
cell O
mass O
, O
while O
beta O
cell O
mass O
was O
similar O
to O
that O
in O
mice O
on O
HFD O
+ O
vehicle O
. O
Isolated O
islets O
displayed O
improved O
glucose O
stimulated O
insulin B
secretion O
after O
GRA O
treatment O
(0.061 O
+/- O
0.007 O
vs O
0.030 O
+/- O
0.004 O
pmol O
islet(-1) O
h(-1) O
at O
16.7 O
mmol/l O
glucose; O
p O
< O
0.001) O
, O
without O
affecting O
islet O
glucose O
oxidation O
. O
CONCLUSIONS/INTERPRETATION O
: O
Chronic O
glucagon O
receptor O
antagonism O
in O
HFD-fed O
mice O
improves O
islet O
sensitivity O
to O
glucose O
and O
increases O
insulin O
secretion O
, O
suggesting O
improvement O
of O
key O

sodium O
hydrosulphide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP B
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

sodium O
hydrosulphide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A B
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

sodium O
hydrosulphide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R B
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

NaHS O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP B
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
( O
NaHS O
 O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

NaHS O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A B
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
( O
NaHS O
 O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

NaHS O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R B
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
( O
NaHS O
 O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

Caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE B
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance B
P I
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP B
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP B
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A B
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 B
receptor I
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

caerulein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein O
treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O

Caerulein O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS B
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O

H(2)S O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP B
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O

H(2)S O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A B
expression O
and O
NK1-R O
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O

H(2)S O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O
expression O
and O
NK1-R B
expression O
in O
the O
acini O
. O
To O
determine O
whether O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O

DL-propargylglycine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
synthesizing O
enzymes O
, O
CSE B
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O

PAG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
CSE B
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
( O
PAG O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP B
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
H(2)S O
itself O
provoked O
inflammation O
in O
acinar O
cells O
, O
the O
cells O
were O
treated O
with O
H(2)S O
donor O
drug O
, O
sodium O
hydrosulphide O
(NaHS) O
, O
(10 O
, O
50 O
and O
100 O
muM) O
, O
that O
resulted O
in O
a O
significant O
increase O
in O
SP O
concentration O
and O
expression O
of O
PPT-A O
and O
NK1-R O
in O
acinar O
cells O
. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S O
may O
be O
mediated O
by O
SP-NK-1R O
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells O
. O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
( O
H(2)S O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE B
and O
CBS O
, O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
( O
H(2)S O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase B
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
( O
H(2)S O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
( O
H(2)S O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase B
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE B
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O
acini O
. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein O
(10(-7) O
M O
for O
30 O
and O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE O
mRNA O
expression O
while O
CBS B
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O

Hydrogen O
sulphide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells O
. O
Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE B
and O

Hydrogen O
sulphide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells O
. O
Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase B
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O

Hydrogen O
sulphide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells O
. O
Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O

Hydrogen O
sulphide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells O
. O
Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase B
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O

H(2)S O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
60 O
min) O
. O
Caerulein O
increased O
the O
levels O
of O
H(2)S O
and O
CSE B
mRNA O
expression O
while O
CBS O
mRNA O
expression O
was O
decreased O
. O
In O
addition O
, O
cells O
pre-treated O
with O
DL-propargylglycine O
(PAG O
, O
3 O
mM) O
, O
a O
CSE O
inhibitor O
, O
reduced O
the O
formation O
of O
H(2)S O
in O
caerulein O
treated O
cells O
, O
suggesting O
that O
CSE O
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S O
formation O
in O
mouse O
acinar O
cells O
. O
Furthermore O
, O
substance O
P O
(SP) O
concentration O
in O
the O
acini O
and O
expression O
of O
SP O
gene O
(preprotachykinin-A O
, O
PPT-A) O
and O
neurokinin-1 O
receptor O
(NK-1R) O
, O
the O
primary O
receptor O
for O
SP O
, O
are O
increased O
in O
secretagogue O
caerulein-treated O
acinar O
cells O
. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S O
by O
PAG O
significantly O
suppressed O
SP O
concentration O
, O
PPT-A O

L-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE B
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O

L-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase B
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O

L-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase O
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O

L-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Hydrogen O
sulfide O
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis O
: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells.Hydrogen O
sulphide O
(H(2)S) O
is O
synthesized O
from O
L-cysteine O
via O
the O
action O
of O
cystathionine-gamma-lyase B
(CSE) O
and O
cystathionine-beta-synthase O
(CBS) O
. O
We O
have O
earlier O
shown O
that O
H(2)S O
acts O
as O
a O
mediator O
of O
inflammation O
. O
However O
the O
mechanism O
remains O
unclear O
. O
In O
this O
study O
, O
we O
investigated O
the O
presence O
of O
H(2)S O
and O
the O
expression O
of O
H(2)S O
synthesizing O
enzymes O
, O
CSE O
and O
CBS O
, O
in O
isolated O
mouse O
pancreatic O

1400W O
dihydrochloride O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin B
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
dihydrochloride O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
dihydrochloride O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
( O
1400W O
 O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin B
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
( O
1400W O
 O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
( O
1400W O
 O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin B
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin B
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O
the O
increased O

1400W O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O
the O
increased O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
( O
DXM O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
( O
DXM O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
( O
DXM O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O

1400W O
dihydrochloride O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

1400W O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 O
, O
VEGF O
, O
and O
iNOS B
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
( O
1400W O
 O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O

sotalol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
newborns O
. O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 O
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

sotalol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
newborns O
. O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 B
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

sotalol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
newborns O
. O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 O
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

ibutilide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 O
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

ibutilide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 B
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

ibutilide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death O
. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated O
, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O
as O
, O
e.g. O
, O
sotalol O
or O
ibutilide O
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding O
gene O
KCNH2 O
(HERG) O
. O
Quinidine O
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients O
. O

PLP O
acts O
as O
PART-OF O
for O
what O
entity O
? O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP O
interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O
the O
results O
regarding O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
represent O
a O
distinct O
eukaryotic O
group O
: O
gene O
cloning O
and O
recombinant O
protein O
characterization.Several O
d-amino O
acids O
have O
been O
identified O
in O
plants O
. O
However O
, O
the O
biosynthetic O
pathway O
to O
them O
is O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine B
racemase I
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine O
racemases O
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
gene O
cloning O
and O
recombinant O
protein O
characterization.Several O
d-amino O
acids O
have O
been O
identified O
in O
plants O
. O
However O
, O
the O
biosynthetic O
pathway O
to O
them O
is O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O

pyridoxal O
5-phosphate O
acts O
as O
PART-OF O
for O
what O
entity O
? O
biosynthetic O
pathway O
to O
them O
is O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
. O

PLP O
acts O
as O
PART-OF O
for O
what O
entity O
? O
them O
is O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
( O
PLP O
-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
. O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
them O
is O
unclear O
. O
In O
this O
study O
, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine O
racemase O
from O
barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B
racemases I
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine O
racemase O
activity O
is O
increased O
by O
ATP O
. O
In O
addition O

ATP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine B
racemase I
activity O
is O
increased O
by O
ATP O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine O
racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O
not O
form O
a O
precipitate O
with O
barley O
and O
rice O
serine O
racemases O
. O
This O
suggests O
that O
plant O
serine O
racemases O
represent O
a O
distinct O
group O
in O

PLP O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
amino O
acid O
residues O
. O
The O
deduced O
amino O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine O
racemases O
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine B
racemase I
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine O
racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O

Ca(2+) O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
acid O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine O
racemases O
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
Mg(2+) O
, O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine B
racemase I
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine O
racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O
not O
form O
a O
precipitate O
with O
barley O

Mg(2+) O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine O
racemases O
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
or O
Mn(2+) O
, O
but O
not O
ATP O
, O
whereas O
mammalian O
serine B
racemase I
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine O
racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O
not O
form O
a O
precipitate O
with O
barley O
and O

Mn(2+) O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
significant O
identity O
to O
plant O
and O
mammalian O
serine O
racemases O
and O
contained O
conserved O
pyridoxal O
5-phosphate O
(PLP)-binding O
lysine O
and O
PLP-interacting O
amino O
acid O
residues O
. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine O
but O
also O
dehydration O
of O
serine O
to O
pyruvate O
. O
The O
enzyme O
requires O
PLP O
and O
divalent O
cations O
such O
as O
Ca(2+) O
, O
Mg(2+) O
, O
or O
Mn(2+) O
but O
not O
ATP O
, O
whereas O
mammalian O
serine B
racemase I
activity O
is O
increased O
by O
ATP O
. O
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP O
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine O
racemases O
, O
the O
antiserum O
against O
Arabidopsis O
serine O
racemase O
did O
not O
form O
a O
precipitate O
with O
barley O
and O
rice O
serine O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
warfarin O
dose O
. O
METHODS O
: O
Sixty-five O
patients O
with O
stable O
anticoagulation O
were O
genotyped O
for O
CYP2C9 B
and O
VKORC1 O
with O
Tag-It O
allele-specific O
primer O
extension O
technology O
. O
Plasma O
S-warfarin O
concentrations O
and O
warfarin O
maintenance O
dose O
were O
compared O
among O
patients O
on O
the O
basis O
of O
the O
VKORC1 O
-1639G>A O
genotype O
. O
RESULTS O
: O
Eighty O
percent O
of O
CYP2C9*1/*1 O
patients O
stabilized O
on O
<4.0 O
mg/day O
warfarin O
had O
at O
least O
1 O
VKORC1 O
-1639A O
allele O
. O
Mean O
warfarin O
doses O
(SD) O
were O
6.7 O
(3.3) O
, O
4.3 O
(2.2) O
, O
and O
2.7 O
(1.2) O
mg/day O
for O
patients O
with O
the O
VKORC1 O
-1639GG O
, O
GA O
, O
and O
AA O
genotypes O
, O
respectively O
. O
Steady-state O
plasma O
concentrations O
of O
S-warfarin O
were O
lowest O
in O
patients O
with O
the O
VKORC1 O
-1639AA O
genotype O
and O
demonstrated O
a O
positive O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
warfarin O
dose O
. O
METHODS O
: O
Sixty-five O
patients O
with O
stable O
anticoagulation O
were O
genotyped O
for O
CYP2C9 O
and O
VKORC1 B
with O
Tag-It O
allele-specific O
primer O
extension O
technology O
. O
Plasma O
S-warfarin O
concentrations O
and O
warfarin O
maintenance O
dose O
were O
compared O
among O
patients O
on O
the O
basis O
of O
the O
VKORC1 O
-1639G>A O
genotype O
. O
RESULTS O
: O
Eighty O
percent O
of O
CYP2C9*1/*1 O
patients O
stabilized O
on O
<4.0 O
mg/day O
warfarin O
had O
at O
least O
1 O
VKORC1 O
-1639A O
allele O
. O
Mean O
warfarin O
doses O
(SD) O
were O
6.7 O
(3.3) O
, O
4.3 O
(2.2) O
, O
and O
2.7 O
(1.2) O
mg/day O
for O
patients O
with O
the O
VKORC1 O
-1639GG O
, O
GA O
, O
and O
AA O
genotypes O
, O
respectively O
. O
Steady-state O
plasma O
concentrations O
of O
S-warfarin O
were O
lowest O
in O
patients O
with O
the O
VKORC1 O
-1639AA O
genotype O
and O
demonstrated O
a O
positive O

warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Estimation O
of O
warfarin O
maintenance O
dose O
based O
on O
VKORC1 B
(-1639 O
G>A) O
and O
CYP2C9 O
genotypes.BACKGROUND O
: O
CYP2C9 O
polymorphisms O
are O
associated O
with O
decreased O
S-warfarin O
clearance O
and O
lower O
maintenance O
dosage O
. O
Decreased O
expression O
of O
VKORC1 O
resulting O
from O
the O
-1639G>A O
substitution O
has O
also O
been O
implicated O
in O
lower O
warfarin O
dose O
requirements O
. O
We O
investigated O
the O
additional O
contribution O
of O
this O
polymorphism O
to O
the O
variance O
in O
warfarin O
dose O
. O
METHODS O
: O
Sixty-five O
patients O
with O
stable O
anticoagulation O
were O
genotyped O
for O
CYP2C9 O
and O
VKORC1 O
with O
Tag-It O
allele-specific O
primer O
extension O
technology O
. O
Plasma O
S-warfarin O
concentrations O
and O
warfarin O
maintenance O
dose O
were O
compared O
among O
patients O
on O
the O
basis O
of O

S-warfarin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Estimation O
of O
warfarin O
maintenance O
dose O
based O
on O
VKORC1 O
(-1639 O
G>A) O
and O
CYP2C9 B
genotypes.BACKGROUND O
: O
CYP2C9 O
polymorphisms O
are O
associated O
with O
decreased O
S-warfarin O
clearance O
and O
lower O
maintenance O
dosage O
. O
Decreased O
expression O
of O
VKORC1 O
resulting O
from O
the O
-1639G>A O
substitution O
has O
also O
been O
implicated O
in O
lower O
warfarin O
dose O
requirements O
. O
We O
investigated O
the O
additional O
contribution O
of O
this O
polymorphism O
to O
the O
variance O
in O
warfarin O
dose O
. O
METHODS O
: O
Sixty-five O
patients O
with O
stable O
anticoagulation O
were O
genotyped O
for O
CYP2C9 O
and O
VKORC1 O

AGGACA O
acts O
as O
PART-OF O
for O
what O
entity O
? O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT B
basal O
expression O
and O
TZD O
responsiveness O
because O
they O
are O
, O
respectively O
, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O

hexanucleotide O
acts O
as O
PART-OF O
for O
what O
entity O
? O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT B
basal O
expression O
and O
TZD O
responsiveness O
because O
they O
are O
, O
respectively O
, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O

TZD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha B
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

TZD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma B
in O
adipocytes O
. O

TZD O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
rosiglitazone O
. O
Conversely O
, O
the O
ratio O
of O
fatty O
acid O
to O
glycerol O
released O
into O
the O
medium O
decreased O
. O
Regulation O
of O
cAspAT O
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma B
is O
indirectly O
necessary O
for O
both O
cAspAT O
basal O
expression O
and O
TZD O
responsiveness O
because O
they O
are O
, O
respectively O
, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O

TZD O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT B
basal O
expression O
and O
TZD O
responsiveness O
because O
they O
are O
, O
respectively O
, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD O
responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O

thiazolidinedione O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Cytosolic O
aspartate O
aminotransferase O
, O
a O
new O
partner O
in O
adipocyte O
glyceroneogenesis O
and O
an O
atypical O
target O
of O
thiazolidinedion O
.We O
show O
that O
cytosolic O
aspartate O
aminotransferase O
(cAspAT) O
is O
involved O
in O
adipocyte O
glyceroneogenesis O
, O
a O
regulated O
pathway O
that O
controls O
fatty O
acid O
homeostasis O
by O
promoting O
glycerol O
3-phosphate O
formation O
for O
fatty O
acid O
re-esterification O
during O
fasting O
. O
cAspAT O
activity O
, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate O
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A O
adipocytes O
was O

thiazolidinedione O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
cytosolic O
aspartate O
aminotransferase O
(cAspAT) O
is O
involved O
in O
adipocyte O
glyceroneogenesis O
, O
a O
regulated O
pathway O
that O
controls O
fatty O
acid O
homeostasis O
by O
promoting O
glycerol O
3-phosphate O
formation O
for O
fatty O
acid O
re-esterification O
during O
fasting O
. O
cAspAT B
activity O
, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate O
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A O
adipocytes O
was O
stimulated O
by O
the O
thiazolidinedione O
(TZD) O
rosiglitazone O
. O
Conversely O
, O
the O
ratio O
of O
fatty O
acid O
to O
glycerol O
released O
into O
the O
medium O
decreased O
. O
Regulation O
of O
cAspAT O
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT O
basal O
expression O

TZD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
aminotransferase O
(cAspAT) O
is O
involved O
in O
adipocyte O
glyceroneogenesis O
, O
a O
regulated O
pathway O
that O
controls O
fatty O
acid O
homeostasis O
by O
promoting O
glycerol O
3-phosphate O
formation O
for O
fatty O
acid O
re-esterification O
during O
fasting O
. O
cAspAT B
activity O
, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate O
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A O
adipocytes O
was O
stimulated O
by O
the O
thiazolidinedione O
( O
TZD O
rosiglitazone O
. O
Conversely O
, O
the O
ratio O
of O
fatty O
acid O
to O
glycerol O
released O
into O
the O
medium O
decreased O
. O
Regulation O
of O
cAspAT O
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT O
basal O
expression O
and O

rosiglitazone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
aminotransferase O
(cAspAT) O
is O
involved O
in O
adipocyte O
glyceroneogenesis O
, O
a O
regulated O
pathway O
that O
controls O
fatty O
acid O
homeostasis O
by O
promoting O
glycerol O
3-phosphate O
formation O
for O
fatty O
acid O
re-esterification O
during O
fasting O
. O
cAspAT B
activity O
, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate O
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A O
adipocytes O
was O
stimulated O
by O
the O
thiazolidinedione O
(TZD) O
rosiglitazone O
Conversely O
, O
the O
ratio O
of O
fatty O
acid O
to O
glycerol O
released O
into O
the O
medium O
decreased O
. O
Regulation O
of O
cAspAT O
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma)/retinoid O
X O
receptor-alpha O
direct O
binding O
. O
Nevertheless O
, O
PPARgamma O
is O
indirectly O
necessary O
for O
both O
cAspAT O
basal O
expression O
and O
TZD O

rosiglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
negative O
PPARgamma O
. O
The O
cAspAT O
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha B
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

rosiglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
negative O
PPARgamma O
. O
The O
cAspAT B
TZD-responsive O
site O
was O
restricted O
to O
a O
single O
AGGACA O
hexanucleotide O
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

TZD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha B
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT O
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

TZD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha O
binding O
. O
RORalpha O
ectopic O
expression O
activated O
the O
cAspAT B
gene O
transcription O
in O
absence O
of O
rosiglitazone O
, O
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT O
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

TZD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone O
treatment O
of O
adipocytes O
. O
Finally O
, O
the O
amounts O
of O
RORalpha O
and O
cAspAT B
mRNAs O
were O
similarly O
increased O
by O
TZD O
treatment O
of O
human O
adipose O
tissue O
explants O
, O
confirming O
coordinated O
regulation O
. O
Our O
data O
identify O
cAspAT O
as O
a O
new O
member O
of O
glyceroneogenesis O
, O
transcriptionally O
regulated O
by O
TZD O
via O
the O
control O
of O
RORalpha O
expression O
by O
PPARgamma O
in O
adipocytes O
. O

4-HNE O
acts O
as O
NOT O
for O
what O
entity O
? O
cells O
in O
the O
absence O
of O
4-HNE O
, O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 B
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 O
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O

4-HNE O
acts O
as O
NOT O
for O
what O
entity O
? O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 B
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 O
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O
of O
4-HNE O
associated O
with O
severe O
oxidative O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O
4-HNE O
exposures O
associated O
with O
increased O
GSH O
utilization O
. O
As O
expected O
, O
the O
hGSTA4 O
cells O
showed O
resistance O
to O
4-HNE O
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 O
at O
levels O
conferring O
high O
GST- O
4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O
of O
4-HNE O
associated O
with O
severe O
oxidative O
stress O
indicates O
a O
role O
of O
other O
aldehyde O
metabolizing O
enzymes O
, O
and/or O
GSH-electrophile O
transporter O
proteins O
, O
in O
providing O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
( O
4-HNE O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione B
S-transferase I
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
( O
4-HNE O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
lipid O
peroxidation O
at O
all O
4-HNE O
doses O
. O
In O
summary O
, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 B
at O
levels O
conferring O
high O
GST-4-HNE O
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE O
oxidative O
injury O
. O
However O
, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 O
cells O
challenged O
with O
levels O
of O
4-HNE O
associated O
with O
severe O
oxidative O
stress O
indicates O
a O
role O
of O
other O
aldehyde O
metabolizing O
enzymes O
, O
and/or O
GSH-electrophile O
transporter O
proteins O
, O
in O
providing O
full O
cellular O
protection O
against O
4-HNE O
toxicity O
. O

4-Hydroxynonenal O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury O
. O
4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione B
S-transferase I
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O

4-Hydroxynonenal O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury O
. O
4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human B
GSTA4-4 I
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O
the O
current O
study O
, O
we O
determined O
the O
effect O
of O
over-expression O
of O
hGSTA4 O
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE O
injury O
. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 O
vector O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O
the O
current O
study O
, O
we O
determined O
the O
effect O
of O
over-expression O
of O
hGSTA4 O
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE O
injury O
. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 O
vector O

alpha,beta-unsaturated O
aldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione B
S-transferase I
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O

alpha,beta-unsaturated O
aldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 O
provides O
protection O
against O
4-hydroxynonenal-mediated O
oxidative O
injury.4-Hydroxynonenal O
(4-HNE) O
is O
a O
mutagenic O
alpha,beta-unsaturated O
aldehyde O
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione O
S-transferase O
(GST) O
isoforms O
. O
The O
alpha O
class O
human O
GSTA4-4 O
enzyme O
(hGSTA4-4) O
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE O
conjugation O
. O
However O
, O
hGST4-4 O
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
human O
cells O
and O
there O
are O
other O
aldehyde O
metabolizing O
enzymes O
that O
detoxify O
4-HNE O
. O
In O
the O
current O
study O
, O
we O
determined O
the O
effect O
of O
over-expression O
of O
hGSTA4 O
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE O
injury O
. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 O
vector O
construct O
exhibited O
high O
steady-state O
hGSTA4 O
mRNA O
, O
high O
GST- O
4-HNE O
catalytic O
activities O
, O
but O
lower O
basal O
glutathione O
(GSH) O
concentrations O
relative O
to O
insert-free O
vector O
(control) O
cells O
. O
Exposure O
to O
4-HNE O
elicited O
an O
increase O
in O
GSH O
concentrations O
in O
the O
control O
and O
hGSTA4 O
cells O
, O
although O
the O
dose-response O
of O
GSH O
induction O
differed O
among O
the O
two O
cell O
types O
. O
Specifically O
, O
hGSTA4 O
cells O
had O
significantly O
higher O
GSH O
concentrations O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
glutathione O
(GSH) O
concentrations O
relative O
to O
insert-free O
vector O
(control) O
cells O
. O
Exposure O
to O
4-HNE O
elicited O
an O
increase O
in O
GSH O
concentrations O
in O
the O
control O
and O
hGSTA4 B
cells O
, O
although O
the O
dose-response O
of O
GSH O
induction O
differed O
among O
the O
two O
cell O
types O
. O
Specifically O
, O
hGSTA4 O
cells O
had O
significantly O
higher O
GSH O
concentrations O
when O
exposed O
to O
5-15 O
microM O
4-HNE O
but O
not O
at O
20 O
microM O
4-HNE O
, O
suggesting O
extensive O
GSH O
utilization O
at O
high O
concentrations O
of O
4-HNE O
. O
The O
hGSTA4 O
cells O
exhibited O
a O
significant O
growth O
advantage O
relative O
to O
control O
cells O
in O
the O
absence O
of O
4-HNE O
, O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 O
cells O
did O

4-HNE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
vector O
(control) O
cells O
. O
Exposure O
to O
4-HNE O
elicited O
an O
increase O
in O
GSH O
concentrations O
in O
the O
control O
and O
hGSTA4 B
cells O
, O
although O
the O
dose-response O
of O
GSH O
induction O
differed O
among O
the O
two O
cell O
types O
. O
Specifically O
, O
hGSTA4 O
cells O
had O
significantly O
higher O
GSH O
concentrations O
when O
exposed O
to O
5-15 O
microM O
4-HNE O
, O
but O
not O
at O
20 O
microM O
4-HNE O
suggesting O
extensive O
GSH O
utilization O
at O
high O
concentrations O
of O
4-HNE O
. O
The O
hGSTA4 O
cells O
exhibited O
a O
significant O
growth O
advantage O
relative O
to O
control O
cells O
in O
the O
absence O
of O
4-HNE O
, O
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE O
. O
However O
, O
the O
hGSTA4 O
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O

saccharin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
caloric O
advantage O
they O
provide O
, O
one O
key O
concern O
in O
their O
use O
is O
their O
aversive O
aftertaste O
that O
has O
been O
characterized O
on O
a O
sensory O
level O
as O
bitter O
and/or O
metallic O
. O
Recently O
, O
it O
has O
been O
shown O
that O
the O
activation O
of O
particular O
T2R B
bitter O
taste O
receptors O
is O
partially O
involved O
with O
the O
bitter O
aftertaste O
sensation O
of O
saccharin O
and O
acesulfame-K O
. O
To O
more O
fully O
understand O
the O
biology O
behind O
these O
phenomena O
we O
have O
addressed O
the O
question O
of O
whether O
AS O
could O
stimulate O
transient O
receptor O
potential O
vanilloid-1 O
(TRPV1) O
receptors O
, O
as O
these O
receptors O
are O
activated O
by O
a O
large O
range O
of O
structurally O
different O
chemicals O
. O
Moreover O
, O
TRPV1 O
receptors O
and/or O
their O
variants O
are O
found O
in O

acesulfame-K O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
they O
provide O
, O
one O
key O
concern O
in O
their O
use O
is O
their O
aversive O
aftertaste O
that O
has O
been O
characterized O
on O
a O
sensory O
level O
as O
bitter O
and/or O
metallic O
. O
Recently O
, O
it O
has O
been O
shown O
that O
the O
activation O
of O
particular O
T2R B
bitter O
taste O
receptors O
is O
partially O
involved O
with O
the O
bitter O
aftertaste O
sensation O
of O
saccharin O
and O
acesulfame-K O
To O
more O
fully O
understand O
the O
biology O
behind O
these O
phenomena O
we O
have O
addressed O
the O
question O
of O
whether O
AS O
could O
stimulate O
transient O
receptor O
potential O
vanilloid-1 O
(TRPV1) O
receptors O
, O
as O
these O
receptors O
are O
activated O
by O
a O
large O
range O
of O
structurally O
different O
chemicals O
. O
Moreover O
, O
TRPV1 O
receptors O
and/or O
their O
variants O
are O
found O
in O
taste O
receptor O

CuSO(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
imaging O
on O
TRPV1 B
receptors O
heterologously O
expressed O
in O
the O
human O
embryonic O
kidney O
(HEK) O
293 O
cells O
and O
on O
dissociated O
primary O
sensory O
neurons O
, O
we O
find O
that O
in O
both O
systems O
, O
AS O
activate O
TRPV1 O
receptors O
, O
and O
, O
moreover O
, O
they O
sensitize O
these O
channels O
to O
acid O
and O
heat O
. O
We O
also O
found O
that O
TRPV1 O
receptors O
are O
activated O
by O
CuSO(4) O
ZnSO(4) O
, O
and O
FeSO(4) O
, O
three O
salts O
known O
to O
produce O
a O
metallic O
taste O
sensation O
. O
In O
summary O
, O
our O
results O
identify O
a O
novel O
group O
of O
compounds O
that O
activate O
TRPV1 O
and O
, O
consequently O
, O
provide O
a O
molecular O
mechanism O
that O
may O
account O
for O
off O
tastes O
of O
sweeteners O
and O
metallic O
tasting O
salts O
. O

ZnSO(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
on O
TRPV1 B
receptors O
heterologously O
expressed O
in O
the O
human O
embryonic O
kidney O
(HEK) O
293 O
cells O
and O
on O
dissociated O
primary O
sensory O
neurons O
, O
we O
find O
that O
in O
both O
systems O
, O
AS O
activate O
TRPV1 O
receptors O
, O
and O
, O
moreover O
, O
they O
sensitize O
these O
channels O
to O
acid O
and O
heat O
. O
We O
also O
found O
that O
TRPV1 O
receptors O
are O
activated O
by O
CuSO(4) O
, O
ZnSO(4) O
and O
FeSO(4) O
, O
three O
salts O
known O
to O
produce O
a O
metallic O
taste O
sensation O
. O
In O
summary O
, O
our O
results O
identify O
a O
novel O
group O
of O
compounds O
that O
activate O
TRPV1 O
and O
, O
consequently O
, O
provide O
a O
molecular O
mechanism O
that O
may O
account O
for O
off O
tastes O
of O
sweeteners O
and O
metallic O
tasting O
salts O
. O

FeSO(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
receptors O
heterologously O
expressed O
in O
the O
human O
embryonic O
kidney O
(HEK) O
293 O
cells O
and O
on O
dissociated O
primary O
sensory O
neurons O
, O
we O
find O
that O
in O
both O
systems O
, O
AS O
activate O
TRPV1 B
receptors O
, O
and O
, O
moreover O
, O
they O
sensitize O
these O
channels O
to O
acid O
and O
heat O
. O
We O
also O
found O
that O
TRPV1 O
receptors O
are O
activated O
by O
CuSO(4) O
, O
ZnSO(4) O
, O
and O
FeSO(4) O
three O
salts O
known O
to O
produce O
a O
metallic O
taste O
sensation O
. O
In O
summary O
, O
our O
results O
identify O
a O
novel O
group O
of O
compounds O
that O
activate O
TRPV1 O
and O
, O
consequently O
, O
provide O
a O
molecular O
mechanism O
that O
may O
account O
for O
off O
tastes O
of O
sweeteners O
and O
metallic O
tasting O
salts O
. O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine B
ammonia-lyase I
(PAL) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL) O
and O
chalcone B
synthase I
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate B
peroxidase I
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

anthocyanin O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
vinifera O
cv O
. O
Cardinal) O
stored O
at O
0 O
degrees O
C O
. O
In O
the O
present O
work O
, O
we O
analyzed O
whether O
total O
anthocyanin O
content O
, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O
treatment O
. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin O
biosynthesis O
such O
as O
l-phenylalanine O
ammonia-lyase O
(PAL) O
and O
chalcone O
synthase O
(CHS) O
, O
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate O
peroxidase O
(APX) O
. O
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin O
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes O
, O
although O
levels O
were O
lower O
in O
CO2-treated O
fruit O
. O
By O
contrast O
, O
antioxidant O
activity O
decreased O

candesartan O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
treatment O
, O
providing O
24-h O
blood O
pressure O
(BP) O
control O
with O
a O
trough:peak O
ratio O
close O
to O
100% O
. O
SCOPE O
: O
A O
Medline O
literature O
search O
was O
undertaken O
to O
identify O
randomised O
, O
controlled O
trials O
that O
examined O
the O
efficacy O
and O
cardiovascular O
outcomes O
associated O
with O
candesartan O
cilexetil O
in O
hypertension O
and O
chronic O
heart O
failure O
(CHF) O
. O
FINDINGS O
: O
Compared O
with O
other O
ARBs O
, O
candesartan O
demonstrates O
the O
strongest O
binding O
affinity O
to O
the O
angiotensin O
II O
type O
1 O
receptor O
. O
Clinical O
trials O
have O
demonstrated O
that O
candesartan O
is O
well O
tolerated O
in O
combination O
with O
diuretics O
or O
calcium O
channel O
blockers O
(CCBs) O
, O
making O
it O
a O
suitable O
treatment O
option O
for O
patients O
whose O
hypertension O
is O
not O
adequately O
controlled O
by O
monotherapy O
. O
Subsequently O
, O
candesartan O
became O

candesartan O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
search O
was O
undertaken O
to O
identify O
randomised O
, O
controlled O
trials O
that O
examined O
the O
efficacy O
and O
cardiovascular O
outcomes O
associated O
with O
candesartan O
cilexetil O
in O
hypertension O
and O
chronic O
heart O
failure O
(CHF) O
. O
FINDINGS O
: O
Compared O
with O
other O
ARBs O
, O
candesartan O
demonstrates O
the O
strongest O
binding O
affinity O
to O
the O
angiotensin O
II O
type O
1 O
receptor O
. O
Clinical O
trials O
have O
demonstrated O
that O
candesartan O
is O
well O
tolerated O
in O
combination O
with O
diuretics O
or O
calcium B
channel I
blockers O
(CCBs) O
, O
making O
it O
a O
suitable O
treatment O
option O
for O
patients O
whose O
hypertension O
is O
not O
adequately O
controlled O
by O
monotherapy O
. O
Subsequently O
, O
candesartan O
became O
the O
only O
ARB O
licensed O
in O
the O
UK O
to O
treat O
patients O
with O
CHF O
and O
left O
ventricular O
ejection O
fraction O
< O

phenolics O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
we O
observed O
significant O
overexpression O
of O
glutathione O
peroxidase O
(6 O
h O
after O
treatment O
: O
P<.05) O
, O
glutathione O
reductase O
and O
gamma-glutamylcysteine O
synthetase O
(12 O
h O
after O
treatment O
: O
P<.05) O
. O
Notably O
, O
when O
GSH O
depletion O
occurred O
, O
p66Shc B
protein O
expression O
increased O
by O
about O
300% O
with O
respect O
to O
control O
(P<.001; O
LipE O
vs O
. O
control) O
. O
These O
effects O
were O
fully O
counteracted O
by O
dietary O
phenolics O
which O
inhibited O
ROS O
overproduction O
and O
GSH O
consumption O
, O
rendered O
the O
reactive O
transcription O
of O
glutathione-associated O
enzymes O
unnecessary O
and O
blocked O
the O
intracellular O
signals O
leading O
to O
the O
overexpression O
and O
rearrangement O
of O
p66Shc O
signalling O
molecule O
. O
Altogether O
, O
these O
results O
suggest O
that O
the O
impairment O
of O
the O
antioxidant O
system O
hijacks O
intestinal O
cells O
towards O
an O
apoptotic-prone O
phenotype O
via O

sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Efficacy O
and O
safety O
of O
the O
dipeptidyl B
peptidase-4 I
inhibitor O
, O
sitagliptin O
, O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
inadequately O
controlled O
on O
glimepiride O
alone O
or O
on O
glimepiride O
and O
metformin.AIM O
: O
To O
assess O
the O
efficacy O
and O
safety O
of O
a O
24-week O
treatment O
with O
sitagliptin O
a O
highly O
selective O
once-daily O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
in O
patients O
with O
type O
2 O
diabetes O
who O
had O
inadequate O
glycaemic O
control O
[glycosylated O
haemoglobin O
(HbA(1c)) O
>or=7.5% O
and O
<or=10.5%] O
while O
on O
glimepiride O
alone O
or O
in O
combination O
with O
metformin O
. O
METHODS O
: O
After O
a O
screening O
, O
diet/exercise O
run-in O
and O
drug O
wash-off O
period O
, O
a O
glimepiride O
+/- O
metformin O

sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Efficacy O
and O
safety O
of O
the O
dipeptidyl O
peptidase-4 O
inhibitor O
, O
sitagliptin O
, O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
inadequately O
controlled O
on O
glimepiride O
alone O
or O
on O
glimepiride O
and O
metformin.AIM O
: O
To O
assess O
the O
efficacy O
and O
safety O
of O
a O
24-week O
treatment O
with O
sitagliptin O
a O
highly O
selective O
once-daily O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
in O
patients O
with O
type O
2 O
diabetes O
who O
had O
inadequate O
glycaemic O
control O
[glycosylated O
haemoglobin O
(HbA(1c)) O
>or=7.5% O
and O
<or=10.5%] O
while O
on O
glimepiride O
alone O
or O
in O
combination O
with O
metformin O
. O
METHODS O
: O
After O
a O
screening O
, O
diet/exercise O
run-in O
and O
drug O
wash-off O
period O
, O
a O
glimepiride O
+/- O
metformin O

sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Efficacy O
and O
safety O
of O
the O
dipeptidyl B
peptidase-4 I
inhibitor O
, O
sitaglipti O
 O
, O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
inadequately O
controlled O
on O
glimepiride O
alone O
or O
on O
glimepiride O
and O
metformin.AIM O
: O
To O
assess O
the O
efficacy O
and O
safety O
of O
a O
24-week O
treatment O
with O
sitagliptin O
, O
a O
highly O
selective O
once-daily O
oral O
dipeptidyl O
peptidase-4 O
(DPP-4) O
inhibitor O
, O
in O
patients O
with O
type O
2 O
diabetes O
who O
had O
inadequate O
glycaemic O

NE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
not O
change O
these O
parameters O
. O
Indeed O
, O
CORT O
, O
NE O
and O
antibody O
synthesis O
were O
similar O
after O
T9 O
contusion O
or O
transection O
SCI O
. O
In O
contrast O
, O
high-level O
SCI O
(T3) O
caused O
sustained O
increases O
in O
CORT O
and O
splenic O
NE O
along O
with O
impaired O
antibody O
synthesis O
and O
elevated O
splenocyte O
apoptosis O
. O
The O
immunosuppressive O
effects O
of O
T3 O
SCI O
were O
caused O
by O
NE O
acting O
at O
beta2-adrenergic B
receptors I
(beta2AR) O
and O
could O
be O
reversed O
using O
beta2AR O
blockers O
. O
Interestingly O
, O
impaired O
antibody O
after O
T3 O
SCI O
could O
be O
mimicked O
after O
T9 O
SCI O
with O
a O
beta2AR O
agonist O
. O
These O
data O
illustrate O
the O
immunosuppressive O
effects O
of O
the O
SNS O
after O
high-level O
SCI O
and O
indicate O
that O
immune O
deficits O
may O
be O
overcome O
using O

NE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
not O
change O
these O
parameters O
. O
Indeed O
, O
CORT O
, O
NE O
and O
antibody O
synthesis O
were O
similar O
after O
T9 O
contusion O
or O
transection O
SCI O
. O
In O
contrast O
, O
high-level O
SCI O
(T3) O
caused O
sustained O
increases O
in O
CORT O
and O
splenic O
NE O
along O
with O
impaired O
antibody O
synthesis O
and O
elevated O
splenocyte O
apoptosis O
. O
The O
immunosuppressive O
effects O
of O
T3 O
SCI O
were O
caused O
by O
NE O
acting O
at O
beta2-adrenergic O
receptors O
(beta2AR) O
and O
could O
be O
reversed O
using O
beta2AR B
blockers O
. O
Interestingly O
, O
impaired O
antibody O
after O
T3 O
SCI O
could O
be O
mimicked O
after O
T9 O
SCI O
with O
a O
beta2AR O
agonist O
. O
These O
data O
illustrate O
the O
immunosuppressive O
effects O
of O
the O
SNS O
after O
high-level O
SCI O
and O
indicate O
that O
immune O
deficits O
may O
be O
overcome O
using O

Miglustat O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
effects O
over O
1 O
year.Niemann-Pick O
disease O
type O
C O
(NP-C) O
is O
a O
lipid O
storage O
disorder O
characterized O
by O
the O
accumulation O
of O
unesterified O
cholesterol O
and O
glycolipids O
in O
the O
lysosomal/late O
endosomal O
system O
of O
certain O
cells O
in O
the O
central O
nervous O
system O
(CNS) O
and O
visceral O
organs O
. O
Clinical O
symptoms O
include O
progressive O
neurological O
deterioration O
and O
visceral O
organomegaly O
. O
Miglustat O
a O
small O
iminosugar O
molecule O
approved O
for O
the O
treatment O
of O
Gaucher O
disease O
, O
reversibly O
inhibits O
glucosylceramide O
synthase O
, O
which O
catalyses O
the O
first O
committed O
step O
in O
glycosphingolipid O
synthesis O
. O
The O
physicochemical O
properties O
of O
miglustat O
allow O
it O
to O
cross O
the O
blood-brain O
barrier O
and O
suggest O
possible O
benefits O
in O
lysosomal O
storage O
diseases O
affecting O
the O
CNS O
. O
Here O
, O
we O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine B
hydroxylase I
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH O
receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH-exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH O
receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH-exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH O
exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O
decreased O
anxiety O
in O
the O
elevated O
plus-maze O
and O
a O
trend O
for O
decreased O
TH-ir O
in O
the O
mPFC O
. O
Neither O
PND35 O
nor O
PND135 O
rats O
showed O
major O
structural O
differences O
with O
MPH O
exposure O
. O
These O
findings O
suggest O
that O
developmental O
exposure O
to O
high O
therapeutic O
doses O
of O
MPH O
has O
short-term O
effects O

MPH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine B
transporter I
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O

MPH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O

MPH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH O
receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH-exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O

MPH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH O
exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O
decreased O
anxiety O
in O
the O
elevated O
plus-maze O
and O
a O
trend O
for O
decreased O
TH-ir O
in O
the O
mPFC O
. O
Neither O
PND35 O
nor O
PND135 O
rats O
showed O
major O
structural O
differences O
with O
MPH O
exposure O
. O
These O
findings O
suggest O
that O
developmental O
exposure O
to O
high O
therapeutic O
doses O
of O
MPH O
has O
short-term O
effects O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
were O
tested O
against O
the O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist)-induced O
contraction O
in O
isolated O
hamster O
ureteral O
preparations O
using O
a O
functional O
experimental O
approach O
. O
In O
the O
smooth O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor B
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor B
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine O
induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O
mainly O
via O
alpha(1A)-adrenoceptors O
. O
If O
these O
findings O
hold O
true O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor B
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine O
induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O
mainly O
via O
alpha(1A)-adrenoceptors O
. O
If O
these O
findings O
hold O
true O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor B
antagonist) O
competitively O
antagonized O
the O
phenylephrine O
induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O
mainly O
via O
alpha(1A)-adrenoceptors O
. O
If O
these O
findings O
hold O
true O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
subtypes O
in O
hamster O
ureters O
according O
to O
gene O
and O
protein O
expressions O
and O
contractile O
function O
. O
Real-time O
quantitative O
reverse-transcription O
polymerase O
chain O
reaction O
and O
immunohistochemical O
analysis O
were O
performed O
to O
determine O
mRNA O
levels O
and O
receptor O
protein O
expressions O
respectively O
, O
for O
alpha(1A)- O
, O
alpha(1B)- O
and O
alpha(1D)-adrenoceptors O
in O
hamster O
ureteral O
smooth O
muscle O
. O
alpha(1)-Adrenoceptor O
antagonists O
were O
tested O
against O
the O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist)-induced O
contraction O
in O
isolated O
hamster O
ureteral O
preparations O
using O
a O
functional O
experimental O
approach O
. O
In O
the O
smooth O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O

Noradrenaline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
alpha(1)-Adrenoceptor O
antagonists O
were O
tested O
against O
the O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist)-induced O
contraction O
in O
isolated O
hamster O
ureteral O
preparations O
using O
a O
functional O
experimental O
approach O
. O
In O
the O
smooth O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor B
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O

Prazosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
approach O
. O
In O
the O
smooth O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor B
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O

silodosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
muscle O
, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor B
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor O
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O

BMY-7378 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
for O
alpha(1a)- O
, O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride) O
(selective O
alpha(1D)-adrenoceptor B
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O

8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
alpha(1b)- O
and O
alpha(1d)-adrenoceptors O
were O
10.7% O
, O
1.2% O
and O
88.1% O
, O
respectively O
, O
and O
protein O
expressions O
were O
identified O
for O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
immunohistochemically O
. O
Noradrenaline O
and O
phenylephrine O
(alpha(1)-adrenoceptor O
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction O
, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05 O
, O
respectively O
. O
Prazosin O
(nonselective O
alpha(1)-adrenoceptor O
antagonist) O
, O
silodosin O
(selective O
alpha(1A)-adrenoceptor O
antagonist) O
and O
BMY-7378 O
( O
8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione O
dihydrochloride O
(selective O
alpha(1D)-adrenoceptor B
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced O
contraction O
(pA(2) O
values O
, O
8.60+/-0.07 O
, O
9.44+/-0.06 O
and O
5.75+/-0.07 O
, O
respectively) O
. O
Chloroethylclonidine O
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine O
. O
Thus O
, O
in O
hamster O
ureters O
, O
alpha(1A)- O
and O
alpha(1D)-adrenoceptors O
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor O
, O
with O
contraction O
being O
mediated O
mainly O
via O

tryptophan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
IFN-gamma-induced O
IDO B
and O
WRS O
expression O
in O
microglia O
is O
differentially O
regulated O
by O
IL-4.Indoleamine O
2,3-dioxygenase O
(IDO) O
, O
a O
tryptophan O
catabolizing O
enzyme O
, O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
various O
neurological O
disorders O
. O
IDO O
expression O
is O
induced O
by O
IFN-gamma O
and O
leads O
to O
neurotoxicity O
by O
generating O
quinolinic O
acid O
. O
Additionally O
, O
it O
inhibits O
the O
immune O
response O
through O
both O
tryptophan O
depletion O
and O
generating O
other O
tryptophan O
catabolites O
. O
IL-4 O
and O
IL-13 O
have O
been O
shown O
to O
control O

tryptophan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
IFN-gamma-induced O
IDO O
and O
WRS O
expression O
in O
microglia O
is O
differentially O
regulated O
by O
IL-4.Indoleamine O
2,3-dioxygenase O
(IDO) O
, O
a O
tryptophan O
catabolizing O
enzyme O
, O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
various O
neurological O
disorders O
. O
IDO O
expression O
is O
induced O
by O
IFN-gamma O
and O
leads O
to O
neurotoxicity O
by O
generating O
quinolinic O
acid O
. O
Additionally O
, O
it O
inhibits O
the O
immune O
response O
through O
both O
tryptophan O
depletion O
and O
generating O
other O
tryptophan O
catabolites O
. O
IL-4 O
and O
IL-13 O
have O
been O
shown O
to O
control O

Dexmedetomidine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
by O
2-fold O
and O
skin O
vascular O
resistance O
increased O
from O
13.2 O
+/- O
2.3 O
to O
20.1 O
+/- O
2.2 O
resistance O
units O
while O
mean O
arterial O
pressure O
increased O
by O
14 O
+/- O
3 O
mm O
Hg O
and O
heart O
rate O
by O
18 O
+/- O
3 O
beats/min O
(p O
< O
0.01) O
. O
Dexmedetomidine O
abolished O
these O
increases O
, O
whereas O
intravenous O
saline O
was O
without O
effect O
. O
Dexmedetomidine O
was O
effective O
in O
blocking O
these O
sympathomimetic O
actions O
of O
cocaine O
even O
in O
all O
7 O
subjects O
who O
were O
homozygous O
for O
the O
Del322-325 O
polymorphism O
in O
the O
alpha2C O
AR O
, O
a O
loss-of-function O
mutation O
that O
is O
highly O
enriched O
in O
blacks O
. O
CONCLUSIONS O
: O
The O
data O
advance O
the O
novel O
hypothesis O
that O
central O
sympatholysis O
with O
dexmedetomidine O
constitutes O
a O
highly O

dexmedetomidine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
was O
without O
effect O
. O
Dexmedetomidine O
was O
effective O
in O
blocking O
these O
sympathomimetic O
actions O
of O
cocaine O
even O
in O
all O
7 O
subjects O
who O
were O
homozygous O
for O
the O
Del322-325 O
polymorphism O
in O
the O
alpha2C B
AR O
, O
a O
loss-of-function O
mutation O
that O
is O
highly O
enriched O
in O
blacks O
. O
CONCLUSIONS O
: O
The O
data O
advance O
the O
novel O
hypothesis O
that O
central O
sympatholysis O
with O
dexmedetomidine O
constitutes O
a O
highly O
effective O
countermeasure O
for O
cocaine's O
sympathomimetic O
actions O
on O
the O
human O
cardiovascular O
system O
, O
even O
in O
individuals O
carrying O
the O
alpha2CDel322-325 O
polymorphism O
. O
(Study O
to O
Improve O
Scientific O
Understanding O
of O
the O
Cardiovascular O
Actions O
of O
Cocaine; O
http://clinicaltrials.gov/ct/show/NCT00338546?order=1; O
NCT00338546) O
. O

dexmedetomidine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Central O
sympatholysis O
as O
a O
novel O
countermeasure O
for O
cocaine-induced O
sympathetic O
activation O
and O
vasoconstriction O
in O
humans.OBJECTIVES O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
cocaine's O
sympathomimetic O
actions O
can O
be O
reversed O
by O
a O
potent O
centrally O
acting O
alpha2 B
adrenergic I
receptor I
(AR) O
agonist O
( O
dexmedetomidine O
 O
. O
BACKGROUND O
: O
We O
recently O
showed O
that O
cocaine O
stimulates O
the O
human O
cardiovascular O
system O
primarily O
by O
acting O
in O
the O
brain O
to O
increase O
sympathetic O
nerve O
activity O
(SNA) O
, O
the O
neural O
stimulus O
to O
norepinephrine O
release O
. O
Thus O
, O
SNA O
constitutes O
a O
putative O
new O
drug O
target O
to O
block O
cocaine's O
adverse O
cardiovascular O
effects O
at O
their O
origin O
. O
METHODS O
: O
In O

dexmedetomidine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Central O
sympatholysis O
as O
a O
novel O
countermeasure O
for O
cocaine-induced O
sympathetic O
activation O
and O
vasoconstriction O
in O
humans.OBJECTIVES O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
cocaine's O
sympathomimetic O
actions O
can O
be O
reversed O
by O
a O
potent O
centrally O
acting O
alpha2 O
adrenergic O
receptor O
(AR) O
agonist O
( O
dexmedetomidine O
 O
. O
BACKGROUND O
: O
We O
recently O
showed O
that O
cocaine O
stimulates O
the O
human O
cardiovascular O
system O
primarily O
by O
acting O
in O
the O
brain O
to O
increase O
sympathetic O
nerve O
activity O
(SNA) O
, O
the O
neural O
stimulus O
to O
norepinephrine O
release O
. O
Thus O
, O
SNA O
constitutes O
a O
putative O
new O
drug O
target O
to O
block O
cocaine's O
adverse O
cardiovascular O
effects O
at O
their O
origin O
. O
METHODS O
: O
In O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
preferential O
COX-2 B
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 O
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 O
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 B
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 O
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
preferential O
COX-2 B
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 O
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 O
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O

Acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 O
and O
COX-2 B
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 O
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O
vivo O
IC(50) O
values O
(COX-1 O
: O
105.2 O
micromol/L; O
COX-2 O
: O
26.3 O
micromol/L) O
of O
acetaminophen O
compared O
favorably O
with O
its O
in O
vitro O
IC(50) O
values O
. O
In O
contrast O
to O
previous O
concepts O
, O
acetaminophen O
inhibited O
COX-2 O
by O
more O
than O
80% O
, O
i.e. O
, O

paracetamol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Acetaminophen O
(paracetamo O
) O
is O
a O
selective O
cyclooxygenase-2 B
inhibitor O
in O
man.For O
more O
than O
three O
decades O
, O
acetaminophen O
(INN O
, O
paracetamol) O
has O
been O
claimed O
to O
be O
devoid O
of O
significant O
inhibition O
of O
peripheral O
prostanoids O
. O
Meanwhile O
, O
attempts O
to O
explain O
its O
action O
by O
inhibition O
of O
a O
central O
cyclooxygenase O
(COX)-3 O
have O
been O
rejected O
. O
The O
fact O
that O
acetaminophen O
acts O
functionally O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 O
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O
vivo O
IC(50) O
values O
(COX-1 O
: O
105.2 O
micromol/L; O
COX-2 O
: O
26.3 O
micromol/L) O
of O
acetaminophen O
compared O
favorably O
with O
its O
in O
vitro O
IC(50) O
values O
. O
In O
contrast O
to O
previous O
concepts O
, O
acetaminophen O
inhibited O
COX-2 O
by O
more O
than O
80% O
, O
i.e. O
, O
to O
a O
degree O
comparable O
to O
nonsteroidal O
antiinflammatory O
drugs O
(NSAIDs) O
and O
selective O
COX-2 O
inhibitors O
. O
However O
, O
a O
>95% O
COX-1 B
blockade O
relevant O
for O
suppression O
of O
platelet O
function O
was O
not O
achieved O
. O
Our O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 B
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O
vivo O
IC(50) O
values O
(COX-1 O
: O
105.2 O
micromol/L; O
COX-2 O
: O
26.3 O
micromol/L) O
of O
acetaminophen O
compared O
favorably O
with O
its O
in O
vitro O
IC(50) O
values O
. O
In O
contrast O
to O
previous O
concepts O
, O
acetaminophen O
inhibited O
COX-2 O
by O
more O
than O
80% O
, O
i.e. O
, O
to O
a O
degree O
comparable O
to O
nonsteroidal O
antiinflammatory O
drugs O
(NSAIDs) O
and O
selective O
COX-2 O
inhibitors O
. O
However O
, O
a O
>95% O
COX-1 O
blockade O
relevant O
for O
suppression O
of O
platelet O
function O
was O
not O
achieved O
. O
Our O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibitions O
were O
56% O
(COX-1) O
and O
83% O
(COX-2) O
. O
Acetaminophen O
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 B
for O
at O
least O
5 O
h O
postadministration O
. O
Ex O
vivo O
IC(50) O
values O
(COX-1 O
: O
105.2 O
micromol/L; O
COX-2 O
: O
26.3 O
micromol/L) O
of O
acetaminophen O
compared O
favorably O
with O
its O
in O
vitro O
IC(50) O
values O
. O
In O
contrast O
to O
previous O
concepts O
, O
acetaminophen O
inhibited O
COX-2 O
by O
more O
than O
80% O
, O
i.e. O
, O
to O
a O
degree O
comparable O
to O
nonsteroidal O
antiinflammatory O
drugs O
(NSAIDs) O
and O
selective O
COX-2 O
inhibitors O
. O
However O
, O
a O
>95% O
COX-1 O
blockade O
relevant O
for O
suppression O
of O
platelet O
function O
was O
not O
achieved O
. O
Our O
data O
may O
explain O
acetaminophen's O
analgesic O
and O
antiinflammatory O
action O
as O
well O
as O
its O
superior O
overall O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
suppression O
of O
platelet O
function O
was O
not O
achieved O
. O
Our O
data O
may O
explain O
acetaminophen's O
analgesic O
and O
antiinflammatory O
action O
as O
well O
as O
its O
superior O
overall O
gastrointestinal O
safety O
profile O
compared O
with O
NSAIDs O
. O
In O
view O
of O
its O
substantial O
COX-2 B
inhibition O
, O
recently O
defined O
cardiovascular O
warnings O
for O
use O
of O
COX-2 O
inhibitors O
should O
also O
be O
considered O
for O
acetaminophen O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Acetaminophen O
(paracetamol) O
is O
a O
selective O
cyclooxygenase-2 O
inhibitor O
in O
man.For O
more O
than O
three O
decades O
, O
acetaminophen O
(INN O
, O
paracetamol) O
has O
been O
claimed O
to O
be O
devoid O
of O
significant O
inhibition O
of O
peripheral O
prostanoids O
. O
Meanwhile O
, O
attempts O
to O
explain O
its O
action O
by O
inhibition O
of O
a O
central O
cyclooxygenase O
(COX)-3 O
have O
been O
rejected O
. O
The O
fact O
that O
acetaminophen O
acts O
functionally O
as O
a O
selective O
COX-2 B
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O

acetaminophen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
prostanoids O
. O
Meanwhile O
, O
attempts O
to O
explain O
its O
action O
by O
inhibition O
of O
a O
central O
cyclooxygenase O
(COX)-3 O
have O
been O
rejected O
. O
The O
fact O
that O
acetaminophen O
acts O
functionally O
as O
a O
selective O
COX-2 O
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX B
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 O
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O

thromboxane O
B(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
(COX)-3 O
have O
been O
rejected O
. O
The O
fact O
that O
acetaminophen O
acts O
functionally O
as O
a O
selective O
COX-2 O
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 B
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O

prostaglandin O
E(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
The O
fact O
that O
acetaminophen O
acts O
functionally O
as O
a O
selective O
COX-2 B
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 O
blockade O
. O
Ex O
vivo O
COX O
inhibition O
and O
pharmacokinetics O
of O
acetaminophen O
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally O
. O
Coagulation-induced O
thromboxane O
B(2) O
and O
lipopolysaccharide-induced O
prostaglandin O
E(2) O
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 O
and O
COX-2 O
activity O
. O
In O
vitro O
, O
acetaminophen O
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 O
inhibition O
(IC(50)=113.7 O
micromol/L O
for O
COX-1; O
IC(50)=25.8 O
micromol/L O
for O
COX-2) O
. O
Following O
oral O
administration O
of O
the O
drug O
, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) O

cibenzoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

cibenzoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
have O
been O
found O
to O
have O
an O
NCX B
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

KB-R7943 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
There O
are O
three O
mammalian O
NCX B
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O
of O
NCX2 O
and O
NCX3 O
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle O
. O
The O
pharmacology O
of O
NCX O
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943 O
a O
prototype O
benzyloxyphenyl O
NCX O
inhibitor O
, O
in O
1996 O
. O
Currently O
, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors O
: O
SEA0400 O
, O
SN-6 O
, O
and O
YM-244769 O
. O
Intriguingly O
, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl O
NCX O
inhibitors O
is O
directly O
coupled O
to O
the O
rate O
of O
Na(+)(i)-dependent O
inactivation O
. O
Therefore O
, O
the O
benzyloxyphenyl O
inhibitors O
are O
apparently O
dormant O
during O
the O
forward O
mode O
under O

benzyloxyphenyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mammalian O
NCX B
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O
of O
NCX2 O
and O
NCX3 O
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle O
. O
The O
pharmacology O
of O
NCX O
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943 O
, O
a O
prototype O
benzyloxyphenyl O
NCX O
inhibitor O
, O
in O
1996 O
. O
Currently O
, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors O
: O
SEA0400 O
, O
SN-6 O
, O
and O
YM-244769 O
. O
Intriguingly O
, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl O
NCX O
inhibitors O
is O
directly O
coupled O
to O
the O
rate O
of O
Na(+)(i)-dependent O
inactivation O
. O
Therefore O
, O
the O
benzyloxyphenyl O
inhibitors O
are O
apparently O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O

benzyloxyphenyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NCX3 O
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle O
. O
The O
pharmacology O
of O
NCX B
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943 O
, O
a O
prototype O
benzyloxyphenyl O
NCX O
inhibitor O
, O
in O
1996 O
. O
Currently O
, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors O
: O
SEA0400 O
, O
SN-6 O
, O
and O
YM-244769 O
. O
Intriguingly O
, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl O
NCX O
inhibitors O
is O
directly O
coupled O
to O
the O
rate O
of O
Na(+)(i)-dependent O
inactivation O
. O
Therefore O
, O
the O
benzyloxyphenyl O
inhibitors O
are O
apparently O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O

amiodarone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

amiodarone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX B
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

dronedarone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

dronedarone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX B
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

bepridil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

bepridil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX B
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

aprindine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

aprindine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion O
channel O
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX B
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

Ca(2+) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Na+/Ca2+ O
exchange O
inhibitors O
: O
a O
new O
class O
of O
calcium O
regulators.The O
Na(+)/Ca(2+) B
exchanger I
(NCX) O
is O
a O
bidirectional O
transporter O
that O
normally O
extrudes O
Ca(2+) O
from O
the O
cell O
(forward O
mode) O
, O
but O
also O
brings O
Ca(2+) O
into O
the O
cell O
(reverse O
mode) O
under O
special O
conditions O
such O
as O
intracellular O
Na(+) O
(Na(+)(i)) O
accumulation O
or O
membrane O
depolarization O
. O
There O
are O
three O
mammalian O
NCX O
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O
of O
NCX2 O
and O
NCX3 O
is O
limited O
mainly O
to O
the O

Ca(2+) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Na+/Ca2+ O
exchange O
inhibitors O
: O
a O
new O
class O
of O
calcium O
regulators.The O
Na(+)/Ca(2+) B
exchanger I
(NCX) O
is O
a O
bidirectional O
transporter O
that O
normally O
extrudes O
Ca(2+) O
from O
the O
cell O
(forward O
mode) O
, O
but O
also O
brings O
Ca(2+) O
into O
the O
cell O
(reverse O
mode) O
under O
special O
conditions O
such O
as O
intracellular O
Na(+) O
(Na(+)(i)) O
accumulation O
or O
membrane O
depolarization O
. O
There O
are O
three O
mammalian O
NCX O
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O

Conivaptan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
critical O
role O
in O
the O
regulation O
of O
serum O
osmolality O
and O
in O
circulatory O
homeostasis O
. O
The O
actions O
of O
AVP O
are O
mediated O
by O
three O
receptor O
subtypes O
V1a O
, O
V2 O
, O
and O
V1b O
. O
The O
V1a O
receptor O
regulates O
vasodilation O
and O
cellular O
hypertrophy O
while O
the O
V2 O
receptor O
regulates O
free O
water O
excretion O
. O
The O
V1b O
receptor O
regulates O
adrenocorticotropin O
hormone O
release O
. O
Conivaptan O
is O
a O
nonpeptide O
dual O
V1a/V2 B
AVP I
receptor I
antagonist O
. O
It O
binds O
with O
high O
affinity O
, O
competitively O
, O
and O
reversibly O
to O
the O
V1a/V2 O
receptor O
subtypes; O
its O
antagonistic O
effect O
is O
concentration O
dependent O
. O
It O
inhibits O
CYP3A4 O
liver O
enzyme O
and O
elevates O
plasma O
levels O
of O
other O
drugs O
metabolized O
by O
this O
enzyme O
. O
It O
is O
approved O
only O
for O
short-term O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS B
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O
C-terminus O
of O
the O
protein O
. O
This O
article O
discusses O
the O
detailed O
kinetic O
characterization O
of O
MjAdSS O
. O
Initial O
velocity O
and O
product O
inhibition O
studies O
, O
carried O
out O
at O
70 O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS O
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O
C-terminus O
of O
the O
protein O
. O
This O
article O
discusses O
the O
detailed O
kinetic O
characterization O
of O
MjAdSS O
. O
Initial O
velocity O
and O
product O
inhibition O
studies O
, O
carried O
out O
at O
70 O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS B
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O
C-terminus O
of O
the O
protein O
. O
This O
article O
discusses O
the O
detailed O
kinetic O
characterization O
of O
MjAdSS O
. O
Initial O
velocity O
and O
product O
inhibition O
studies O
, O
carried O
out O
at O
70 O
degrees O
C O
, O
suggest O
a O
rapid O
equilibrium O
random O
AB O
steady-state O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS B
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O
C O
terminus O
of O
the O
protein O
. O
This O
article O
discusses O
the O
detailed O
kinetic O
characterization O
of O
MjAdSS O
. O
Initial O
velocity O
and O
product O
inhibition O
studies O
, O
carried O
out O
at O
70 O
degrees O
C O
, O
suggest O
a O
rapid O
equilibrium O
random O
AB O
steady-state O
ordered O
C O
kinetic O
mechanism O
for O
the O
MjAdSS O
catalyzed O
reaction O
. O
AdSS O
are O
known O
to O
exhibit O
monomer-dimer O
equilibrium O
with O

Phosphate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
show O
that O
MjAdSS B
is O
an O
equilibrium O
mixture O
of O
dimers O
and O
tetramers O
with O
the O
tetramer O
being O
the O
catalytically O
active O
form O
. O
The O
tetramer O
dissociates O
into O
dimers O
with O
a O
minor O
increase O
in O
ionic O
strength O
of O
the O
buffer O
, O
while O
the O
dimer O
is O
extremely O
stable O
and O
does O
not O
dissociate O
even O
at O
1.2 O
M O
NaCl O
. O
Phosphate O
a O
product O
of O
the O
reaction O
, O
was O
found O
to O
be O
a O
potent O
inhibitor O
of O
MjAdSS O
showing O
biphasic O
inhibition O
of O
enzyme O
activity O
. O
The O
inhibition O
was O
competitive O
with O
IMP O
and O
noncompetitive O
with O
GTP O
. O
MjAdSS O
, O
like O
the O
mouse O
acidic O
isozyme O
, O
exhibits O
substrate O
inhibition O
, O
with O
IMP O
inhibiting O
enzyme O
activity O
at O
subsaturating O
GTP O
concentrations O
. O
Regulation O

Mg2+ O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS O
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O

adenylosuccinate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS O
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O

adenylosuccinate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS B
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O
short O
AdSS O
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O

Mg2+ O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Kinetic O
characterization O
of O
adenylosuccinate O
synthetase O
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii.Adenylosuccinate O
synthetase O
(AdSS) O
catalyzes O
the O
Mg2+ O
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate O
to O
form O
adenylosuccinate O
, O
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP O
to O
GDP O
. O
AdSS B
from O
the O
thermophilic O
archaea O
, O
Methanocaldococcus O
jannaschii O
(MjAdSS) O
is O
345 O
amino O
acids O
long O
against O
an O
average O
length O
of O
430-457 O
amino O
acids O
for O
most O
mesophilic O
AdSS O
. O
This O

Vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 B
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil O
. O
Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O

Vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 O
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil O
. O
Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 B
catalytic I
domain I
in O
complex O
with O
vardenafil O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 B
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1- O
vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 B
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE O
structures O
. O
The O
conformational O
variation O
of O
both O
PDE5 O
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 B
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE O
structures O
. O
The O
conformational O
variation O
of O
both O
PDE5 O
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O
different O
potencies O
of O
the O
drugs O
. O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 B
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 O
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE B
structures O
. O
The O
conformational O
variation O
of O
both O
PDE5 O
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O
different O
potencies O
of O
the O
drugs O
. O

vardenafil O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 B
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafi O
and O
sildenafil.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O

sildenafil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 B
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafi O
.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O

Tyr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 B
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr O
612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

Gln O
acts O
as O
PART-OF O
for O
what O
entity O
? O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 B
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln O
817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 B
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe O
820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

Tyr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr O
612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O

Gln O
acts O
as O
PART-OF O
for O
what O
entity O
? O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln O
817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe O
820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O

Val O
acts O
as O
PART-OF O
for O
what O
entity O
? O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val O
782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O

His O
acts O
as O
PART-OF O
for O
what O
entity O
? O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His O
613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O

Leu O
acts O
as O
PART-OF O
for O
what O
entity O
? O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu O
765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic I
(C) I
domain I
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe O
786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Critical O
amino O
acid O
in O
phosphodiesterase-5 B
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A B
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A B
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O

tadalafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A B
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A B
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A B
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A B
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A B
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A B
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O

tadalafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A B
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

tadalafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A B
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 O
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 B
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O
role O
of O
PDE5 B
catalytic-site O
residues O
for O
cGMP O
and O
inhibitors O
, O
indicate O
that O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
are O
the O
most O
important O
cGMP O
or O
inhibitor O
contacts O
studied O
, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors O
. O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O

vardenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O

sildenafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O

tadalafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O

tadalafil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O

3-isobutyl-1-methylxanthine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O

3-isobutyl-1-methylxanthine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O

3-isobutyl-1-methylxanthine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
( O
IBMX O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
( O
IBMX O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O

IBMX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
3-isobutyl-1-methylxanthine O
( O
IBMX O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O

cyclic O
guanosine O
monophosphate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase B
5 I
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O

cyclic O
guanosine O
monophosphate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase B
5 I
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
( O
cGMP O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 O
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphate O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
( O
cGMP O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 B
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 O
and O
Val-782 O
, O
and O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O

cyclic O
guanosine O
monophosphate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Critical O
amino O
acids O
in O
phosphodiesterase-5 B
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic O
guanosine O
monophosphat O
and O
inhibitors.The O
molecular O
bases O
for O
phosphodiesterase O
5 O
(PDE5) O
catalytic-site O
affinity O
for O
cyclic O
guanosine O
monophosphate O
(cGMP) O
and O
potency O
of O
inhibitors O
are O
poorly O
understood O
. O
Cocrystal O
structures O
of O
PDE5 O
catalytic O
(C) O
domain O
with O
inhibitors O
reveal O
a O
hydrogen O
bond O
and O
hydrophobic O
interactions O
with O
Tyr-612 O
, O
hydrogen O
bonds O
with O
Gln-817 O
, O
a O
hydrophobic O
clamp O
formed O

cGMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O
selective O
and O
nonselective O
inhibitors O
, O
and O
that O
higher O
vardenafil O
potency O
over O
sildenafil O
and O
tadalafil O
results O
from O
stronger O
contacts O
with O
Tyr-612 O
, O
Gln-817 O
, O
and O
Phe-820 O
. O
Affinity O
of O
V782A B
for O
cGMP O
vardenafil O
, O
sildenafil O
, O
tadalafil O
, O
or O
IBMX O
was O
reduced O
5.5- O
, O
23- O
, O
10- O
, O
3- O
, O
and O
12-fold O
, O
respectively O
. O
Change O
in O
affinity O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
or O
IBMX O
in O
Y612F O
, O
H613A O
, O
L765A O
, O
or O
F786A O
was O
less O
, O
but O
affinity O
of O
H613A O
or O
F786A O
for O
tadalafil O
was O
weakened O
37- O
and O
17-fold O
, O
respectively O
. O
The O
results O
quantify O
the O

tadalafil O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
contacts O
with O
His-613 O
, O
Leu-765 O
, O
and O
Phe-786 O
[Sung O
et O
al O
. O
(2003) O
Nature O
425 O
, O
98-102; O
Huai O
et O
al O
. O
(2004) O
J O
. O
Biol O
. O
Chem O
. O
279 O
, O
13095-13101] O
. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 O
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A O
and O
55-fold O
in O
F820A O
. O
Catalytic-site O
affinities O
for O
cGMP O
, O
vardenafil O
, O
sildenafil O
, O
tadalafil O
or O
3-isobutyl-1-methylxanthine O
(IBMX) O
were O
respectively O
weakened O
14- O
, O
123- O
, O
30- O
, O
51- O
, O
and O
43-fold O
for O
Y612A; O
63- O
, O
511- O
, O
43- O
, O
95- O
and O
61-fold O
for O
Q817A; O
and O
59- O
, O
448- O
, O
71- O
, O
137- O
, O
and O
93-fold O
for O
F820A O
. O
The O
data O
indicate O
that O
these O
three O
amino O
acids O
are O
major O
determinants O
of O
affinity O
for O
cGMP O
and O
potency O
of O

atorvastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
dipeptidyl O
peptidase-IV O
(DPP-IV) O
by O
atorvastatin.Dipeptidyl O
peptidase-IV O
(DPP-IV) O
is O
an O
enzyme O
responsible O
for O
the O
inactivation O
of O
the O
glucoregulatory O
incretin O
hormones O
glucagon-like O
peptide-1 O
(GLP-1) O
and O
glucose-dependent O
insulinotropic O
polypeptide O
(GIP) O
. O
In O
this O
report O
, O
we O
show O
that O
the O
hypolipidemic O
agent O
atorvastatin O
is O
a O
competitive O
inhibitor O
of O
porcine B
DPP-IV I
in O
vitro O
, O
with O
K(i)=57.8+/-2.3 O
microM O
. O
These O
results O
may O
have O
implications O
in O
the O
development O
of O
novel O
DPP-IV O
inhibitors O
based O
on O
the O
use O
of O
atorvastatin O
as O
a O
lead O
compound O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O

atorvastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
incretin O
hormones O
glucagon-like O
peptide-1 O
(GLP-1) O
and O
glucose-dependent O
insulinotropic O
polypeptide O
(GIP) O
. O
In O
this O
report O
, O
we O
show O
that O
the O
hypolipidemic O
agent O
atorvastatin O
is O
a O
competitive O
inhibitor O
of O
porcine O
DPP-IV B
in O
vitro O
, O
with O
K(i)=57.8+/-2.3 O
microM O
. O
These O
results O
may O
have O
implications O
in O
the O
development O
of O
novel O
DPP-IV O
inhibitors O
based O
on O
the O
use O
of O
atorvastatin O
as O
a O
lead O
compound O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O

atorvastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
dipeptidyl B
peptidase-IV I
(DPP-IV) O
by O
atorvastati O
.Dipeptidyl O
peptidase-IV O
(DPP-IV) O
is O
an O
enzyme O
responsible O
for O
the O
inactivation O
of O
the O
glucoregulatory O
incretin O
hormones O
glucagon-like O
peptide-1 O
(GLP-1) O
and O
glucose-dependent O
insulinotropic O
polypeptide O
(GIP) O
. O
In O
this O
report O
, O
we O
show O
that O
the O
hypolipidemic O
agent O
atorvastatin O
is O
a O
competitive O
inhibitor O
of O
porcine O
DPP-IV O
in O
vitro O
, O
with O
K(i)=57.8+/-2.3 O
microM O
. O
These O
results O
may O
have O

atorvastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
dipeptidyl O
peptidase-IV O
(DPP-IV) O
by O
atorvastati O
.Dipeptidyl O
peptidase-IV O
(DPP-IV) O
is O
an O
enzyme O
responsible O
for O
the O
inactivation O
of O
the O
glucoregulatory O
incretin O
hormones O
glucagon-like O
peptide-1 O
(GLP-1) O
and O
glucose-dependent O
insulinotropic O
polypeptide O
(GIP) O
. O
In O
this O
report O
, O
we O
show O
that O
the O
hypolipidemic O
agent O
atorvastatin O
is O
a O
competitive O
inhibitor O
of O
porcine O
DPP-IV B
in O
vitro O
, O
with O
K(i)=57.8+/-2.3 O
microM O
. O
These O
results O
may O
have O

Eprosartan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Not O
only O
have O
ARBs O
shown O
good O
efficacy O
and O
tolerability O
, O
they O
also O
appear O
to O
have O
a O
protective O
effect O
that O
goes O
beyond O
that O
expected O
from O
the O
reduction O
of O
blood O
pressure O
. O
The O
ARB O
eprosartan O
is O
a O
nonbiphenyl O
nontetrazole O
angiotensin O
II O
type O
1 O
receptor O
(AT1) O
antagonist O
, O
which O
acts O
to O
decrease O
total O
peripheral O
resistance O
. O
Eprosartan O
acts O
at O
vascular O
AT1 B
receptors I
(postsynaptically) O
and O
at O
presynaptic O
AT1 O
receptors O
, O
where O
it O
inhibits O
noradrenaline O
release O
. O
In O
clinical O
studies O
, O
eprosartan O
has O
been O
shown O
to O
significantly O
reduce O
cardiovascular O
and O
cerebrovascular O
events O
, O
whilst O
avoiding O
the O
persistent O
cough O
that O
commonly O
occurs O
with O
the O
use O
of O
angiotensin-converting O
enzyme O
inhibitors O
. O
Eprosartan O
can O
also O
be O

Eprosartan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Not O
only O
have O
ARBs O
shown O
good O
efficacy O
and O
tolerability O
, O
they O
also O
appear O
to O
have O
a O
protective O
effect O
that O
goes O
beyond O
that O
expected O
from O
the O
reduction O
of O
blood O
pressure O
. O
The O
ARB O
eprosartan O
is O
a O
nonbiphenyl O
nontetrazole O
angiotensin O
II O
type O
1 O
receptor O
(AT1) O
antagonist O
, O
which O
acts O
to O
decrease O
total O
peripheral O
resistance O
. O
Eprosartan O
acts O
at O
vascular O
AT1 B
receptors I
(postsynaptically) O
and O
at O
presynaptic O
AT1 O
receptors O
, O
where O
it O
inhibits O
noradrenaline O
release O
. O
In O
clinical O
studies O
, O
eprosartan O
has O
been O
shown O
to O
significantly O
reduce O
cardiovascular O
and O
cerebrovascular O
events O
, O
whilst O
avoiding O
the O
persistent O
cough O
that O
commonly O
occurs O
with O
the O
use O
of O
angiotensin-converting O
enzyme O
inhibitors O
. O
Eprosartan O
can O
also O
be O

eprosartan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
blood O
pressure O
and O
treating O
heart O
failure O
in O
a O
broad O
range O
of O
patients O
, O
including O
those O
with O
diabetes O
and O
the O
elderly O
. O
Not O
only O
have O
ARBs O
shown O
good O
efficacy O
and O
tolerability O
, O
they O
also O
appear O
to O
have O
a O
protective O
effect O
that O
goes O
beyond O
that O
expected O
from O
the O
reduction O
of O
blood O
pressure O
. O
The O
ARB O
eprosartan O
is O
a O
nonbiphenyl O
nontetrazole O
angiotensin B
II I
type I
1 I
receptor I
(AT1) O
antagonist O
, O
which O
acts O
to O
decrease O
total O
peripheral O
resistance O
. O
Eprosartan O
acts O
at O
vascular O
AT1 O
receptors O
(postsynaptically) O
and O
at O
presynaptic O
AT1 O
receptors O
, O
where O
it O
inhibits O
noradrenaline O
release O
. O
In O
clinical O
studies O
, O
eprosartan O
has O
been O
shown O
to O
significantly O
reduce O
cardiovascular O
and O
cerebrovascular O
events O
, O

eprosartan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
blood O
pressure O
and O
treating O
heart O
failure O
in O
a O
broad O
range O
of O
patients O
, O
including O
those O
with O
diabetes O
and O
the O
elderly O
. O
Not O
only O
have O
ARBs O
shown O
good O
efficacy O
and O
tolerability O
, O
they O
also O
appear O
to O
have O
a O
protective O
effect O
that O
goes O
beyond O
that O
expected O
from O
the O
reduction O
of O
blood O
pressure O
. O
The O
ARB O
eprosartan O
is O
a O
nonbiphenyl O
nontetrazole O
angiotensin O
II O
type O
1 O
receptor O
(AT1) O
antagonist O
, O
which O
acts O
to O
decrease O
total O
peripheral O
resistance O
. O
Eprosartan O
acts O
at O
vascular O
AT1 B
receptors O
(postsynaptically) O
and O
at O
presynaptic O
AT1 O
receptors O
, O
where O
it O
inhibits O
noradrenaline O
release O
. O
In O
clinical O
studies O
, O
eprosartan O
has O
been O
shown O
to O
significantly O
reduce O
cardiovascular O
and O
cerebrovascular O
events O
, O

lomustine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
reaction O
products O
at O
times O
yields O
mass O
spectra O
hard O
to O
interpret O
. O
Chromatographic O
separation O
at O
protein O
level O
could O
reduce O
the O
complexity O
of O
a O
sample O
, O
thus O
allowing O
more O
accurate O
mass O
spectrometric O
analysis O
. O
In O
this O
report O
, O
we O
demonstrate O
the O
utility O
of O
reversed-phase O
protein O
chromatography O
and O
FT-ICR O
mass O
spectrometry O
in O
analyzing O
CCNU O
( O
lomustine O
1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea O
, O
MW O
: O
233.7Da) O
modification O
of O
stathmin O
. O
With O
this O
combined O
approach O
, O
we O
determined O
the O
stoichiometry O
as O
well O
as O
sites O
of O
CCNU O
incorporation O
into O
the O
protein O
, O
demonstrating O
differential O
reactivity O
of O
several O
lysyl O
residues O
to O
CCNU O
alkylation O
. O

1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
reaction O
products O
at O
times O
yields O
mass O
spectra O
hard O
to O
interpret O
. O
Chromatographic O
separation O
at O
protein O
level O
could O
reduce O
the O
complexity O
of O
a O
sample O
, O
thus O
allowing O
more O
accurate O
mass O
spectrometric O
analysis O
. O
In O
this O
report O
, O
we O
demonstrate O
the O
utility O
of O
reversed-phase O
protein O
chromatography O
and O
FT-ICR O
mass O
spectrometry O
in O
analyzing O
CCNU O
(lomustine O
, O
1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea O
MW O
: O
233.7Da) O
modification O
of O
stathmin O
. O
With O
this O
combined O
approach O
, O
we O
determined O
the O
stoichiometry O
as O
well O
as O
sites O
of O
CCNU O
incorporation O
into O
the O
protein O
, O
demonstrating O
differential O
reactivity O
of O
several O
lysyl O
residues O
to O
CCNU O
alkylation O
. O

rolipram O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
modulate O
human O
eosinophil O
or O
neutrophil O
apoptosis O
or O
beta O
2-adrenoceptor O
agonist- O
or O
cytokine-afforded O
survival O
. O
We O
also O
evaluated O
whether O
a O
PDE4 B
inhibitor O
could O
modulate O
the O
effect O
of O
a O
corticosteroid O
on O
eosinophil O
and O
neutrophil O
apoptosis O
. O
Apoptosis O
was O
measured O
by O
using O
the O
relative O
DNA O
fragmentation O
assay O
and O
Annexin-V O
binding O
. O
Inhibitors O
of O
PDE4 O
( O
rolipram O
0.1-10 O
microM) O
and O
PDE3 O
(cilostazol; O
0.1-10 O
microM) O
delayed O
spontaneous O
eosinophil O
apoptosis O
maximally O
by O
25% O
and O
15% O
, O
respectively O
. O
A O
combination O
of O
a O
PDE4 O
or O
PDE3 O
inhibitor O
(10 O
microM) O
with O
salbutamol O
(100 O
nM) O
further O
delayed O
eosinophil O
apoptosis O
maximally O
by O
42-49% O
. O
In O
neutrophils O
, O
rolipram O
(10 O
microM) O
also O
decreased O
apoptosis O
with O
a O
maximal O

cilostazol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
apoptosis O
or O
beta O
2-adrenoceptor O
agonist- O
or O
cytokine-afforded O
survival O
. O
We O
also O
evaluated O
whether O
a O
PDE4 O
inhibitor O
could O
modulate O
the O
effect O
of O
a O
corticosteroid O
on O
eosinophil O
and O
neutrophil O
apoptosis O
. O
Apoptosis O
was O
measured O
by O
using O
the O
relative O
DNA O
fragmentation O
assay O
and O
Annexin-V O
binding O
. O
Inhibitors O
of O
PDE4 O
(rolipram; O
0.1-10 O
microM) O
and O
PDE3 B
( O
cilostazol O
0.1-10 O
microM) O
delayed O
spontaneous O
eosinophil O
apoptosis O
maximally O
by O
25% O
and O
15% O
, O
respectively O
. O
A O
combination O
of O
a O
PDE4 O
or O
PDE3 O
inhibitor O
(10 O
microM) O
with O
salbutamol O
(100 O
nM) O
further O
delayed O
eosinophil O
apoptosis O
maximally O
by O
42-49% O
. O
In O
neutrophils O
, O
rolipram O
(10 O
microM) O
also O
decreased O
apoptosis O
with O
a O
maximal O
inhibition O
of O
13% O
. O
The O
combination O

zaprinast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(10 O
microM) O
with O
salbutamol O
(100 O
nM) O
further O
delayed O
eosinophil O
apoptosis O
maximally O
by O
42-49% O
. O
In O
neutrophils O
, O
rolipram O
(10 O
microM) O
also O
decreased O
apoptosis O
with O
a O
maximal O
inhibition O
of O
13% O
. O
The O
combination O
of O
rolipram O
(10 O
microM) O
and O
salbutamol O
(100 O
nM) O
produced O
a O
27% O
inhibition O
of O
neutrophil O
apoptosis O
. O
Inhibitor O
of O
cGMP-specific B
PDE5 I
( O
zaprinast O
0.1-10 O
microM) O
did O
not O
affect O
eosinophil O
apoptosis O
and O
only O
slightly O
increased O
spontaneous O
neutrophil O
apoptosis O
. O
The O
effect O
of O
budesonide O
on O
apoptosis O
was O
not O
significantly O
modulated O
by O
a O
PDE4 O
inhibitor O
in O
eosinophils O
or O
neutrophils O
. O
The O
present O
results O
show O
that O
selective O
inhibitors O
of O
cAMP-hydrolyzing O
PDEs O
(PDE3 O
and O
PDE4) O
delay O
eosinophil O
apoptosis O
and O
, O

carboxylic O
acid O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
hypercholesterolemia O
. O
Recently O
, O
they O
are O
reported O
to O
have O
beneficial O
effects O
on O
certain O
cancers O
. O
In O
this O
study O
, O
we O
show O
that O
statins O
inhibited O
the O
histone O
deacetylase O
(HDAC) O
activity O
and O
increased O
the O
accumulation O
of O
acetylated O
histone-H3 O
and O
the O
expression O
of O
p21(WAF/CIP) O
in O
human O
cancer O
cells O
. O
Computational O
modeling O
showed O
the O
direct O
interaction O
of O
the O
carboxylic O
acid O
moiety O
of O
statins O
with O
the O
catalytic O
site O
of O
HDAC2 O
. O
In O
the O
subsequent O
enzymatic O
assay O
, O
it O
was O
shown O
that O
lovastatin O
inhibited O
HDAC2 B
activity O
competitively O
with O
a O
K(i) O
value O
of O
31.6 O
micromol/L O
. O
Sp1 O
but O
not O
p53 O
sites O
were O
found O
to O
be O
the O
statins-responsive O
element O
shown O
by O
p21 O
luciferase-promoter O
assays O
. O
DNA O
affinity O

Statins O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Statins O
increase O
p21 O
through O
inhibition O
of O
histone O
deacetylase O
activity O
and O
release O
of O
promoter-associated O
HDAC1/2 O
. O
Statins O
are O
3-hydroxy-3-methylglutaryl-CoA B
reductase I
inhibitors O
broadly O
used O
for O
the O
control O
of O
hypercholesterolemia O
. O
Recently O
, O
they O
are O
reported O
to O
have O
beneficial O
effects O
on O
certain O
cancers O
. O
In O
this O
study O
, O
we O
show O
that O
statins O
inhibited O
the O
histone O
deacetylase O
(HDAC) O
activity O
and O
increased O
the O
accumulation O
of O
acetylated O
histone-H3 O
and O
the O
expression O
of O
p21(WAF/CIP) O
in O
human O

lovastatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
histone O
deacetylase O
(HDAC) O
activity O
and O
increased O
the O
accumulation O
of O
acetylated O
histone-H3 O
and O
the O
expression O
of O
p21(WAF/CIP) O
in O
human O
cancer O
cells O
. O
Computational O
modeling O
showed O
the O
direct O
interaction O
of O
the O
carboxylic O
acid O
moiety O
of O
statins O
with O
the O
catalytic O
site O
of O
HDAC2 O
. O
In O
the O
subsequent O
enzymatic O
assay O
, O
it O
was O
shown O
that O
lovastatin O
inhibited O
HDAC2 B
activity O
competitively O
with O
a O
K(i) O
value O
of O
31.6 O
micromol/L O
. O
Sp1 O
but O
not O
p53 O
sites O
were O
found O
to O
be O
the O
statins-responsive O
element O
shown O
by O
p21 O
luciferase-promoter O
assays O
. O
DNA O
affinity O
protein O
binding O
assay O
and O
chromatin O
immunoprecipitation O
assay O
showed O
the O
dissociation O
of O
HDAC1/2 O
and O
association O
of O
CBP O
, O
leading O
to O
the O

Flavopiridol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Flavopiridol O
Hoechst O
AG.Hoechst O
is O
developing O
flavopiridol O
, O
a O
synthetic O
flavonoid O
based O
on O
an O
extract O
from O
an O
Indian O
plant O
, O
for O
the O
potential O
treatment O
of O
cancer O
. O
Flavopiridol O
a O
cyclin-dependent B
kinase I
inhibitor O
, O
arrests O
cell O
division O
and O
causes O
apoptosis O
in O
non-small O
lung O
cancer O
cells O
[283660] O
. O
A O
phase O
II O
trial O
, O
in O
collaboration O
with O
the O
National O
Cancer O
Institute O
, O
has O
commenced O
at O
the O
University O
of O
Chicago O
Medical O
Center O
, O
which O
involves O
patients O
with O
high O
or O
intermediate-grade O
lymphoma O
or O
multiple O
myeloma O
[272937] O
, O
[277372] O
. O

flavopiridol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
commenced O
at O
the O
University O
of O
Chicago O
Medical O
Center O
, O
which O
involves O
patients O
with O
high O
or O
intermediate-grade O
lymphoma O
or O
multiple O
myeloma O
[272937] O
, O
[277372] O
. O
In O
ex O
vivo O
experiments O
with O
tumor O
cells O
from O
refractory O
chronic O
lymphoblastic O
leukemia O
, O
dose-dependent O
CDK2 B
inhibition O
associated O
with O
apoptotic O
changes O
was O
seen O
at O
concentrations O
greater O
than O
100 O
nM O
of O
flavopiridol O
In O
vitro O
pharmacokinetic O
studies O
have O
shown O
that O
flavopiridol O
undergoes O
hepatic O
biotransformation O
to O
its O
corresponding O
glucoronide O
by O
uridine O
diphosphate O
glucoronosyltransferases O
[283791] O
. O
Flavopiridol O
inhibits O
CDK O
with O
an O
IC50 O
value O
of O
0.4 O
mM O
[285707] O
. O
Preclinical O
toxicology O
studies O
in O
rats O
and O
dogs O
demonstrated O
dose-related O
leukopenia O
and O
drug-related O
lesions O
in O
the O
thymus O
, O
spleen O
and O

Flavopiridol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
ex O
vivo O
experiments O
with O
tumor O
cells O
from O
refractory O
chronic O
lymphoblastic O
leukemia O
, O
dose-dependent O
CDK2 O
inhibition O
associated O
with O
apoptotic O
changes O
was O
seen O
at O
concentrations O
greater O
than O
100 O
nM O
of O
flavopiridol O
. O
In O
vitro O
pharmacokinetic O
studies O
have O
shown O
that O
flavopiridol O
undergoes O
hepatic O
biotransformation O
to O
its O
corresponding O
glucoronide O
by O
uridine O
diphosphate O
glucoronosyltransferases O
[283791] O
. O
Flavopiridol O
inhibits O
CDK B
with O
an O
IC50 O
value O
of O
0.4 O
mM O
[285707] O
. O
Preclinical O
toxicology O
studies O
in O
rats O
and O
dogs O
demonstrated O
dose-related O
leukopenia O
and O
drug-related O
lesions O
in O
the O
thymus O
, O
spleen O
and O
bone O
marrow O
. O
The O
gastrointestinal O
and O
bone O
marrow O
toxicity O
was O
dose-limiting O
[178579] O
. O
Hoechst O
Marion O
Roussel O
expects O
to O
launch O
flavopiridol O
in O
the O
year O

taxanes O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Optimization O
of O
taxane O
binding O
to O
microtubules O
: O
binding O
affinity O
dissection O
and O
incremental O
construction O
of O
a O
high-affinity O
analog O
of O
paclitaxel.The O
microtubule B
binding O
affinities O
of O
a O
series O
of O
synthetic O
taxanes O
have O
been O
measured O
with O
the O
aims O
of O
dissecting O
individual O
group O
contributions O
and O
obtaining O
a O
rationale O
for O
the O
design O
of O
novel O
compounds O
with O
the O
ability O
to O
overcome O
drug O
resistance O
. O
As O
previously O
observed O
for O
epothilones O
, O
the O
positive O
and O
negative O
contributions O
of O
the O
different O
substituents O
to O
the O
binding O
free O
energies O
are O
cumulative O
. O

docetaxel O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
positive O
and O
negative O
contributions O
of O
the O
different O
substituents O
to O
the O
binding O
free O
energies O
are O
cumulative O
. O
By O
combining O
the O
most O
favorable O
substitutions O
we O
increased O
the O
binding O
affinity O
of O
paclitaxel O
500-fold O
. O
Insight O
into O
the O
structural O
basis O
for O
this O
improvement O
was O
gained O
with O
molecular O
modeling O
and O
NMR O
data O
obtained O
for O
microtubule-bound O
docetaxel O
Taxanes O
with O
affinities O
for O
microtubules O
well O
above O
their O
affinities O
for O
P-glycoprotein O
are O
shown O
not O
to O
be O
affected O
by O
multidrug O
resistance O
. O
This O
finding O
strongly O
indicates O
that O
optimization O
of O
the O
ligand-target O
interaction O
is O
a O
good O
strategy O
to O
overcome O
multidrug O
resistance O
mediated O
by O
efflux O
pumps O
. O

Taxanes O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
positive O
and O
negative O
contributions O
of O
the O
different O
substituents O
to O
the O
binding O
free O
energies O
are O
cumulative O
. O
By O
combining O
the O
most O
favorable O
substitutions O
we O
increased O
the O
binding O
affinity O
of O
paclitaxel O
500-fold O
. O
Insight O
into O
the O
structural O
basis O
for O
this O
improvement O
was O
gained O
with O
molecular O
modeling O
and O
NMR O
data O
obtained O
for O
microtubule-bound O
docetaxel O
. O
Taxanes O
with O
affinities O
for O
microtubules B
well O
above O
their O
affinities O
for O
P-glycoprotein O
are O
shown O
not O
to O
be O
affected O
by O
multidrug O
resistance O
. O
This O
finding O
strongly O
indicates O
that O
optimization O
of O
the O
ligand-target O
interaction O
is O
a O
good O
strategy O
to O
overcome O
multidrug O
resistance O
mediated O
by O
efflux O
pumps O
. O

Taxanes O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
positive O
and O
negative O
contributions O
of O
the O
different O
substituents O
to O
the O
binding O
free O
energies O
are O
cumulative O
. O
By O
combining O
the O
most O
favorable O
substitutions O
we O
increased O
the O
binding O
affinity O
of O
paclitaxel O
500-fold O
. O
Insight O
into O
the O
structural O
basis O
for O
this O
improvement O
was O
gained O
with O
molecular O
modeling O
and O
NMR O
data O
obtained O
for O
microtubule-bound O
docetaxel O
. O
Taxanes O
with O
affinities O
for O
microtubules O
well O
above O
their O
affinities O
for O
P-glycoprotein B
are O
shown O
not O
to O
be O
affected O
by O
multidrug O
resistance O
. O
This O
finding O
strongly O
indicates O
that O
optimization O
of O
the O
ligand-target O
interaction O
is O
a O
good O
strategy O
to O
overcome O
multidrug O
resistance O
mediated O
by O
efflux O
pumps O
. O

paclitaxel O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Optimization O
of O
taxane O
binding O
to O
microtubules O
: O
binding O
affinity O
dissection O
and O
incremental O
construction O
of O
a O
high-affinity O
analog O
of O
paclitaxe O
.The O
microtubule O
binding O
affinities O
of O
a O
series O
of O
synthetic O
taxanes O
have O
been O
measured O
with O
the O
aims O
of O
dissecting O
individual O
group O
contributions O
and O
obtaining O
a O
rationale O
for O
the O
design O
of O
novel O
compounds O
with O
the O
ability O
to O
overcome O
drug O
resistance O
. O
As O
previously O
observed O
for O
epothilones O
, O
the O
positive O
and O
negative O
contributions O
of O

taxane O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Optimization O
of O
taxan O
binding O
to O
microtubules O
: O
binding O
affinity O
dissection O
and O
incremental O
construction O
of O
a O
high-affinity O
analog O
of O
paclitaxel.The O
microtubule O
binding O
affinities O
of O
a O
series O
of O
synthetic O
taxanes O
have O
been O
measured O
with O
the O
aims O
of O
dissecting O
individual O
group O
contributions O
and O
obtaining O
a O
rationale O
for O
the O
design O
of O
novel O
compounds O
with O
the O
ability O
to O

9-hydroxyrisperidone O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
ABCB1 O
polymorphisms O
influence O
steady-state O
plasma O
levels O
of O
9-hydroxyrisperidone O
and O
risperidone O
active O
moiety.Risperidone O
is O
metabolized O
to O
its O
active O
metabolite O
, O
9-hydroxyrisperidone O
mainly O
by O
the O
cytochrome B
P450 I
enzymes O
CYP2D6 O
and O
3A4 O
. O
Its O
antipsychotic O
effect O
is O
assumed O
to O
be O
related O
to O
the O
active O
moiety O
, O
that O
is O
, O
the O
sum O
of O
risperidone O
and O
9-hydroxyrisperidone O
. O
Both O
risperidone O
and O
9-hydroxyrisperidone O
are O
substrates O
of O
P-glycoprotein O
(P-gp) O
, O
a O
transport O
protein O
involved O
in O
drug O
absorption O
, O
distribution O
, O
and O
elimination O
. O
The O

risperidone O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
ABCB1 O
polymorphisms O
influence O
steady-state O
plasma O
levels O
of O
9-hydroxyrisperidone O
and O
risperidone O
active O
moiety.Risperidone O
is O
metabolized O
to O
its O
active O
metabolite O
, O
9-hydroxyrisperidone O
, O
mainly O
by O
the O
cytochrome O
P450 O
enzymes O
CYP2D6 O
and O
3A4 O
. O
Its O
antipsychotic O
effect O
is O
assumed O
to O
be O
related O
to O
the O
active O
moiety O
, O
that O
is O
, O
the O
sum O
of O
risperidone O
and O
9-hydroxyrisperidone O
. O
Both O
risperidone O
and O
9-hydroxyrisperidone O
are O
substrates O
of O
P-glycoprotein B
(P-gp) O
, O
a O
transport O
protein O
involved O
in O
drug O
absorption O
, O
distribution O
, O
and O
elimination O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
influence O
of O
polymorphisms O
in O
genes O
encoding O
CYP3A5 O
and O
P-gp O
(ABCB1) O
on O
the O
steady-state O
plasma O
levels O
of O
risperidone O
, O
9-hydroxyrisperidone O
, O
and O
the O
active O
moiety O
, O

risperidone O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
ABCB1 O
polymorphisms O
influence O
steady-state O
plasma O
levels O
of O
9-hydroxyrisperidone O
and O
risperidone O
active O
moiety.Risperidone O
is O
metabolized O
to O
its O
active O
metabolite O
, O
9-hydroxyrisperidone O
, O
mainly O
by O
the O
cytochrome O
P450 O
enzymes O
CYP2D6 O
and O
3A4 O
. O
Its O
antipsychotic O
effect O
is O
assumed O
to O
be O
related O
to O
the O
active O
moiety O
, O
that O
is O
, O
the O
sum O
of O
risperidone O
and O
9-hydroxyrisperidone O
. O
Both O
risperidone O
and O
9-hydroxyrisperidone O
are O
substrates O
of O
P-glycoprotein O
(P-gp) O
, O
a O
transport O
protein O
involved O
in O
drug O
absorption O
, O
distribution O
, O
and O
elimination O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
influence O
of O
polymorphisms O
in O
genes O
encoding O
CYP3A5 O
and O
P-gp B
(ABCB1) O
on O
the O
steady-state O
plasma O
levels O
of O
risperidone O
, O
9-hydroxyrisperidone O
, O
and O
the O
active O
moiety O
, O

9-hydroxyrisperidone O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
influence O
steady-state O
plasma O
levels O
of O
9-hydroxyrisperidone O
and O
risperidone O
active O
moiety.Risperidone O
is O
metabolized O
to O
its O
active O
metabolite O
, O
9-hydroxyrisperidone O
, O
mainly O
by O
the O
cytochrome O
P450 O
enzymes O
CYP2D6 O
and O
3A4 O
. O
Its O
antipsychotic O
effect O
is O
assumed O
to O
be O
related O
to O
the O
active O
moiety O
, O
that O
is O
, O
the O
sum O
of O
risperidone O
and O
9-hydroxyrisperidone O
. O
Both O
risperidone O
and O
9-hydroxyrisperidone O
are O
substrates O
of O
P-glycoprotein B
(P-gp) O
, O
a O
transport O
protein O
involved O
in O
drug O
absorption O
, O
distribution O
, O
and O
elimination O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
influence O
of O
polymorphisms O
in O
genes O
encoding O
CYP3A5 O
and O
P-gp O
(ABCB1) O
on O
the O
steady-state O
plasma O
levels O
of O
risperidone O
, O
9-hydroxyrisperidone O
, O
and O
the O
active O
moiety O
, O
taking O
CYP2D6 O

9-hydroxyrisperidone O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
influence O
steady-state O
plasma O
levels O
of O
9-hydroxyrisperidone O
and O
risperidone O
active O
moiety.Risperidone O
is O
metabolized O
to O
its O
active O
metabolite O
, O
9-hydroxyrisperidone O
, O
mainly O
by O
the O
cytochrome O
P450 O
enzymes O
CYP2D6 O
and O
3A4 O
. O
Its O
antipsychotic O
effect O
is O
assumed O
to O
be O
related O
to O
the O
active O
moiety O
, O
that O
is O
, O
the O
sum O
of O
risperidone O
and O
9-hydroxyrisperidone O
. O
Both O
risperidone O
and O
9-hydroxyrisperidone O
are O
substrates O
of O
P-glycoprotein O
(P-gp) O
, O
a O
transport O
protein O
involved O
in O
drug O
absorption O
, O
distribution O
, O
and O
elimination O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
influence O
of O
polymorphisms O
in O
genes O
encoding O
CYP3A5 O
and O
P-gp B
(ABCB1) O
on O
the O
steady-state O
plasma O
levels O
of O
risperidone O
, O
9-hydroxyrisperidone O
, O
and O
the O
active O
moiety O
, O
taking O
CYP2D6 O

Risperidone O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
ABCB1 O
polymorphisms O
influence O
steady-state O
plasma O
levels O
of O
9-hydroxyrisperidone O
and O
risperidone O
active O
moiety O
. O
Risperidone O
is O
metabolized O
to O
its O
active O
metabolite O
, O
9-hydroxyrisperidone O
, O
mainly O
by O
the O
cytochrome B
P450 I
enzymes O
CYP2D6 O
and O
3A4 O
. O
Its O
antipsychotic O
effect O
is O
assumed O
to O
be O
related O
to O
the O
active O
moiety O
, O
that O
is O
, O
the O
sum O
of O
risperidone O
and O
9-hydroxyrisperidone O
. O
Both O
risperidone O
and O
9-hydroxyrisperidone O
are O
substrates O
of O
P-glycoprotein O
(P-gp) O
, O
a O
transport O
protein O
involved O

PGE(2) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid B
receptors I
EP(1) I
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O

PGE(2) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O

ONO-8713 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
and O
EP(1) B
through O
EP(4) O
and O
secretes O
PGE(2) O
. O
PGE(2) O
and O
the O
EP(2) O
receptor O
agonist O
butaprost O
stimulated O
MB O
cell O
proliferation O
. O
Treatment O
of O
MB O
cells O
with O
COX O
inhibitors O
suppressed O
PGE(2) O
production O
and O
induced O
caspase-dependent O
apoptosis O
. O
Similarly O
, O
specific O
COX-2 O
silencing O
by O
small O
interfering O
RNA O
inhibited O
MB O
cell O
growth O
. O
EP(1) O
and O
EP(3) O
receptor O
antagonists O
ONO-8713 O
and O
ONO-AE3-240 O
, O
but O
not O
the O
EP(4) O
antagonists O
ONO-AE3-208 O
and O
AH O
23848 O
, O
inhibited O
tumor O
cell O
proliferation O
, O
indicating O
the O
significance O
of O
EP(1) O
and O
EP(3) O
but O
not O
EP(4) O
for O
MB O
growth O
. O
Administration O
of O
COX O
inhibitors O
at O
clinically O
achievable O
nontoxic O
concentrations O
significantly O
inhibited O
growth O
of O
established O
human O
MB O
xenografts O
. O
Apoptosis O
was O
increased O
, O
proliferation O

ONO-8713 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
and O
EP(1) O
through O
EP(4) O
and O
secretes O
PGE(2) O
. O
PGE(2) O
and O
the O
EP(2) O
receptor O
agonist O
butaprost O
stimulated O
MB O
cell O
proliferation O
. O
Treatment O
of O
MB O
cells O
with O
COX O
inhibitors O
suppressed O
PGE(2) O
production O
and O
induced O
caspase-dependent O
apoptosis O
. O
Similarly O
, O
specific O
COX-2 O
silencing O
by O
small O
interfering O
RNA O
inhibited O
MB O
cell O
growth O
. O
EP(1) O
and O
EP(3) B
receptor I
antagonists O
ONO-8713 O
and O
ONO-AE3-240 O
, O
but O
not O
the O
EP(4) O
antagonists O
ONO-AE3-208 O
and O
AH O
23848 O
, O
inhibited O
tumor O
cell O
proliferation O
, O
indicating O
the O
significance O
of O
EP(1) O
and O
EP(3) O
but O
not O
EP(4) O
for O
MB O
growth O
. O
Administration O
of O
COX O
inhibitors O
at O
clinically O
achievable O
nontoxic O
concentrations O
significantly O
inhibited O
growth O
of O
established O
human O
MB O
xenografts O
. O
Apoptosis O
was O
increased O
, O
proliferation O

ONO-AE3-240 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
through O
EP(4) O
and O
secretes O
PGE(2) O
. O
PGE(2) O
and O
the O
EP(2) O
receptor O
agonist O
butaprost O
stimulated O
MB O
cell O
proliferation O
. O
Treatment O
of O
MB O
cells O
with O
COX O
inhibitors O
suppressed O
PGE(2) O
production O
and O
induced O
caspase-dependent O
apoptosis O
. O
Similarly O
, O
specific O
COX-2 O
silencing O
by O
small O
interfering O
RNA O
inhibited O
MB O
cell O
growth O
. O
EP(1) B
and O
EP(3) O
receptor O
antagonists O
ONO-8713 O
and O
ONO-AE3-240 O
but O
not O
the O
EP(4) O
antagonists O
ONO-AE3-208 O
and O
AH O
23848 O
, O
inhibited O
tumor O
cell O
proliferation O
, O
indicating O
the O
significance O
of O
EP(1) O
and O
EP(3) O
but O
not O
EP(4) O
for O
MB O
growth O
. O
Administration O
of O
COX O
inhibitors O
at O
clinically O
achievable O
nontoxic O
concentrations O
significantly O
inhibited O
growth O
of O
established O
human O
MB O
xenografts O
. O
Apoptosis O
was O
increased O
, O
proliferation O
was O
reduced O
, O

ONO-AE3-240 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
through O
EP(4) O
and O
secretes O
PGE(2) O
. O
PGE(2) O
and O
the O
EP(2) O
receptor O
agonist O
butaprost O
stimulated O
MB O
cell O
proliferation O
. O
Treatment O
of O
MB O
cells O
with O
COX O
inhibitors O
suppressed O
PGE(2) O
production O
and O
induced O
caspase-dependent O
apoptosis O
. O
Similarly O
, O
specific O
COX-2 O
silencing O
by O
small O
interfering O
RNA O
inhibited O
MB O
cell O
growth O
. O
EP(1) O
and O
EP(3) B
receptor I
antagonists O
ONO-8713 O
and O
ONO-AE3-240 O
but O
not O
the O
EP(4) O
antagonists O
ONO-AE3-208 O
and O
AH O
23848 O
, O
inhibited O
tumor O
cell O
proliferation O
, O
indicating O
the O
significance O
of O
EP(1) O
and O
EP(3) O
but O
not O
EP(4) O
for O
MB O
growth O
. O
Administration O
of O
COX O
inhibitors O
at O
clinically O
achievable O
nontoxic O
concentrations O
significantly O
inhibited O
growth O
of O
established O
human O
MB O
xenografts O
. O
Apoptosis O
was O
increased O
, O
proliferation O
was O
reduced O
, O

ONO-AE3-208 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
and O
the O
EP(2) O
receptor O
agonist O
butaprost O
stimulated O
MB O
cell O
proliferation O
. O
Treatment O
of O
MB O
cells O
with O
COX O
inhibitors O
suppressed O
PGE(2) O
production O
and O
induced O
caspase-dependent O
apoptosis O
. O
Similarly O
, O
specific O
COX-2 O
silencing O
by O
small O
interfering O
RNA O
inhibited O
MB O
cell O
growth O
. O
EP(1) O
and O
EP(3) O
receptor O
antagonists O
ONO-8713 O
and O
ONO-AE3-240 O
, O
but O
not O
the O
EP(4) B
antagonists O
ONO-AE3-208 O
and O
AH O
23848 O
, O
inhibited O
tumor O
cell O
proliferation O
, O
indicating O
the O
significance O
of O
EP(1) O
and O
EP(3) O
but O
not O
EP(4) O
for O
MB O
growth O
. O
Administration O
of O
COX O
inhibitors O
at O
clinically O
achievable O
nontoxic O
concentrations O
significantly O
inhibited O
growth O
of O
established O
human O
MB O
xenografts O
. O
Apoptosis O
was O
increased O
, O
proliferation O
was O
reduced O
, O
and O
angiogenesis O
was O
inhibited O
in O
MBs O

AH O
23848 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
EP(2) O
receptor O
agonist O
butaprost O
stimulated O
MB O
cell O
proliferation O
. O
Treatment O
of O
MB O
cells O
with O
COX O
inhibitors O
suppressed O
PGE(2) O
production O
and O
induced O
caspase-dependent O
apoptosis O
. O
Similarly O
, O
specific O
COX-2 O
silencing O
by O
small O
interfering O
RNA O
inhibited O
MB O
cell O
growth O
. O
EP(1) O
and O
EP(3) O
receptor O
antagonists O
ONO-8713 O
and O
ONO-AE3-240 O
, O
but O
not O
the O
EP(4) B
antagonists O
ONO-AE3-208 O
and O
AH O
23848 O
inhibited O
tumor O
cell O
proliferation O
, O
indicating O
the O
significance O
of O
EP(1) O
and O
EP(3) O
but O
not O
EP(4) O
for O
MB O
growth O
. O
Administration O
of O
COX O
inhibitors O
at O
clinically O
achievable O
nontoxic O
concentrations O
significantly O
inhibited O
growth O
of O
established O
human O
MB O
xenografts O
. O
Apoptosis O
was O
increased O
, O
proliferation O
was O
reduced O
, O
and O
angiogenesis O
was O
inhibited O
in O
MBs O
treated O
with O
COX O

prostaglandin O
E2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 B
prostaglandin O
E O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O

PGE(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases B
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O

PGE(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O

PGE(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin B
E I
synthases I
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O

PGE(2) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases B
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O
levels O
of O
COX-2 O
, O
microsomal O
prostaglandin O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O
levels O
of O
COX-2 O
, O
microsomal O
prostaglandin O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin B
E I
synthases I
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O
levels O
of O
COX-2 O
, O
microsomal O
prostaglandin O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Tumor-growth-promoting O
cyclooxygenase-2 O
prostaglandin O
E2 O
pathway O
provides O
medulloblastoma O
therapeutic O
targets.Prostaglandin O
E(2) O
(PGE(2)) O
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression O
. O
PGE(2) O
is O
synthesized O
from O
arachidonic O
acid O
by O
cyclooxygenases O
(COX) O
and O
prostaglandin O
E O
synthases O
(PGES) O
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid O
receptors O
EP(1) O
through O
EP(4) O
. O
In O
this O
study O
, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB) O
, O
the O
most O
common O
malignant O
childhood O
brain O
tumor O
, O
expresses O
high O
levels O
of O
COX-2 O
, O
microsomal O
prostaglandin O

Plerixafor O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cells O
harvested O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal B
cell-derived I
factor-1 I
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O

Plerixafor O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cells O
harvested O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O

Plerixafor O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cells O
harvested O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O

Plerixafor O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cells O
harvested O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine B
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O

AMD3100 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
( O
AMD3100 O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal B
cell-derived I
factor-1 I
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O

AMD3100 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
( O
AMD3100 O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O

AMD3100 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
( O
AMD3100 O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O

AMD3100 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
( O
AMD3100 O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine B
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O

bicyclam O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal B
cell-derived I
factor-1 I
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O
autologous O
stem O
cell O
transplantation O
, O
the O

bicyclam O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O
autologous O
stem O
cell O
transplantation O
, O
the O

bicyclam O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine O
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O
autologous O
stem O
cell O
transplantation O
, O
the O

bicyclam O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation O
. O
While O
G-CSF O
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization O
, O
the O
use O
of O
G-CSF O
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation O
. O
Plerixafor O
(AMD3100 O
, O
Genzyme O
Corporation) O
is O
a O
bicyclam O
molecule O
that O
antagonizes O
the O
binding O
of O
the O
chemokine B
stromal O
cell-derived O
factor-1 O
(SDF-1) O
to O
its O
cognate O
receptor O
CXCR4 O
. O
Plerixafor O
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF O
. O
In O
clinical O
studies O
of O
autologous O
stem O
cell O
transplantation O
, O
the O

naltrexone O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
[Pharmacological O
effects O
of O
a O
mu-opioid B
receptor I
antagonist O
naltrexon O
on O
alcohol O
dependence].Alcohol O
is O
one O
of O
the O
most O
commonly O
abused O
substances O
, O
and O
its O
chronic O
intake O
leads O
to O
the O
development O
of O
ethanol O
dependence O
in O
both O
humans O
and O
laboratory O
animals O
. O
In O
many O
countries O
, O
a O
mu-opioid O
receptor O
antagonist O
naltrexone O
has O
been O
used O
in O
the O
treatment O
of O
alcohol O
dependence O
. O
The O
introduction O
of O
naltrexone O

naltrexone O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
[Pharmacological O
effects O
of O
a O
mu-opioid B
receptor I
antagonist O
naltrexone O
on O
alcohol O
dependence].Alcohol O
is O
one O
of O
the O
most O
commonly O
abused O
substances O
, O
and O
its O
chronic O
intake O
leads O
to O
the O
development O
of O
ethanol O
dependence O
in O
both O
humans O
and O
laboratory O
animals O
. O
In O
many O
countries O
, O
a O
mu-opioid O
receptor O
antagonist O
naltrexone O
has O
been O
used O
in O
the O
treatment O
of O
alcohol O
dependence O
. O
The O
introduction O
of O
naltrexone O
for O
the O
treatment O
of O
alcohol O
dependence O
has O
been O
mainly O
based O
on O
behavioral O
animal O
models O
that O
provide O
evidence O
of O
the O
involvement O
of O
the O
endogenous O
opioid O
system O
in O
alcohol O
drinking O
and O
dependence O
. O
It O
has O
been O
well O
known O
that O

PLZ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O

PLZ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T B
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O

PLZ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T B
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O

VIG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O

VIG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T B
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O

VIG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T B
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O

PLZ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases B
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O

tranylcypromine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
, O
also O
inhibited O
MAO B
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O
Pretreatment O
of O
rats O
with O
the O
MAO O
inhibitor O
tranylcypromine O
prevented O
the O
increase O
in O
brain O
GABA O
and O
ALA O
levels O
with O
PLZ O
, O
but O
did O
not O
block O
the O
effect O
of O
VIG O
on O
GABA O
. O
These O
observations O
with O
tranylcypromine O
and O
PLZ O
support O
the O
hypothesis O
that O
an O
active O
metabolite O
of O
PLZ O
produced O
by O
the O
actions O
of O
MAO O
on O
this O
drug O
plays O
a O
major O
role O

tranylcypromine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO B
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
, O
also O
inhibited O
MAO O
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O

tranylcypromine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases B
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
, O
also O
inhibited O
MAO O
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O

phenelzine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine B
oxidase I
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O

phenelzine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O

vigabatrin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA B
transaminase I
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O

vigabatrin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T B
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O

VIG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
( O
VIG O
 O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA B
transaminase I
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O

VIG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
( O
VIG O
 O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA O
and O
ALA O
and O
on O
activities O
of O
MAO O
, O
GABA-T B
and O
ALA O
transaminase O
(ALA-T) O
. O
METHODS O
: O
Male O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O

PLZ O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine B
oxidase I
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
( O
PLZ O
 O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O

PLZ O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine O
oxidase O
inhibitor O
phenelzine O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
( O
PLZ O
 O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O
by O
inhibition O
of O
GABA O
transaminase O
(GABA-T) O
, O
with O
regard O
to O
their O
actions O
on O

PLZ O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
rats O
were O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T B
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O

VIG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
administered O
PLZ O
(10 O
mg/kg) O
or O
VIG O
(1,000 O
mg/kg) O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T B
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O

PLZ O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T O
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO B
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O

PLZ O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
i.p. O
, O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA O
and O
ALA O
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO O
, O
GABA-T O
and O
ALA-T B
(radiochemical O
assays) O
. O
RESULTS O
: O
Both O
PLZ O
and O
VIG O
inhibited O
GABA-T O
and O
elevated O
GABA O
levels O
. O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O

phenelzine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Neurochemical O
effects O
of O
the O
monoamine B
oxidase I
inhibitor O
phenelzin O
on O
brain O
GABA O
and O
alanine O
: O
A O
comparison O
with O
vigabatrin.PURPOSE O
: O
To O
compare O
phenelzine O
(PLZ) O
, O
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O
monoamine O
oxidase O
(MAO) O
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino O
acids O
?-aminobutyric O
acid O
(GABA) O
and O
alanine O
(ALA) O
, O
with O
vigabatrin O
(VIG) O
, O
an O
anticonvulsant O
which O
elevates O
brain O
GABA O

VIG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Only O
PLZ O
inhibited O
MAO O
and O
ALA-T O
and O
elevated O
ALA O
levels O
. O
The O
effects O
of O
PLZ O
on O
both O
amino O
acids O
and O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T B
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
, O
also O
inhibited O
MAO O
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O
Pretreatment O
of O
rats O
with O
the O
MAO O
inhibitor O
tranylcypromine O
prevented O
the O
increase O
in O
brain O
GABA O
and O
ALA O
levels O
with O
PLZ O
, O
but O

VIG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO B
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
also O
inhibited O
MAO O
and O
ALA-T O
(and O
increased O
brain O
ALA O
levels) O
. O
Pretreatment O
of O
rats O
with O
the O
MAO O
inhibitor O
tranylcypromine O
prevented O
the O
increase O
in O
brain O
GABA O
and O
ALA O
levels O
with O
PLZ O
, O
but O
did O
not O
block O
the O
effect O
of O
VIG O
on O
GABA O
. O
These O
observations O
with O
tranylcypromine O
and O
PLZ O
support O
the O
hypothesis O
that O

VIG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
their O
transaminases O
were O
blocked O
by O
pre-treatment O
with O
the O
MAO O
inhibitor O
tranylcypromine O
. O
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T O
or O
the O
elevation O
of O
brain O
GABA O
levels O
produced O
by O
VIG O
. O
CONCLUSIONS O
: O
At O
the O
doses O
studied O
, O
PLZ O
was O
as O
effective O
as O
VIG O
at O
elevating O
brain O
GABA O
levels O
, O
but O
, O
unlike O
VIG O
also O
inhibited O
MAO O
and O
ALA-T B
(and O
increased O
brain O
ALA O
levels) O
. O
Pretreatment O
of O
rats O
with O
the O
MAO O
inhibitor O
tranylcypromine O
prevented O
the O
increase O
in O
brain O
GABA O
and O
ALA O
levels O
with O
PLZ O
, O
but O
did O
not O
block O
the O
effect O
of O
VIG O
on O
GABA O
. O
These O
observations O
with O
tranylcypromine O
and O
PLZ O
support O
the O
hypothesis O
that O

Ramelteon O
acts O
as O
AGONIST O
for O
what O
entity O
? O
is O
affected O
by O
insomnia O
, O
and O
this O
number O
is O
increasing O
due O
to O
more O
stressful O
working O
conditions O
and O
the O
progressive O
aging O
of O
society O
. O
However O
, O
current O
treatment O
of O
insomnia O
with O
hypnotics O
, O
gamma-aminobutyric O
acid O
A O
(GABA(A)) O
receptor O
modulators O
, O
induces O
various O
side O
effects O
, O
including O
cognitive O
impairment O
, O
motor O
disturbance O
, O
dependence O
, O
tolerance O
, O
hangover O
, O
and O
rebound O
insomnia O
. O
Ramelteon O
(Rozerem; O
Takeda O
Pharmaceutical O
Company O
Limited O
, O
Osaka O
, O
Japan) O
is O
an O
orally O
active O
, O
highly O
selective O
melatonin O
MT(1)/MT(2) O
receptor O
agonist O
. O
Unlike O
the O
sedative O
hypnotics O
that O
target O
GABA(A) O
receptor O
complexes O
, O
ramelteon O
is O
a O
chronohypnotic O
that O
acts O
on O
the O
melatonin O
MT(1) B
and O
MT(2) O
receptors O
, O
which O
are O
primarily O
located O
in O
the O
suprachiasmatic O
nucleus O
, O
the O
body's O

Ramelteon O
acts O
as O
AGONIST O
for O
what O
entity O
? O
is O
affected O
by O
insomnia O
, O
and O
this O
number O
is O
increasing O
due O
to O
more O
stressful O
working O
conditions O
and O
the O
progressive O
aging O
of O
society O
. O
However O
, O
current O
treatment O
of O
insomnia O
with O
hypnotics O
, O
gamma-aminobutyric O
acid O
A O
(GABA(A)) O
receptor O
modulators O
, O
induces O
various O
side O
effects O
, O
including O
cognitive O
impairment O
, O
motor O
disturbance O
, O
dependence O
, O
tolerance O
, O
hangover O
, O
and O
rebound O
insomnia O
. O
Ramelteon O
(Rozerem; O
Takeda O
Pharmaceutical O
Company O
Limited O
, O
Osaka O
, O
Japan) O
is O
an O
orally O
active O
, O
highly O
selective O
melatonin O
MT(1)/MT(2) O
receptor O
agonist O
. O
Unlike O
the O
sedative O
hypnotics O
that O
target O
GABA(A) O
receptor O
complexes O
, O
ramelteon O
is O
a O
chronohypnotic O
that O
acts O
on O
the O
melatonin O
MT(1) O
and O
MT(2) B
receptors O
, O
which O
are O
primarily O
located O
in O
the O
suprachiasmatic O
nucleus O
, O
the O
body's O

ramelteon O
acts O
as O
AGONIST O
for O
what O
entity O
? O
hypnotics O
, O
gamma-aminobutyric O
acid O
A O
(GABA(A)) O
receptor O
modulators O
, O
induces O
various O
side O
effects O
, O
including O
cognitive O
impairment O
, O
motor O
disturbance O
, O
dependence O
, O
tolerance O
, O
hangover O
, O
and O
rebound O
insomnia O
. O
Ramelteon O
(Rozerem; O
Takeda O
Pharmaceutical O
Company O
Limited O
, O
Osaka O
, O
Japan) O
is O
an O
orally O
active O
, O
highly O
selective O
melatonin O
MT(1)/MT(2) O
receptor O
agonist O
. O
Unlike O
the O
sedative O
hypnotics O
that O
target O
GABA(A) O
receptor O
complexes O
, O
ramelteon O
is O
a O
chronohypnotic O
that O
acts O
on O
the O
melatonin O
MT(1) B
and O
MT(2) O
receptors O
, O
which O
are O
primarily O
located O
in O
the O
suprachiasmatic O
nucleus O
, O
the O
body's O
"master O
clock." O
As O
such O
, O
ramelteon O
possesses O
the O
first O
new O
therapeutic O
mechanism O
of O
action O
for O
a O
prescription O
insomnia O
medication O
in O
over O
three O
decades O
. O
Ramelteon O
has O
demonstrated O
sleep-promoting O
effects O

ramelteon O
acts O
as O
AGONIST O
for O
what O
entity O
? O
hypnotics O
, O
gamma-aminobutyric O
acid O
A O
(GABA(A)) O
receptor O
modulators O
, O
induces O
various O
side O
effects O
, O
including O
cognitive O
impairment O
, O
motor O
disturbance O
, O
dependence O
, O
tolerance O
, O
hangover O
, O
and O
rebound O
insomnia O
. O
Ramelteon O
(Rozerem; O
Takeda O
Pharmaceutical O
Company O
Limited O
, O
Osaka O
, O
Japan) O
is O
an O
orally O
active O
, O
highly O
selective O
melatonin O
MT(1)/MT(2) O
receptor O
agonist O
. O
Unlike O
the O
sedative O
hypnotics O
that O
target O
GABA(A) O
receptor O
complexes O
, O
ramelteon O
is O
a O
chronohypnotic O
that O
acts O
on O
the O
melatonin O
MT(1) O
and O
MT(2) B
receptors O
, O
which O
are O
primarily O
located O
in O
the O
suprachiasmatic O
nucleus O
, O
the O
body's O
"master O
clock." O
As O
such O
, O
ramelteon O
possesses O
the O
first O
new O
therapeutic O
mechanism O
of O
action O
for O
a O
prescription O
insomnia O
medication O
in O
over O
three O
decades O
. O
Ramelteon O
has O
demonstrated O
sleep-promoting O
effects O

ramelteon O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Pharmacology O
of O
ramelteo O
 O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
: O
a O
novel O
therapeutic O
drug O
for O
sleep O
disorders.An O
estimated O
one-third O
of O
the O
general O
population O
is O
affected O
by O
insomnia O
, O
and O
this O
number O
is O
increasing O
due O
to O
more O
stressful O
working O
conditions O
and O
the O
progressive O
aging O
of O
society O
. O
However O
, O
current O
treatment O
of O
insomnia O
with O
hypnotics O
, O
gamma-aminobutyric O
acid O

ramelteon O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Pharmacology O
of O
ramelteo O
 O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
: O
a O
novel O
therapeutic O
drug O
for O
sleep O
disorders.An O
estimated O
one-third O
of O
the O
general O
population O
is O
affected O
by O
insomnia O
, O
and O
this O
number O
is O
increasing O
due O
to O
more O
stressful O
working O
conditions O
and O
the O
progressive O
aging O
of O
society O
. O
However O
, O
current O
treatment O
of O
insomnia O
with O
hypnotics O
, O
gamma-aminobutyric O
acid O

SoRI-9804 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Studies O
of O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
( O
SoRI-9804 O
 O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O

N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Studies O
of O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
(SoRI-9804) O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O
release O
of O

SoRI-20040 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Studies O
of O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
(SoRI-9804) O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
( O
SoRI-20040 O
 O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O
release O
of O

N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Studies O
of O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
(SoRI-9804) O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O
release O
of O
[(3)H]1-methyl-4-phenylpyridinium O
(MPP(+))or[(3)H]dopamine O
from O

SoRI-20041 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Studies O
of O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
(SoRI-9804) O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
( O
SoRI-20041 O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O
release O
of O
[(3)H]1-methyl-4-phenylpyridinium O
(MPP(+))or[(3)H]dopamine O
from O
striatal O

[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Studies O
of O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
(SoRI-9804) O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O
release O
of O
[(3)H]1-methyl-4-phenylpyridinium O
(MPP(+))or[(3)H]dopamine O
from O
striatal O
synaptosomes O
("DAT-mediated O
DA O
release") O
in O

RTI-55 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Studies O
of O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
(SoRI-9804) O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
( O
RTI-55 O
binding O
, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O
release O
of O
[(3)H]1-methyl-4-phenylpyridinium O
(MPP(+))or[(3)H]dopamine O
from O
striatal O
synaptosomes O
("DAT-mediated O
DA O
release") O
in O
a O
dose-dependent O

[(125)I]RTI-55 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Studies O
of O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
(SoRI-9804) O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O
release O
of O
[(3)H]1-methyl-4-phenylpyridinium O
(MPP(+))or[(3)H]dopamine O
from O
striatal O
synaptosomes O
("DAT-mediated O
DA O
release") O
in O
a O
dose-dependent O
manner O
. O
SoRI-20041 O
, O
which O
does O
not O
alter O
DAT-mediated O

[(3)H]dopamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
(SoRI-9804) O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O
release O
of O
[(3)H]1-methyl-4-phenylpyridinium O
(MPP(+))or[(3)H]dopamine O
from O
striatal O
synaptosomes O
("DAT-mediated O
DA O
release") O
in O
a O
dose-dependent O
manner O
. O
SoRI-20041 O
, O
which O
does O
not O
alter O
DAT-mediated O
DA O
release O
measured O
with O
[(3)H]DA O
, O
reversed O
the O

N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Studies O
of O
the O
biogenic O
amine O
transporters O
. O
13 O
. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced O
dopamine O
release.Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine O
(DA) O
transporter O
(DAT) O
. O
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine O
(SoRI-9804) O
, O
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine O
(SoRI-20040) O
, O
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine O
(SoRI-20041) O
partially O
inhibited O
[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic O
acid O
methyl O
ester O
(RTI-55) O
binding O
, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O

SoRI-20041 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 O
from O
the O
DAT O
, O
and O
partially O
inhibited O
[(3)H]dopamine O
uptake O
. O
In O
the O
present O
study O
, O
we O
report O
that O
SoRI-9804 O
and O
SoRI-20040 O
, O
at O
doses O
that O
do O
not O
alter O
release O
, O
partially O
inhibited O
d-amphetamine-induced O
DAT-mediated O
release O
of O
[(3)H]1-methyl-4-phenylpyridinium O
(MPP(+))or[(3)H]dopamine O
from O
striatal O
synaptosomes O
("DAT-mediated O
DA O
release") O
in O
a O
dose-dependent O
manner O
. O
SoRI-20041 O
which O
does O
not O
alter O
DAT-mediated O
DA O
release O
measured O
with O
[(3)H]DA O
, O
reversed O
the O
effect O
of O
SoRI-20040 O
. O
SoRI-20040 O
and O
SoRI-9804 O
also O
partially O
inhibited O
DAT-mediated O
DA O
release O
induced O
by O
DA O
or O
(+/-)-3,4-methylenedioxyamphetamine O
, O
demonstrating O
that O
the O
observed O
partial O
inhibition O
is O
not O
specific O
for O
a O
particular O
DAT B
substrate O
. O
SoRI-9804 O
and O
SoRI-20040 O
did O
not O
attenuate O

Acarbose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
glucose O
tolerance O
(IGT) O
. O
Since O
postprandial O
hyperglycemia O
and O
insulin O
resistance O
are O
thought O
to O
play O
a O
central O
role O
in O
the O
development O
and O
progression O
of O
CVD O
in O
patients O
with O
IGT O
, O
amelioration O
of O
postprandial O
hyperglycemia O
as O
well O
as O
insulin O
resistance O
is O
a O
therapeutic O
target O
for O
the O
prevention O
of O
CVD O
in O
these O
high-risk O
patients O
. O
Acarbose O
an O
alpha-glucosidase B
inhibitor O
, O
delays O
the O
absorption O
of O
carbohydrate O
from O
the O
small O
intestine O
, O
thereby O
reducing O
postprandial O
hyperglycemia O
. O
Further O
, O
recently O
, O
acarbose O
has O
been O
shown O
to O
improve O
insulin O
resistance O
in O
vivo O
. O
These O
findings O
suggest O
that O
acarbose O
is O
a O
promising O
metabolic O
modifier O
that O
could O
reduce O
the O
risk O
of O
CVD O
in O
patients O
with O
the O

acarbose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
utility O
of O
acarbos O
 O
, O
an O
alpha-glucosidase B
inhibitor O
in O
cardiometabolic O
disorders.Diabetes O
is O
associated O
with O
an O
increase O
risk O
for O
cardiovascular O
disease O
(CVD) O
. O
Recently O
, O
macrovascular O
complications O
of O
diabetes O
have O
been O
shown O
to O
start O
before O
the O
development O
of O
diabetes O
. O
Indeed O
, O
several O
clinical O
studies O
have O
confirmed O
the O
increased O
risk O
of O
CVD O
in O
patients O
with O
impaired O
glucose O
tolerance O

Tolvaptan O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
to O
increased O
afterload O
and O
cardiac O
myocyte O
fibrosis O
, O
causing O
progression O
of O
CHF O
. O
However O
, O
after O
52 O
weeks O
of O
tolvaptan O
therapy O
there O
was O
no O
worsening O
of O
left O
ventricular O
dilatation O
. O
In O
addition O
, O
tolvaptan O
is O
metabolized O
by O
the O
CYP3A4 O
system; O
thus O
physicians O
should O
be O
aware O
of O
the O
potential O
for O
increased O
interactions O
with O
other O
medications O
. O
Tolvaptan O
is O
a O
breakthrough O
in O
the O
therapy O
of O
hyponatremia O
as O
it O
directly O
combats O
elevated O
AVP B
levels O
associated O
with O
the O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
, O
congestive O
heart O
failure O
, O
and O
cirrhosis O
of O
the O
liver O
. O

tolvaptan O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
It O
appears O
to O
be O
safe O
and O
effective O
at O
promoting O
aquaresis O
and O
raising O
serum O
sodium O
levels O
in O
both O
short- O
and O
long-term O
studies O
. O
Tolvaptan O
is O
also O
effective O
for O
treatment O
of O
congestive O
heart O
failure O
(CHF) O
exacerbation O
, O
but O
whether O
there O
are O
long O
standing O
beneficial O
effects O
on O
CHF O
is O
still O
controversial O
. O
Prolonged O
use O
of O
tolvaptan O
leads O
to O
increased O
endogenous O
levels O
of O
AVP O
and O
perhaps O
over-stimulation O
of O
V(1A) O
receptors O
. O
Theoretically O
this O
activation O
could O
lead O
to O
increased O
afterload O
and O
cardiac O
myocyte O
fibrosis O
, O
causing O
progression O
of O
CHF O
. O
However O
, O
after O
52 O
weeks O
of O
tolvaptan O
therapy O
there O
was O
no O
worsening O
of O
left O
ventricular O
dilatation O
. O
In O
addition O
, O
tolvaptan O
is O
metabolized O

tolvaptan O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
It O
appears O
to O
be O
safe O
and O
effective O
at O
promoting O
aquaresis O
and O
raising O
serum O
sodium O
levels O
in O
both O
short- O
and O
long-term O
studies O
. O
Tolvaptan O
is O
also O
effective O
for O
treatment O
of O
congestive O
heart O
failure O
(CHF) O
exacerbation O
, O
but O
whether O
there O
are O
long O
standing O
beneficial O
effects O
on O
CHF O
is O
still O
controversial O
. O
Prolonged O
use O
of O
tolvaptan O
leads O
to O
increased O
endogenous O
levels O
of O
AVP B
and O
perhaps O
over-stimulation O
of O
V(1A) O
receptors O
. O
Theoretically O
this O
activation O
could O
lead O
to O
increased O
afterload O
and O
cardiac O
myocyte O
fibrosis O
, O
causing O
progression O
of O
CHF O
. O
However O
, O
after O
52 O
weeks O
of O
tolvaptan O
therapy O
there O
was O
no O
worsening O
of O
left O
ventricular O
dilatation O
. O
In O
addition O
, O
tolvaptan O
is O
metabolized O

Tolvaptan O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Tolvaptan O
and O
its O
potential O
in O
the O
treatment O
of O
hyponatremia O
. O
Tolvaptan O
is O
a O
selective O
arginine B
vasopressin I
(AVP) I
V(2) I
receptor I
blocker O
used O
to O
induce O
free O
water O
diuresis O
in O
the O
treatment O
of O
euvolemic O
or O
hypervolemic O
hyponatremia O
. O
Currently O
the O
orally O
active O
medication O
is O
in O
the O
final O
stages O
prior O
to O
approval O
by O
the O
FDA O
for O
outpatient O
therapy O
. O
It O
appears O
to O
be O
safe O
and O
effective O

tolvaptan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
use O
of O
tolvaptan O
leads O
to O
increased O
endogenous O
levels O
of O
AVP O
and O
perhaps O
over-stimulation O
of O
V(1A) O
receptors O
. O
Theoretically O
this O
activation O
could O
lead O
to O
increased O
afterload O
and O
cardiac O
myocyte O
fibrosis O
, O
causing O
progression O
of O
CHF O
. O
However O
, O
after O
52 O
weeks O
of O
tolvaptan O
therapy O
there O
was O
no O
worsening O
of O
left O
ventricular O
dilatation O
. O
In O
addition O
, O
tolvaptan O
is O
metabolized O
by O
the O
CYP3A4 B
system; O
thus O
physicians O
should O
be O
aware O
of O
the O
potential O
for O
increased O
interactions O
with O
other O
medications O
. O
Tolvaptan O
is O
a O
breakthrough O
in O
the O
therapy O
of O
hyponatremia O
as O
it O
directly O
combats O
elevated O
AVP O
levels O
associated O
with O
the O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
, O
congestive O
heart O
failure O
, O

Tacrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
commonest O
cause O
of O
dementia O
affecting O
older O
people O
. O
One O
of O
the O
therapeutic O
strategies O
aimed O
at O
ameliorating O
the O
clinical O
manifestations O
of O
Alzheimer's O
disease O
is O
to O
enhance O
cholinergic O
neurotransmission O
in O
relevant O
parts O
of O
the O
brain O
by O
the O
use O
of O
cholinesterase B
inhibitors O
to O
delay O
the O
breakdown O
of O
acetylcholine O
released O
into O
synaptic O
clefts O
. O
Tacrine O
the O
first O
of O
the O
cholinesterase O
inhibitors O
to O
undergo O
extensive O
trials O
for O
this O
purpose O
, O
was O
associated O
with O
significant O
adverse O
effects O
including O
hepatotoxicity O
. O
Other O
cholinesterase O
inhibitors O
, O
including O
rivastigmine O
, O
with O
superior O
properties O
in O
terms O
of O
specificity O
of O
action O
and O
low O
risk O
of O
adverse O
effects O
, O
have O
now O
been O
introduced O
. O
Rivastigmine O
has O
received O
approval O

rivastigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
neurotransmission O
in O
relevant O
parts O
of O
the O
brain O
by O
the O
use O
of O
cholinesterase B
inhibitors O
to O
delay O
the O
breakdown O
of O
acetylcholine O
released O
into O
synaptic O
clefts O
. O
Tacrine O
, O
the O
first O
of O
the O
cholinesterase O
inhibitors O
to O
undergo O
extensive O
trials O
for O
this O
purpose O
, O
was O
associated O
with O
significant O
adverse O
effects O
including O
hepatotoxicity O
. O
Other O
cholinesterase O
inhibitors O
, O
including O
rivastigmine O
with O
superior O
properties O
in O
terms O
of O
specificity O
of O
action O
and O
low O
risk O
of O
adverse O
effects O
, O
have O
now O
been O
introduced O
. O
Rivastigmine O
has O
received O
approval O
for O
use O
in O
60 O
countries O
including O
all O
member O
states O
of O
the O
European O
Union O
and O
the O
USA O
. O
OBJECTIVES O
: O
To O
determine O
the O
clinical O
efficacy O
and O
safety O
of O
rivastigmine O

ketoconazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
presence O
of O
multiple O
doses O
of O
ketoconazole O
, O
single-dose O
ambrisentan O
AUC(0-infinity) O
estimate O
was O
increased O
by O
35.3% O
, O
whereas O
C(max) O
was O
increased O
by O
20.0% O
. O
For O
the O
4-hydroxymethyl O
ambrisentan O
metabolite O
, O
AUC(0-infinity) O
estimate O
was O
decreased O
by O
4.0% O
, O
whereas O
C(max) O
was O
decreased O
by O
16.5% O
. O
Concomitant O
administration O
of O
ambrisentan O
and O
ketoconazole O
was O
well O
tolerated O
. O
In O
summary O
, O
ketoconazole O
had O
no O
clinically O
significant O
effect O
on O
the O
pharmacokinetics O
or O
safety O
profile O
of O
ambrisentan; O
therefore O
, O
no O
changes O
in O
ambrisentan O
dose O
should O
be O
necessary O
when O
the O
drug O
is O
administered O
concomitantly O
with O
known O
CYP3A4 B
inhibitors O
. O

ketoconazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
ketoconazole O
on O
the O
pharmacokinetic O
profile O
of O
ambrisentan.Ambrisentan O
is O
an O
endothelin O
type O
A O
(ET(A))-selective O
receptor O
antagonist O
that O
is O
metabolized O
primarily O
by O
glucuronidation O
but O
also O
undergoes O
oxidative O
metabolism O
by O
CYP3A4 O
. O
The O
potential O
for O
ketoconazole O
the O
archetypal O
strong O
inhibitor O
of O
CYP3A4 O
, O
to O
alter O
the O
pharmacokinetic O
profile O
of O
ambrisentan O
and O
its O
oxidative O
metabolite O
, O
4-hydroxymethyl O
ambrisentan O
, O
was O
assessed O
in O
an O
open-label O
, O
nonrandomized O
, O
2-period O
, O
single-sequence O
study O
in O
16 O
healthy O
men O
. O
Participants O
received O
a O
single O
dose O
of O
ambrisentan O
10 O
mg O
alone O
and O
after O
4 O
days O
of O
ketoconazole O
400 O

Ambrisentan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Effect O
of O
ketoconazole O
on O
the O
pharmacokinetic O
profile O
of O
ambrisentan O
. O
Ambrisentan O
is O
an O
endothelin B
type I
A I
(ET(A))-selective I
receptor I
antagonist O
that O
is O
metabolized O
primarily O
by O
glucuronidation O
but O
also O
undergoes O
oxidative O
metabolism O
by O
CYP3A4 O
. O
The O
potential O
for O
ketoconazole O
, O
the O
archetypal O
strong O
inhibitor O
of O
CYP3A4 O
, O
to O
alter O
the O
pharmacokinetic O
profile O
of O
ambrisentan O
and O
its O
oxidative O
metabolite O
, O
4-hydroxymethyl O
ambrisentan O
, O
was O
assessed O
in O
an O
open-label O
, O

Ambrisentan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Effect O
of O
ketoconazole O
on O
the O
pharmacokinetic O
profile O
of O
ambrisentan O
. O
Ambrisentan O
is O
an O
endothelin O
type O
A O
(ET(A))-selective O
receptor O
antagonist O
that O
is O
metabolized O
primarily O
by O
glucuronidation O
but O
also O
undergoes O
oxidative O
metabolism O
by O
CYP3A4 O
. O
The O
potential O
for O
ketoconazole O
, O
the O
archetypal O
strong O
inhibitor O
of O
CYP3A4 O
, O
to O
alter O
the O
pharmacokinetic O
profile O
of O
ambrisentan O
and O
its O
oxidative O
metabolite O
, O
4-hydroxymethyl O
ambrisentan O
, O
was O
assessed O
in O
an O
open-label O
, O

probucol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
plasma-alpha-tocopherol O
concentrations O
. O
From O
in O
vitro O
experiments O
using O
[(3)H]alpha-tocopheryl O
acetate O
and O
McARH7777 O
cells O
that O
stably O
express O
alpha-tocopherol O
transfer O
protein O
(alpha-TTP) O
, O
the O
following O
results O
were O
obtained O
. O
First O
, O
addition O
of O
apolipoprotein O
A-I O
(apoA-I) O
, O
a O
direct O
acceptor O
of O
the O
ATP-binding O
cassette O
transporter O
A1 O
(ABCA1)-secreted O
lipids O
, O
increased O
alpha-tocopherol O
secretion O
in O
a O
dose-dependent O
manner O
. O
Second O
, O
probucol O
an O
antiatherogenic O
compound O
reported O
to O
be O
an O
inactivator O
of O
ABCA1 B
reduced O
hepatic O
alpha-tocopherol O
secretion O
. O
Third O
, O
ABCA1-RNAi O
suppressed O
hepatic O
alpha-tocopherol O
secretion O
. O
In O
a O
mouse O
in O
vivo O
experiment O
, O
addition O
of O
1% O
probucol O
to O
the O
diet O
decreased O
plasma O
alpha-tocopherol O
concentrations O
. O
These O
results O
strongly O
suggest O
that O
ABCA1 O
is O
substantially O
involved O
in O
hepatic O
alpha-tocopherol O

alpha-tocopherol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
have O
the O
most O
important O
role O
in O
regulating O
plasma-alpha-tocopherol O
concentrations O
. O
From O
in O
vitro O
experiments O
using O
[(3)H]alpha-tocopheryl O
acetate O
and O
McARH7777 O
cells O
that O
stably O
express O
alpha-tocopherol O
transfer O
protein O
(alpha-TTP) O
, O
the O
following O
results O
were O
obtained O
. O
First O
, O
addition O
of O
apolipoprotein B
A-I I
(apoA-I) O
, O
a O
direct O
acceptor O
of O
the O
ATP-binding O
cassette O
transporter O
A1 O
(ABCA1)-secreted O
lipids O
, O
increased O
alpha-tocopherol O
secretion O
in O
a O
dose-dependent O
manner O
. O
Second O
, O
probucol O
, O
an O
antiatherogenic O
compound O
reported O
to O
be O
an O
inactivator O
of O
ABCA1 O
reduced O
hepatic O
alpha-tocopherol O
secretion O
. O
Third O
, O
ABCA1-RNAi O
suppressed O
hepatic O
alpha-tocopherol O
secretion O
. O
In O
a O
mouse O
in O
vivo O
experiment O
, O
addition O
of O
1% O
probucol O
to O
the O
diet O
decreased O
plasma O
alpha-tocopherol O
concentrations O
. O
These O
results O
strongly O
suggest O
that O

alpha-tocopherol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
have O
the O
most O
important O
role O
in O
regulating O
plasma-alpha-tocopherol O
concentrations O
. O
From O
in O
vitro O
experiments O
using O
[(3)H]alpha-tocopheryl O
acetate O
and O
McARH7777 O
cells O
that O
stably O
express O
alpha-tocopherol O
transfer O
protein O
(alpha-TTP) O
, O
the O
following O
results O
were O
obtained O
. O
First O
, O
addition O
of O
apolipoprotein O
A-I O
(apoA-I) O
, O
a O
direct O
acceptor O
of O
the O
ATP-binding O
cassette O
transporter O
A1 O
(ABCA1)-secreted O
lipids O
, O
increased O
alpha-tocopherol O
secretion O
in O
a O
dose-dependent O
manner O
. O
Second O
, O
probucol O
, O
an O
antiatherogenic O
compound O
reported O
to O
be O
an O
inactivator O
of O
ABCA1 O
reduced O
hepatic O
alpha-tocopherol O
secretion O
. O
Third O
, O
ABCA1-RNAi O
suppressed O
hepatic O
alpha-tocopherol O
secretion O
. O
In O
a O
mouse O
in O
vivo O
experiment O
, O
addition O
of O
1% O
probucol O
to O
the O
diet O
decreased O
plasma O
alpha-tocopherol O
concentrations O
. O
These O
results O
strongly O
suggest O
that O

alpha-tocopherol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
have O
the O
most O
important O
role O
in O
regulating O
plasma-alpha-tocopherol O
concentrations O
. O
From O
in O
vitro O
experiments O
using O
[(3)H]alpha-tocopheryl O
acetate O
and O
McARH7777 O
cells O
that O
stably O
express O
alpha-tocopherol O
transfer O
protein O
(alpha-TTP) O
, O
the O
following O
results O
were O
obtained O
. O
First O
, O
addition O
of O
apolipoprotein O
A-I O
(apoA-I) O
, O
a O
direct O
acceptor O
of O
the O
ATP-binding B
cassette I
transporter I
A1 I
(ABCA1)-secreted O
lipids O
, O
increased O
alpha-tocopherol O
secretion O
in O
a O
dose-dependent O
manner O
. O
Second O
, O
probucol O
, O
an O
antiatherogenic O
compound O
reported O
to O
be O
an O
inactivator O
of O
ABCA1 O
reduced O
hepatic O
alpha-tocopherol O
secretion O
. O
Third O
, O
ABCA1-RNAi O
suppressed O
hepatic O
alpha-tocopherol O
secretion O
. O
In O
a O
mouse O
in O
vivo O
experiment O
, O
addition O
of O
1% O
probucol O
to O
the O
diet O
decreased O
plasma O
alpha-tocopherol O
concentrations O
. O
These O
results O
strongly O
suggest O
that O

alpha-tocopherol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
have O
the O
most O
important O
role O
in O
regulating O
plasma-alpha-tocopherol O
concentrations O
. O
From O
in O
vitro O
experiments O
using O
[(3)H]alpha-tocopheryl O
acetate O
and O
McARH7777 O
cells O
that O
stably O
express O
alpha-tocopherol O
transfer O
protein O
(alpha-TTP) O
, O
the O
following O
results O
were O
obtained O
. O
First O
, O
addition O
of O
apolipoprotein O
A-I O
(apoA-I) O
, O
a O
direct O
acceptor O
of O
the O
ATP-binding O
cassette O
transporter O
A1 O
(ABCA1)-secreted O
lipids O
, O
increased O
alpha-tocopherol O
secretion O
in O
a O
dose-dependent O
manner O
. O
Second O
, O
probucol O
, O
an O
antiatherogenic O
compound O
reported O
to O
be O
an O
inactivator O
of O
ABCA1 B
reduced O
hepatic O
alpha-tocopherol O
secretion O
. O
Third O
, O
ABCA1-RNAi O
suppressed O
hepatic O
alpha-tocopherol O
secretion O
. O
In O
a O
mouse O
in O
vivo O
experiment O
, O
addition O
of O
1% O
probucol O
to O
the O
diet O
decreased O
plasma O
alpha-tocopherol O
concentrations O
. O
These O
results O
strongly O
suggest O
that O

alpha-tocopherol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
ATP-binding B
cassette I
transporter I
A1 I
is O
involved O
in O
hepatic O
alpha-tocophero O
secretion.Vitamin O
E O
(alpha-tocopherol) O
is O
an O
essential O
fat-soluble O
nutrient O
with O
antioxidant O
properties O
. O
alpha-Tocopherol O
transfer O
protein O
(alpha-TTP) O
, O
the O
product O
of O
the O
gene O
responsible O
for O
familial O
isolated O
vitamin O
E O
deficiency O
, O
plays O
an O
important O
role O
in O
maintaining O
the O
plasma O
alpha-tocopherol O
level O
by O
mediating O
the O
secretion O
of O
alpha-tocopherol O
by O
the O
liver O
. O
However O
, O
the O
mechanisms O

alpha-tocopherol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
the O
following O
results O
were O
obtained O
. O
First O
, O
addition O
of O
apolipoprotein O
A-I O
(apoA-I) O
, O
a O
direct O
acceptor O
of O
the O
ATP-binding O
cassette O
transporter O
A1 O
(ABCA1)-secreted O
lipids O
, O
increased O
alpha-tocopherol O
secretion O
in O
a O
dose-dependent O
manner O
. O
Second O
, O
probucol O
, O
an O
antiatherogenic O
compound O
reported O
to O
be O
an O
inactivator O
of O
ABCA1 B
reduced O
hepatic O
alpha-tocopherol O
secretion O
. O
Third O
, O
ABCA1-RNAi O
suppressed O
hepatic O
alpha-tocopherol O
secretion O
. O
In O
a O
mouse O
in O
vivo O
experiment O
, O
addition O
of O
1% O
probucol O
to O
the O
diet O
decreased O
plasma O
alpha-tocopherol O
concentrations O
. O
These O
results O
strongly O
suggest O
that O
ABCA1 O
is O
substantially O
involved O
in O
hepatic O
alpha-tocopherol O
secretion O
. O

alpha-tocopherol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
probucol O
, O
an O
antiatherogenic O
compound O
reported O
to O
be O
an O
inactivator O
of O
ABCA1 B
reduced O
hepatic O
alpha-tocopherol O
secretion O
. O
Third O
, O
ABCA1-RNAi O
suppressed O
hepatic O
alpha-tocopherol O
secretion O
. O
In O
a O
mouse O
in O
vivo O
experiment O
, O
addition O
of O
1% O
probucol O
to O
the O
diet O
decreased O
plasma O
alpha-tocopherol O
concentrations O
. O
These O
results O
strongly O
suggest O
that O
ABCA1 O
is O
substantially O
involved O
in O
hepatic O
alpha-tocopherol O
secretion O
. O

alpha-tocopherol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
ATP-binding O
cassette O
transporter O
A1 O
is O
involved O
in O
hepatic O
alpha-tocopherol O
secretion.Vitamin O
E O
(alpha-tocopherol) O
is O
an O
essential O
fat-soluble O
nutrient O
with O
antioxidant O
properties O
. O
alpha-Tocopherol O
transfer O
protein O
(alpha-TTP) O
, O
the O
product O
of O
the O
gene O
responsible O
for O
familial O
isolated O
vitamin O
E O
deficiency O
, O
plays O
an O
important O
role O
in O
maintaining O
the O
plasma O
alpha-tocopherol O
level O
by O
mediating O
the O
secretion O
of O
alpha-tocopherol O
by O
the O
liver O
. O
However O
, O
the O
mechanisms O
underlying O
hepatic O
alpha-tocopherol O
secretion O
are O
not O
fully O
understood O
. O
This O
study O
was O
undertaken O
to O
elucidate O
the O
mechanism O
of O
alpha-tocopherol O
re-efflux O
from O
hepatocytes O
, O
the O
cells O
that O
have O
the O
most O
important O
role O
in O
regulating O
plasma-alpha-tocopherol O
concentrations O
. O
From O
in O
vitro O

alpha-tocopherol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
ATP-binding O
cassette O
transporter O
A1 O
is O
involved O
in O
hepatic O
alpha-tocopherol O
secretion.Vitamin O
E O
(alpha-tocopherol) O
is O
an O
essential O
fat-soluble O
nutrient O
with O
antioxidant O
properties O
. O
alpha-Tocopherol B
transfer I
protein I
(alpha-TTP) O
, O
the O
product O
of O
the O
gene O
responsible O
for O
familial O
isolated O
vitamin O
E O
deficiency O
, O
plays O
an O
important O
role O
in O
maintaining O
the O
plasma O
alpha-tocopherol O
level O
by O
mediating O
the O
secretion O
of O
alpha-tocopherol O
by O
the O
liver O
. O
However O
, O
the O
mechanisms O
underlying O
hepatic O
alpha-tocopherol O
secretion O
are O
not O
fully O
understood O
. O
This O
study O
was O
undertaken O
to O
elucidate O
the O
mechanism O
of O
alpha-tocopherol O
re-efflux O
from O
hepatocytes O
, O
the O
cells O
that O
have O
the O
most O
important O
role O
in O
regulating O
plasma-alpha-tocopherol O
concentrations O
. O
From O
in O
vitro O

alpha-tocopherol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
transporter O
A1 O
is O
involved O
in O
hepatic O
alpha-tocopherol O
secretion.Vitamin O
E O
(alpha-tocopherol) O
is O
an O
essential O
fat-soluble O
nutrient O
with O
antioxidant O
properties O
. O
alpha-Tocopherol O
transfer O
protein O
(alpha-TTP) O
, O
the O
product O
of O
the O
gene O
responsible O
for O
familial O
isolated O
vitamin O
E O
deficiency O
, O
plays O
an O
important O
role O
in O
maintaining O
the O
plasma O
alpha-tocopherol O
level O
by O
mediating O
the O
secretion O
of O
alpha-tocopherol O
by O
the O
liver O
. O
However O
, O
the O
mechanisms O
underlying O
hepatic O
alpha-tocopherol O
secretion O
are O
not O
fully O
understood O
. O
This O
study O
was O
undertaken O
to O
elucidate O
the O
mechanism O
of O
alpha-tocopherol O
re-efflux O
from O
hepatocytes O
, O
the O
cells O
that O
have O
the O
most O
important O
role O
in O
regulating O
plasma-alpha-tocopherol O
concentrations O
. O
From O
in O
vitro O
experiments O
using O
[(3)H]alpha-tocopheryl O
acetate O
and O
McARH7777 O
cells O

alpha-tocopherol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
transporter O
A1 O
is O
involved O
in O
hepatic O
alpha-tocopherol O
secretion.Vitamin O
E O
(alpha-tocopherol) O
is O
an O
essential O
fat-soluble O
nutrient O
with O
antioxidant O
properties O
. O
alpha-Tocopherol B
transfer I
protein I
(alpha-TTP) O
, O
the O
product O
of O
the O
gene O
responsible O
for O
familial O
isolated O
vitamin O
E O
deficiency O
, O
plays O
an O
important O
role O
in O
maintaining O
the O
plasma O
alpha-tocopherol O
level O
by O
mediating O
the O
secretion O
of O
alpha-tocopherol O
by O
the O
liver O
. O
However O
, O
the O
mechanisms O
underlying O
hepatic O
alpha-tocopherol O
secretion O
are O
not O
fully O
understood O
. O
This O
study O
was O
undertaken O
to O
elucidate O
the O
mechanism O
of O
alpha-tocopherol O
re-efflux O
from O
hepatocytes O
, O
the O
cells O
that O
have O
the O
most O
important O
role O
in O
regulating O
plasma-alpha-tocopherol O
concentrations O
. O
From O
in O
vitro O
experiments O
using O
[(3)H]alpha-tocopheryl O
acetate O
and O
McARH7777 O
cells O

metformin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
fragmentation O
. O
The O
mechanisms O
underlying O
the O
pro-apoptotic O
action O
of O
compound O
C O
involved O
induction O
of O
oxidative O
stress O
and O
downregulation O
of O
antiapoptotic O
molecule O
Bcl-2 O
, O
while O
no O
alteration O
of O
pro-apoptotic O
Bax O
was O
observed O
. O
Compound O
C O
diminished O
AMPK B
phosphorylation O
and O
enzymatic O
activity O
, O
resulting O
in O
reduced O
phosphorylation O
of O
its O
target O
acetyl O
CoA O
carboxylase O
. O
AMPK O
activators O
metformin O
and O
AICAR O
partly O
prevented O
the O
cell O
cycle O
block O
, O
oxidative O
stress O
and O
apoptosis O
induced O
by O
compound O
C O
. O
The O
small O
interfering O
RNA O
(siRNA) O
targeting O
of O
human O
AMPK O
mimicked O
compound O
C-induced O
G(2)/M O
cell O
cycle O
arrest O
, O
but O
failed O
to O
induce O
oxidative O
stress O
and O
apoptosis O
in O
U251 O
glioma O
cells O
. O
In O
conclusion O
, O
our O
data O
indicate O

AICAR O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
mechanisms O
underlying O
the O
pro-apoptotic O
action O
of O
compound O
C O
involved O
induction O
of O
oxidative O
stress O
and O
downregulation O
of O
antiapoptotic O
molecule O
Bcl-2 O
, O
while O
no O
alteration O
of O
pro-apoptotic O
Bax O
was O
observed O
. O
Compound O
C O
diminished O
AMPK B
phosphorylation O
and O
enzymatic O
activity O
, O
resulting O
in O
reduced O
phosphorylation O
of O
its O
target O
acetyl O
CoA O
carboxylase O
. O
AMPK O
activators O
metformin O
and O
AICAR O
partly O
prevented O
the O
cell O
cycle O
block O
, O
oxidative O
stress O
and O
apoptosis O
induced O
by O
compound O
C O
. O
The O
small O
interfering O
RNA O
(siRNA) O
targeting O
of O
human O
AMPK O
mimicked O
compound O
C-induced O
G(2)/M O
cell O
cycle O
arrest O
, O
but O
failed O
to O
induce O
oxidative O
stress O
and O
apoptosis O
in O
U251 O
glioma O
cells O
. O
In O
conclusion O
, O
our O
data O
indicate O
that O
AMPK O

methamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal B
vesicular I
monoamine I
transporter I
(VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 O
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O

methamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal O
vesicular O
monoamine O
transporter O
(VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 B
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O

3,4-methylenedioxymethamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal B
vesicular I
monoamine I
transporter I
(VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 O
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O

3,4-methylenedioxymethamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal O
vesicular O
monoamine O
transporter O
(VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 B
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal B
vesicular I
monoamine I
transporter I
(VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
( O
MDMA O
 O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 O
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Inhibitory O
effect O
of O
selective O
serotonin O
reuptake O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal O
vesicular O
monoamine O
transporter O
(VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
( O
MDMA O
 O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 B
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O

reserpine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 B
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O
reserpine>>fluoxetine O
, O
paroxetine>fluvoxamine O
, O
methamphetamine>MDMA O
. O
Moreover O
, O
kinetic O
analysis O
revealed O
that O
inhibition O
by O
reserpine O
a O
typical O
VMAT2 O
inhibitor O
, O
was O
uncompetitive O
, O
decreasing O
maximum O
velocity O
and O
affinity O
for O
dopamine O
. O
Inhibition O
by O
fluoxetine O
was O
noncompetitive O
, O
only O
decreasing O
maximum O
velocity O
for O
dopamine O
. O
These O
results O
suggest O
that O
fluoxetine O
inhibited O
the O
activity O
of O
VMAT2 O
by O
a O
mechanism O
different O
from O
that O
of O
reserpine O
and O
did O
not O
directly O
interact O
with O
the O

reserpine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Moreover O
, O
kinetic O
analysis O
revealed O
that O
inhibition O
by O
reserpine O
, O
a O
typical O
VMAT2 B
inhibitor O
, O
was O
uncompetitive O
, O
decreasing O
maximum O
velocity O
and O
affinity O
for O
dopamine O
. O
Inhibition O
by O
fluoxetine O
was O
noncompetitive O
, O
only O
decreasing O
maximum O
velocity O
for O
dopamine O
. O
These O
results O
suggest O
that O
fluoxetine O
inhibited O
the O
activity O
of O
VMAT2 O
by O
a O
mechanism O
different O
from O
that O
of O
reserpine O
and O
did O
not O
directly O
interact O
with O
the O
active O
site O
of O
VMAT2 O
. O

fluoxetine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O
reserpine>>fluoxetine O
, O
paroxetine>fluvoxamine O
, O
methamphetamine>MDMA O
. O
Moreover O
, O
kinetic O
analysis O
revealed O
that O
inhibition O
by O
reserpine O
, O
a O
typical O
VMAT2 B
inhibitor O
, O
was O
uncompetitive O
, O
decreasing O
maximum O
velocity O
and O
affinity O
for O
dopamine O
. O
Inhibition O
by O
fluoxetine O
was O
noncompetitive O
, O
only O
decreasing O
maximum O
velocity O
for O
dopamine O
. O
These O
results O
suggest O
that O
fluoxetine O
inhibited O
the O
activity O
of O
VMAT2 O
by O
a O
mechanism O
different O
from O
that O
of O
reserpine O
and O
did O
not O
directly O
interact O
with O
the O
active O
site O
of O
VMAT2 O
. O

fluoxetine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O
reserpine>>fluoxetine O
, O
paroxetine>fluvoxamine O
, O
methamphetamine>MDMA O
. O
Moreover O
, O
kinetic O
analysis O
revealed O
that O
inhibition O
by O
reserpine O
, O
a O
typical O
VMAT2 B
inhibitor O
, O
was O
uncompetitive O
, O
decreasing O
maximum O
velocity O
and O
affinity O
for O
dopamine O
. O
Inhibition O
by O
fluoxetine O
was O
noncompetitive O
, O
only O
decreasing O
maximum O
velocity O
for O
dopamine O
. O
These O
results O
suggest O
that O
fluoxetine O
inhibited O
the O
activity O
of O
VMAT2 O
by O
a O
mechanism O
different O
from O
that O
of O
reserpine O
and O
did O
not O
directly O
interact O
with O
the O
active O
site O
of O
VMAT2 O
. O

dopamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O
reserpine>>fluoxetine O
, O
paroxetine>fluvoxamine O
, O
methamphetamine>MDMA O
. O
Moreover O
, O
kinetic O
analysis O
revealed O
that O
inhibition O
by O
reserpine O
, O
a O
typical O
VMAT2 B
inhibitor O
, O
was O
uncompetitive O
, O
decreasing O
maximum O
velocity O
and O
affinity O
for O
dopamine O
Inhibition O
by O
fluoxetine O
was O
noncompetitive O
, O
only O
decreasing O
maximum O
velocity O
for O
dopamine O
. O
These O
results O
suggest O
that O
fluoxetine O
inhibited O
the O
activity O
of O
VMAT2 O
by O
a O
mechanism O
different O
from O
that O
of O
reserpine O
and O
did O
not O
directly O
interact O
with O
the O
active O
site O
of O
VMAT2 O
. O

[(3)H]dopamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
inhibitors O
on O
the O
vesicular O
monoamine O
transporter O
2.The O
neuronal O
vesicular O
monoamine O
transporter O
(VMAT2) O
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants O
, O
such O
as O
methamphetamine O
and O
3,4-methylenedioxymethamphetamine O
(MDMA) O
. O
The O
present O
study O
examined O
the O
effect O
of O
antidepressants O
, O
such O
as O
selective O
serotonin O
reuptake O
inhibitors O
(SSRIs) O
, O
on O
VMAT2 B
activity O
by O
measuring O
adenosine O
triphosphate-dependent O
[(3)H]dopamine O
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum O
. O
SSRIs O
, O
fluoxetine O
, O
paroxetine O
, O
and O
fluvoxamine O
, O
inhibited O
vesicular O
[(3)H]dopamine O
uptake O
in O
vitro O
. O
The O
rank O
order O
of O
potency O
was O
reserpine>>fluoxetine O
, O
paroxetine>fluvoxamine O
, O
methamphetamine>MDMA O
. O
Moreover O
, O
kinetic O
analysis O
revealed O
that O
inhibition O
by O
reserpine O
, O
a O
typical O
VMAT2 O
inhibitor O
, O
was O
uncompetitive O
, O
decreasing O
maximum O
velocity O
and O
affinity O
for O
dopamine O
. O

tricyclic O
acts O
as O
NOT O
for O
what O
entity O
? O
TrkA/TrkB O
heterodimerization O
and O
has O
potent O
neurotrophic O
activity.Neurotrophins O
, O
the O
cognate O
ligands O
for O
the O
Trk O
receptors O
, O
are O
homodimers O
and O
induce O
Trk O
dimerization O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA B
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O

amitriptyline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Amitriptyline O
is O
a O
TrkA B
and O
TrkB O
receptor O
agonist O
that O
promotes O
TrkA/TrkB O
heterodimerization O
and O
has O
potent O
neurotrophic O
activity.Neurotrophins O
, O
the O
cognate O
ligands O
for O
the O
Trk O
receptors O
, O
are O
homodimers O
and O
induce O
Trk O
dimerization O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA O
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O

amitriptyline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Amitriptyline O
is O
a O
TrkA O
and O
TrkB B
receptor O
agonist O
that O
promotes O
TrkA/TrkB O
heterodimerization O
and O
has O
potent O
neurotrophic O
activity.Neurotrophins O
, O
the O
cognate O
ligands O
for O
the O
Trk O
receptors O
, O
are O
homodimers O
and O
induce O
Trk O
dimerization O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA O
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O

Amitriptyline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA B
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O

Amitriptyline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA O
and O
TrkB B
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O

amitriptyline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA B
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity O
. O
Thus O
, O
amitriptyline O
acts O
as O
a O
TrkA O
and O
TrkB O

Amitriptyline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA B
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O

Amitriptyline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA O
and O
TrkB B
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O

amitriptyline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA B
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity O
. O
Thus O
, O
amitriptyline O
acts O
as O
a O
TrkA O
and O
TrkB O
agonist O
and O
possesses O
marked O
neurotrophic O
activity O
. O

Amitriptyline O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
TrkB O
receptor O
agonist O
that O
promotes O
TrkA/TrkB O
heterodimerization O
and O
has O
potent O
neurotrophic O
activity.Neurotrophins O
, O
the O
cognate O
ligands O
for O
the O
Trk O
receptors O
, O
are O
homodimers O
and O
induce O
Trk O
dimerization O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA B
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O

amitriptyline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity O
. O
Thus O
, O
amitriptyline O
acts O
as O
a O
TrkA O
and O
TrkB B
agonist O
and O
possesses O
marked O
neurotrophic O
activity O
. O

amitriptyline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
promotes O
TrkA-TrkB O
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA B
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity O
. O
Thus O
, O
amitriptyline O
acts O
as O
a O
TrkA O
and O
TrkB O
agonist O
and O
possesses O
marked O
neurotrophic O
activity O
. O

voglibose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
changeover O
from O
voglibose O
to O
acarbose O
on O
postprandial O
triglycerides O
in O
type O
2 O
diabetes O
mellitus O
patients.INTRODUCTION O
: O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
the O
alpha-glucosidase B
inhibitors O
acarbose O
and O
voglibose O
on O
postprandial O
plasma O
glucose O
and O
serum O
triglyceride O
levels O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
. O
METHODS O
: O
Twenty-one O
Japanese O
patients O
with O
type O
2 O
diabetes O
were O
enrolled O
in O
this O
study O
. O
Subjects O
had O
been O
treated O
with O
voglibose O
for O
at O
least O
3 O
months O
. O
They O
underwent O
a O
400 O
kcal O
balanced O
food O
meal O
tolerance O
test O

acarbose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
changeover O
from O
voglibose O
to O
acarbose O
on O
postprandial O
triglycerides O
in O
type O
2 O
diabetes O
mellitus O
patients.INTRODUCTION O
: O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
the O
alpha-glucosidase B
inhibitors O
acarbose O
and O
voglibose O
on O
postprandial O
plasma O
glucose O
and O
serum O
triglyceride O
levels O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
. O
METHODS O
: O
Twenty-one O
Japanese O
patients O
with O
type O
2 O
diabetes O
were O
enrolled O
in O
this O
study O
. O
Subjects O
had O
been O
treated O
with O
voglibose O
for O
at O
least O
3 O
months O
. O
They O
underwent O
a O
400 O
kcal O
balanced O
food O
meal O

glucose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
changeover O
from O
voglibose O
to O
acarbose O
on O
postprandial O
triglycerides O
in O
type O
2 O
diabetes O
mellitus O
patients.INTRODUCTION O
: O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
the O
alpha-glucosidase B
inhibitors O
acarbose O
and O
voglibose O
on O
postprandial O
plasma O
glucose O
and O
serum O
triglyceride O
levels O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
. O
METHODS O
: O
Twenty-one O
Japanese O
patients O
with O
type O
2 O
diabetes O
were O
enrolled O
in O
this O
study O
. O
Subjects O
had O
been O
treated O
with O
voglibose O
for O
at O
least O
3 O
months O
. O
They O
underwent O
a O
400 O
kcal O
balanced O
food O
meal O
tolerance O
test O
before O
and O
8 O
weeks O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Cellular O
mechanisms O
of O
insulin O
resistance O
: O
role O
of O
stress-regulated O
serine O
kinases O
and O
insulin O
receptor O
substrates O
(IRS) O
serine O
phosphorylation.Insulin O
receptor O
substrates O
(IRS) O
serine O
phosphorylation O
is O
a O
time-controlled O
physiological O
feedback O
mechanism O
in O
insulin O
signaling O
that O
is O
hijacked O
by O
metabolic O
and O
inflammatory O
stresses O
to O
promote O
insulin O
resistance O
. O
Kinases O
, O
including O
IKKbeta O
, O
JNK O
, O
ERK O
, O
mTOR O
, O
and O
S6K O
, O
activated O
by O
the O
inducers O
of O
insulin O
resistance O
induce O
uncontrolled O
IRS B
serine O
phosphorylation O
. O
Studies O
with O
genetically O
modified O
mice O
reveal O
that O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Cellular O
mechanisms O
of O
insulin O
resistance O
: O
role O
of O
stress-regulated O
serine O
kinases O
and O
insulin O
receptor O
substrates O
(IRS) O
serine O
phosphorylation.Insulin O
receptor O
substrates O
(IRS) O
serine O
phosphorylation O
is O
a O
time-controlled O
physiological O
feedback O
mechanism O
in O
insulin O
signaling O
that O
is O
hijacked O
by O
metabolic O
and O
inflammatory O
stresses O
to O
promote O
insulin O
resistance O
. O
Kinases O
, O
including O
IKKbeta O
, O
JNK O
, O
ERK O
, O
mTOR O
, O
and O
S6K O
, O
activated O
by O
the O
inducers O
of O
insulin O
resistance O
induce O
uncontrolled O
IRS O
serine O
phosphorylation O
. O
Studies O
with O
genetically O
modified O
mice O
reveal O
that O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
receptor O
substrates O
(IRS) O
serine O
phosphorylation.Insulin O
receptor O
substrates O
(IRS) O
serine O
phosphorylation O
is O
a O
time-controlled O
physiological O
feedback O
mechanism O
in O
insulin O
signaling O
that O
is O
hijacked O
by O
metabolic O
and O
inflammatory O
stresses O
to O
promote O
insulin O
resistance O
. O
Kinases O
, O
including O
IKKbeta O
, O
JNK O
, O
ERK O
, O
mTOR O
, O
and O
S6K O
, O
activated O
by O
the O
inducers O
of O
insulin O
resistance O
induce O
uncontrolled O
IRS B
serine O
phosphorylation O
. O
Studies O
with O
genetically O
modified O
mice O
reveal O
that O
these O
kinases O
integrate O
signals O
from O
metabolic O
and O
inflammatory O
stresses O
in O
adipose O
tissue O
, O
liver O
, O
and O
hypothalamus O
leading O
to O
peripheral O
and O
central O
insulin O
resistance O
. O
Moreover O
, O
IKKbeta/NF-kappaB O
and O
JNK1 O
pathways O
in O
myeloid O
cells O
represent O
a O
core O
mechanism O
involved O
in O
inflammation O
linked O
to O
obesity O
. O
These O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Cellular O
mechanisms O
of O
insulin O
resistance O
: O
role O
of O
stress-regulated O
serine O
kinases O
and O
insulin O
receptor O
substrates O
(IRS) O
serin O
phosphorylation.Insulin O
receptor O
substrates O
(IRS) O
serine O
phosphorylation O
is O
a O
time-controlled O
physiological O
feedback O
mechanism O
in O
insulin O
signaling O
that O
is O
hijacked O
by O
metabolic O
and O
inflammatory O
stresses O
to O
promote O
insulin O
resistance O
. O
Kinases O
, O
including O
IKKbeta O
, O
JNK O
, O
ERK O
, O
mTOR O
, O
and O
S6K O
, O
activated O
by O
the O
inducers O
of O
insulin O
resistance O
induce O
uncontrolled O
IRS B
serine O
phosphorylation O
. O
Studies O
with O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Cellular O
mechanisms O
of O
insulin O
resistance O
: O
role O
of O
stress-regulated O
serine O
kinases O
and O
insulin B
receptor I
substrates I
(IRS) O
serin O
phosphorylation.Insulin O
receptor O
substrates O
(IRS) O
serine O
phosphorylation O
is O
a O
time-controlled O
physiological O
feedback O
mechanism O
in O
insulin O
signaling O
that O
is O
hijacked O
by O
metabolic O
and O
inflammatory O
stresses O
to O
promote O
insulin O
resistance O
. O
Kinases O
, O
including O
IKKbeta O
, O
JNK O
, O
ERK O
, O
mTOR O
, O
and O
S6K O
, O
activated O
by O
the O
inducers O
of O
insulin O
resistance O
induce O
uncontrolled O
IRS O
serine O
phosphorylation O
. O
Studies O
with O

esmolol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Esmolol O
reduces O
autonomic O
hypersensitivity O
and O
length O
of O
seizures O
induced O
by O
electroconvulsive O
therapy.We O
evaluated O
the O
clinical O
effectiveness O
of O
esmolol O
an O
ultra-short-acting O
beta B
1-adrenergic I
receptor I
blocking O
drug O
, O
to O
control O
the O
sinus O
tachycardia O
and O
increase O
in O
arterial O
blood O
pressures O
induced O
by O
electroconvulsive O
therapy O
(ECT) O
. O
Each O
of O
20 O
patients O
, O
ASA O
physical O
status O
I-III O
, O
participated O
in O
a O
double-blind O
, O
randomized O
study O
, O
involving O
four O
match-pair O
trials O
(placebo O
versus O
esmolol) O
during O
ECT O
. O
Each O
patient O
acted O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Histamine O
and O
asthma O
: O
an O
appraisal O
based O
on O
specific O
H1-receptor B
antagonism.H1-receptor O
antagonists O
have O
been O
utilized O
, O
following O
their O
initial O
chemical O
synthesis O
in O
1933 O
, O
both O
in O
the O
treatment O
of O
conditions O
in O
which O
histamine O
is O
considered O
to O
be O
of O
pathogenic O
importance O
and O
conversely O
to O
help O
elucidate O
the O
role O
of O
histamine O
in O
disease O
, O
through O
an O
evaluation O
of O
their O
influence O
on O
disease O
expression O
. O
While O
there O
is O
considerable O
indirect O
evidence O
to O
implicate O
histamine O
in O
the O
pathogenesis O
of O
asthma O
, O
a O
critical O
evaluation O
of O
H1-receptor O
antagonism O
in O
this O
condition O
has O
, O
until O
recently O
, O
proved O
difficult O
, O
as O
many O
of O
the O
early O
H1-receptor O
antagonists O
possessed O
additional O
actions O
, O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
initial O
chemical O
synthesis O
in O
1933 O
, O
both O
in O
the O
treatment O
of O
conditions O
in O
which O
histamine O
is O
considered O
to O
be O
of O
pathogenic O
importance O
and O
conversely O
to O
help O
elucidate O
the O
role O
of O
histamine O
in O
disease O
, O
through O
an O
evaluation O
of O
their O
influence O
on O
disease O
expression O
. O
While O
there O
is O
considerable O
indirect O
evidence O
to O
implicate O
histamine O
in O
the O
pathogenesis O
of O
asthma O
, O
a O
critical O
evaluation O
of O
H1-receptor B
antagonism O
in O
this O
condition O
has O
, O
until O
recently O
, O
proved O
difficult O
, O
as O
many O
of O
the O
early O
H1-receptor O
antagonists O
possessed O
additional O
actions O
, O
such O
as O
anti-cholinergic O
, O
local O
anaesthetic O
, O
alpha-adrenoceptor O
antagonistic O
and O
anti-serotonin O
activity O
. O
In O
addition O
, O
H1-receptor O
antagonists O
have O
been O
shown O
to O
have O
effects O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
initial O
chemical O
synthesis O
in O
1933 O
, O
both O
in O
the O
treatment O
of O
conditions O
in O
which O
histamine O
is O
considered O
to O
be O
of O
pathogenic O
importance O
and O
conversely O
to O
help O
elucidate O
the O
role O
of O
histamine O
in O
disease O
, O
through O
an O
evaluation O
of O
their O
influence O
on O
disease O
expression O
. O
While O
there O
is O
considerable O
indirect O
evidence O
to O
implicate O
histamine O
in O
the O
pathogenesis O
of O
asthma O
, O
a O
critical O
evaluation O
of O
H1-receptor B
antagonism O
in O
this O
condition O
has O
, O
until O
recently O
, O
proved O
difficult O
, O
as O
many O
of O
the O
early O
H1-receptor O
antagonists O
possessed O
additional O
actions O
, O
such O
as O
anti-cholinergic O
, O
local O
anaesthetic O
, O
alpha-adrenoceptor O
antagonistic O
and O
anti-serotonin O
activity O
. O
In O
addition O
, O
H1-receptor O
antagonists O
have O
been O
shown O
to O
have O
effects O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Histamine O
and O
asthma O
: O
an O
appraisal O
based O
on O
specific O
H1-receptor B
antagonism.H1-receptor O
antagonists O
have O
been O
utilized O
, O
following O
their O
initial O
chemical O
synthesis O
in O
1933 O
, O
both O
in O
the O
treatment O
of O
conditions O
in O
which O
histamine O
is O
considered O
to O
be O
of O
pathogenic O
importance O
and O
conversely O
to O
help O
elucidate O
the O
role O
of O
histamine O
in O
disease O
, O
through O
an O
evaluation O
of O
their O
influence O
on O
disease O
expression O
. O
While O
there O
is O
considerable O
indirect O
evidence O
to O
implicate O
histamine O
in O
the O
pathogenesis O
of O
asthma O
, O
a O
critical O
evaluation O
of O
H1-receptor O
antagonism O
in O
this O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
thus O
the O
degree O
of O
H1-receptor B
blockade O
achievable O
within O
the O
airways O
. O
The O
recent O
development O
of O
H1-receptor O
antagonists O
devoid O
of O
clinical O
sedative O
effects O
has O
enabled O
the O
administration O
of O
doses O
of O
H1-antihistamines O
which O
achieve O
a O
greater O
degree O
of O
H1-receptor O
blockade O
within O
the O
airways O
, O
thus O
permitting O
a O
better O
appraisal O
of O
the O
role O
of O
histamine O
in O
this O
condition O
. O
Furthermore O
, O
the O
receptor O
specificity O
of O
many O
of O
these O
agents O
has O
been O
focused O
such O
that O
terfenadine O
, O
astemizole O
, O
loratadine O
and O
cetirizine O
are O
devoid O
of O
anticholinergic O
activity O
and O
exhibit O
little O
alpha-antagonistic O
or O
anti-serotonin O
activity O
of O
clinical O
relevance O
. O
However O
, O
of O
these O
agents O
both O
loratadine O
and O
cetirizine O
possess O
additional O
actions O
likely O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
thus O
the O
degree O
of O
H1-receptor B
blockade O
achievable O
within O
the O
airways O
. O
The O
recent O
development O
of O
H1-receptor O
antagonists O
devoid O
of O
clinical O
sedative O
effects O
has O
enabled O
the O
administration O
of O
doses O
of O
H1-antihistamines O
which O
achieve O
a O
greater O
degree O
of O
H1-receptor O
blockade O
within O
the O
airways O
, O
thus O
permitting O
a O
better O
appraisal O
of O
the O
role O
of O
histamine O
in O
this O
condition O
. O
Furthermore O
, O
the O
receptor O
specificity O
of O
many O
of O
these O
agents O
has O
been O
focused O
such O
that O
terfenadine O
, O
astemizole O
, O
loratadine O
and O
cetirizine O
are O
devoid O
of O
anticholinergic O
activity O
and O
exhibit O
little O
alpha-antagonistic O
or O
anti-serotonin O
activity O
of O
clinical O
relevance O
. O
However O
, O
of O
these O
agents O
both O
loratadine O
and O
cetirizine O
possess O
additional O
actions O
likely O

carbenoxolone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
under O
reducing O
conditions O
. O
We O
subsequently O
found O
that O
Panx1 B
channel O
currents O
exhibit O
a O
significant O
reduction O
when O
exposed O
to O
reducing O
agents O
, O
and O
that O
this O
effect O
is O
attenuated O
in O
the O
presence O
of O
Kvbeta3 O
. O
Apparently O
, O
Kvbeta3 O
is O
involved O
in O
regulating O
the O
susceptibility O
of O
Panx1 O
channels O
to O
redox O
potential O
. O
Furthermore O
, O
the O
Panx1 O
channel O
blockers O
carbenoxolone O
and O
Probenecid O
were O
less O
effective O
in O
inhibiting O
Panx1 O
currents O
when O
Kvbeta3 O
was O
co-expressed O
. O
The O
influence O
of O
Kvbeta3 O
on O
Panx1 O
is O
the O
first O
example O
of O
modulation O
of O
Panx1 O
channel O
function(s) O
by O
interacting O
proteins O
, O
and O
suggests O
the O
physiological O
importance O
of O
sensing O
changes O
in O
redox O
potentials O
. O

Probenecid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
conditions O
. O
We O
subsequently O
found O
that O
Panx1 B
channel O
currents O
exhibit O
a O
significant O
reduction O
when O
exposed O
to O
reducing O
agents O
, O
and O
that O
this O
effect O
is O
attenuated O
in O
the O
presence O
of O
Kvbeta3 O
. O
Apparently O
, O
Kvbeta3 O
is O
involved O
in O
regulating O
the O
susceptibility O
of O
Panx1 O
channels O
to O
redox O
potential O
. O
Furthermore O
, O
the O
Panx1 O
channel O
blockers O
carbenoxolone O
and O
Probenecid O
were O
less O
effective O
in O
inhibiting O
Panx1 O
currents O
when O
Kvbeta3 O
was O
co-expressed O
. O
The O
influence O
of O
Kvbeta3 O
on O
Panx1 O
is O
the O
first O
example O
of O
modulation O
of O
Panx1 O
channel O
function(s) O
by O
interacting O
proteins O
, O
and O
suggests O
the O
physiological O
importance O
of O
sensing O
changes O
in O
redox O
potentials O
. O

17alpha-methyltestosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
its O
performance O
and O
transferability O
were O
thoroughly O
studied O
. O
The O
investigation O
followed O
a O
generic O
protocol O
prepared O
for O
all O
reporter O
gene O
assays O
evaluated O
within O
ReProTect O
, O
and O
in O
both O
laboratories O
at O
least O
three O
independent O
experiments O
were O
performed O
. O
The O
highest O
concentration O
to O
be O
tested O
was O
limited O
to O
10 O
microM O
, O
if O
needed O
. O
A O
few O
compounds O
, O
17alpha-methyltestosterone O
(17alpha-MT) O
, O
vinclozolin O
and O
linuron O
, O
were O
studied O
using O
a O
real O
world O
scenario O
, O
i.e. O
, O
assuming O
that O
their O
interaction O
with O
the O
AR B
was O
not O
known O
: O
A O
prescreening O
for O
agonism O
and O
true O
, O
competitive O
antagonism O
was O
used O
to O
select O
conditions O
such O
as O
the O
appropriate O
mode O
of O
action O
, O
and O
the O
working O
range O
excluding O
cytotoxicity O
for O

17alpha-MT O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
transferability O
were O
thoroughly O
studied O
. O
The O
investigation O
followed O
a O
generic O
protocol O
prepared O
for O
all O
reporter O
gene O
assays O
evaluated O
within O
ReProTect O
, O
and O
in O
both O
laboratories O
at O
least O
three O
independent O
experiments O
were O
performed O
. O
The O
highest O
concentration O
to O
be O
tested O
was O
limited O
to O
10 O
microM O
, O
if O
needed O
. O
A O
few O
compounds O
, O
17alpha-methyltestosterone O
( O
17alpha-MT O
 O
, O
vinclozolin O
and O
linuron O
, O
were O
studied O
using O
a O
real O
world O
scenario O
, O
i.e. O
, O
assuming O
that O
their O
interaction O
with O
the O
AR B
was O
not O
known O
: O
A O
prescreening O
for O
agonism O
and O
true O
, O
competitive O
antagonism O
was O
used O
to O
select O
conditions O
such O
as O
the O
appropriate O
mode O
of O
action O
, O
and O
the O
working O
range O
excluding O
cytotoxicity O
for O

vinclozolin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
transferability O
were O
thoroughly O
studied O
. O
The O
investigation O
followed O
a O
generic O
protocol O
prepared O
for O
all O
reporter O
gene O
assays O
evaluated O
within O
ReProTect O
, O
and O
in O
both O
laboratories O
at O
least O
three O
independent O
experiments O
were O
performed O
. O
The O
highest O
concentration O
to O
be O
tested O
was O
limited O
to O
10 O
microM O
, O
if O
needed O
. O
A O
few O
compounds O
, O
17alpha-methyltestosterone O
(17alpha-MT) O
, O
vinclozolin O
and O
linuron O
, O
were O
studied O
using O
a O
real O
world O
scenario O
, O
i.e. O
, O
assuming O
that O
their O
interaction O
with O
the O
AR B
was O
not O
known O
: O
A O
prescreening O
for O
agonism O
and O
true O
, O
competitive O
antagonism O
was O
used O
to O
select O
conditions O
such O
as O
the O
appropriate O
mode O
of O
action O
, O
and O
the O
working O
range O
excluding O
cytotoxicity O
for O
the O
final O

linuron O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
were O
thoroughly O
studied O
. O
The O
investigation O
followed O
a O
generic O
protocol O
prepared O
for O
all O
reporter O
gene O
assays O
evaluated O
within O
ReProTect O
, O
and O
in O
both O
laboratories O
at O
least O
three O
independent O
experiments O
were O
performed O
. O
The O
highest O
concentration O
to O
be O
tested O
was O
limited O
to O
10 O
microM O
, O
if O
needed O
. O
A O
few O
compounds O
, O
17alpha-methyltestosterone O
(17alpha-MT) O
, O
vinclozolin O
and O
linuron O
were O
studied O
using O
a O
real O
world O
scenario O
, O
i.e. O
, O
assuming O
that O
their O
interaction O
with O
the O
AR B
was O
not O
known O
: O
A O
prescreening O
for O
agonism O
and O
true O
, O
competitive O
antagonism O
was O
used O
to O
select O
conditions O
such O
as O
the O
appropriate O
mode O
of O
action O
, O
and O
the O
working O
range O
excluding O
cytotoxicity O
for O
the O
final O
screening O
. O
All O

tinzaparin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
14-18 O
monomers O
reduced O
inhibition O
slightly O
, O
while O
the O
pentasaccharide O
fondaparinux O
was O
without O
effects O
. O
To O
confirm O
molecular O
recognition O
of O
tinzaparin O
by O
VLA-4 O
, O
a O
surface O
acoustic O
wave-biosensor O
was O
applied O
. O
A O
VLA-4 B
containing O
membrane O
preparation O
of O
MV3 O
cells O
was O
immobilised O
at O
the O
sensors O
to O
allow O
for O
detection O
of O
kinetic O
binding O
constants O
of O
tinzaparin O
compared O
to O
VCAM-1 O
. O
Tinzaparin O
binds O
to O
VLA-4 O
with O
affinity O
in O
the O
low O
micromolar O
range O
(4.61 O
x O
10(-6) O
M) O
, O
which O
clearly O
indicates O
specific O
molecular O
recognition O
. O
Furthermore O
, O
tinzaparin O
displays O
a O
nearly O
identical O
k(off) O
compared O
to O
VCAM-1 O
(5.13 O
x O
10(-3) O
s(-1) O
versus O
3.44 O
x O
10(-3) O
s(-1)) O
which O
is O
evident O
for O
interference O
with O

Tinzaparin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
inhibition O
slightly O
, O
while O
the O
pentasaccharide O
fondaparinux O
was O
without O
effects O
. O
To O
confirm O
molecular O
recognition O
of O
tinzaparin O
by O
VLA-4 O
, O
a O
surface O
acoustic O
wave-biosensor O
was O
applied O
. O
A O
VLA-4 B
containing O
membrane O
preparation O
of O
MV3 O
cells O
was O
immobilised O
at O
the O
sensors O
to O
allow O
for O
detection O
of O
kinetic O
binding O
constants O
of O
tinzaparin O
compared O
to O
VCAM-1 O
. O
Tinzaparin O
binds O
to O
VLA-4 O
with O
affinity O
in O
the O
low O
micromolar O
range O
(4.61 O
x O
10(-6) O
M) O
, O
which O
clearly O
indicates O
specific O
molecular O
recognition O
. O
Furthermore O
, O
tinzaparin O
displays O
a O
nearly O
identical O
k(off) O
compared O
to O
VCAM-1 O
(5.13 O
x O
10(-3) O
s(-1) O
versus O
3.44 O
x O
10(-3) O
s(-1)) O
which O
is O
evident O
for O
interference O
with O
the O
ligand O
binding O
. O
The O

tinzaparin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
size O
of O
heparin O
has O
an O
important O
impact O
on O
inhibition O
. O
Unfractionated O
heparin O
(UFH) O
and O
tinzaparin O
, O
a O
low-molecular-weight O
heparin O
(LMWH) O
representing O
a O
mean O
of O
about O
18-20 O
monomers O
, O
displayed O
high O
inhibitory O
activity O
. O
Fractionating O
tinzaparin O
to O
14-18 O
monomers O
reduced O
inhibition O
slightly O
, O
while O
the O
pentasaccharide O
fondaparinux O
was O
without O
effects O
. O
To O
confirm O
molecular O
recognition O
of O
tinzaparin O
by O
VLA-4 O
, O
a O
surface O
acoustic O
wave-biosensor O
was O
applied O
. O
A O
VLA-4 B
containing O
membrane O
preparation O
of O
MV3 O
cells O
was O
immobilised O
at O
the O
sensors O
to O
allow O
for O
detection O
of O
kinetic O
binding O
constants O
of O
tinzaparin O
compared O
to O
VCAM-1 O
. O
Tinzaparin O
binds O
to O
VLA-4 O
with O
affinity O
in O
the O
low O
micromolar O
range O
(4.61 O
x O
10(-6) O
M) O
, O

Bambuterol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effects O
of O
bambuterol O
and O
terbutaline O
on O
isolated O
rat's O
tracheal O
smooth O
muscle.Terbutaline O
(Bricanyl) O
and O
its O
prodrug O
Bambuterol O
(Bambec) O
are O
highly O
potent O
beta(2)-adrenoceptor B
agonists O
often O
used O
in O
asthma O
patients O
. O
Terbutaline O
in O
the O
form O
of O
inhaled O
short-acting O
bronchodilator O
relieves O
asthmatic O
symptoms O
. O
However O
, O
the O
effects O
of O
bambuterol O
given O
intratracheally O
have O
rarely O
been O
explored O
. O
To O
verify O
the O
effect O
of O
bambuterol O
and O
terbutaline O
, O
which O
act O
on O
the O
tracheal O
smooth O
muscle O
directly O

Bambec O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effects O
of O
bambuterol O
and O
terbutaline O
on O
isolated O
rat's O
tracheal O
smooth O
muscle.Terbutaline O
(Bricanyl) O
and O
its O
prodrug O
Bambuterol O
( O
Bambec O
are O
highly O
potent O
beta(2)-adrenoceptor B
agonists O
often O
used O
in O
asthma O
patients O
. O
Terbutaline O
in O
the O
form O
of O
inhaled O
short-acting O
bronchodilator O
relieves O
asthmatic O
symptoms O
. O
However O
, O
the O
effects O
of O
bambuterol O
given O
intratracheally O
have O
rarely O
been O
explored O
. O
To O
verify O
the O
effect O
of O
bambuterol O
and O
terbutaline O
, O
which O
act O
on O
the O
tracheal O
smooth O
muscle O
directly O
in O

Terbutaline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effects O
of O
bambuterol O
and O
terbutaline O
on O
isolated O
rat's O
tracheal O
smooth O
muscle O
. O
Terbutaline O
(Bricanyl) O
and O
its O
prodrug O
Bambuterol O
(Bambec) O
are O
highly O
potent O
beta(2)-adrenoceptor B
agonists O
often O
used O
in O
asthma O
patients O
. O
Terbutaline O
in O
the O
form O
of O
inhaled O
short-acting O
bronchodilator O
relieves O
asthmatic O
symptoms O
. O
However O
, O
the O
effects O
of O
bambuterol O
given O
intratracheally O
have O
rarely O
been O
explored O
. O
To O
verify O
the O
effect O
of O
bambuterol O
and O
terbutaline O
, O
which O
act O
on O

Bricanyl O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effects O
of O
bambuterol O
and O
terbutaline O
on O
isolated O
rat's O
tracheal O
smooth O
muscle.Terbutaline O
( O
Bricanyl O
and O
its O
prodrug O
Bambuterol O
(Bambec) O
are O
highly O
potent O
beta(2)-adrenoceptor B
agonists O
often O
used O
in O
asthma O
patients O
. O
Terbutaline O
in O
the O
form O
of O
inhaled O
short-acting O
bronchodilator O
relieves O
asthmatic O
symptoms O
. O
However O
, O
the O
effects O
of O
bambuterol O
given O
intratracheally O
have O
rarely O
been O
explored O
. O
To O
verify O
the O
effect O
of O
bambuterol O
and O
terbutaline O
, O
which O
act O
on O
the O

D-amphetamine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Polymorphisms O
in O
dopamine O
transporter O
(SLC6A3) O
are O
associated O
with O
stimulant O
effects O
of O
D-amphetamin O
 O
: O
an O
exploratory O
pharmacogenetic O
study O
using O
healthy O
volunteers.Individuals O
vary O
in O
their O
subjective O
responses O
to O
stimulant O
drugs O
, O
and O
these O
differences O
are O
believed O
to O
be O
partially O
genetic O
in O
origin O
. O
We O
evaluated O
associations O
between O
mood O
, O
cognitive O
and O
cardiovascular O
responses O
to O
d-amphetamine O
and O
four O
polymorphisms O
in O
the O
dopamine O
transporter O
(SLC6A3) O
: O
rs460000 O
, O
rs3756450 O
, O
rs37022 O

D-amphetamine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Polymorphisms O
in O
dopamine B
transporter I
(SLC6A3) O
are O
associated O
with O
stimulant O
effects O
of O
D-amphetamin O
 O
: O
an O
exploratory O
pharmacogenetic O
study O
using O
healthy O
volunteers.Individuals O
vary O
in O
their O
subjective O
responses O
to O
stimulant O
drugs O
, O
and O
these O
differences O
are O
believed O
to O
be O
partially O
genetic O
in O
origin O
. O
We O
evaluated O
associations O
between O
mood O
, O
cognitive O
and O
cardiovascular O
responses O
to O
d-amphetamine O
and O
four O
polymorphisms O
in O
the O
dopamine O
transporter O
(SLC6A3) O
: O
rs460000 O
, O
rs3756450 O
, O
rs37022 O

CDCA O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 B
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
. O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

CDCA O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 B
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
. O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

GW4064 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 B
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
. O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

GW4064 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 B
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
. O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

chenodeoxycholic O
acid O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
gastric O
carcinogenesis O
. O
Caudal-type O
homeobox O
2 O
(Cdx2) O
plays O
a O
key O
role O
in O
the O
exhibition O
of O
intestinal O
phenotypes O
by O
regulating O
the O
expression O
of O
intestine-specific O
genes O
such O
as O
goblet-specific O
gene O
mucin O
2 O
(MUC2) O
. O
We O
investigated O
the O
involvement O
of O
the O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
(CDCA)-induced O
expression O
of O
Cdx2 B
and O
MUC2 O
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O

chenodeoxycholic O
acid O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
gastric O
carcinogenesis O
. O
Caudal-type O
homeobox O
2 O
(Cdx2) O
plays O
a O
key O
role O
in O
the O
exhibition O
of O
intestinal O
phenotypes O
by O
regulating O
the O
expression O
of O
intestine-specific O
genes O
such O
as O
goblet-specific O
gene O
mucin O
2 O
(MUC2) O
. O
We O
investigated O
the O
involvement O
of O
the O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
(CDCA)-induced O
expression O
of O
Cdx2 O
and O
MUC2 B
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O

CDCA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Caudal-type O
homeobox O
2 O
(Cdx2) O
plays O
a O
key O
role O
in O
the O
exhibition O
of O
intestinal O
phenotypes O
by O
regulating O
the O
expression O
of O
intestine-specific O
genes O
such O
as O
goblet-specific O
gene O
mucin O
2 O
(MUC2) O
. O
We O
investigated O
the O
involvement O
of O
the O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
( O
CDCA O
-induced O
expression O
of O
Cdx2 B
and O
MUC2 O
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O

CDCA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Caudal-type O
homeobox O
2 O
(Cdx2) O
plays O
a O
key O
role O
in O
the O
exhibition O
of O
intestinal O
phenotypes O
by O
regulating O
the O
expression O
of O
intestine-specific O
genes O
such O
as O
goblet-specific O
gene O
mucin O
2 O
(MUC2) O
. O
We O
investigated O
the O
involvement O
of O
the O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
( O
CDCA O
-induced O
expression O
of O
Cdx2 O
and O
MUC2 B
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O

CDCA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
(CDCA)-induced O
expression O
of O
Cdx2 B
and O
MUC2 O
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O

CDCA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
(CDCA)-induced O
expression O
of O
Cdx2 O
and O
MUC2 B
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O

CDCA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 B
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
. O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

CDCA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 B
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
. O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

guggulsterone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 B
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

guggulsterone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 B
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

CDCA O
acts O
as O
AGONIST O
for O
what O
entity O
? O
of O
intestine-specific O
genes O
such O
as O
goblet-specific O
gene O
mucin O
2 O
(MUC2) O
. O
We O
investigated O
the O
involvement O
of O
the O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
(CDCA)-induced O
expression O
of O
Cdx2 O
and O
MUC2 O
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR B
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O

GW4064 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
genes O
such O
as O
goblet-specific O
gene O
mucin O
2 O
(MUC2) O
. O
We O
investigated O
the O
involvement O
of O
the O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
(CDCA)-induced O
expression O
of O
Cdx2 O
and O
MUC2 O
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
an O
FXR B
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O

guggulsterone O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
the O
involvement O
of O
the O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
(CDCA)-induced O
expression O
of O
Cdx2 O
and O
MUC2 O
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR B
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O

p-hydroxybenzoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O

p-hydroxybenzoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O

p-hydroxybenzoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O

p-hydroxybenzoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O

Phenols O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA B
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O

sulfonamides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA B
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides O
sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O
various O
amino O
acid O
residues O
. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O

sulfamates O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA B
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides O
/ O
sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O
various O
amino O
acid O
residues O
. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O
between O

coumarins O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA B
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O
various O
amino O
acid O
residues O
. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O
between O
the O
many O
CA O
isozymes O
found O

p-coumaric O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O

p-coumaric O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O

p-coumaric O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O

p-coumaric O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O

caffeic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O

caffeic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O

caffeic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O

caffeic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O

polyphenols O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian B
isoforms I
I-XIV I
with O
a O
series O
of O
natural O
product O
polyphenol O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O

phenolic O
acids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian B
isoforms I
I-XIV I
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acid O
.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O

ferulic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O

ferulic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O

ferulic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O

ferulic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O

phenolic O
acids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O

phenolic O
acids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O

phenolic O
acids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O

phenolic O
acids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O

gallic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O

gallic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O

gallic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O

gallic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O

syringic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O

syringic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O

syringic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O

syringic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O

quercetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O

quercetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O

quercetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O

quercetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O

ellagic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O

ellagic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O

ellagic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O

ellagic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O

phenol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O

phenol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O

phenol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O

phenol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O

METH O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
FLX O
, O
or O
both) O
animals O
was O
made O
. O
Considering O
that O
hemispheric O
dominance O
is O
important O
for O
LTM O
, O
hence O
right O
vs O
. O
left O
hemisphere O
of O
the O
brain O
was O
compared O
. O
Results O
showed O
that O
trained O
animals O
decreased O
cortical O
SERT B
binding O
relative O
to O
untrained O
ones O
. O
In O
untrained O
and O
trained O
treated O
animals O
with O
the O
amnesic O
dose O
(1.0mg/kg) O
of O
METH O
SERT O
binding O
in O
several O
areas O
including O
hippocampus O
and O
cortex O
decreased O
, O
more O
remarkably O
in O
the O
trained O
animals O
. O
In O
contrast O
, O
FLX O
improved O
memory O
, O
increased O
SERT O
binding O
, O
prevented O
the O
METH O
amnesic O
effect O
and O
re-established O
the O
SERT O
binding O
. O
In O
general O
, O
memory O
and O
amnesia O
seemed O
to O
make O
SERT O
more O
vulnerable O
to O
drugs O
effects O
. O

d-methamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Autoradiographic O
study O
of O
serotonin O
transporter O
during O
memory O
formation.Serotonin O
transporter O
(SERT) O
has O
been O
associated O
with O
drugs O
of O
abuse O
like O
d-methamphetamine O
(METH) O
. O
METH O
is O
well O
known O
to O
produce O
effects O
on O
the O
monoamine O
systems O
but O
it O
is O
unclear O
how O
METH O
affects O
SERT O
and O
memory O
. O
Here O
the O
effects O
of O
METH O
and O
the O
serotonin O
reuptake O
inhibitor O
fluoxetine O
(FLX) O
on O
autoshaping O
and O
novel O
object O
recognition O
(NOR) O
were O
investigated O
. O
Notably O
, O
both O
memory O
tasks O
recruit O
different O

d-methamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Autoradiographic O
study O
of O
serotonin O
transporter O
during O
memory O
formation.Serotonin O
transporter O
(SERT) O
has O
been O
associated O
with O
drugs O
of O
abuse O
like O
d-methamphetamine O
(METH) O
. O
METH O
is O
well O
known O
to O
produce O
effects O
on O
the O
monoamine O
systems O
but O
it O
is O
unclear O
how O
METH O
affects O
SERT B
and O
memory O
. O
Here O
the O
effects O
of O
METH O
and O
the O
serotonin O
reuptake O
inhibitor O
fluoxetine O
(FLX) O
on O
autoshaping O
and O
novel O
object O
recognition O
(NOR) O
were O
investigated O
. O
Notably O
, O
both O
memory O
tasks O
recruit O
different O

METH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
90min) O
in O
NOR O
and O
impaired O
both O
STM O
and O
long-term O
memory O
(LTM; O
lasting O
24 O
and O
48h) O
in O
autoshaping O
, O
indicating O
that O
METH O
had O
long-lasting O
effects O
in O
the O
latter O
task O
. O
A O
comparative O
autoradiography O
study O
of O
the O
relationship O
between O
the O
binding O
pattern O
of O
SERT B
in O
autoshaping O
new O
untrained O
vs O
. O
trained O
treated O
( O
METH O
FLX O
, O
or O
both) O
animals O
was O
made O
. O
Considering O
that O
hemispheric O
dominance O
is O
important O
for O
LTM O
, O
hence O
right O
vs O
. O
left O
hemisphere O
of O
the O
brain O
was O
compared O
. O
Results O
showed O
that O
trained O
animals O
decreased O
cortical O
SERT O
binding O
relative O
to O
untrained O
ones O
. O
In O
untrained O
and O
trained O
treated O
animals O
with O
the O
amnesic O
dose O
(1.0mg/kg) O
of O

FLX O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
90min) O
in O
NOR O
and O
impaired O
both O
STM O
and O
long-term O
memory O
(LTM; O
lasting O
24 O
and O
48h) O
in O
autoshaping O
, O
indicating O
that O
METH O
had O
long-lasting O
effects O
in O
the O
latter O
task O
. O
A O
comparative O
autoradiography O
study O
of O
the O
relationship O
between O
the O
binding O
pattern O
of O
SERT B
in O
autoshaping O
new O
untrained O
vs O
. O
trained O
treated O
(METH O
, O
FLX O
or O
both) O
animals O
was O
made O
. O
Considering O
that O
hemispheric O
dominance O
is O
important O
for O
LTM O
, O
hence O
right O
vs O
. O
left O
hemisphere O
of O
the O
brain O
was O
compared O
. O
Results O
showed O
that O
trained O
animals O
decreased O
cortical O
SERT O
binding O
relative O
to O
untrained O
ones O
. O
In O
untrained O
and O
trained O
treated O
animals O
with O
the O
amnesic O
dose O
(1.0mg/kg) O
of O
METH O

METH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Autoradiographic O
study O
of O
serotonin O
transporter O
during O
memory O
formation.Serotonin O
transporter O
(SERT) O
has O
been O
associated O
with O
drugs O
of O
abuse O
like O
d-methamphetamine O
( O
METH O
 O
. O
METH O
is O
well O
known O
to O
produce O
effects O
on O
the O
monoamine O
systems O
but O
it O
is O
unclear O
how O
METH O
affects O
SERT O
and O
memory O
. O
Here O
the O
effects O
of O
METH O
and O
the O
serotonin O
reuptake O
inhibitor O
fluoxetine O
(FLX) O
on O
autoshaping O
and O
novel O
object O
recognition O
(NOR) O
were O
investigated O
. O
Notably O
, O
both O
memory O
tasks O
recruit O
different O

METH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Autoradiographic O
study O
of O
serotonin O
transporter O
during O
memory O
formation.Serotonin O
transporter O
(SERT) O
has O
been O
associated O
with O
drugs O
of O
abuse O
like O
d-methamphetamine O
( O
METH O
 O
. O
METH O
is O
well O
known O
to O
produce O
effects O
on O
the O
monoamine O
systems O
but O
it O
is O
unclear O
how O
METH O
affects O
SERT B
and O
memory O
. O
Here O
the O
effects O
of O
METH O
and O
the O
serotonin O
reuptake O
inhibitor O
fluoxetine O
(FLX) O
on O
autoshaping O
and O
novel O
object O
recognition O
(NOR) O
were O
investigated O
. O
Notably O
, O
both O
memory O
tasks O
recruit O
different O

METH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Autoradiographic O
study O
of O
serotonin O
transporter O
during O
memory O
formation.Serotonin O
transporter O
(SERT) O
has O
been O
associated O
with O
drugs O
of O
abuse O
like O
d-methamphetamine O
(METH) O
. O
METH O
is O
well O
known O
to O
produce O
effects O
on O
the O
monoamine O
systems O
but O
it O
is O
unclear O
how O
METH O
affects O
SERT B
and O
memory O
. O
Here O
the O
effects O
of O
METH O
and O
the O
serotonin O
reuptake O
inhibitor O
fluoxetine O
(FLX) O
on O
autoshaping O
and O
novel O
object O
recognition O
(NOR) O
were O
investigated O
. O
Notably O
, O
both O
memory O
tasks O
recruit O
different O
behavioral O
, O
neural O
and O
cognitive O
demand O
. O
In O
autoshaping O
task O
a O
dose-response O
curve O
for O
METH O
was O
determined O
. O
METH O
(1.0mg/kg) O
impaired O

Testosterone O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
of O
EGFP-labeled O
hAR B
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR O
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O

TEST O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
hAR B
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR O
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
( O
TEST O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O

NAN O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR B
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
( O
NAN O
 O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O

oxandrolone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR B
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O

OXA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR B
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
( O
OXA O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O

testosterone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR B
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O

steroids O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
hAR B
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)) O
. O
The O
data O
obtained O
agrees O
with O
the O

ANE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
hAR B
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)) O
. O
The O
data O
obtained O
agrees O
with O
the O
existing O

DHT O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR B
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)) O
. O
The O
data O
obtained O
agrees O
with O
the O
existing O
qualitative O
data O

steroids O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
qualitative O
nucleocytoplasmic O
transport O
of O
nuclear O
hormone O
receptors O
(NHRs) O
has O
been O
studied O
, O
there O
is O
little O
documentation O
of O
the O
cellular O
kinetics O
of O
this O
transport O
. O
Here O
, O
translocation O
studies O
using O
the O
human O
androgen O
receptor O
(hAR) O
and O
the O
human O
glucocorticoid O
receptor O
(hGR) O
were O
performed O
to O
aid O
in O
identifying O
the O
mechanism O
by O
which O
anabolic-androgenic O
steroids O
(AAS) O
were O
activating O
hAR O
and O
potentially O
interacting O
with O
hGR B
and O
how O
glucocorticoid O
ligands O
were O
interacting O
with O
the O
hGR O
and O
hAR O
. O
The O
real-time O
analysis O
of O
EGFP-labeled O
hAR O
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O

steroids O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR B
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O

androstenedione O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR B
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O

ANE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR B
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
( O
ANE O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O

dihydrotestosterone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR B
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O

DHT O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
a O
physiologically O
relevant O
cell-based O
model O
. O
After O
transient O
transfection O
, O
the O
hAR B
and O
hGR O
individually O
translocate O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR O
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
( O
DHT O
 O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O

steroids O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
as O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR B
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O

methyltrienelone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
expected O
(i.e. O
, O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR B
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O

MET O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR B
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
( O
MET O
 O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O

nandrolone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system O
. O
Testosterone O
(TEST) O
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR B
of O
0.0525 O
min(-1) O
. O
The O
other O
endogenous O
steroids O
, O
androstenedione O
(ANE) O
and O
dihydrotestosterone O
(DHT) O
, O
had O
considerably O
lower O
hAR O
transport O
rates O
. O
The O
rates O
of O
hAR O
transport O
for O
the O
exogenous O
steroids O
methyltrienelone O
(MET) O
, O
nandrolone O
(NAN) O
, O
and O
oxandrolone O
(OXA) O
are O
lower O
than O
that O
of O
testosterone O
and O
similar O
to O
those O
of O
the O
endogenous O
steroids O
ANE O
and O
DHT O
. O
The O
hGR O
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented O
. O
The O
synthetic O
GC O
, O
DEX O
, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O

steroids O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
qualitative O
nucleocytoplasmic O
transport O
of O
nuclear O
hormone O
receptors O
(NHRs) O
has O
been O
studied O
, O
there O
is O
little O
documentation O
of O
the O
cellular O
kinetics O
of O
this O
transport O
. O
Here O
, O
translocation O
studies O
using O
the O
human O
androgen O
receptor O
(hAR) O
and O
the O
human O
glucocorticoid O
receptor O
(hGR) O
were O
performed O
to O
aid O
in O
identifying O
the O
mechanism O
by O
which O
anabolic-androgenic O
steroids O
(AAS) O
were O
activating O
hAR B
and O
potentially O
interacting O
with O
hGR O
and O
how O
glucocorticoid O
ligands O
were O
interacting O
with O
the O
hGR O
and O
hAR O
. O
The O
real-time O
analysis O
of O
EGFP-labeled O
hAR O
and O
hGR O
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs O
in O
a O
physiologically O
relevant O
cell-based O

ketanserin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
into O
the O
lungs O
and O
antibody O
responses O
to O
the O
antigen O
were O
also O
measured O
. O
In O
vitro O
study O
of O
tracheal O
airway O
smooth O
muscle O
from O
naive O
mice O
demonstrated O
concentration-related O
contractions O
to O
methacholine O
and O
5-HT O
, O
but O
no O
responses O
to O
histamine O
or O
adenosine O
or O
its O
stable O
analogue O
, O
5'-N-ethyl-carboxamidoadenosine O
. O
The O
contractions O
to O
5-HT O
were O
inhibited O
by O
ketanserin O
and O
alosetron O
indicating O
involvement O
of O
5-HT(2A) B
and O
5-HT(3) O
receptors O
, O
respectively O
. O
In O
an O
acute O
model O
of O
allergic O
asthma O
, O
OVA-treated O
mice O
were O
shown O
to O
be O
atopic O
by O
inflammatory O
cell O
influx O
to O
the O
lungs O
after O
OVA O
challenge O
, O
increases O
in O
total O
IgE O
and O
OVA-specific O
IgG O
levels O
and O
contractions O
to O
OVA O
in O
isolated O
trachea O
. O

alosetron O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
lungs O
and O
antibody O
responses O
to O
the O
antigen O
were O
also O
measured O
. O
In O
vitro O
study O
of O
tracheal O
airway O
smooth O
muscle O
from O
naive O
mice O
demonstrated O
concentration-related O
contractions O
to O
methacholine O
and O
5-HT O
, O
but O
no O
responses O
to O
histamine O
or O
adenosine O
or O
its O
stable O
analogue O
, O
5'-N-ethyl-carboxamidoadenosine O
. O
The O
contractions O
to O
5-HT O
were O
inhibited O
by O
ketanserin O
and O
alosetron O
indicating O
involvement O
of O
5-HT(2A) O
and O
5-HT(3) B
receptors O
, O
respectively O
. O
In O
an O
acute O
model O
of O
allergic O
asthma O
, O
OVA-treated O
mice O
were O
shown O
to O
be O
atopic O
by O
inflammatory O
cell O
influx O
to O
the O
lungs O
after O
OVA O
challenge O
, O
increases O
in O
total O
IgE O
and O
OVA-specific O
IgG O
levels O
and O
contractions O
to O
OVA O
in O
isolated O
trachea O
. O
In O
the O

TAS-102 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
TK-1 O
expression O
was O
detected O
prominently O
in O
gastrointestinal O
adenocarcinomas O
and O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
. O
Gastrointestinal O
adenocarcinomas O
and O
squamous O
cell O
uterine O
carcinomas O
were O
often O
accompanied O
by O
high O
TS B
expression O
, O
indicating O
activation O
of O
pyrimidine O
synthesis O
through O
both O
the O
salvage O
and O
de O
novo O
pathways O
. O
These O
results O
led O
us O
to O
consider O
that O
TAS-102 O
may O
also O
be O
effective O
for O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
, O
as O
well O
as O
for O
gastrointestinal O
adenocarcinomas O
, O
even O
in O
fluoropyrimidine-resistant O
cases O
with O
high O
TS O
expression O
. O
In O
contrast O
, O
thyroid O
papillary O
carcinomas O
, O
lung O
adenocarcinomas O
, O
hepatocellular O
carcinomas O
, O
pancreatic O
ductal O
carcinomas O
, O
and O
renal O
cell O
carcinomas O
, O
which O
exhibit O
low O
TK-1 O
expression O
, O
may O
be O
resistant O

fluoropyrimidine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
uterine O
carcinomas O
were O
often O
accompanied O
by O
high O
TS B
expression O
, O
indicating O
activation O
of O
pyrimidine O
synthesis O
through O
both O
the O
salvage O
and O
de O
novo O
pathways O
. O
These O
results O
led O
us O
to O
consider O
that O
TAS-102 O
may O
also O
be O
effective O
for O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
, O
as O
well O
as O
for O
gastrointestinal O
adenocarcinomas O
, O
even O
in O
fluoropyrimidine O
resistant O
cases O
with O
high O
TS O
expression O
. O
In O
contrast O
, O
thyroid O
papillary O
carcinomas O
, O
lung O
adenocarcinomas O
, O
hepatocellular O
carcinomas O
, O
pancreatic O
ductal O
carcinomas O
, O
and O
renal O
cell O
carcinomas O
, O
which O
exhibit O
low O
TK-1 O
expression O
, O
may O
be O
resistant O
to O
TAS-102 O
. O
In O
non-small O
cell O
lung O
cancers O
, O
high O
TK-1 O
expression O
was O
demonstrated O
in O
squamous O
cell O
carcinomas O
, O
but O
not O
in O

TAS-102 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
also O
be O
effective O
for O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
, O
as O
well O
as O
for O
gastrointestinal O
adenocarcinomas O
, O
even O
in O
fluoropyrimidine-resistant O
cases O
with O
high O
TS O
expression O
. O
In O
contrast O
, O
thyroid O
papillary O
carcinomas O
, O
lung O
adenocarcinomas O
, O
hepatocellular O
carcinomas O
, O
pancreatic O
ductal O
carcinomas O
, O
and O
renal O
cell O
carcinomas O
, O
which O
exhibit O
low O
TK-1 B
expression O
, O
may O
be O
resistant O
to O
TAS-102 O
In O
non-small O
cell O
lung O
cancers O
, O
high O
TK-1 O
expression O
was O
demonstrated O
in O
squamous O
cell O
carcinomas O
, O
but O
not O
in O
adenocarcinomas O
. O
This O
result O
suggests O
that O
TAS-102 O
efficacy O
and O
the O
pyrimidine O
synthetic O
pathway O
may O
differ O
depending O
on O
histological O
type O
. O
Our O
results O
indicate O
that O
administration O
of O
TAS-102 O
could O
be O
selected O
on O
the O
basis O
of O

fluoropyrimidine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidine O
synthetic O
enzymes O
, O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate O
synthase O
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS B
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine O
based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O
drug O
containing O
trifluorothymidine O
, O
which O
is O
phosphorylated O
by O
TK-1 O
to O
its O
active O
monophosphated O
form O
, O
that O
in O
turn O
can O
inhibit O
TS O
. O
TAS-102 O
has O
been O
shown O
to O
exhibit O
antitumor O
activity O
in O
fluoropyrimidine-resistant O
human O
cancer O
cells O
. O
TAS-102 O
is O
currently O
undergoing O
clinical O
trials O
for O
use O
in O
gastrointestinal O
cancers O
. O

TAS-102 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidine O
synthetic O
enzymes O
, O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate O
synthase O
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS B
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O
drug O
containing O
trifluorothymidine O
, O
which O
is O
phosphorylated O
by O
TK-1 O
to O
its O
active O
monophosphated O
form O
, O
that O
in O
turn O
can O
inhibit O
TS O
. O
TAS-102 O
has O
been O
shown O
to O
exhibit O
antitumor O
activity O
in O
fluoropyrimidine-resistant O
human O
cancer O
cells O
. O
TAS-102 O
is O
currently O
undergoing O
clinical O
trials O
for O
use O
in O
gastrointestinal O
cancers O
. O
In O
the O
present O

pyrimidine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidine O
synthetic O
enzymes O
, O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate O
synthase O
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS O
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O
drug O
containing O
trifluorothymidine O
, O
which O
is O
phosphorylated O
by O
TK-1 O
to O
its O
active O
monophosphated O
form O
, O
that O
in O
turn O
can O
inhibit O
TS O
. O
TAS-102 O
has O
been O
shown O
to O
exhibit O
antitumor O
activity O

pyrimidine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidine O
synthetic O
enzymes O
, O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate O
synthase O
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS O
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O
drug O
containing O
trifluorothymidine O
, O
which O
is O
phosphorylated O
by O
TK-1 O
to O
its O
active O
monophosphated O
form O
, O
that O
in O
turn O
can O
inhibit O
TS O
. O
TAS-102 O
has O
been O
shown O
to O
exhibit O
antitumor O
activity O

pyrimidine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidine O
synthetic O
enzymes O
, O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate B
synthase I
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS O
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O
drug O
containing O
trifluorothymidine O
, O
which O
is O
phosphorylated O
by O
TK-1 O
to O
its O
active O
monophosphated O
form O
, O
that O
in O
turn O
can O
inhibit O
TS O
. O
TAS-102 O
has O
been O
shown O
to O
exhibit O
antitumor O
activity O

pyrimidine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidine O
synthetic O
enzymes O
, O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate O
synthase O
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS B
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O
drug O
containing O
trifluorothymidine O
, O
which O
is O
phosphorylated O
by O
TK-1 O
to O
its O
active O
monophosphated O
form O
, O
that O
in O
turn O
can O
inhibit O
TS O
. O
TAS-102 O
has O
been O
shown O
to O
exhibit O
antitumor O
activity O

pyrimidine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidin O
synthetic O
enzymes O
, O
thymidine B
kinase-1 I
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate O
synthase O
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS O
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O

pyrimidine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidin O
synthetic O
enzymes O
, O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate B
synthase I
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS O
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O

pyrimidine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
TS B
in O
various O
types O
of O
cancer O
. O
TK-1 O
and O
TS O
expression O
was O
markedly O
different O
between O
cancer O
types O
. O
High O
TK-1 O
expression O
was O
detected O
prominently O
in O
gastrointestinal O
adenocarcinomas O
and O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
. O
Gastrointestinal O
adenocarcinomas O
and O
squamous O
cell O
uterine O
carcinomas O
were O
often O
accompanied O
by O
high O
TS O
expression O
, O
indicating O
activation O
of O
pyrimidine O
synthesis O
through O
both O
the O
salvage O
and O
de O
novo O
pathways O
. O
These O
results O
led O
us O
to O
consider O
that O
TAS-102 O
may O
also O
be O
effective O
for O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas O
, O
as O
well O
as O
for O
gastrointestinal O
adenocarcinomas O
, O
even O
in O
fluoropyrimidine-resistant O
cases O
with O
high O
TS O
expression O
. O
In O
contrast O
, O
thyroid O
papillary O
carcinomas O
, O
lung O
adenocarcinomas O
, O

TAS-102 O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Immunohistochemical O
characterization O
of O
pyrimidine O
synthetic O
enzymes O
, O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate O
synthase O
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS O
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O
drug O
containing O
trifluorothymidine O
, O
which O
is O
phosphorylated O
by O
TK-1 B
to O
its O
active O
monophosphated O
form O
, O
that O
in O
turn O
can O
inhibit O
TS O
. O
TAS-102 O
has O
been O
shown O
to O
exhibit O
antitumor O
activity O
in O
fluoropyrimidine-resistant O
human O
cancer O
cells O
. O
TAS-102 O
is O
currently O
undergoing O
clinical O
trials O
for O
use O
in O
gastrointestinal O
cancers O
. O
In O
the O
present O

trifluorothymidine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
thymidine O
kinase-1 O
and O
thymidylate O
synthase O
, O
in O
various O
types O
of O
cancer.Thymidine O
kinase-1 O
(TK-1) O
and O
thymidylate O
synthase O
(TS) O
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine O
synthesis O
, O
respectively O
. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS O
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based O
chemotherapy O
. O
TAS-102 O
is O
a O
novel O
drug O
containing O
trifluorothymidine O
which O
is O
phosphorylated O
by O
TK-1 B
to O
its O
active O
monophosphated O
form O
, O
that O
in O
turn O
can O
inhibit O
TS O
. O
TAS-102 O
has O
been O
shown O
to O
exhibit O
antitumor O
activity O
in O
fluoropyrimidine-resistant O
human O
cancer O
cells O
. O
TAS-102 O
is O
currently O
undergoing O
clinical O
trials O
for O
use O
in O
gastrointestinal O
cancers O
. O
In O
the O
present O
study O
, O
we O
used O
immunohistochemistry O
to O
investigate O

TFP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
These O
observations O
suggest O
that O
S100A4 B
is O
an O
excellent O
target O
for O
therapeutic O
intervention O
. O
Using O
a O
unique O
biosensor-based O
assay O
, O
trifluoperazine O
(TFP) O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA O
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
, O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O
observed O
in O
the O
protein O
upon O
complex O
formation O
. O
NMR O
chemical O
shift O
perturbations O
are O
consistent O
with O
the O
crystal O
structure O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 O
in O
solution O
. O
Remarkably O
, O

TFP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
suggest O
that O
S100A4 B
is O
an O
excellent O
target O
for O
therapeutic O
intervention O
. O
Using O
a O
unique O
biosensor-based O
assay O
, O
trifluoperazine O
(TFP) O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA O
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
, O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O
observed O
in O
the O
protein O
upon O
complex O
formation O
. O
NMR O
chemical O
shift O
perturbations O
are O
consistent O
with O
the O
crystal O
structure O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 O
in O
solution O
. O
Remarkably O
, O
TFP O
binding O

TFP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O
observed O
in O
the O
protein O
upon O
complex O
formation O
. O
NMR O
chemical O
shift O
perturbations O
are O
consistent O
with O
the O
crystal O
structure O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 B
in O
solution O
. O
Remarkably O
, O
TFP O
binding O
results O
in O
the O
assembly O
of O
five O
Ca(2+)-S100A4/TFP O
dimers O
into O
a O
tightly O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 O
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O

TFP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O
observed O
in O
the O
protein O
upon O
complex O
formation O
. O
NMR O
chemical O
shift O
perturbations O
are O
consistent O
with O
the O
crystal O
structure O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 B
in O
solution O
. O
Remarkably O
, O
TFP O
binding O
results O
in O
the O
assembly O
of O
five O
Ca(2+)-S100A4/TFP O
dimers O
into O
a O
tightly O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 O
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O

TFP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
consistent O
with O
the O
crystal O
structure O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 B
in O
solution O
. O
Remarkably O
, O
TFP O
binding O
results O
in O
the O
assembly O
of O
five O
Ca(2+)-S100A4/TFP O
dimers O
into O
a O
tightly O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 O
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O

prochlorperazine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
structure O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 B
in O
solution O
. O
Remarkably O
, O
TFP O
binding O
results O
in O
the O
assembly O
of O
five O
Ca(2+)-S100A4/TFP O
dimers O
into O
a O
tightly O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 O
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4 O
/ O
prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O

PCP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 B
in O
solution O
. O
Remarkably O
, O
TFP O
binding O
results O
in O
the O
assembly O
of O
five O
Ca(2+)-S100A4/TFP O
dimers O
into O
a O
tightly O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 O
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
( O
PCP O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O
that O

TFP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
assembly O
of O
five O
Ca(2+)-S100A4/TFP O
dimers O
into O
a O
tightly O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 B
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4 O
/ O
TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O

TFP O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
marker O
for O
metastatic O
disease O
, O
but O
rather O
has O
a O
direct O
role O
in O
metastatic O
progression O
. O
These O
observations O
suggest O
that O
S100A4 B
is O
an O
excellent O
target O
for O
therapeutic O
intervention O
. O
Using O
a O
unique O
biosensor-based O
assay O
, O
trifluoperazine O
(TFP) O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA O
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O
observed O
in O
the O
protein O
upon O
complex O
formation O
. O
NMR O
chemical O
shift O
perturbations O
are O
consistent O
with O
the O
crystal O
structure O
and O
demonstrate O

phenothiazines O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 B
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O
via O
small O
molecule-induced O
oligomerization O
. O

TFP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 B
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O
via O
small O
molecule-induced O
oligomerization O
. O

trifluoperazine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Ca(2+)-binding O
proteins O
, O
regulates O
carcinoma O
cell O
motility O
via O
interactions O
with O
myosin-IIA O
. O
Numerous O
studies O
indicate O
that O
S100A4 B
is O
not O
simply O
a O
marker O
for O
metastatic O
disease O
, O
but O
rather O
has O
a O
direct O
role O
in O
metastatic O
progression O
. O
These O
observations O
suggest O
that O
S100A4 O
is O
an O
excellent O
target O
for O
therapeutic O
intervention O
. O
Using O
a O
unique O
biosensor-based O
assay O
, O
trifluoperazine O
(TFP) O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA O
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
, O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O

trifluoperazine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Ca(2+)-binding O
proteins O
, O
regulates O
carcinoma O
cell O
motility O
via O
interactions O
with O
myosin-IIA O
. O
Numerous O
studies O
indicate O
that O
S100A4 O
is O
not O
simply O
a O
marker O
for O
metastatic O
disease O
, O
but O
rather O
has O
a O
direct O
role O
in O
metastatic O
progression O
. O
These O
observations O
suggest O
that O
S100A4 O
is O
an O
excellent O
target O
for O
therapeutic O
intervention O
. O
Using O
a O
unique O
biosensor-based O
assay O
, O
trifluoperazine O
(TFP) O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA O
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
, O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O

TFP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
regulates O
carcinoma O
cell O
motility O
via O
interactions O
with O
myosin-IIA O
. O
Numerous O
studies O
indicate O
that O
S100A4 B
is O
not O
simply O
a O
marker O
for O
metastatic O
disease O
, O
but O
rather O
has O
a O
direct O
role O
in O
metastatic O
progression O
. O
These O
observations O
suggest O
that O
S100A4 O
is O
an O
excellent O
target O
for O
therapeutic O
intervention O
. O
Using O
a O
unique O
biosensor-based O
assay O
, O
trifluoperazine O
( O
TFP O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA O
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
, O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O
observed O

TFP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
regulates O
carcinoma O
cell O
motility O
via O
interactions O
with O
myosin-IIA O
. O
Numerous O
studies O
indicate O
that O
S100A4 O
is O
not O
simply O
a O
marker O
for O
metastatic O
disease O
, O
but O
rather O
has O
a O
direct O
role O
in O
metastatic O
progression O
. O
These O
observations O
suggest O
that O
S100A4 O
is O
an O
excellent O
target O
for O
therapeutic O
intervention O
. O
Using O
a O
unique O
biosensor-based O
assay O
, O
trifluoperazine O
( O
TFP O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA O
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
, O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O
observed O

TFP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 B
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O
via O
small O
molecule-induced O
oligomerization O
. O

TFP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 O
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA B
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O
via O
small O
molecule-induced O
oligomerization O
. O

TFP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 B
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O
via O
small O
molecule-induced O
oligomerization O
. O

phenothiazines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 B
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O
via O
small O
molecule-induced O
oligomerization O
. O

phenothiazines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA B
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O
via O
small O
molecule-induced O
oligomerization O
. O

corticosteroid O
acts O
as O
NOT O
for O
what O
entity O
? O
afternoon O
. O
Any O
pulse O
that O
had O
commenced O
at O
the O
time O
of O
injection O
was O
unaffected O
, O
and O
subsequent O
pulsatility O
was O
inhibited O
. O
Prednisolone O
also O
inhibited O
ACTH O
and O
cortisol O
secretion O
in O
response O
to O
exogenous O
CRH O
stimulation O
, O
inferring O
rapid O
feedback O
inhibition O
at O
the O
anterior O
pituitary O
. O
Circulating O
POMC B
peptide O
concentrations O
were O
unaffected O
, O
suggesting O
that O
the O
rapid O
corticosteroid O
inhibitory O
effect O
specifically O
targeted O
ACTH O
secretion O
from O
pituitary O
corticotrophs O
. O
Prednisolone O
fast O
feedback O
was O
only O
reduced O
by O
glucocorticoid O
receptor O
antagonist O
pretreatment O
and O
not O
by O
mineralocorticoid O
receptor O
antagonism O
, O
suggesting O
a O
glucocorticoid O
receptor-mediated O
pathway O
. O
The O
intravenous O
prednisolone O
suppression O
test O
provides O
a O
powerful O
new O
tool O
to O
investigate O
HPA O
abnormalities O
underlying O
metabolic O
and O
psychiatric O

Prednisolone O
acts O
as O
NOT O
for O
what O
entity O
? O
injection O
was O
unaffected O
, O
and O
subsequent O
pulsatility O
was O
inhibited O
. O
Prednisolone O
also O
inhibited O
ACTH O
and O
cortisol O
secretion O
in O
response O
to O
exogenous O
CRH O
stimulation O
, O
inferring O
rapid O
feedback O
inhibition O
at O
the O
anterior O
pituitary O
. O
Circulating O
POMC O
peptide O
concentrations O
were O
unaffected O
, O
suggesting O
that O
the O
rapid O
corticosteroid O
inhibitory O
effect O
specifically O
targeted O
ACTH O
secretion O
from O
pituitary O
corticotrophs O
. O
Prednisolone O
fast O
feedback O
was O
only O
reduced O
by O
glucocorticoid O
receptor O
antagonist O
pretreatment O
and O
not O
by O
mineralocorticoid B
receptor I
antagonism O
, O
suggesting O
a O
glucocorticoid O
receptor-mediated O
pathway O
. O
The O
intravenous O
prednisolone O
suppression O
test O
provides O
a O
powerful O
new O
tool O
to O
investigate O
HPA O
abnormalities O
underlying O
metabolic O
and O
psychiatric O
disease O
states O
. O

Prednisolone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
injection O
was O
unaffected O
, O
and O
subsequent O
pulsatility O
was O
inhibited O
. O
Prednisolone O
also O
inhibited O
ACTH O
and O
cortisol O
secretion O
in O
response O
to O
exogenous O
CRH O
stimulation O
, O
inferring O
rapid O
feedback O
inhibition O
at O
the O
anterior O
pituitary O
. O
Circulating O
POMC O
peptide O
concentrations O
were O
unaffected O
, O
suggesting O
that O
the O
rapid O
corticosteroid O
inhibitory O
effect O
specifically O
targeted O
ACTH O
secretion O
from O
pituitary O
corticotrophs O
. O
Prednisolone O
fast O
feedback O
was O
only O
reduced O
by O
glucocorticoid B
receptor I
antagonist O
pretreatment O
and O
not O
by O
mineralocorticoid O
receptor O
antagonism O
, O
suggesting O
a O
glucocorticoid O
receptor-mediated O
pathway O
. O
The O
intravenous O
prednisolone O
suppression O
test O
provides O
a O
powerful O
new O
tool O
to O
investigate O
HPA O
abnormalities O
underlying O
metabolic O
and O
psychiatric O
disease O
states O
. O

Prednisolone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
injection O
was O
unaffected O
, O
and O
subsequent O
pulsatility O
was O
inhibited O
. O
Prednisolone O
also O
inhibited O
ACTH O
and O
cortisol O
secretion O
in O
response O
to O
exogenous O
CRH O
stimulation O
, O
inferring O
rapid O
feedback O
inhibition O
at O
the O
anterior O
pituitary O
. O
Circulating O
POMC O
peptide O
concentrations O
were O
unaffected O
, O
suggesting O
that O
the O
rapid O
corticosteroid O
inhibitory O
effect O
specifically O
targeted O
ACTH O
secretion O
from O
pituitary O
corticotrophs O
. O
Prednisolone O
fast O
feedback O
was O
only O
reduced O
by O
glucocorticoid B
receptor I
antagonist O
pretreatment O
and O
not O
by O
mineralocorticoid O
receptor O
antagonism O
, O
suggesting O
a O
glucocorticoid O
receptor-mediated O
pathway O
. O
The O
intravenous O
prednisolone O
suppression O
test O
provides O
a O
powerful O
new O
tool O
to O
investigate O
HPA O
abnormalities O
underlying O
metabolic O
and O
psychiatric O
disease O
states O
. O

corticosteroid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Rapid O
glucocorticoid O
receptor-mediated O
inhibition O
of O
hypothalamic-pituitary-adrenal O
ultradian O
activity O
in O
healthy O
males.A O
complex O
dynamic O
ultradian O
rhythm O
underlies O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
circadian O
rhythm O
. O
We O
have O
investigated O
in O
normal O
human O
male O
subjects O
the O
importance O
, O
site O
of O
action O
, O
and O
receptor-mediated O
processes O
involved O
in O
rapid O
basal O
corticosteroid O
feedback O
and O
its O
interaction O
with O
corticotrophin B
releasing I
hormone I
(CRH) O
drive O
. O
Pro-opiomelanocortin O
(POMC) O
, O
ACTH O
, O
and O
cortisol O
were O
measured O
every O
10 O
min O
from O
healthy O
males O
during O
the O
awakening O
period O
or O
late O
afternoon O
using O
an O
automated O
blood O
sampling O
system O
. O
Mathematical O
modeling O
into O
discrete O
pulses O
of O
activity O
revealed O
that O
intravenous O
infusion O
of O
the O

corticosteroid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Rapid O
glucocorticoid O
receptor-mediated O
inhibition O
of O
hypothalamic-pituitary-adrenal O
ultradian O
activity O
in O
healthy O
males.A O
complex O
dynamic O
ultradian O
rhythm O
underlies O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
circadian O
rhythm O
. O
We O
have O
investigated O
in O
normal O
human O
male O
subjects O
the O
importance O
, O
site O
of O
action O
, O
and O
receptor-mediated O
processes O
involved O
in O
rapid O
basal O
corticosteroid O
feedback O
and O
its O
interaction O
with O
corticotrophin O
releasing O
hormone O
(CRH) O
drive O
. O
Pro-opiomelanocortin O
(POMC) O
, O
ACTH O
, O
and O
cortisol O
were O
measured O
every O
10 O
min O
from O
healthy O
males O
during O
the O
awakening O
period O
or O
late O
afternoon O
using O
an O
automated O
blood O
sampling O
system O
. O
Mathematical O
modeling O
into O
discrete O
pulses O
of O
activity O
revealed O
that O
intravenous O
infusion O
of O
the O

Prednisolone O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
into O
discrete O
pulses O
of O
activity O
revealed O
that O
intravenous O
infusion O
of O
the O
synthetic O
mixed O
glucocorticoid/mineralocorticoid O
agonist O
prednisolone O
produced O
rapid O
inhibition O
of O
ACTH O
and O
cortisol O
pulsatility O
within O
30 O
min O
in O
the O
morning O
and O
afternoon O
. O
Any O
pulse O
that O
had O
commenced O
at O
the O
time O
of O
injection O
was O
unaffected O
, O
and O
subsequent O
pulsatility O
was O
inhibited O
. O
Prednisolone O
also O
inhibited O
ACTH O
and O
cortisol O
secretion O
in O
response O
to O
exogenous O
CRH B
stimulation O
, O
inferring O
rapid O
feedback O
inhibition O
at O
the O
anterior O
pituitary O
. O
Circulating O
POMC O
peptide O
concentrations O
were O
unaffected O
, O
suggesting O
that O
the O
rapid O
corticosteroid O
inhibitory O
effect O
specifically O
targeted O
ACTH O
secretion O
from O
pituitary O
corticotrophs O
. O
Prednisolone O
fast O
feedback O
was O
only O
reduced O
by O
glucocorticoid O
receptor O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
revealed O
that O
intravenous O
infusion O
of O
the O
synthetic O
mixed O
glucocorticoid/mineralocorticoid O
agonist O
prednisolone O
produced O
rapid O
inhibition O
of O
ACTH O
and O
cortisol O
pulsatility O
within O
30 O
min O
in O
the O
morning O
and O
afternoon O
. O
Any O
pulse O
that O
had O
commenced O
at O
the O
time O
of O
injection O
was O
unaffected O
, O
and O
subsequent O
pulsatility O
was O
inhibited O
. O
Prednisolone O
also O
inhibited O
ACTH O
and O
cortisol O
secretion O
in O
response O
to O
exogenous O
CRH B
stimulation O
, O
inferring O
rapid O
feedback O
inhibition O
at O
the O
anterior O
pituitary O
. O
Circulating O
POMC O
peptide O
concentrations O
were O
unaffected O
, O
suggesting O
that O
the O
rapid O
corticosteroid O
inhibitory O
effect O
specifically O
targeted O
ACTH O
secretion O
from O
pituitary O
corticotrophs O
. O
Prednisolone O
fast O
feedback O
was O
only O
reduced O
by O
glucocorticoid O
receptor O
antagonist O
pretreatment O
and O
not O
by O

Rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
role O
of O
rasagiline O
in O
the O
treatment O
of O
Parkinson's O
disease.Parkinson's O
disease O
(PD) O
is O
the O
second O
most O
common O
neurodegenerative O
disorder O
, O
affecting O
1% O
to O
2% O
of O
people O
older O
than O
60 O
years O
. O
Treatment O
of O
PD O
consists O
of O
symptomatic O
therapies O
while O
neuroprotective O
strategies O
have O
remained O
elusive O
. O
Rasagiline O
is O
a O
novel O
, O
potent O
, O
and O
irreversible O
monoamine B
oxidase I
type I
B I
(MAO-B) O
inhibitor O
which O
has O
been O
approved O
for O
treatment O
of O
PD O
. O
Rasagiline O
inhibits O
MAO-B O
more O
potently O
than O
selegiline O
and O
has O
the O
advantage O
of O
once-daily O
dosing O
. O
In O
several O
large O
, O
randomized O
, O
placebo-controlled O
trials O
, O
rasagiline O
has O
demonstrated O
efficacy O
as O
monotherapy O
in O
early O
PD O

Rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
role O
of O
rasagiline O
in O
the O
treatment O
of O
Parkinson's O
disease.Parkinson's O
disease O
(PD) O
is O
the O
second O
most O
common O
neurodegenerative O
disorder O
, O
affecting O
1% O
to O
2% O
of O
people O
older O
than O
60 O
years O
. O
Treatment O
of O
PD O
consists O
of O
symptomatic O
therapies O
while O
neuroprotective O
strategies O
have O
remained O
elusive O
. O
Rasagiline O
is O
a O
novel O
, O
potent O
, O
and O
irreversible O
monoamine O
oxidase O
type O
B O
(MAO-B) O
inhibitor O
which O
has O
been O
approved O
for O
treatment O
of O
PD O
. O
Rasagiline O
inhibits O
MAO-B B
more O
potently O
than O
selegiline O
and O
has O
the O
advantage O
of O
once-daily O
dosing O
. O
In O
several O
large O
, O
randomized O
, O
placebo-controlled O
trials O
, O
rasagiline O
has O
demonstrated O
efficacy O
as O
monotherapy O
in O
early O
PD O

Rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
second O
most O
common O
neurodegenerative O
disorder O
, O
affecting O
1% O
to O
2% O
of O
people O
older O
than O
60 O
years O
. O
Treatment O
of O
PD O
consists O
of O
symptomatic O
therapies O
while O
neuroprotective O
strategies O
have O
remained O
elusive O
. O
Rasagiline O
is O
a O
novel O
, O
potent O
, O
and O
irreversible O
monoamine O
oxidase O
type O
B O
(MAO-B) O
inhibitor O
which O
has O
been O
approved O
for O
treatment O
of O
PD O
. O
Rasagiline O
inhibits O
MAO-B B
more O
potently O
than O
selegiline O
and O
has O
the O
advantage O
of O
once-daily O
dosing O
. O
In O
several O
large O
, O
randomized O
, O
placebo-controlled O
trials O
, O
rasagiline O
has O
demonstrated O
efficacy O
as O
monotherapy O
in O
early O
PD O
and O
as O
adjunctive O
therapy O
in O
advanced O
PD O
. O
In O
addition O
, O
rasagiline O
has O
been O
shown O
to O
have O
neuroprotective O
effects O
in O
in O
vitro O
and O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O
in O
patients O
with O
clear O
cell O
renal O
cancers O
and O
progressive O
disease O
on O
or O
within O
6 O
months O
of O
the O
VEGFR B
tyrosine O
kinase O
inhibitors O
sunitinib O
and/or O
sorafenib O
The O
primary O
endpoint O
of O
progression-free O
survival O
was O
increased O
from O
median O
1.9 O
to O
4.9 O
months O
(hazard O
ratio O
0.33 O
, O
P O
< O
0.001) O
and O
25% O
were O
still O
progression-free O
after O
10 O
months O
of O
everolimus O
therapy O
. O
There O
was O
a O
delay O
in O
time O
to O
decline O
of O
performance O
status O
and O
trends O
to O
improvement O
in O
quality O
of O

sorafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O
in O
patients O
with O
clear O
cell O
renal O
cancers O
and O
progressive O
disease O
on O
or O
within O
6 O
months O
of O
the O
VEGFR O
tyrosine B
kinase I
inhibitors O
sunitinib O
and/or O
sorafenib O
The O
primary O
endpoint O
of O
progression-free O
survival O
was O
increased O
from O
median O
1.9 O
to O
4.9 O
months O
(hazard O
ratio O
0.33 O
, O
P O
< O
0.001) O
and O
25% O
were O
still O
progression-free O
after O
10 O
months O
of O
everolimus O
therapy O
. O
There O
was O
a O
delay O
in O
time O
to O
decline O
of O
performance O
status O
and O
trends O
to O
improvement O
in O
quality O
of O

Everolimus O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Everolimus O
: O
the O
first O
approved O
product O
for O
patients O
with O
advanced O
renal O
cell O
cancer O
after O
sunitinib O
and/or O
sorafenib O
. O
Everolimus O
(RAD001 O
, O
Afinitor((R)) O
Novartis) O
is O
the O
first O
oral O
inhibitor O
of O
mTOR B
(mammalian O
target O
of O
rapamycin) O
to O
reach O
the O
oncology O
clinic O
. O
Everolimus O
10 O
mg O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O

Everolimus O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Everolimus O
: O
the O
first O
approved O
product O
for O
patients O
with O
advanced O
renal O
cell O
cancer O
after O
sunitinib O
and/or O
sorafenib O
. O
Everolimus O
(RAD001 O
, O
Afinitor((R)) O
Novartis) O
is O
the O
first O
oral O
inhibitor O
of O
mTOR O
(mammalian O
target O
of O
rapamycin) O
to O
reach O
the O
oncology O
clinic O
. O
Everolimus O
10 O
mg O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O

RAD001 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Everolimus O
: O
the O
first O
approved O
product O
for O
patients O
with O
advanced O
renal O
cell O
cancer O
after O
sunitinib O
and/or O
sorafenib.Everolimus O
( O
RAD001 O
Afinitor((R)) O
Novartis) O
is O
the O
first O
oral O
inhibitor O
of O
mTOR B
(mammalian O
target O
of O
rapamycin) O
to O
reach O
the O
oncology O
clinic O
. O
Everolimus O
10 O
mg O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O

RAD001 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Everolimus O
: O
the O
first O
approved O
product O
for O
patients O
with O
advanced O
renal O
cell O
cancer O
after O
sunitinib O
and/or O
sorafenib.Everolimus O
( O
RAD001 O
Afinitor((R)) O
Novartis) O
is O
the O
first O
oral O
inhibitor O
of O
mTOR O
(mammalian O
target O
of O
rapamycin) O
to O
reach O
the O
oncology O
clinic O
. O
Everolimus O
10 O
mg O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O

Afinitor((R)) O
Novartis O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Everolimus O
: O
the O
first O
approved O
product O
for O
patients O
with O
advanced O
renal O
cell O
cancer O
after O
sunitinib O
and/or O
sorafenib.Everolimus O
(RAD001 O
, O
Afinitor((R)) O
Novartis O
is O
the O
first O
oral O
inhibitor O
of O
mTOR B
(mammalian O
target O
of O
rapamycin) O
to O
reach O
the O
oncology O
clinic O
. O
Everolimus O
10 O
mg O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O
in O
patients O

Afinitor((R)) O
Novartis O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Everolimus O
: O
the O
first O
approved O
product O
for O
patients O
with O
advanced O
renal O
cell O
cancer O
after O
sunitinib O
and/or O
sorafenib.Everolimus O
(RAD001 O
, O
Afinitor((R)) O
Novartis O
is O
the O
first O
oral O
inhibitor O
of O
mTOR O
(mammalian O
target O
of O
rapamycin) O
to O
reach O
the O
oncology O
clinic O
. O
Everolimus O
10 O
mg O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O
in O
patients O

sunitinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O
in O
patients O
with O
clear O
cell O
renal O
cancers O
and O
progressive O
disease O
on O
or O
within O
6 O
months O
of O
the O
VEGFR B
tyrosine O
kinase O
inhibitors O
sunitinib O
and/or O
sorafenib O
. O
The O
primary O
endpoint O
of O
progression-free O
survival O
was O
increased O
from O
median O
1.9 O
to O
4.9 O
months O
(hazard O
ratio O
0.33 O
, O
P O
< O
0.001) O
and O
25% O
were O
still O
progression-free O
after O
10 O
months O
of O
everolimus O
therapy O
. O
There O
was O
a O
delay O
in O
time O
to O
decline O
of O
performance O
status O
and O
trends O
to O
improvement O
in O

sunitinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O
in O
patients O
with O
clear O
cell O
renal O
cancers O
and O
progressive O
disease O
on O
or O
within O
6 O
months O
of O
the O
VEGFR O
tyrosine B
kinase I
inhibitors O
sunitinib O
and/or O
sorafenib O
. O
The O
primary O
endpoint O
of O
progression-free O
survival O
was O
increased O
from O
median O
1.9 O
to O
4.9 O
months O
(hazard O
ratio O
0.33 O
, O
P O
< O
0.001) O
and O
25% O
were O
still O
progression-free O
after O
10 O
months O
of O
everolimus O
therapy O
. O
There O
was O
a O
delay O
in O
time O
to O
decline O
of O
performance O
status O
and O
trends O
to O
improvement O
in O

Ca2+ O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Predicting O
cardiomyopathic O
phenotypes O
by O
altering O
Ca2 O
affinity O
of O
cardiac O
troponin O
C.Cardiac O
diseases O
associated O
with O
mutations O
in O
troponin O
subunits O
include O
hypertrophic O
cardiomyopathy O
(HCM) O
, O
dilated O
cardiomyopathy O
(DCM) O
, O
and O
restrictive O
cardiomyopathy O
(RCM) O
. O
Altered O
calcium O
handling O
in O
these O
diseases O
is O
evidenced O
by O
changes O
in O
the O
Ca(2+) O
sensitivity O
of O
contraction O
. O
Mutations O
in O
the O
Ca(2+) O
sensor O
, O
troponin O
C O
(TnC) O
, O
were O
generated O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
identified O
with O
RCM-like O
properties O
(a O
large O
increase O
in O
Ca(2+) O
sensitivity O
, O
partial O
loss O
of O
ATPase O
inhibition O
, O
and O
increased O
basal O
force) O
. O
Two O
mutations O
were O
identified O
(E40A O
and O
I61Q) O
with O
DCM O
properties O
(decreased O
Ca(2+) O
sensitivity O
, O
maximal O
force O
recovery O
, O
and O
activation O
of O
the O
ATPase O
at O
high O
[Ca(2+)]) O
. O
Steady-state O
fluorescence O
was O
utilized O
to O
assess O
Ca(2+) O
affinity O
in O
isolated O
cardiac B
(c)TnCs I
containing O
F27W O
and O
did O
not O
necessarily O
mirror O
the O
fiber O
Ca(2+) O
sensitivity O
. O
Circular O
dichroism O
of O
mutant O
cTnCs O
revealed O
a O
trend O
where O
increased O
alpha-helical O
content O
correlated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
identified O
with O
RCM-like O
properties O
(a O
large O
increase O
in O
Ca(2+) O
sensitivity O
, O
partial O
loss O
of O
ATPase O
inhibition O
, O
and O
increased O
basal O
force) O
. O
Two O
mutations O
were O
identified O
(E40A O
and O
I61Q) O
with O
DCM O
properties O
(decreased O
Ca(2+) O
sensitivity O
, O
maximal O
force O
recovery O
, O
and O
activation O
of O
the O
ATPase O
at O
high O
[Ca(2+)]) O
. O
Steady-state O
fluorescence O
was O
utilized O
to O
assess O
Ca(2+) O
affinity O
in O
isolated O
cardiac O
(c)TnCs O
containing O
F27W B
and O
did O
not O
necessarily O
mirror O
the O
fiber O
Ca(2+) O
sensitivity O
. O
Circular O
dichroism O
of O
mutant O
cTnCs O
revealed O
a O
trend O
where O
increased O
alpha-helical O
content O
correlated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
increased O
basal O
force) O
. O
Two O
mutations O
were O
identified O
(E40A O
and O
I61Q) O
with O
DCM O
properties O
(decreased O
Ca(2+) O
sensitivity O
, O
maximal O
force O
recovery O
, O
and O
activation O
of O
the O
ATPase O
at O
high O
[Ca(2+)]) O
. O
Steady-state O
fluorescence O
was O
utilized O
to O
assess O
Ca(2+) O
affinity O
in O
isolated O
cardiac B
(c)TnCs I
containing O
F27W O
and O
did O
not O
necessarily O
mirror O
the O
fiber O
Ca(2+) O
sensitivity O
. O
Circular O
dichroism O
of O
mutant O
cTnCs O
revealed O
a O
trend O
where O
increased O
alpha-helical O
content O
correlated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O
cTnC O
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM O
, O
RCM O
, O
and O
DCM O
mutations; O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
maximal O
force O
recovery O
, O
and O
activation O
of O
the O
ATPase O
at O
high O
[Ca(2+)]) O
. O
Steady-state O
fluorescence O
was O
utilized O
to O
assess O
Ca(2+) O
affinity O
in O
isolated O
cardiac O
(c)TnCs O
containing O
F27W O
and O
did O
not O
necessarily O
mirror O
the O
fiber O
Ca(2+) O
sensitivity O
. O
Circular O
dichroism O
of O
mutant O
cTnCs B
revealed O
a O
trend O
where O
increased O
alpha-helical O
content O
correlated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O
cTnC O
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM O
, O
RCM O
, O
and O
DCM O
mutations; O
2) O
a O
region O
in O
cTnC O
associated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
was O
identified; O
and O
3) O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
trend O
where O
increased O
alpha-helical O
content O
correlated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O
cTnC B
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM O
, O
RCM O
, O
and O
DCM O
mutations; O
2) O
a O
region O
in O
cTnC O
associated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
was O
identified; O
and O
3) O
the O
F27W O
reporter O
mutation O
affected O
Ca(2+) O
sensitivity O
, O
maximal O
force O
, O
and O
ATPase O
activation O
of O
some O
mutants O
. O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
trend O
where O
increased O
alpha-helical O
content O
correlated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O
cTnC B
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM O
, O
RCM O
, O
and O
DCM O
mutations; O
2) O
a O
region O
in O
cTnC O
associated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
was O
identified; O
and O
3) O
the O
F27W O
reporter O
mutation O
affected O
Ca(2+) O
sensitivity O
, O
maximal O
force O
, O
and O
ATPase O
activation O
of O
some O
mutants O
. O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O
cTnC B
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM O
, O
RCM O
, O
and O
DCM O
mutations; O
2) O
a O
region O
in O
cTnC O
associated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
was O
identified; O
and O
3) O
the O
F27W O
reporter O
mutation O
affected O
Ca(2+) O
sensitivity O
, O
maximal O
force O
, O
and O
ATPase O
activation O
of O
some O
mutants O
. O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O
cTnC B
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM O
, O
RCM O
, O
and O
DCM O
mutations; O
2) O
a O
region O
in O
cTnC O
associated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
was O
identified; O
and O
3) O
the O
F27W O
reporter O
mutation O
affected O
Ca(2+) O
sensitivity O
, O
maximal O
force O
, O
and O
ATPase O
activation O
of O
some O
mutants O
. O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Predicting O
cardiomyopathic O
phenotypes O
by O
altering O
Ca2+ O
affinity O
of O
cardiac O
troponin O
C.Cardiac O
diseases O
associated O
with O
mutations O
in O
troponin O
subunits O
include O
hypertrophic O
cardiomyopathy O
(HCM) O
, O
dilated O
cardiomyopathy O
(DCM) O
, O
and O
restrictive O
cardiomyopathy O
(RCM) O
. O
Altered O
calcium O
handling O
in O
these O
diseases O
is O
evidenced O
by O
changes O
in O
the O
Ca(2+) O
sensitivity O
of O
contraction O
. O
Mutations O
in O
the O
Ca(2+) O
sensor O
, O
troponin B
C I
(TnC) O
, O
were O
generated O
to O
increase/decrease O
the O
Ca(2+) O
sensitivity O
of O
cardiac O
skinned O
fibers O
to O
create O
the O
characteristic O
effects O
of O
DCM O
, O
HCM O
, O
and O
RCM O
. O
We O
also O
used O
a O
reconstituted O
assay O
to O
determine O
the O
mutation O
effects O
on O
ATPase O
activation O
and O
inhibition O
. O
One O
mutant O
(A23Q) O
was O
found O
with O
HCM-like O
properties O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Predicting O
cardiomyopathic O
phenotypes O
by O
altering O
Ca2+ O
affinity O
of O
cardiac O
troponin O
C.Cardiac O
diseases O
associated O
with O
mutations O
in O
troponin O
subunits O
include O
hypertrophic O
cardiomyopathy O
(HCM) O
, O
dilated O
cardiomyopathy O
(DCM) O
, O
and O
restrictive O
cardiomyopathy O
(RCM) O
. O
Altered O
calcium O
handling O
in O
these O
diseases O
is O
evidenced O
by O
changes O
in O
the O
Ca(2+) O
sensitivity O
of O
contraction O
. O
Mutations O
in O
the O
Ca(2+) O
sensor O
, O
troponin O
C O
(TnC) O
, O
were O
generated O
to O
increase/decrease O
the O
Ca(2+) O
sensitivity O
of O
cardiac O
skinned O
fibers O
to O
create O
the O
characteristic O
effects O
of O
DCM O
, O
HCM O
, O
and O
RCM O
. O
We O
also O
used O
a O
reconstituted O
assay O
to O
determine O
the O
mutation O
effects O
on O
ATPase O
activation O
and O
inhibition O
. O
One O
mutant O
(A23Q) O
was O
found O
with O
HCM-like O
properties O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
troponin O
C.Cardiac O
diseases O
associated O
with O
mutations O
in O
troponin O
subunits O
include O
hypertrophic O
cardiomyopathy O
(HCM) O
, O
dilated O
cardiomyopathy O
(DCM) O
, O
and O
restrictive O
cardiomyopathy O
(RCM) O
. O
Altered O
calcium O
handling O
in O
these O
diseases O
is O
evidenced O
by O
changes O
in O
the O
Ca(2+) O
sensitivity O
of O
contraction O
. O
Mutations O
in O
the O
Ca(2+) O
sensor O
, O
troponin B
C I
(TnC) O
, O
were O
generated O
to O
increase/decrease O
the O
Ca(2+) O
sensitivity O
of O
cardiac O
skinned O
fibers O
to O
create O
the O
characteristic O
effects O
of O
DCM O
, O
HCM O
, O
and O
RCM O
. O
We O
also O
used O
a O
reconstituted O
assay O
to O
determine O
the O
mutation O
effects O
on O
ATPase O
activation O
and O
inhibition O
. O
One O
mutant O
(A23Q) O
was O
found O
with O
HCM-like O
properties O
(increased O
Ca(2+) O
sensitivity O
of O
force O
and O
normal O
levels O
of O
ATPase O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
troponin O
C.Cardiac O
diseases O
associated O
with O
mutations O
in O
troponin O
subunits O
include O
hypertrophic O
cardiomyopathy O
(HCM) O
, O
dilated O
cardiomyopathy O
(DCM) O
, O
and O
restrictive O
cardiomyopathy O
(RCM) O
. O
Altered O
calcium O
handling O
in O
these O
diseases O
is O
evidenced O
by O
changes O
in O
the O
Ca(2+) O
sensitivity O
of O
contraction O
. O
Mutations O
in O
the O
Ca(2+) O
sensor O
, O
troponin O
C O
(TnC) O
, O
were O
generated O
to O
increase/decrease O
the O
Ca(2+) O
sensitivity O
of O
cardiac O
skinned O
fibers O
to O
create O
the O
characteristic O
effects O
of O
DCM O
, O
HCM O
, O
and O
RCM O
. O
We O
also O
used O
a O
reconstituted O
assay O
to O
determine O
the O
mutation O
effects O
on O
ATPase O
activation O
and O
inhibition O
. O
One O
mutant O
(A23Q) O
was O
found O
with O
HCM-like O
properties O
(increased O
Ca(2+) O
sensitivity O
of O
force O
and O
normal O
levels O
of O
ATPase O

JNJ O
7777120 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
goblet O
cell O
hyperplasia O
(GCH) O
, O
and O
collagen O
deposition O
in O
a O
sub-chronic O
model O
of O
asthma O
. O
In O
addition O
, O
effects O
on O
Th2 O
mediated O
lung O
dysfunction O
were O
also O
determined O
. O
METHODS O
: O
Mice O
were O
sensitized O
to O
ovalbumin O
(OVA) O
followed O
by O
repeated O
airway O
challenge O
with O
OVA O
. O
After O
inflammation O
was O
established O
mice O
were O
dosed O
with O
the O
H4R B
antagonist O
, O
JNJ O
7777120 O
or O
anti-IL-13 O
antibody O
for O
comparison O
. O
Airway O
hyperreactivity O
(AHR) O
was O
measured O
, O
lungs O
lavaged O
and O
tissues O
collected O
for O
analysis O
. O
RESULTS O
: O
Therapeutic O
H4R O
antagonism O
inhibited O
T O
cell O
infiltration O
in O
to O
the O
lung O
and O
decreased O
Th2 O
cytokines O
IL-13 O
and O
IL-5 O
. O
IL-13 O
dependent O
remodeling O
parameters O
such O
as O
GCH O
and O
lung O
collagen O
were O
reduced O
. O
Intervention O

VP-16 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase O
3 O
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O
in O
the O

MXF O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase O
3 O
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O
cleavable O
complexes O
formed O
by O
both O

MXF O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase O
3 O
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF B
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O
cleavable O
complexes O
formed O
by O
both O

MXF O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
MXF O
on O
the O
mode O
of O
action O
of O
VP-16 O
, O
on O
proliferation O
and O
apoptosis O
of O
HT-29 O
cells O
. O
Decatenation O
assay O
, O
band O
depletion O
and O
Western O
blot O
analysis O
, O
cytotoxic O
assay O
(MTT) O
, O
flow O
cytometric O
studies O
(cell O
cycle O
and O
survivin O
expression) O
, O
apoptosis O
(DAPI-sulforhodamine O
staining O
and O
caspase O
3 O
activity) O
and O
IL-8 O
and O
VEGF O
secretion O
were O
determined O
. O
MXF O
or O
VP-16 O
slightly O
affected O
cellular O
topo B
II I
activity O
in O
nuclear O
extracts O
derived O
from O
drug-treated O
cells O
while O
the O
combination O
enhanced O
inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O

VP-16 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
on O
the O
mode O
of O
action O
of O
VP-16 O
, O
on O
proliferation O
and O
apoptosis O
of O
HT-29 O
cells O
. O
Decatenation O
assay O
, O
band O
depletion O
and O
Western O
blot O
analysis O
, O
cytotoxic O
assay O
(MTT) O
, O
flow O
cytometric O
studies O
(cell O
cycle O
and O
survivin O
expression) O
, O
apoptosis O
(DAPI-sulforhodamine O
staining O
and O
caspase O
3 O
activity) O
and O
IL-8 O
and O
VEGF O
secretion O
were O
determined O
. O
MXF O
or O
VP-16 O
slightly O
affected O
cellular O
topo B
II I
activity O
in O
nuclear O
extracts O
derived O
from O
drug-treated O
cells O
while O
the O
combination O
enhanced O
inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O

MXF O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase B
3 I
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O

VP-16 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
the O
reduction O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase B
3 I
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O
due O

VP-16 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase B
3 I
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O

MXF O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo B
II I
activity O
by O
the O
combined O
MXF O
VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O
cleavable O
complexes O
formed O
by O
both O
drugs O
. O
The O
unique O
combination O
of O
MXF/VP-16 O
may O
have O
clinical O
benefits O
and O
a O
cytotoxic O
drug O
'sparing O
effect' O
and O
should O
be O
further O
studied O
in O
vivo O
. O

VP-16 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo B
II I
activity O
by O
the O
combined O
MXF O
/ O
VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O
cleavable O
complexes O
formed O
by O
both O
drugs O
. O
The O
unique O
combination O
of O
MXF/VP-16 O
may O
have O
clinical O
benefits O
and O
a O
cytotoxic O
drug O
'sparing O
effect' O
and O
should O
be O
further O
studied O
in O
vivo O
. O

Etoposide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Moxifloxacin O
enhances O
etoposide-induced O
cytotoxic O
, O
apoptotic O
and O
anti-topoisomerase O
II O
effects O
in O
a O
human O
colon O
carcinoma O
cell O
line O
. O
Etoposide O
(VP-16) O
is O
a O
topoisomerase-II B
(topo O
II) O
inhibitor O
chemotherapeutic O
agent O
. O
Studies O
have O
shown O
that O
a O
combination O
of O
VP-16 O
with O
other O
drugs O
demonstrates O
better O
clinical O
responses O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
moxifloxacin O
(MXF) O
and O
VP-16 O
on O
cellular O
topo O
II O
activity O
in O
drug-treated O
cells O
and O
evaluate O

Etoposide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Moxifloxacin O
enhances O
etoposide-induced O
cytotoxic O
, O
apoptotic O
and O
anti-topoisomerase O
II O
effects O
in O
a O
human O
colon O
carcinoma O
cell O
line O
. O
Etoposide O
(VP-16) O
is O
a O
topoisomerase-II O
(topo O
II) O
inhibitor O
chemotherapeutic O
agent O
. O
Studies O
have O
shown O
that O
a O
combination O
of O
VP-16 O
with O
other O
drugs O
demonstrates O
better O
clinical O
responses O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
moxifloxacin O
(MXF) O
and O
VP-16 O
on O
cellular O
topo B
II I
activity O
in O
drug-treated O
cells O
and O
evaluate O

MXF O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
MXF O
on O
the O
mode O
of O
action O
of O
VP-16 O
, O
on O
proliferation O
and O
apoptosis O
of O
HT-29 O
cells O
. O
Decatenation O
assay O
, O
band O
depletion O
and O
Western O
blot O
analysis O
, O
cytotoxic O
assay O
(MTT) O
, O
flow O
cytometric O
studies O
(cell O
cycle O
and O
survivin O
expression) O
, O
apoptosis O
(DAPI-sulforhodamine O
staining O
and O
caspase O
3 O
activity) O
and O
IL-8 O
and O
VEGF O
secretion O
were O
determined O
. O
MXF O
or O
VP-16 O
slightly O
affected O
cellular O
topo B
II I
activity O
in O
nuclear O
extracts O
derived O
from O
drug-treated O
cells O
while O
the O
combination O
enhanced O
inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O

VP-16 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
the O
mode O
of O
action O
of O
VP-16 O
, O
on O
proliferation O
and O
apoptosis O
of O
HT-29 O
cells O
. O
Decatenation O
assay O
, O
band O
depletion O
and O
Western O
blot O
analysis O
, O
cytotoxic O
assay O
(MTT) O
, O
flow O
cytometric O
studies O
(cell O
cycle O
and O
survivin O
expression) O
, O
apoptosis O
(DAPI-sulforhodamine O
staining O
and O
caspase O
3 O
activity) O
and O
IL-8 O
and O
VEGF O
secretion O
were O
determined O
. O
MXF O
or O
VP-16 O
slightly O
affected O
cellular O
topo B
II I
activity O
in O
nuclear O
extracts O
derived O
from O
drug-treated O
cells O
while O
the O
combination O
enhanced O
inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O

VP-16 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Moxifloxacin O
enhances O
etoposide-induced O
cytotoxic O
, O
apoptotic O
and O
anti-topoisomerase O
II O
effects O
in O
a O
human O
colon O
carcinoma O
cell O
line.Etoposide O
( O
VP-16 O
is O
a O
topoisomerase-II B
(topo O
II) O
inhibitor O
chemotherapeutic O
agent O
. O
Studies O
have O
shown O
that O
a O
combination O
of O
VP-16 O
with O
other O
drugs O
demonstrates O
better O
clinical O
responses O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
moxifloxacin O
(MXF) O
and O
VP-16 O
on O
cellular O
topo O
II O
activity O
in O
drug-treated O
cells O
and O
evaluate O
the O

VP-16 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Moxifloxacin O
enhances O
etoposide-induced O
cytotoxic O
, O
apoptotic O
and O
anti-topoisomerase O
II O
effects O
in O
a O
human O
colon O
carcinoma O
cell O
line.Etoposide O
( O
VP-16 O
is O
a O
topoisomerase-II O
(topo O
II) O
inhibitor O
chemotherapeutic O
agent O
. O
Studies O
have O
shown O
that O
a O
combination O
of O
VP-16 O
with O
other O
drugs O
demonstrates O
better O
clinical O
responses O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
moxifloxacin O
(MXF) O
and O
VP-16 O
on O
cellular O
topo B
II I
activity O
in O
drug-treated O
cells O
and O
evaluate O
the O

rasagiline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
either O
wild-type O
or O
A53T O
mutant O
alpha-synuclein B
over-expression O
. O
This O
protection O
was O
associated O
with O
a O
reduction O
in O
caspase O
3 O
activation O
, O
a O
reduction O
in O
superoxide O
generation O
and O
a O
trend O
to O
ameliorate O
the O
fall O
in O
mitochondrial O
membrane O
potential O
. O
Rasagiline O
induced O
an O
increase O
in O
cellular O
glutathione O
levels O
. O
The O
results O
support O
a O
role O
for O
rasagiline O
in O
protecting O
dopaminergic O
cells O
against O
free O
radical O
mediated O
damage O
and O
apoptosis O
in O
the O
presence O
of O
alpha-synuclein O
over-expression O
. O
The O
data O
are O
of O
relevance O
to O
the O
interpretation O
of O
the O
potential O
mechanisms O
of O
action O
of O
rasagiline O
in O
explaining O
the O
results O
of O
disease O
modification O
trials O
in O
PD O
. O

rasagiline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
radical O
metabolism O
and O
mitochondrial O
dysfunction O
in O
contributing O
to O
cell O
death O
. O
We O
have O
used O
a O
combination O
of O
alpha-synuclein O
and O
free O
radical O
mediated O
toxicity O
in O
a O
dopaminergic O
cell O
line O
to O
provide O
a O
model O
of O
nigral O
toxicity O
in O
order O
to O
investigate O
the O
potential O
molecular O
mechanisms O
that O
mediate O
rasagiline O
protection O
. O
We O
demonstrate O
that O
rasagiline O
protects O
against O
cell O
death O
induced O
by O
the O
combination O
of O
free O
radicals O
generated O
by O
paraquat O
and O
either O
wild-type O
or O
A53T B
mutant O
alpha-synuclein O
over-expression O
. O
This O
protection O
was O
associated O
with O
a O
reduction O
in O
caspase O
3 O
activation O
, O
a O
reduction O
in O
superoxide O
generation O
and O
a O
trend O
to O
ameliorate O
the O
fall O
in O
mitochondrial O
membrane O
potential O
. O

rasagiline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
radical O
metabolism O
and O
mitochondrial O
dysfunction O
in O
contributing O
to O
cell O
death O
. O
We O
have O
used O
a O
combination O
of O
alpha-synuclein B
and O
free O
radical O
mediated O
toxicity O
in O
a O
dopaminergic O
cell O
line O
to O
provide O
a O
model O
of O
nigral O
toxicity O
in O
order O
to O
investigate O
the O
potential O
molecular O
mechanisms O
that O
mediate O
rasagiline O
protection O
. O
We O
demonstrate O
that O
rasagiline O
protects O
against O
cell O
death O
induced O
by O
the O
combination O
of O
free O
radicals O
generated O
by O
paraquat O
and O
either O
wild-type O
or O
A53T O
mutant O
alpha-synuclein O
over-expression O
. O
This O
protection O
was O
associated O
with O
a O
reduction O
in O
caspase O
3 O
activation O
, O
a O
reduction O
in O
superoxide O
generation O
and O
a O
trend O
to O
ameliorate O
the O
fall O
in O
mitochondrial O
membrane O
potential O
. O

Rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Rasagiline O
protects O
against O
alpha-synuclein O
induced O
sensitivity O
to O
oxidative O
stress O
in O
dopaminergic O
cells O
. O
Rasagiline O
is O
a O
propargylamine O
and O
irreversible O
monoamine B
oxidase I
(MAO) I
B I
inhibitor O
used O
for O
the O
treatment O
of O
Parkinson's O
disease O
(PD) O
. O
It O
has O
demonstrated O
neuroprotective O
properties O
in O
laboratory O
studies O
. O
Current O
concepts O
of O
PD O
aetiopathogenesis O
include O
the O
role O
of O
alpha-synuclein O
, O
protein O
aggregation O
, O
free O
radical O
metabolism O
and O
mitochondrial O
dysfunction O
in O
contributing O
to O
cell O
death O
. O

propargylamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Rasagiline O
protects O
against O
alpha-synuclein O
induced O
sensitivity O
to O
oxidative O
stress O
in O
dopaminergic O
cells.Rasagiline O
is O
a O
propargylamine O
and O
irreversible O
monoamine B
oxidase I
(MAO) I
B I
inhibitor O
used O
for O
the O
treatment O
of O
Parkinson's O
disease O
(PD) O
. O
It O
has O
demonstrated O
neuroprotective O
properties O
in O
laboratory O
studies O
. O
Current O
concepts O
of O
PD O
aetiopathogenesis O
include O
the O
role O
of O
alpha-synuclein O
, O
protein O
aggregation O
, O
free O
radical O
metabolism O
and O
mitochondrial O
dysfunction O
in O
contributing O
to O
cell O
death O
. O
We O
have O
used O

dfbp O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
however O
, O
detailed O
understanding O
of O
its O
mechanism O
has O
been O
obscured O
by O
its O
instability O
. O
In O
order O
to O
understand O
how O
this O
class O
of O
positive O
inotropes O
function O
, O
we O
investigated O
the O
mode O
of O
action O
of O
two O
fluorine O
containing O
novel O
analogs O
of O
levosimendan; O
2',4'-difluoro(1,1'-biphenyl)-4-yloxy O
acetic O
acid O
(dfbp-o) O
and O
2',4'-difluoro(1,1'-biphenyl)-4-yl O
acetic O
acid O
(dfbp) O
. O
The O
affinities O
of O
dfbp O
and O
dfbp-o O
for O
the O
regulatory O
domain O
of O
cTnC B
were O
measured O
in O
the O
absence O
and O
presence O
of O
cTnI O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O

dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
understanding O
of O
its O
mechanism O
has O
been O
obscured O
by O
its O
instability O
. O
In O
order O
to O
understand O
how O
this O
class O
of O
positive O
inotropes O
function O
, O
we O
investigated O
the O
mode O
of O
action O
of O
two O
fluorine O
containing O
novel O
analogs O
of O
levosimendan; O
2',4'-difluoro(1,1'-biphenyl)-4-yloxy O
acetic O
acid O
(dfbp-o) O
and O
2',4'-difluoro(1,1'-biphenyl)-4-yl O
acetic O
acid O
(dfbp) O
. O
The O
affinities O
of O
dfbp O
and O
dfbp-o O
for O
the O
regulatory O
domain O
of O
cTnC B
were O
measured O
in O
the O
absence O
and O
presence O
of O
cTnI O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O

dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
function O
, O
we O
investigated O
the O
mode O
of O
action O
of O
two O
fluorine O
containing O
novel O
analogs O
of O
levosimendan; O
2',4'-difluoro(1,1'-biphenyl)-4-yloxy O
acetic O
acid O
(dfbp-o) O
and O
2',4'-difluoro(1,1'-biphenyl)-4-yl O
acetic O
acid O
(dfbp) O
. O
The O
affinities O
of O
dfbp O
and O
dfbp-o O
for O
the O
regulatory O
domain O
of O
cTnC B
were O
measured O
in O
the O
absence O
and O
presence O
of O
cTnI O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI-dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O

dfbp O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
two O
fluorine O
containing O
novel O
analogs O
of O
levosimendan; O
2',4'-difluoro(1,1'-biphenyl)-4-yloxy O
acetic O
acid O
(dfbp-o) O
and O
2',4'-difluoro(1,1'-biphenyl)-4-yl O
acetic O
acid O
(dfbp) O
. O
The O
affinities O
of O
dfbp O
and O
dfbp-o O
for O
the O
regulatory O
domain O
of O
cTnC B
were O
measured O
in O
the O
absence O
and O
presence O
of O
cTnI O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI-dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC O
and O
cTnI O
making O
critical O

Dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
fluorine O
containing O
novel O
analogs O
of O
levosimendan; O
2',4'-difluoro(1,1'-biphenyl)-4-yloxy O
acetic O
acid O
(dfbp-o) O
and O
2',4'-difluoro(1,1'-biphenyl)-4-yl O
acetic O
acid O
(dfbp) O
. O
The O
affinities O
of O
dfbp O
and O
dfbp-o O
for O
the O
regulatory O
domain O
of O
cTnC O
were O
measured O
in O
the O
absence O
and O
presence O
of O
cTnI B
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI-dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC O
and O
cTnI O
making O
critical O
interactions O

Dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
fluorine O
containing O
novel O
analogs O
of O
levosimendan; O
2',4'-difluoro(1,1'-biphenyl)-4-yloxy O
acetic O
acid O
(dfbp-o) O
and O
2',4'-difluoro(1,1'-biphenyl)-4-yl O
acetic O
acid O
(dfbp) O
. O
The O
affinities O
of O
dfbp O
and O
dfbp-o O
for O
the O
regulatory O
domain O
of O
cTnC B
were O
measured O
in O
the O
absence O
and O
presence O
of O
cTnI O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI-dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC O
and O
cTnI O
making O
critical O
interactions O

dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
presence O
of O
cTnI O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI- O
dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC B
and O
cTnI O
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC O
. O
The O
structural O
and O
functional O
data O
reveal O

dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
presence O
of O
cTnI B
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI- O
dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC O
and O
cTnI O
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC O
. O
The O
structural O
and O
functional O
data O
reveal O

dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI O
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI-dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC B
and O
cTnI O
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC O
. O
The O
structural O
and O
functional O
data O
reveal O
that O
the O
levosimendan O
class O
of O

dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI B
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI-dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC O
and O
cTnI O
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC O
. O
The O
structural O
and O
functional O
data O
reveal O
that O
the O
levosimendan O
class O
of O

dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
by O
NMR O
spectroscopy O
, O
and O
dfbp-o O
was O
found O
to O
bind O
more O
strongly O
than O
dfbp O
. O
Dfbp-o O
also O
increased O
the O
affinity O
of O
cTnI B
for O
cTnC O
. O
Dfbp-o O
increased O
the O
Ca(2+)-sensitivity O
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI-dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC O
and O
cTnI O
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC O
. O
The O
structural O
and O
functional O
data O
reveal O
that O
the O
levosimendan O
class O
of O

dfbp-o O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan O
. O
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O
cTnC-cTnI-dfbp-o O
ternary O
complex O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC B
and O
cTnI O
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC O
. O
The O
structural O
and O
functional O
data O
reveal O
that O
the O
levosimendan O
class O
of O
Ca(2+)-sensitizers O
work O
by O
binding O
to O
the O
regulatory O
domain O
of O
cTnC O
and O
stabilizing O
the O
pivotal O
cTnC-cTnI O
regulatory O
unit O
via O
a O
network O
of O
hydrophobic O
and O
electrostatic O
interactions O
, O
in O
contrast O
to O

levosimendan O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC B
and O
cTnI O
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC O
. O
The O
structural O
and O
functional O
data O
reveal O
that O
the O
levosimendan O
class O
of O
Ca(2+)-sensitizers O
work O
by O
binding O
to O
the O
regulatory O
domain O
of O
cTnC O
and O
stabilizing O
the O
pivotal O
cTnC-cTnI O
regulatory O
unit O
via O
a O
network O
of O
hydrophobic O
and O
electrostatic O
interactions O
, O
in O
contrast O
to O
the O
destabilizing O
effects O
of O
antagonists O
such O
as O
W7 O
at O
the O
same O
interface O
. O

Ca(2+) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
structural O
and O
functional O
perspective O
into O
the O
mechanism O
of O
Ca2+-sensitizers O
that O
target O
the O
cardiac O
troponin O
complex.The O
Ca(2+) O
dependent O
interaction O
between O
troponin B
I I
(cTnI) O
and O
troponin O
C O
(cTnC) O
triggers O
contraction O
in O
heart O
muscle O
. O
Heart O
failure O
is O
characterized O
by O
a O
decrease O
in O
cardiac O
output O
, O
and O
compounds O
that O
increase O
the O
sensitivity O
of O
cardiac O
muscle O
to O
Ca(2+) O
have O
therapeutic O
potential O
. O
The O
Ca(2+)-sensitizer O
, O
levosimendan O
, O
targets O
cTnC; O
however O
, O
detailed O
understanding O
of O
its O

Ca(2+) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
structural O
and O
functional O
perspective O
into O
the O
mechanism O
of O
Ca2+-sensitizers O
that O
target O
the O
cardiac O
troponin O
complex.The O
Ca(2+) O
dependent O
interaction O
between O
troponin O
I O
(cTnI) O
and O
troponin O
C O
(cTnC) O
triggers O
contraction O
in O
heart O
muscle O
. O
Heart O
failure O
is O
characterized O
by O
a O
decrease O
in O
cardiac O
output O
, O
and O
compounds O
that O
increase O
the O
sensitivity O
of O
cardiac O
muscle O
to O
Ca(2+) O
have O
therapeutic O
potential O
. O
The O
Ca(2+)-sensitizer O
, O
levosimendan O
, O
targets O
cTnC; O
however O
, O
detailed O
understanding O
of O
its O

Ca(2+) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
structural O
and O
functional O
perspective O
into O
the O
mechanism O
of O
Ca2+-sensitizers O
that O
target O
the O
cardiac O
troponin O
complex.The O
Ca(2+) O
dependent O
interaction O
between O
troponin O
I O
(cTnI) O
and O
troponin B
C I
(cTnC) O
triggers O
contraction O
in O
heart O
muscle O
. O
Heart O
failure O
is O
characterized O
by O
a O
decrease O
in O
cardiac O
output O
, O
and O
compounds O
that O
increase O
the O
sensitivity O
of O
cardiac O
muscle O
to O
Ca(2+) O
have O
therapeutic O
potential O
. O
The O
Ca(2+)-sensitizer O
, O
levosimendan O
, O
targets O
cTnC; O
however O
, O
detailed O
understanding O
of O
its O

Ca(2+) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
structural O
and O
functional O
perspective O
into O
the O
mechanism O
of O
Ca2+-sensitizers O
that O
target O
the O
cardiac O
troponin O
complex.The O
Ca(2+) O
dependent O
interaction O
between O
troponin O
I O
(cTnI) O
and O
troponin O
C O
(cTnC) O
triggers O
contraction O
in O
heart O
muscle O
. O
Heart O
failure O
is O
characterized O
by O
a O
decrease O
in O
cardiac O
output O
, O
and O
compounds O
that O
increase O
the O
sensitivity O
of O
cardiac O
muscle O
to O
Ca(2+) O
have O
therapeutic O
potential O
. O
The O
Ca(2+)-sensitizer O
, O
levosimendan O
, O
targets O
cTnC; O
however O
, O
detailed O
understanding O
of O
its O

levosimendan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC B
and O
cTnI O
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC O
. O
The O
structural O
and O
functional O
data O
reveal O
that O
the O
levosimendan O
class O
of O
Ca(2+)-sensitizers O
work O
by O
binding O
to O
the O
regulatory O
domain O
of O
cTnC O
and O
stabilizing O
the O
pivotal O
cTnC-cTnI O
regulatory O
unit O
via O
a O
network O
of O
hydrophobic O
and O
electrostatic O
interactions O
, O
in O
contrast O
to O
the O
destabilizing O
effects O
of O
antagonists O
such O
as O
W7 O
at O
the O
same O
interface O
. O

levosimendan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
showed O
that O
dfbp-o O
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC O
and O
cTnI B
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI O
. O
In O
the O
absence O
of O
cTnI O
, O
docking O
localized O
dfbp-o O
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC O
. O
The O
structural O
and O
functional O
data O
reveal O
that O
the O
levosimendan O
class O
of O
Ca(2+)-sensitizers O
work O
by O
binding O
to O
the O
regulatory O
domain O
of O
cTnC O
and O
stabilizing O
the O
pivotal O
cTnC-cTnI O
regulatory O
unit O
via O
a O
network O
of O
hydrophobic O
and O
electrostatic O
interactions O
, O
in O
contrast O
to O
the O
destabilizing O
effects O
of O
antagonists O
such O
as O
W7 O
at O
the O
same O
interface O
. O

sodium O
salicylate O
acts O
as O
NOT O
for O
what O
entity O
? O
Salicylate O
pre-treatment O
attenuates O
intensity O
of O
bronchial O
and O
nasal O
symptoms O
precipitated O
by O
aspirin O
in O
aspirin-intolerant O
patients.Aspirin O
(ASA) O
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
, O
which O
are O
cyclooxygenase O
(COX) O
inhibitors O
, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant O
patients O
, O
while O
sodium O
salicylate O
hardly O
active O
on O
COX B
by O
itself O
, O
is O
well O
tolerated O
by O
these O
patients O
. O
However O
, O
salicylate O
moiety O
appears O
to O
interfere O
with O
aspirin O
inhibitory O
action O
on O
platelets O
and O
vascular O
COX O
. O
Such O
interaction O
, O
if O
present O
at O
the O
level O
of O
respiratory O
tract O
, O
may O
be O
of O
interest O
to O
pathogenesis O
of O
ASA-induced O
asthma O
. O
We O
performed O
a O

salicylate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Salicylate O
pre-treatment O
attenuates O
intensity O
of O
bronchial O
and O
nasal O
symptoms O
precipitated O
by O
aspirin O
in O
aspirin-intolerant O
patients.Aspirin O
(ASA) O
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
, O
which O
are O
cyclooxygenase O
(COX) O
inhibitors O
, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant O
patients O
, O
while O
sodium O
salicylate O
, O
hardly O
active O
on O
COX B
by O
itself O
, O
is O
well O
tolerated O
by O
these O
patients O
. O
However O
, O
salicylate O
moiety O
appears O
to O
interfere O
with O
aspirin O
inhibitory O
action O
on O
platelets O
and O
vascular O
COX O
. O
Such O
interaction O
, O
if O
present O
at O
the O
level O
of O
respiratory O
tract O
, O
may O
be O
of O
interest O
to O
pathogenesis O
of O
ASA-induced O
asthma O
. O
We O
performed O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
cross-over O
study O
on O
the O
effect O
of O
choline O
magnesium O
trisalicylate O
(CMT O
, O
trilisate) O

aspirin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
bronchial O
and O
nasal O
symptoms O
precipitated O
by O
aspirin O
in O
aspirin-intolerant O
patients.Aspirin O
(ASA) O
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
, O
which O
are O
cyclooxygenase O
(COX) O
inhibitors O
, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant O
patients O
, O
while O
sodium O
salicylate O
, O
hardly O
active O
on O
COX B
by O
itself O
, O
is O
well O
tolerated O
by O
these O
patients O
. O
However O
, O
salicylate O
moiety O
appears O
to O
interfere O
with O
aspirin O
inhibitory O
action O
on O
platelets O
and O
vascular O
COX O
. O
Such O
interaction O
, O
if O
present O
at O
the O
level O
of O
respiratory O
tract O
, O
may O
be O
of O
interest O
to O
pathogenesis O
of O
ASA-induced O
asthma O
. O
We O
performed O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
cross-over O
study O
on O
the O
effect O
of O
choline O
magnesium O
trisalicylate O
(CMT O
, O
trilisate) O
pre-treatment O
on O
ASA-induced O
adverse O
reactions O
in O

Aspirin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Salicylate O
pre-treatment O
attenuates O
intensity O
of O
bronchial O
and O
nasal O
symptoms O
precipitated O
by O
aspirin O
in O
aspirin-intolerant O
patients O
. O
Aspirin O
(ASA) O
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
, O
which O
are O
cyclooxygenase B
(COX) O
inhibitors O
, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant O
patients O
, O
while O
sodium O
salicylate O
, O
hardly O
active O
on O
COX O
by O
itself O
, O
is O
well O
tolerated O
by O
these O
patients O
. O
However O
, O
salicylate O
moiety O
appears O
to O
interfere O
with O
aspirin O
inhibitory O
action O
on O
platelets O
and O
vascular O
COX O
. O
Such O
interaction O
, O

Aspirin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Salicylate O
pre-treatment O
attenuates O
intensity O
of O
bronchial O
and O
nasal O
symptoms O
precipitated O
by O
aspirin O
in O
aspirin-intolerant O
patients O
. O
Aspirin O
(ASA) O
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
, O
which O
are O
cyclooxygenase O
(COX) O
inhibitors O
, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant O
patients O
, O
while O
sodium O
salicylate O
, O
hardly O
active O
on O
COX B
by O
itself O
, O
is O
well O
tolerated O
by O
these O
patients O
. O
However O
, O
salicylate O
moiety O
appears O
to O
interfere O
with O
aspirin O
inhibitory O
action O
on O
platelets O
and O
vascular O
COX O
. O
Such O
interaction O
, O

ASA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Salicylate O
pre-treatment O
attenuates O
intensity O
of O
bronchial O
and O
nasal O
symptoms O
precipitated O
by O
aspirin O
in O
aspirin-intolerant O
patients.Aspirin O
( O
ASA O
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
, O
which O
are O
cyclooxygenase B
(COX) O
inhibitors O
, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant O
patients O
, O
while O
sodium O
salicylate O
, O
hardly O
active O
on O
COX O
by O
itself O
, O
is O
well O
tolerated O
by O
these O
patients O
. O
However O
, O
salicylate O
moiety O
appears O
to O
interfere O
with O
aspirin O
inhibitory O
action O
on O
platelets O
and O
vascular O
COX O
. O
Such O
interaction O
, O
if O

ASA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Salicylate O
pre-treatment O
attenuates O
intensity O
of O
bronchial O
and O
nasal O
symptoms O
precipitated O
by O
aspirin O
in O
aspirin-intolerant O
patients.Aspirin O
( O
ASA O
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
, O
which O
are O
cyclooxygenase O
(COX) O
inhibitors O
, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant O
patients O
, O
while O
sodium O
salicylate O
, O
hardly O
active O
on O
COX B
by O
itself O
, O
is O
well O
tolerated O
by O
these O
patients O
. O
However O
, O
salicylate O
moiety O
appears O
to O
interfere O
with O
aspirin O
inhibitory O
action O
on O
platelets O
and O
vascular O
COX O
. O
Such O
interaction O
, O
if O

salicylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
lower O
(P O
less O
than O
0.02 O
and O
P O
less O
than O
0.002 O
, O
respectively) O
after O
trilisate O
pre-treatment O
as O
compared O
to O
placebo O
. O
Trilisate O
also O
attenuated O
nasal O
symptoms O
in O
three O
out O
of O
five O
patients O
. O
Although O
the O
precise O
mechanism O
of O
the O
protective O
action O
of O
trilisate O
is O
unknown O
, O
our O
data O
support O
the O
possibility O
of O
interaction O
between O
salicylate O
and O
ASA O
on O
cyclo-oxygenase B
locus O
in O
the O
respiratory O
tract O
in O
ASA-intolerant O
patients O
. O

ASA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
less O
than O
0.02 O
and O
P O
less O
than O
0.002 O
, O
respectively) O
after O
trilisate O
pre-treatment O
as O
compared O
to O
placebo O
. O
Trilisate O
also O
attenuated O
nasal O
symptoms O
in O
three O
out O
of O
five O
patients O
. O
Although O
the O
precise O
mechanism O
of O
the O
protective O
action O
of O
trilisate O
is O
unknown O
, O
our O
data O
support O
the O
possibility O
of O
interaction O
between O
salicylate O
and O
ASA O
on O
cyclo-oxygenase B
locus O
in O
the O
respiratory O
tract O
in O
ASA-intolerant O
patients O
. O

BDZs O
acts O
as O
NOT O
for O
what O
entity O
? O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs B
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

diazepam O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

BDZs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC B
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

pentobarbital O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs B
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

barbiturates O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type B
voltage-gated I
calcium I
channels I
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O

barbiturates O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs B
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O

ethanol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type B
voltage-gated I
calcium I
channels I
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O

ethanol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs B
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O

neurosteroids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type B
voltage-gated I
calcium I
channels I
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O

neurosteroids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs B
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O

pentobarbital O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 B
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O

pentobarbital O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 B
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O

dihydropyridine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 B
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O

dihydropyridine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 B
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O

DHP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 B
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
( O
DHP O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O

DHP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 B
channels O
, O
similar O
to O
dihydropyridine O
( O
DHP O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O

BDZs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 B
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O

pentobarbital O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 B
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O

BDZs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type B
voltage-gated I
calcium I
channels I
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O

BDZs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs B
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O

dihydropyridine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC B
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O

DHP O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
( O
DHP O
L-VGCC B
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O

BDZs O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
( O
BDZs O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) B
receptors I
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O

BDZs O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
( O
BDZs O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R B
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O

Benzodiazepines O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors O
. O
Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) B
receptors I
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O

Benzodiazepines O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors O
. O
Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R B
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O

barbiturates O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R B
modulators O
, O
including O
barbiturates O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O

ethanol O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R B
modulators O
, O
including O
barbiturates O
, O
ethanol O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O

neurosteroids O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R B
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O

BDZs O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R B
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O

amphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
VMAT2 O
: O
a O
dynamic O
regulator O
of O
brain O
monoaminergic O
neuronal O
function O
interacting O
with O
drugs O
of O
abuse.The O
monoaminergic O
neuron O
, O
in O
particular O
the O
dopaminergic O
neuron O
, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
(AMPH) O
and O
cocaine O
(COC) O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT B
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O

amphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
VMAT2 O
: O
a O
dynamic O
regulator O
of O
brain O
monoaminergic O
neuronal O
function O
interacting O
with O
drugs O
of O
abuse.The O
monoaminergic O
neuron O
, O
in O
particular O
the O
dopaminergic O
neuron O
, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
(AMPH) O
and O
cocaine O
(COC) O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT O
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O

AMPH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
VMAT2 O
: O
a O
dynamic O
regulator O
of O
brain O
monoaminergic O
neuronal O
function O
interacting O
with O
drugs O
of O
abuse.The O
monoaminergic O
neuron O
, O
in O
particular O
the O
dopaminergic O
neuron O
, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
( O
AMPH O
and O
cocaine O
(COC) O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT B
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O
Here O
, O

AMPH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
VMAT2 O
: O
a O
dynamic O
regulator O
of O
brain O
monoaminergic O
neuronal O
function O
interacting O
with O
drugs O
of O
abuse.The O
monoaminergic O
neuron O
, O
in O
particular O
the O
dopaminergic O
neuron O
, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
( O
AMPH O
and O
cocaine O
(COC) O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT O
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O
Here O
, O

cocaine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
VMAT2 O
: O
a O
dynamic O
regulator O
of O
brain O
monoaminergic O
neuronal O
function O
interacting O
with O
drugs O
of O
abuse.The O
monoaminergic O
neuron O
, O
in O
particular O
the O
dopaminergic O
neuron O
, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
(AMPH) O
and O
cocaine O
(COC) O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT B
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O
Here O
, O
we O
present O

cocaine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
VMAT2 O
: O
a O
dynamic O
regulator O
of O
brain O
monoaminergic O
neuronal O
function O
interacting O
with O
drugs O
of O
abuse.The O
monoaminergic O
neuron O
, O
in O
particular O
the O
dopaminergic O
neuron O
, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
(AMPH) O
and O
cocaine O
(COC) O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT O
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O
Here O
, O
we O
present O

COC O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
VMAT2 O
: O
a O
dynamic O
regulator O
of O
brain O
monoaminergic O
neuronal O
function O
interacting O
with O
drugs O
of O
abuse.The O
monoaminergic O
neuron O
, O
in O
particular O
the O
dopaminergic O
neuron O
, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
(AMPH) O
and O
cocaine O
( O
COC O
 O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT B
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O
Here O
, O
we O
present O

COC O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
VMAT2 O
: O
a O
dynamic O
regulator O
of O
brain O
monoaminergic O
neuronal O
function O
interacting O
with O
drugs O
of O
abuse.The O
monoaminergic O
neuron O
, O
in O
particular O
the O
dopaminergic O
neuron O
, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
(AMPH) O
and O
cocaine O
( O
COC O
 O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT O
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O
Here O
, O
we O
present O

AMPH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
drugs O
of O
abuse O
. O
The O
effects O
of O
amphetamine O
(AMPH) O
and O
cocaine O
(COC) O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT B
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O
Here O
, O
we O
present O
VMAT2 O
as O
a O
target O
that O
enables O
the O
rewarding O
and O
addictive O
actions O
of O
these O
drugs O
, O
based O
on O
imaging O
, O
neurochemical O
, O
biochemical O
, O
cell O
biological O
, O
genetic O
, O
and O
immunohistochemical O
evidence O
. O
The O
presence O
of O
VMAT2 O
in O
noradrenergic O
, O
serotoninergic O
, O
histaminergic O
, O
and O
potentially O
trace O
aminergic O
neurons O
invites O
consideration O

COC O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
abuse O
. O
The O
effects O
of O
amphetamine O
(AMPH) O
and O
cocaine O
(COC) O
, O
for O
example O
, O
depend O
on O
the O
ability O
to O
increase O
dopamine O
in O
the O
synapse O
, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT B
or O
the O
vesicular O
transporter O
for O
monoamine O
storage O
, O
VMAT2 O
. O
The O
potential O
role O
of O
DAT O
as O
a O
target O
for O
AMPH O
and O
COC O
has O
been O
reviewed O
extensively O
. O
Here O
, O
we O
present O
VMAT2 O
as O
a O
target O
that O
enables O
the O
rewarding O
and O
addictive O
actions O
of O
these O
drugs O
, O
based O
on O
imaging O
, O
neurochemical O
, O
biochemical O
, O
cell O
biological O
, O
genetic O
, O
and O
immunohistochemical O
evidence O
. O
The O
presence O
of O
VMAT2 O
in O
noradrenergic O
, O
serotoninergic O
, O
histaminergic O
, O
and O
potentially O
trace O
aminergic O
neurons O
invites O
consideration O
of O
a O

aspirin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
nephrotoxicity O
and O
hypersensitivity O
reactions O
. O
Although O
the O
inhibition O
of O
cyclooxygenases B
by O
aspirin O
, O
which O
leads O
to O
its O
anti-inflammatory/analgesic O
properties O
, O
has O
been O
well O
studied O
, O
the O
mechanisms O
involved O
in O
its O
chemopreventive O
effects O
as O
well O
as O
some O
of O
its O
adverse O
effects O
are O
as O
yet O
ill-defined O
. O
Studies O
over O
the O
past O
decades O
suggest O
that O
, O
besides O
cyclooxygenases O
, O
aspirin O
acetylates O
other O
cellular O
proteins O
. O
These O
studies O
used O
radiolabeled O
3H O
or O
14C O
aspirin O
, O
the O
only O
approach O
used O
to O
date O
for O
the O
detection O
of O
proteins O
acetylated O
by O
aspirin O
. O
In O
a O
recent O
study O
using O
protein-specific O
anti-acetyl O
lysine O
antibodies O
and O
immunological O
methods O
, O
we O
demonstrated O
the O
ability O
of O
aspirin O
to O
acetylate O
the O
tumor O
suppressor O

aspirin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
decades O
suggest O
that O
, O
besides O
cyclooxygenases O
, O
aspirin O
acetylates O
other O
cellular O
proteins O
. O
These O
studies O
used O
radiolabeled O
3H O
or O
14C O
aspirin O
, O
the O
only O
approach O
used O
to O
date O
for O
the O
detection O
of O
proteins O
acetylated O
by O
aspirin O
. O
In O
a O
recent O
study O
using O
protein-specific O
anti-acetyl O
lysine O
antibodies O
and O
immunological O
methods O
, O
we O
demonstrated O
the O
ability O
of O
aspirin O
to O
acetylate O
the O
tumor O
suppressor O
protein O
p53 O
. O
In O
this O
review O
, O
we O
present O
current O
research O
from O
the O
literature O
on O
the O
aspirin-induced O
acetylation O
of O
proteins O
. O
We O
also O
describe O
an O
immunological O
approach O
to O
detecting O
acetylated O
proteins O
in O
aspirin-treated O
cells O
, O
and O
demonstrate O
that O
multiple O
proteins O
are O
acetylated O
. O
Since O
post-translational O
modification O
of O
proteins O
, O
such O

aspirin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
anti-thrombotic O
effects O
. O
More O
recently O
, O
it O
has O
been O
shown O
to O
decrease O
the O
incidence O
of O
cancers O
of O
epithelial O
origin O
. O
In O
most O
cases O
, O
aspirin O
is O
relatively O
safe O
. O
However O
, O
it O
does O
cause O
a O
host O
of O
adverse O
effects O
and O
toxicities O
, O
including O
gastrointestinal O
bleeding O
, O
ulcerations O
, O
nephrotoxicity O
and O
hypersensitivity O
reactions O
. O
Although O
the O
inhibition O
of O
cyclooxygenases B
by O
aspirin O
which O
leads O
to O
its O
anti-inflammatory/analgesic O
properties O
, O
has O
been O
well O
studied O
, O
the O
mechanisms O
involved O
in O
its O
chemopreventive O
effects O
as O
well O
as O
some O
of O
its O
adverse O
effects O
are O
as O
yet O
ill-defined O
. O
Studies O
over O
the O
past O
decades O
suggest O
that O
, O
besides O
cyclooxygenases O
, O
aspirin O
acetylates O
other O
cellular O
proteins O
. O
These O
studies O
used O
radiolabeled O
3H O
or O

PSE O
acts O
as O
NOT O
for O
what O
entity O
? O
in O
stimulated O
Jurkat O
cells O
, O
a O
human O
T-cell O
leukemia O
cell O
line O
. O
To O
further O
characterize O
the O
inhibitory O
mechanisms O
of O
PSE O
at O
the O
transcriptional O
level O
, O
we O
examined O
the O
transcriptional O
activities O
of O
nuclear O
factor O
kappa O
B O
(NF-kappaB) O
, O
nuclear O
factor O
of O
activated O
T O
cells O
(NFAT) O
, O
and O
activator O
protein-1 O
(AP-1) O
transcription O
factors O
and O
found O
that O
PSE O
inhibited O
NF-kappaB-dependent O
transcriptional O
activity O
without O
affecting O
either O
the O
phosphorylation O
, O
the O
degradation O
of O
the O
cytoplasmic O
NF-kappaB O
inhibitory O
protein O
, O
IkappaBalpha O
or O
the O
DNA-binding O
activity O
. O
However O
, O
phosphorylation O
of O
the O
p65/RelA O
subunit O
was O
clearly O
inhibited O
by O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT O
without O
interfering O
with O
the O

PSE O
acts O
as O
NOT O
for O
what O
entity O
? O
in O
stimulated O
Jurkat O
cells O
, O
a O
human O
T-cell O
leukemia O
cell O
line O
. O
To O
further O
characterize O
the O
inhibitory O
mechanisms O
of O
PSE O
at O
the O
transcriptional O
level O
, O
we O
examined O
the O
transcriptional O
activities O
of O
nuclear O
factor O
kappa O
B O
(NF-kappaB) O
, O
nuclear O
factor O
of O
activated O
T O
cells O
(NFAT) O
, O
and O
activator O
protein-1 O
(AP-1) O
transcription O
factors O
and O
found O
that O
PSE O
inhibited O
NF-kappaB-dependent O
transcriptional O
activity O
without O
affecting O
either O
the O
phosphorylation O
, O
the O
degradation O
of O
the O
cytoplasmic O
NF-kappaB O
inhibitory O
protein O
, O
IkappaBalpha B
or O
the O
DNA-binding O
activity O
. O
However O
, O
phosphorylation O
of O
the O
p65/RelA O
subunit O
was O
clearly O
inhibited O
by O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT O
without O
interfering O
with O
the O

PSE O
acts O
as O
NOT O
for O
what O
entity O
? O
(NFAT) O
, O
and O
activator O
protein-1 O
(AP-1) O
transcription O
factors O
and O
found O
that O
PSE O
inhibited O
NF-kappaB-dependent O
transcriptional O
activity O
without O
affecting O
either O
the O
phosphorylation O
, O
the O
degradation O
of O
the O
cytoplasmic O
NF-kappaB O
inhibitory O
protein O
, O
IkappaBalpha O
or O
the O
DNA-binding O
activity O
. O
However O
, O
phosphorylation O
of O
the O
p65/RelA O
subunit O
was O
clearly O
inhibited O
by O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT B
without O
interfering O
with O
the O
calcium-induced O
NFAT O
dephosphorylation O
event O
, O
which O
represents O
the O
major O
signaling O
pathway O
for O
its O
activation O
. O
NFAT O
cooperates O
with O
c-Jun O
, O
a O
compound O
of O
the O
AP-1 O
complex O
, O
to O
activate O
target O
genes O
, O
and O
we O
also O
found O
that O
PSE O
inhibited O
both O
JNK O
activation O
and O
AP-1 O

calcium O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
inhibited O
NF-kappaB-dependent O
transcriptional O
activity O
without O
affecting O
either O
the O
phosphorylation O
, O
the O
degradation O
of O
the O
cytoplasmic O
NF-kappaB O
inhibitory O
protein O
, O
IkappaBalpha O
or O
the O
DNA-binding O
activity O
. O
However O
, O
phosphorylation O
of O
the O
p65/RelA O
subunit O
was O
clearly O
inhibited O
by O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT B
without O
interfering O
with O
the O
calcium O
induced O
NFAT O
dephosphorylation O
event O
, O
which O
represents O
the O
major O
signaling O
pathway O
for O
its O
activation O
. O
NFAT O
cooperates O
with O
c-Jun O
, O
a O
compound O
of O
the O
AP-1 O
complex O
, O
to O
activate O
target O
genes O
, O
and O
we O
also O
found O
that O
PSE O
inhibited O
both O
JNK O
activation O
and O
AP-1 O
transcriptional O
activity O
. O
These O
findings O
provide O
new O
mechanistic O
insights O
into O
the O

PSE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
is O
a O
stereoisomer O
of O
ephedrine O
that O
is O
commonly O
used O
as O
a O
nasal O
decongestant O
in O
combination O
with O
other O
anti-inflammatory O
drugs O
for O
the O
symptomatic O
treatment O
of O
some O
common O
pathologies O
such O
as O
common O
cold O
. O
Herein O
, O
we O
describe O
for O
the O
first O
time O
the O
effects O
of O
PSE O
on O
T-cell O
activation O
events O
. O
We O
found O
that O
PSE O
inhibits O
interleukin-2 O
(IL-2) O
and O
tumor O
necrosis O
factor O
(TNF) O
alpha-gene O
transcription O
in O
stimulated O
Jurkat O
cells O
, O
a O
human O
T-cell O
leukemia O
cell O
line O
. O
To O
further O
characterize O
the O
inhibitory O
mechanisms O
of O
PSE O
at O
the O
transcriptional O
level O
, O
we O
examined O
the O
transcriptional O
activities O
of O
nuclear O
factor O
kappa O
B O
(NF-kappaB) O
, O
nuclear O
factor O
of O
activated O
T O
cells O

PSE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
is O
a O
stereoisomer O
of O
ephedrine O
that O
is O
commonly O
used O
as O
a O
nasal O
decongestant O
in O
combination O
with O
other O
anti-inflammatory O
drugs O
for O
the O
symptomatic O
treatment O
of O
some O
common O
pathologies O
such O
as O
common O
cold O
. O
Herein O
, O
we O
describe O
for O
the O
first O
time O
the O
effects O
of O
PSE O
on O
T-cell O
activation O
events O
. O
We O
found O
that O
PSE O
inhibits O
interleukin-2 B
(IL-2) O
and O
tumor O
necrosis O
factor O
(TNF) O
alpha-gene O
transcription O
in O
stimulated O
Jurkat O
cells O
, O
a O
human O
T-cell O
leukemia O
cell O
line O
. O
To O
further O
characterize O
the O
inhibitory O
mechanisms O
of O
PSE O
at O
the O
transcriptional O
level O
, O
we O
examined O
the O
transcriptional O
activities O
of O
nuclear O
factor O
kappa O
B O
(NF-kappaB) O
, O
nuclear O
factor O
of O
activated O
T O
cells O

PSE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
is O
a O
stereoisomer O
of O
ephedrine O
that O
is O
commonly O
used O
as O
a O
nasal O
decongestant O
in O
combination O
with O
other O
anti-inflammatory O
drugs O
for O
the O
symptomatic O
treatment O
of O
some O
common O
pathologies O
such O
as O
common O
cold O
. O
Herein O
, O
we O
describe O
for O
the O
first O
time O
the O
effects O
of O
PSE O
on O
T-cell O
activation O
events O
. O
We O
found O
that O
PSE O
inhibits O
interleukin-2 O
(IL-2) O
and O
tumor O
necrosis O
factor O
(TNF) O
alpha-gene O
transcription O
in O
stimulated O
Jurkat O
cells O
, O
a O
human O
T-cell O
leukemia O
cell O
line O
. O
To O
further O
characterize O
the O
inhibitory O
mechanisms O
of O
PSE O
at O
the O
transcriptional O
level O
, O
we O
examined O
the O
transcriptional O
activities O
of O
nuclear O
factor O
kappa O
B O
(NF-kappaB) O
, O
nuclear O
factor O
of O
activated O
T O
cells O

PSE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
stimulated O
Jurkat O
cells O
, O
a O
human O
T-cell O
leukemia O
cell O
line O
. O
To O
further O
characterize O
the O
inhibitory O
mechanisms O
of O
PSE O
at O
the O
transcriptional O
level O
, O
we O
examined O
the O
transcriptional O
activities O
of O
nuclear O
factor O
kappa O
B O
(NF-kappaB) O
, O
nuclear O
factor O
of O
activated O
T O
cells O
(NFAT) O
, O
and O
activator O
protein-1 O
(AP-1) O
transcription O
factors O
and O
found O
that O
PSE O
inhibited O
NF-kappaB-dependent O
transcriptional O
activity O
without O
affecting O
either O
the O
phosphorylation O
, O
the O
degradation O
of O
the O
cytoplasmic O
NF-kappaB B
inhibitory O
protein O
, O
IkappaBalpha O
or O
the O
DNA-binding O
activity O
. O
However O
, O
phosphorylation O
of O
the O
p65/RelA O
subunit O
was O
clearly O
inhibited O
by O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT O
without O
interfering O
with O
the O

PSE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
nuclear O
factor O
of O
activated O
T O
cells O
(NFAT) O
, O
and O
activator O
protein-1 O
(AP-1) O
transcription O
factors O
and O
found O
that O
PSE O
inhibited O
NF-kappaB-dependent O
transcriptional O
activity O
without O
affecting O
either O
the O
phosphorylation O
, O
the O
degradation O
of O
the O
cytoplasmic O
NF-kappaB O
inhibitory O
protein O
, O
IkappaBalpha O
or O
the O
DNA-binding O
activity O
. O
However O
, O
phosphorylation O
of O
the O
p65/RelA O
subunit O
was O
clearly O
inhibited O
by O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT O
without O
interfering O
with O
the O
calcium-induced O
NFAT O
dephosphorylation O
event O
, O
which O
represents O
the O
major O
signaling O
pathway O
for O
its O
activation O
. O
NFAT O
cooperates O
with O
c-Jun O
, O
a O
compound O
of O
the O
AP-1 O
complex O
, O
to O
activate O
target O
genes O
, O
and O
we O
also O
found O
that O
PSE O

PSE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
nuclear O
factor O
of O
activated O
T O
cells O
(NFAT) O
, O
and O
activator O
protein-1 O
(AP-1) O
transcription O
factors O
and O
found O
that O
PSE O
inhibited O
NF-kappaB-dependent O
transcriptional O
activity O
without O
affecting O
either O
the O
phosphorylation O
, O
the O
degradation O
of O
the O
cytoplasmic O
NF-kappaB O
inhibitory O
protein O
, O
IkappaBalpha O
or O
the O
DNA-binding O
activity O
. O
However O
, O
phosphorylation O
of O
the O
p65/RelA O
subunit O
was O
clearly O
inhibited O
by O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT O
without O
interfering O
with O
the O
calcium-induced O
NFAT O
dephosphorylation O
event O
, O
which O
represents O
the O
major O
signaling O
pathway O
for O
its O
activation O
. O
NFAT O
cooperates O
with O
c-Jun O
, O
a O
compound O
of O
the O
AP-1 O
complex O
, O
to O
activate O
target O
genes O
, O
and O
we O
also O
found O
that O
PSE O

PSE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(NFAT) O
, O
and O
activator O
protein-1 O
(AP-1) O
transcription O
factors O
and O
found O
that O
PSE O
inhibited O
NF-kappaB-dependent O
transcriptional O
activity O
without O
affecting O
either O
the O
phosphorylation O
, O
the O
degradation O
of O
the O
cytoplasmic O
NF-kappaB O
inhibitory O
protein O
, O
IkappaBalpha O
or O
the O
DNA-binding O
activity O
. O
However O
, O
phosphorylation O
of O
the O
p65/RelA O
subunit O
was O
clearly O
inhibited O
by O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT B
without O
interfering O
with O
the O
calcium-induced O
NFAT O
dephosphorylation O
event O
, O
which O
represents O
the O
major O
signaling O
pathway O
for O
its O
activation O
. O
NFAT O
cooperates O
with O
c-Jun O
, O
a O
compound O
of O
the O
AP-1 O
complex O
, O
to O
activate O
target O
genes O
, O
and O
we O
also O
found O
that O
PSE O
inhibited O
both O
JNK O
activation O
and O
AP-1 O

PSE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT O
without O
interfering O
with O
the O
calcium-induced O
NFAT O
dephosphorylation O
event O
, O
which O
represents O
the O
major O
signaling O
pathway O
for O
its O
activation O
. O
NFAT O
cooperates O
with O
c-Jun O
, O
a O
compound O
of O
the O
AP-1 O
complex O
, O
to O
activate O
target O
genes O
, O
and O
we O
also O
found O
that O
PSE O
inhibited O
both O
JNK B
activation O
and O
AP-1 O
transcriptional O
activity O
. O
These O
findings O
provide O
new O
mechanistic O
insights O
into O
the O
potential O
immunomodulatory O
activities O
of O
PSE O
and O
highlight O
their O
potential O
in O
designing O
novel O
therapeutic O
strategies O
to O
manage O
inflammatory O
diseases O
. O

PSE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PSE O
in O
stimulated O
cells O
. O
In O
addition O
, O
PSE O
inhibited O
the O
transcriptional O
activity O
of O
NFAT O
without O
interfering O
with O
the O
calcium-induced O
NFAT O
dephosphorylation O
event O
, O
which O
represents O
the O
major O
signaling O
pathway O
for O
its O
activation O
. O
NFAT O
cooperates O
with O
c-Jun O
, O
a O
compound O
of O
the O
AP-1 B
complex O
, O
to O
activate O
target O
genes O
, O
and O
we O
also O
found O
that O
PSE O
inhibited O
both O
JNK O
activation O
and O
AP-1 O
transcriptional O
activity O
. O
These O
findings O
provide O
new O
mechanistic O
insights O
into O
the O
potential O
immunomodulatory O
activities O
of O
PSE O
and O
highlight O
their O
potential O
in O
designing O
novel O
therapeutic O
strategies O
to O
manage O
inflammatory O
diseases O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
mouse O
medulla O
oblongata/pons O
and O
adrenal O
to O
a O
Gen-Bank O
reference O
sequence O
. O
Transfection O
of O
the O
brain O
cDNA O
into O
COS-1 O
cells O
resulted O
in O
transporter O
activity O
that O
was O
blocked O
by O
the O
VMAT O
inhibitor O
reserpine O
and O
a O
proton O
ionophore O
, O
but O
not O
by O
tetrabenazine O
, O
which O
has O
a O
high O
affinity O
for O
VMAT-2 O
. O
Antibodies O
to O
either O
the O
C O
or O
N- O
terminus O
of O
VMAT-1 B
detected O
two O
proteins O
(73 O
and O
55 O
kD) O
in O
transfected O
COS-1 O
cells O
. O
The O
C-terminal O
antibodies O
detected O
both O
proteins O
in O
extracts O
of O
mouse O
medulla/pons O
, O
cortex O
, O
hypothalamus O
, O
and O
cerebellum O
but O
only O
the O
73 O
kD O
protein O
and O
higher O
molecular O
weight O
immunoreactive O
proteins O
in O
mouse O
adrenal O
and O
rat O
PC12 O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
oblongata/pons O
and O
adrenal O
to O
a O
Gen-Bank O
reference O
sequence O
. O
Transfection O
of O
the O
brain O
cDNA O
into O
COS-1 O
cells O
resulted O
in O
transporter O
activity O
that O
was O
blocked O
by O
the O
VMAT O
inhibitor O
reserpine O
and O
a O
proton O
ionophore O
, O
but O
not O
by O
tetrabenazine O
, O
which O
has O
a O
high O
affinity O
for O
VMAT-2 O
. O
Antibodies O
to O
either O
the O
C- O
or O
N O
terminus O
of O
VMAT-1 B
detected O
two O
proteins O
(73 O
and O
55 O
kD) O
in O
transfected O
COS-1 O
cells O
. O
The O
C-terminal O
antibodies O
detected O
both O
proteins O
in O
extracts O
of O
mouse O
medulla/pons O
, O
cortex O
, O
hypothalamus O
, O
and O
cerebellum O
but O
only O
the O
73 O
kD O
protein O
and O
higher O
molecular O
weight O
immunoreactive O
proteins O
in O
mouse O
adrenal O
and O
rat O
PC12 O
cells O
, O
which O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
resulted O
in O
transporter O
activity O
that O
was O
blocked O
by O
the O
VMAT O
inhibitor O
reserpine O
and O
a O
proton O
ionophore O
, O
but O
not O
by O
tetrabenazine O
, O
which O
has O
a O
high O
affinity O
for O
VMAT-2 O
. O
Antibodies O
to O
either O
the O
C- O
or O
N- O
terminus O
of O
VMAT-1 O
detected O
two O
proteins O
(73 O
and O
55 O
kD) O
in O
transfected O
COS-1 O
cells O
. O
The O
C O
terminal O
antibodies O
detected O
both O
proteins O
in O
extracts O
of O
mouse O
medulla/pons O
, O
cortex O
, O
hypothalamus O
, O
and O
cerebellum O
but O
only O
the O
73 O
kD O
protein O
and O
higher O
molecular O
weight O
immunoreactive O
proteins O
in O
mouse O
adrenal O
and O
rat O
PC12 O
cells O
, O
which O
are O
positive O
controls O
for O
rodent O
VMAT-1 O
. O
CONCLUSIONS O
: O
These O
findings O
demonstrate O
that O
a O
functional O
VMAT-1 O
mRNA O

tetrabenazine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Sequencing O
confirmed O
identity O
of O
the O
entire O
coding O
sequences O
of O
VMAT-1 O
cDNA O
from O
mouse O
medulla O
oblongata/pons O
and O
adrenal O
to O
a O
Gen-Bank O
reference O
sequence O
. O
Transfection O
of O
the O
brain O
cDNA O
into O
COS-1 O
cells O
resulted O
in O
transporter O
activity O
that O
was O
blocked O
by O
the O
VMAT O
inhibitor O
reserpine O
and O
a O
proton O
ionophore O
, O
but O
not O
by O
tetrabenazine O
which O
has O
a O
high O
affinity O
for O
VMAT-2 O
. O
Antibodies O
to O
either O
the O
C- O
or O
N- O
terminus O
of O
VMAT-1 O
detected O
two O
proteins O
(73 O
and O
55 O
kD) O
in O
transfected O
COS-1 O
cells O
. O
The O
C-terminal O
antibodies O
detected O
both O
proteins O
in O
extracts O
of O
mouse O
medulla/pons O
, O
cortex O
, O
hypothalamus O
, O
and O
cerebellum O
but O
only O
the O
73 O
kD O
protein O

reserpine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
probed O
with O
four O
different O
antibodies O
to O
VMAT-1 O
. O
RESULTS O
: O
Sequencing O
confirmed O
identity O
of O
the O
entire O
coding O
sequences O
of O
VMAT-1 O
cDNA O
from O
mouse O
medulla O
oblongata/pons O
and O
adrenal O
to O
a O
Gen-Bank O
reference O
sequence O
. O
Transfection O
of O
the O
brain O
cDNA O
into O
COS-1 O
cells O
resulted O
in O
transporter O
activity O
that O
was O
blocked O
by O
the O
VMAT B
inhibitor O
reserpine O
and O
a O
proton O
ionophore O
, O
but O
not O
by O
tetrabenazine O
, O
which O
has O
a O
high O
affinity O
for O
VMAT-2 O
. O
Antibodies O
to O
either O
the O
C- O
or O
N- O
terminus O
of O
VMAT-1 O
detected O
two O
proteins O
(73 O
and O
55 O
kD) O
in O
transfected O
COS-1 O
cells O
. O
The O
C-terminal O
antibodies O
detected O
both O
proteins O
in O
extracts O
of O
mouse O
medulla/pons O
, O
cortex O
, O
hypothalamus O
, O

saquinavir O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cancer O
Resistance O
Protein O
- O
BCRP) O
and O
uptake O
(MonoCarboxylate O
Transporter O
1 O
- O
MCT1 O
, O
Organic O
Anion O
Transporting O
Polypeptide O
- O
OATP O
, O
Peptide O
transporter O
1 O
- O
PepT1) O
transporters O
were O
caused O
by O
changes O
in O
electrophysiological O
membrane O
properties O
and O
by O
allosteric O
modifications O
. O
Because O
clinical O
studies O
investigating O
interactions O
between O
garlic O
and O
human B
immunodeficiency I
virus I
protease I
inhibitors O
saquinavir O
and O
ritonavir O
have O
already O
been O
performed O
, O
we O
used O
these O
in O
vivo O
data O
to O
evaluate O
the O
in O
vitro O
results O
and O
the O
reliability O
of O
the O
models O
employed O
as O
screening O
tools O
for O
forecasting O
the O
potential O
of O
first-pass O
intestinal O
metabolism O
changes O
. O
We O
also O
assessed O
the O
probability O
of O
pharmacokinetic O
interactions O
with O
garlic O
of O
the O

ritonavir O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Protein O
- O
BCRP) O
and O
uptake O
(MonoCarboxylate O
Transporter O
1 O
- O
MCT1 O
, O
Organic O
Anion O
Transporting O
Polypeptide O
- O
OATP O
, O
Peptide O
transporter O
1 O
- O
PepT1) O
transporters O
were O
caused O
by O
changes O
in O
electrophysiological O
membrane O
properties O
and O
by O
allosteric O
modifications O
. O
Because O
clinical O
studies O
investigating O
interactions O
between O
garlic O
and O
human B
immunodeficiency I
virus I
protease I
inhibitors O
saquinavir O
and O
ritonavir O
have O
already O
been O
performed O
, O
we O
used O
these O
in O
vivo O
data O
to O
evaluate O
the O
in O
vitro O
results O
and O
the O
reliability O
of O
the O
models O
employed O
as O
screening O
tools O
for O
forecasting O
the O
potential O
of O
first-pass O
intestinal O
metabolism O
changes O
. O
We O
also O
assessed O
the O
probability O
of O
pharmacokinetic O
interactions O
with O
garlic O
of O
the O
novel O
drug O

L-noradrenaline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O
a O
group O
with O
an O
apparent O
pKa O
value O
of O
about O
5.1 O
(20 O
degrees O
C) O
is O
involved O
in O
the O
interaction O
between O
the O
catecholamine O
and O
the O
enzyme O
. O
The O
high-affinity O
binding O
of O
L-noradrenaline O
to O
phenylalanine O
hydroxylase O
, O
as O
studied O
by O
equilibrium O
microdialysis O
(anaerobically) O
and O
ultrafiltration O
(aerobically) O
, O
shows O
positive O
cooperativity O
(h O
= O
1.9); O
at O
pH O
7.2 O
and O
20 O
degrees O
C O
the O
rat O
enzyme O
binds O
about O
0.5 O
mol O
L-noradrenaline/mol O
subunit O
with O
a O
half-maximal O
binding O
(S50) O
at O
0.25 O
microM O
L-noradrenaline O
. O
No O
binding O
to O
the O
ferrous O
form O

L-noradrenaline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
C) O
is O
involved O
in O
the O
interaction O
between O
the O
catecholamine O
and O
the O
enzyme O
. O
The O
high-affinity O
binding O
of O
L-noradrenaline O
to O
phenylalanine O
hydroxylase O
, O
as O
studied O
by O
equilibrium O
microdialysis O
(anaerobically) O
and O
ultrafiltration O
(aerobically) O
, O
shows O
positive O
cooperativity O
(h O
= O
1.9); O
at O
pH O
7.2 O
and O
20 O
degrees O
C O
the O
rat O
enzyme O
binds O
about O
0.5 O
mol O
L-noradrenaline O
mol O
subunit O
with O
a O
half-maximal O
binding O
(S50) O
at O
0.25 O
microM O
L-noradrenaline O
. O
No O
binding O
to O
the O
ferrous O
form O
of O
the O
enzyme O
was O
observed O
. O
The O
affinity O
decreases O
with O
decreasing O
pH O
, O
by O
phosphorylation O
and O
by O
preincubation O
of O
the O
enzyme O
with O
the O
substrate O
L-phenylalanine O
, O
while O
it O
increases O
after O
alkylation O
of O
the O
enzyme O
with O

L-noradrenaline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
enzyme O
. O
The O
high-affinity O
binding O
of O
L-noradrenaline O
to O
phenylalanine O
hydroxylase O
, O
as O
studied O
by O
equilibrium O
microdialysis O
(anaerobically) O
and O
ultrafiltration O
(aerobically) O
, O
shows O
positive O
cooperativity O
(h O
= O
1.9); O
at O
pH O
7.2 O
and O
20 O
degrees O
C O
the O
rat O
enzyme O
binds O
about O
0.5 O
mol O
L-noradrenaline/mol O
subunit O
with O
a O
half-maximal O
binding O
(S50) O
at O
0.25 O
microM O
L-noradrenaline O
No O
binding O
to O
the O
ferrous O
form O
of O
the O
enzyme O
was O
observed O
. O
The O
affinity O
decreases O
with O
decreasing O
pH O
, O
by O
phosphorylation O
and O
by O
preincubation O
of O
the O
enzyme O
with O
the O
substrate O
L-phenylalanine O
, O
while O
it O
increases O
after O
alkylation O
of O
the O
enzyme O
with O
the O
activator O
N-ethylmaleimide O
. O
Preincubation O
of O
the O
enzyme O
with O
L-phenylalanine O
also O
leads O

L-noradrenaline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenalin O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine B
4-monooxygenase I
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O

catecholamines O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
a O
complete O
loss O
of O
the O
cooperativity O
of O
L-noradrenaline O
binding O
(h O
= O
1.0) O
. O
The O
many O
similarities O
in O
binding O
properties O
of O
the O
inhibitor O
L-noradrenaline O
and O
the O
activator/substrate O
L-phenylalanine O
makes O
it O
likely O
that O
the O
cooperative O
interactions O
of O
these O
effectors O
are O
due O
to O
their O
binding O
to O
the O
same O
site O
. O
The O
high-affinity O
of O
catecholamines O
to O
phenylalanine B
hydroxylase I
is O
a O
valuable O
probe O
to O
study O
the O
active O
site O
of O
this O
enzyme O
and O
is O
also O
relevant O
for O
the O
homologous O
enzyme O
tyrosine O
hydroxylase O
, O
which O
is O
purified O
as O
a O
stable O
catecholamine-Fe(III) O
complex O
. O

catecholamines O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
a O
complete O
loss O
of O
the O
cooperativity O
of O
L-noradrenaline O
binding O
(h O
= O
1.0) O
. O
The O
many O
similarities O
in O
binding O
properties O
of O
the O
inhibitor O
L-noradrenaline O
and O
the O
activator/substrate O
L-phenylalanine O
makes O
it O
likely O
that O
the O
cooperative O
interactions O
of O
these O
effectors O
are O
due O
to O
their O
binding O
to O
the O
same O
site O
. O
The O
high-affinity O
of O
catecholamines O
to O
phenylalanine O
hydroxylase O
is O
a O
valuable O
probe O
to O
study O
the O
active O
site O
of O
this O
enzyme O
and O
is O
also O
relevant O
for O
the O
homologous O
enzyme O
tyrosine O
hydroxylase O
, O
which O
is O
purified O
as O
a O
stable O
catecholamine-Fe(III) O
complex O
. O

adrenaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
( O
adrenaline O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O

adrenaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
( O
adrenaline O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O

adrenaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
( O
adrenaline O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine B
4-monooxygenase I
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O

noradrenaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O

noradrenaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O

noradrenaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine B
4-monooxygenase I
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O

dopamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O
a O
group O

dopamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O
a O
group O

dopamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine O
are O
potent O
inhibitors O
of O
phenylalanine B
4-monooxygenase I
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O
a O
group O

Catecholamines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase O
. O
Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O

Catecholamines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase O
. O
Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O

Catecholamines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase O
. O
Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine B
4-monooxygenase I
(phenylalanine O
hydroxylase O
, O
EC O
1.14.16.1) O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O

arsenic O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Green O
tea O
extract O
alleviates O
arsenic-induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
in O
rats.The O
present O
work O
was O
undertaken O
to O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
green O
tea O
(GT O
, O
Camellia O
sinensis) O
leaves O
against O
arsenic O
(NaAsO2)-induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
production O
in O
experimental O
rats O
. O
The O
treatment O
with O
arsenic O
exhibited O
a O
significant O
increase O
in O
some O
serum O
hepatic O
and O
renal O
biochemical O
parameters O
(alanine O
aminotransferase O
, O
aspartate O
aminotransferase O
, O
alkaline O
phosphatase O
, O
total O
protein O
, O
albumin O
, O
bilirubin O
, O
cholesterol O
, O
urea O
and O
creatinine) O
. O
But O
the O
co-administration O
of O
GT O
has O
increased O
the O
level O
of O
plasmatic O
concentration O
of O
biochemical O
parameters O
. O
Exposure O
of O
rats O
to O
arsenic O
caused O
also O
a O

arsenic O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Green O
tea O
extract O
alleviates O
arsenic-induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
in O
rats.The O
present O
work O
was O
undertaken O
to O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
green O
tea O
(GT O
, O
Camellia O
sinensis) O
leaves O
against O
arsenic O
(NaAsO2)-induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
production O
in O
experimental O
rats O
. O
The O
treatment O
with O
arsenic O
exhibited O
a O
significant O
increase O
in O
some O
serum O
hepatic O
and O
renal O
biochemical O
parameters O
(alanine O
aminotransferase O
, O
aspartate O
aminotransferase O
, O
alkaline O
phosphatase O
, O
total O
protein O
, O
albumin O
, O
bilirubin O
, O
cholesterol O
, O
urea O
and O
creatinine) O
. O
But O
the O
co-administration O
of O
GT O
has O
increased O
the O
level O
of O
plasmatic O
concentration O
of O
biochemical O
parameters O
. O
Exposure O
of O
rats O
to O
arsenic O
caused O
also O
a O

arsenic O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Green O
tea O
extract O
alleviates O
arsenic-induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
in O
rats.The O
present O
work O
was O
undertaken O
to O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
green O
tea O
(GT O
, O
Camellia O
sinensis) O
leaves O
against O
arsenic O
(NaAsO2)-induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
production O
in O
experimental O
rats O
. O
The O
treatment O
with O
arsenic O
exhibited O
a O
significant O
increase O
in O
some O
serum O
hepatic O
and O
renal O
biochemical O
parameters O
(alanine O
aminotransferase O
, O
aspartate O
aminotransferase O
, O
alkaline O
phosphatase O
, O
total O
protein O
, O
albumin O
, O
bilirubin O
, O
cholesterol O
, O
urea O
and O
creatinine) O
. O
But O
the O
co-administration O
of O
GT O
has O
increased O
the O
level O
of O
plasmatic O
concentration O
of O
biochemical O
parameters O
. O
Exposure O
of O
rats O
to O
arsenic O
caused O
also O
a O

arsenic O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Green O
tea O
extract O
alleviates O
arsenic-induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
in O
rats.The O
present O
work O
was O
undertaken O
to O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
green O
tea O
(GT O
, O
Camellia O
sinensis) O
leaves O
against O
arsenic O
(NaAsO2)-induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
production O
in O
experimental O
rats O
. O
The O
treatment O
with O
arsenic O
exhibited O
a O
significant O
increase O
in O
some O
serum O
hepatic O
and O
renal O
biochemical O
parameters O
(alanine O
aminotransferase O
, O
aspartate O
aminotransferase O
, O
alkaline O
phosphatase O
, O
total O
protein O
, O
albumin O
, O
bilirubin O
, O
cholesterol O
, O
urea O
and O
creatinine) O
. O
But O
the O
co-administration O
of O
GT O
has O
increased O
the O
level O
of O
plasmatic O
concentration O
of O
biochemical O
parameters O
. O
Exposure O
of O
rats O
to O
arsenic O
caused O
also O
a O

gefitinib O
acts O
as O
UNDEFINED O
for O
what O
entity O
? O
double O
mutant O
, O
in O
the O
apo O
form O
and O
gefitinib- O
and O
AMPPNP-bound O
forms O
, O
adopts O
different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands O
. O
In O
the O
L858R O
mutant O
structure O
, O
the O
active-site O
cleft O
is O
expanded O
by O
the O
repositioning O
of O
Phe723 O
within O
the O
P-loop O
. O
Notably O
, O
the O
introduction O
of O
the O
F723A O
mutation O
greatly O
enhanced O
the O
gefitinib O
sensitivity O
of O
the O
wild-type O
EGFR B
in O
vivo O
, O
supporting O
our O
hypothesis O
that O
the O
expansion O
of O
the O
active-site O
cleft O
results O
in O
enhanced O
gefitinib O
sensitivity O
. O
Taken O
together O
, O
our O
results O
provide O
a O
structural O
basis O
for O
the O
altered O
drug O
sensitivities O
caused O
by O
distinct O
NSCLC-associated O
EGFR O
mutations O
. O

gefitinib O
acts O
as O
NOT O
for O
what O
entity O
? O
are O
constitutively O
active O
and O
oncogenic O
. O
They O
display O
sensitivity O
to O
TK O
inhibitors O
, O
including O
gefitinib O
and O
erlotinib O
. O
In O
contrast O
, O
the O
secondary O
mutation O
of O
the O
gatekeeper O
residue O
, O
T790M O
, O
reportedly O
confers O
inhibitor O
resistance O
on O
the O
oncogenic O
EGFR O
mutants O
. O
In O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M O
mutation O
confers O
gefitinib O
resistance O
on O
the O
G719S B
mutant O
. O
The O
G719S/T790M O
double O
mutant O
has O
enhanced O
activity O
and O
retains O
high O
gefitinib-binding O
affinity O
. O
The O
T790M O
mutation O
increases O
the O
ATP O
affinity O
of O
the O
G719S O
mutant O
, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant O
. O
Structural O
analyses O
of O
the O
G719S/T790M O
double O
mutant O
, O
as O
well O
as O
the O
wild O

Met O
acts O
as O
PART-OF O
for O
what O
entity O
? O
ATP O
affinity O
of O
the O
G719S B
mutant O
, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant O
. O
Structural O
analyses O
of O
the O
G719S/T790M O
double O
mutant O
, O
as O
well O
as O
the O
wild O
type O
and O
the O
G719S O
and O
L858R O
mutants O
, O
revealed O
that O
the O
T790M O
mutation O
stabilizes O
the O
hydrophobic O
spine O
of O
the O
active O
EGFR-TK O
conformation O
. O
The O
Met O
90 O
side O
chain O
of O
the O
G719S/T790M O
double O
mutant O
, O
in O
the O
apo O
form O
and O
gefitinib- O
and O
AMPPNP-bound O
forms O
, O
adopts O
different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands O
. O
In O
the O
L858R O
mutant O
structure O
, O
the O
active-site O
cleft O
is O
expanded O
by O
the O
repositioning O
of O
Phe723 O
within O
the O
P-loop O
. O
Notably O
, O
the O
introduction O
of O

Met O
acts O
as O
PART-OF O
for O
what O
entity O
? O
ATP O
affinity O
of O
the O
G719S O
mutant O
, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant O
. O
Structural O
analyses O
of O
the O
G719S/T790M O
double O
mutant O
, O
as O
well O
as O
the O
wild O
type O
and O
the O
G719S O
and O
L858R O
mutants O
, O
revealed O
that O
the O
T790M B
mutation O
stabilizes O
the O
hydrophobic O
spine O
of O
the O
active O
EGFR-TK O
conformation O
. O
The O
Met O
90 O
side O
chain O
of O
the O
G719S/T790M O
double O
mutant O
, O
in O
the O
apo O
form O
and O
gefitinib- O
and O
AMPPNP-bound O
forms O
, O
adopts O
different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands O
. O
In O
the O
L858R O
mutant O
structure O
, O
the O
active-site O
cleft O
is O
expanded O
by O
the O
repositioning O
of O
Phe723 O
within O
the O
P-loop O
. O
Notably O
, O
the O
introduction O
of O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
hydrophobic O
spine O
of O
the O
active O
EGFR-TK O
conformation O
. O
The O
Met790 O
side O
chain O
of O
the O
G719S/T790M O
double O
mutant O
, O
in O
the O
apo O
form O
and O
gefitinib- O
and O
AMPPNP-bound O
forms O
, O
adopts O
different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands O
. O
In O
the O
L858R B
mutant O
structure O
, O
the O
active-site O
cleft O
is O
expanded O
by O
the O
repositioning O
of O
Phe O
23 O
within O
the O
P-loop O
. O
Notably O
, O
the O
introduction O
of O
the O
F723A O
mutation O
greatly O
enhanced O
the O
gefitinib O
sensitivity O
of O
the O
wild-type O
EGFR O
in O
vivo O
, O
supporting O
our O
hypothesis O
that O
the O
expansion O
of O
the O
active-site O
cleft O
results O
in O
enhanced O
gefitinib O
sensitivity O
. O
Taken O
together O
, O
our O
results O
provide O
a O
structural O
basis O
for O
the O
altered O
drug O

gefitinib O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
contrast O
, O
the O
secondary O
mutation O
of O
the O
gatekeeper O
residue O
, O
T790M O
, O
reportedly O
confers O
inhibitor O
resistance O
on O
the O
oncogenic O
EGFR O
mutants O
. O
In O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M O
mutation O
confers O
gefitinib O
resistance O
on O
the O
G719S B
mutant O
. O
The O
G719S/T790M O
double O
mutant O
has O
enhanced O
activity O
and O
retains O
high O
gefitinib O
binding O
affinity O
. O
The O
T790M O
mutation O
increases O
the O
ATP O
affinity O
of O
the O
G719S O
mutant O
, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant O
. O
Structural O
analyses O
of O
the O
G719S/T790M O
double O
mutant O
, O
as O
well O
as O
the O
wild O
type O
and O
the O
G719S O
and O
L858R O
mutants O
, O
revealed O
that O
the O
T790M O
mutation O
stabilizes O
the O
hydrophobic O

gefitinib O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
contrast O
, O
the O
secondary O
mutation O
of O
the O
gatekeeper O
residue O
, O
T790M O
, O
reportedly O
confers O
inhibitor O
resistance O
on O
the O
oncogenic O
EGFR O
mutants O
. O
In O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M B
mutation O
confers O
gefitinib O
resistance O
on O
the O
G719S O
mutant O
. O
The O
G719S/T790M O
double O
mutant O
has O
enhanced O
activity O
and O
retains O
high O
gefitinib O
binding O
affinity O
. O
The O
T790M O
mutation O
increases O
the O
ATP O
affinity O
of O
the O
G719S O
mutant O
, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant O
. O
Structural O
analyses O
of O
the O
G719S/T790M O
double O
mutant O
, O
as O
well O
as O
the O
wild O
type O
and O
the O
G719S O
and O
L858R O
mutants O
, O
revealed O
that O
the O
T790M O
mutation O
stabilizes O
the O
hydrophobic O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
residue O
, O
T790M O
, O
reportedly O
confers O
inhibitor O
resistance O
on O
the O
oncogenic O
EGFR O
mutants O
. O
In O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M O
mutation O
confers O
gefitinib O
resistance O
on O
the O
G719S B
mutant O
. O
The O
G719S/T790M O
double O
mutant O
has O
enhanced O
activity O
and O
retains O
high O
gefitinib-binding O
affinity O
. O
The O
T790M O
mutation O
increases O
the O
ATP O
affinity O
of O
the O
G719S O
mutant O
, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant O
. O
Structural O
analyses O
of O
the O
G719S/T790M O
double O
mutant O
, O
as O
well O
as O
the O
wild O
type O
and O
the O
G719S O
and O
L858R O
mutants O
, O
revealed O
that O
the O
T790M O
mutation O
stabilizes O
the O
hydrophobic O
spine O
of O
the O
active O
EGFR-TK O
conformation O
. O
The O
Met790 O

gefitinib O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
double O
mutant O
, O
in O
the O
apo O
form O
and O
gefitinib- O
and O
AMPPNP-bound O
forms O
, O
adopts O
different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands O
. O
In O
the O
L858R O
mutant O
structure O
, O
the O
active-site O
cleft O
is O
expanded O
by O
the O
repositioning O
of O
Phe723 O
within O
the O
P-loop O
. O
Notably O
, O
the O
introduction O
of O
the O
F723A B
mutation O
greatly O
enhanced O
the O
gefitinib O
sensitivity O
of O
the O
wild-type O
EGFR O
in O
vivo O
, O
supporting O
our O
hypothesis O
that O
the O
expansion O
of O
the O
active-site O
cleft O
results O
in O
enhanced O
gefitinib O
sensitivity O
. O
Taken O
together O
, O
our O
results O
provide O
a O
structural O
basis O
for O
the O
altered O
drug O
sensitivities O
caused O
by O
distinct O
NSCLC-associated O
EGFR O
mutations O
. O

gefitinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
an O
essential O
role O
in O
multiple O
signaling O
pathways O
, O
including O
cell O
proliferation O
and O
migration O
, O
through O
extracellular O
ligand O
binding O
and O
subsequent O
activation O
of O
its O
intracellular O
tyrosine O
kinase O
(TK) O
domain O
. O
The O
non-small O
cell O
lung O
cancer O
(NSCLC)-associated O
EGFR O
mutants O
, O
L858R O
and O
G719S O
, O
are O
constitutively O
active O
and O
oncogenic O
. O
They O
display O
sensitivity O
to O
TK B
inhibitors O
, O
including O
gefitinib O
and O
erlotinib O
. O
In O
contrast O
, O
the O
secondary O
mutation O
of O
the O
gatekeeper O
residue O
, O
T790M O
, O
reportedly O
confers O
inhibitor O
resistance O
on O
the O
oncogenic O
EGFR O
mutants O
. O
In O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M O
mutation O
confers O
gefitinib O
resistance O
on O
the O
G719S O
mutant O
. O
The O
G719S/T790M O
double O
mutant O
has O
enhanced O
activity O

erlotinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
role O
in O
multiple O
signaling O
pathways O
, O
including O
cell O
proliferation O
and O
migration O
, O
through O
extracellular O
ligand O
binding O
and O
subsequent O
activation O
of O
its O
intracellular O
tyrosine O
kinase O
(TK) O
domain O
. O
The O
non-small O
cell O
lung O
cancer O
(NSCLC)-associated O
EGFR O
mutants O
, O
L858R O
and O
G719S O
, O
are O
constitutively O
active O
and O
oncogenic O
. O
They O
display O
sensitivity O
to O
TK B
inhibitors O
, O
including O
gefitinib O
and O
erlotinib O
In O
contrast O
, O
the O
secondary O
mutation O
of O
the O
gatekeeper O
residue O
, O
T790M O
, O
reportedly O
confers O
inhibitor O
resistance O
on O
the O
oncogenic O
EGFR O
mutants O
. O
In O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M O
mutation O
confers O
gefitinib O
resistance O
on O
the O
G719S O
mutant O
. O
The O
G719S/T790M O
double O
mutant O
has O
enhanced O
activity O
and O
retains O

Epi O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
a O
mouse O
model O
of O
GC O
. O
In O
human O
GC O
cells O
, O
WNT6 O
expression O
was O
enhanced O
by O
caveolin-1 O
(Cav1) O
, O
a O
scaffold O
protein O
of O
plasma O
membrane O
caveolae O
. O
WNT6 O
knock-down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 O
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline O
chemotherapeutics O
epirubicin O
(Epi) O
and O
doxorubicin O
(Dox) O
. O
Epi O
increased O
the O
activity O
of O
the O
human O
WNT6 O
promoter O
through O
Cav1-dependent O
binding O
of O
-catenin O
to O
the O
proximal O
WNT6 O
promoter O
. O
Epi O
increased O
both O
WNT6/Wnt6 O
and O
Cav1 B
expression O
in O
human O
GC O
cells O
and O
within O
the O
tumor O
area O
of O
a O
murine O
model O
of O
GC O
(CEA424-SV40 O
TAg) O
. O
In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O

Epi O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
a O
mouse O
model O
of O
GC O
. O
In O
human O
GC O
cells O
, O
WNT6 O
expression O
was O
enhanced O
by O
caveolin-1 O
(Cav1) O
, O
a O
scaffold O
protein O
of O
plasma O
membrane O
caveolae O
. O
WNT6 O
knock-down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 O
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline O
chemotherapeutics O
epirubicin O
(Epi) O
and O
doxorubicin O
(Dox) O
. O
Epi O
increased O
the O
activity O
of O
the O
human O
WNT6 O
promoter O
through O
Cav1-dependent O
binding O
of O
-catenin B
to O
the O
proximal O
WNT6 O
promoter O
. O
Epi O
increased O
both O
WNT6/Wnt6 O
and O
Cav1 O
expression O
in O
human O
GC O
cells O
and O
within O
the O
tumor O
area O
of O
a O
murine O
model O
of O
GC O
(CEA424-SV40 O
TAg) O
. O
In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O

Epi O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
a O
mouse O
model O
of O
GC O
. O
In O
human O
GC O
cells O
, O
WNT6 O
expression O
was O
enhanced O
by O
caveolin-1 O
(Cav1) O
, O
a O
scaffold O
protein O
of O
plasma O
membrane O
caveolae O
. O
WNT6 O
knock-down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 O
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline O
chemotherapeutics O
epirubicin O
(Epi) O
and O
doxorubicin O
(Dox) O
. O
Epi O
increased O
the O
activity O
of O
the O
human B
WNT6 I
promoter I
through O
Cav1-dependent O
binding O
of O
-catenin O
to O
the O
proximal O
WNT6 O
promoter O
. O
Epi O
increased O
both O
WNT6/Wnt6 O
and O
Cav1 O
expression O
in O
human O
GC O
cells O
and O
within O
the O
tumor O
area O
of O
a O
murine O
model O
of O
GC O
(CEA424-SV40 O
TAg) O
. O
In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O

Epi O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
a O
mouse O
model O
of O
GC O
. O
In O
human O
GC O
cells O
, O
WNT6 O
expression O
was O
enhanced O
by O
caveolin-1 O
(Cav1) O
, O
a O
scaffold O
protein O
of O
plasma O
membrane O
caveolae O
. O
WNT6 O
knock-down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 O
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline O
chemotherapeutics O
epirubicin O
(Epi) O
and O
doxorubicin O
(Dox) O
. O
Epi O
increased O
the O
activity O
of O
the O
human O
WNT6 B
promoter I
through O
Cav1-dependent O
binding O
of O
-catenin O
to O
the O
proximal O
WNT6 O
promoter O
. O
Epi O
increased O
both O
WNT6/Wnt6 O
and O
Cav1 O
expression O
in O
human O
GC O
cells O
and O
within O
the O
tumor O
area O
of O
a O
murine O
model O
of O
GC O
(CEA424-SV40 O
TAg) O
. O
In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O

Epi O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
protein O
of O
plasma O
membrane O
caveolae O
. O
WNT6 B
knock-down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 O
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline O
chemotherapeutics O
epirubicin O
(Epi) O
and O
doxorubicin O
(Dox) O
. O
Epi O
increased O
the O
activity O
of O
the O
human O
WNT6 O
promoter O
through O
Cav1-dependent O
binding O
of O
-catenin O
to O
the O
proximal O
WNT6 O
promoter O
. O
Epi O
increased O
both O
WNT6/Wnt6 O
and O
Cav1 O
expression O
in O
human O
GC O
cells O
and O
within O
the O
tumor O
area O
of O
a O
murine O
model O
of O
GC O
(CEA424-SV40 O
TAg) O
. O
In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O
associated O
with O
the O
tumor O
stage O
and O
the O
nodal O
status O
, O
and O
inversely O
correlated O
with O
the O
response O
to O
ECF O
(Epi O
, O
cisplatin O
, O

Epi O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
protein O
of O
plasma O
membrane O
caveolae O
. O
WNT6 O
knock-down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 O
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline O
chemotherapeutics O
epirubicin O
(Epi) O
and O
doxorubicin O
(Dox) O
. O
Epi O
increased O
the O
activity O
of O
the O
human O
WNT6 O
promoter O
through O
Cav1-dependent O
binding O
of O
-catenin O
to O
the O
proximal O
WNT6 O
promoter O
. O
Epi O
increased O
both O
WNT6/Wnt6 O
and O
Cav1 O
expression O
in O
human O
GC O
cells O
and O
within O
the O
tumor O
area O
of O
a O
murine O
model O
of O
GC O
(CEA424-SV40 O
TAg) O
. O
In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O
associated O
with O
the O
tumor O
stage O
and O
the O
nodal O
status O
, O
and O
inversely O
correlated O
with O
the O
response O
to O
ECF O
(Epi O
, O
cisplatin O
, O

Epi O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
protein O
of O
plasma O
membrane O
caveolae O
. O
WNT6 O
knock-down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 O
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline O
chemotherapeutics O
epirubicin O
(Epi) O
and O
doxorubicin O
(Dox) O
. O
Epi O
increased O
the O
activity O
of O
the O
human O
WNT6 O
promoter O
through O
Cav1-dependent O
binding O
of O
-catenin O
to O
the O
proximal O
WNT6 O
promoter O
. O
Epi O
increased O
both O
WNT6/Wnt6 O
and O
Cav1 B
expression O
in O
human O
GC O
cells O
and O
within O
the O
tumor O
area O
of O
a O
murine O
model O
of O
GC O
(CEA424-SV40 O
TAg) O
. O
In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O
associated O
with O
the O
tumor O
stage O
and O
the O
nodal O
status O
, O
and O
inversely O
correlated O
with O
the O
response O
to O
ECF O
(Epi O
, O
cisplatin O
, O

anthracycline O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(CEA424-SV40 O
TAg) O
. O
In O
GC O
patients O
, O
WNT6 B
expression O
was O
positively O
associated O
with O
the O
tumor O
stage O
and O
the O
nodal O
status O
, O
and O
inversely O
correlated O
with O
the O
response O
to O
ECF O
(Epi O
, O
cisplatin O
, O
5-fluorouracil) O
chemotherapy O
. O
These O
results O
showed O
that O
WNT6 O
and O
Cav1 O
are O
upregulated O
by O
chemotherapeutics O
and O
enhance O
the O
resistance O
of O
GC O
cells O
to O
anthracycline O
drugs O
. O
Understanding O
the O
molecular O
mechanisms O
driving O
WNT6/Cav1-induced O
drug O
resistance O
will O
provide O
benefits O
in O
developing O
new O
therapies O
for O
GC O
. O

anthracycline O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(CEA424-SV40 O
TAg) O
. O
In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O
associated O
with O
the O
tumor O
stage O
and O
the O
nodal O
status O
, O
and O
inversely O
correlated O
with O
the O
response O
to O
ECF O
(Epi O
, O
cisplatin O
, O
5-fluorouracil) O
chemotherapy O
. O
These O
results O
showed O
that O
WNT6 O
and O
Cav1 B
are O
upregulated O
by O
chemotherapeutics O
and O
enhance O
the O
resistance O
of O
GC O
cells O
to O
anthracycline O
drugs O
. O
Understanding O
the O
molecular O
mechanisms O
driving O
WNT6/Cav1-induced O
drug O
resistance O
will O
provide O
benefits O
in O
developing O
new O
therapies O
for O
GC O
. O

LY541850 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Differentiating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 O
receptors O
using O
LY541850 O
, O
an O
mGlu2 O
agonist/mGlu3 O
antagonist.Despite O
the O
potential O
therapeutic O
relevance O
of O
group O
II O
metabotropic O
glutamate O
(mGlu) O
receptors O
, O
there O
has O
been O
a O
lack O
of O
pharmacological O
tools O
for O
separating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 O
receptor O
subtypes O
. O
LY541850 O
was O
claimed O
from O
human B
mGlu I
receptors I
expressed O
in O
non-neuronal O
cells O
to O
be O
a O
selective O
orthosteric O
mGlu2 O
agonist O
and O
mGlu3 O
antagonist O
. O
We O
have O
verified O
this O
pharmacological O
profile O
of O
LY541850 O
in O
hippocampal O
slices O
. O
Field O
excitatory O
post-synaptic O
potentials O
(fEPSPs) O
evoked O
by O
stimulation O
of O
the O
temporo-ammonic O
path O
(TAP) O
input O
to O
CA1 O
stratum O
lacunosum O

LY541850 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Differentiating O
the O
roles O
of O
mGlu2 B
and O
mGlu3 O
receptors O
using O
LY54185 O
 O
, O
an O
mGlu2 O
agonist/mGlu3 O
antagonist.Despite O
the O
potential O
therapeutic O
relevance O
of O
group O
II O
metabotropic O
glutamate O
(mGlu) O
receptors O
, O
there O
has O
been O
a O
lack O
of O
pharmacological O
tools O
for O
separating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 O
receptor O
subtypes O
. O
LY541850 O
was O
claimed O
from O
human O
mGlu O
receptors O
expressed O
in O
non-neuronal O
cells O
to O
be O
a O
selective O

LY541850 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
group O
II O
agonist O
, O
DCG-IV O
, O
inhibited O
the O
fEPSP O
in O
all O
three O
genotypes O
. O
Co-application O
of O
DCG-IV O
and O
LY541850 O
in O
mGlu3-/- O
and O
wild-type O
littermates O
resulted O
in O
an O
additive O
effect O
, O
whereas O
in O
mGlu2-/- O
mice O
, O
LY541850 O
reversed O
the O
inhibitory O
action O
of O
DCG-IV O
. O
These O
results O
confirm O
the O
selective O
mGlu2 B
agonist O
and O
mGlu3 O
antagonist O
actions O
of O
LY541850 O
A O
similar O
profile O
of O
activity O
was O
seen O
in O
medial O
perforant O
path O
synapse O
to O
the O
dentate O
gyrus O
. O
Systemic O
administration O
of O
LY541850 O
to O
wild-type O
mice O
, O
reduced O
the O
increase O
in O
locomotor O
activity O
following O
both O
phencyclidine O
and O
amphetamine O
administration O
. O
These O
data O
support O
the O
hypothesis O
that O
mGlu2 O
receptors O
mediate O
the O
antipsychotic O
effects O
of O
mixed O

PAHs O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
there O
is O
a O
statistically O
significant O
positive O
association O
between O
AKR1A1 O
, O
AKR1C1 O
, O
and O
AKR1C3 O
mRNA O
induction O
and O
urine O
cotinine O
levels O
in O
individuals O
with O
a O
body O
mass O
index O
(BMI) O
less O
than O
25 O
. O
However O
, O
AKR1A1*2 O
and O
AKR1C3*2 O
alleles O
did O
not O
influence O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
mRNA O
levels O
. O
These O
results O
suggest O
that O
AKRs O
induction O
by O
PAHs O
in O
smokers' O
PBLs O
is O
associated O
with O
BMI; O
therefore O
, O
the O
role O
of O
adipose O
tissue O
accumulation O
in O
PAHs' O
effects O
needs O
further O
investigation O
. O

oxygen O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O

PAHs O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O

o-quinones O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
( O
o-quinones O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O

PAHs O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O
the O
effect O
of O
PAHs O
on O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
(PBLs) O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
tobacco O
smoke O
exposure O
, O
and O
AKR1A1*2 O
and O
AKR1C3*2 O
polymorphisms O
, O
on O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
messenger O
RNA O
(mRNA) O
levels O
in O
PBLs O
from O
smokers O
. O
In O
the O
smoker O
group O
, O
there O
is O
a O
statistically O
significant O
positive O

polycyclic O
aromatic O
hydrocarbons O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O

PAHs O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
there O
is O
a O
statistically O
significant O
positive O
association O
between O
AKR1A1 O
, O
AKR1C1 O
, O
and O
AKR1C3 O
mRNA O
induction O
and O
urine O
cotinine O
levels O
in O
individuals O
with O
a O
body O
mass O
index O
(BMI) O
less O
than O
25 O
. O
However O
, O
AKR1A1*2 O
and O
AKR1C3*2 O
alleles O
did O
not O
influence O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
mRNA O
levels O
. O
These O
results O
suggest O
that O
AKRs O
induction O
by O
PAHs O
in O
smokers' O
PBLs O
is O
associated O
with O
BMI; O
therefore O
, O
the O
role O
of O
adipose O
tissue O
accumulation O
in O
PAHs' O
effects O
needs O
further O
investigation O
. O

oxygen O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O

PAHs O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O
the O
effect O
of O
PAHs O
on O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
(PBLs) O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
tobacco O
smoke O
exposure O
, O
and O
AKR1A1*2 O
and O
AKR1C3*2 O
polymorphisms O
, O
on O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
messenger O
RNA O
(mRNA) O

PAHs O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
( O
PAHs O
 O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O

o-quinones O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
( O
o-quinones O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O

PAHs O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O
the O
effect O
of O
PAHs O
on O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
(PBLs) O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
tobacco O
smoke O
exposure O
, O
and O
AKR1A1*2 O
and O
AKR1C3*2 O
polymorphisms O
, O
on O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
messenger O
RNA O
(mRNA) O
levels O
in O
PBLs O
from O
smokers O
. O
In O
the O
smoker O
group O
, O
there O
is O
a O
statistically O
significant O
positive O

polycyclic O
aromatic O
hydrocarbons O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O

PAHs O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
there O
is O
a O
statistically O
significant O
positive O
association O
between O
AKR1A1 O
, O
AKR1C1 O
, O
and O
AKR1C3 O
mRNA O
induction O
and O
urine O
cotinine O
levels O
in O
individuals O
with O
a O
body O
mass O
index O
(BMI) O
less O
than O
25 O
. O
However O
, O
AKR1A1*2 O
and O
AKR1C3*2 O
alleles O
did O
not O
influence O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
mRNA O
levels O
. O
These O
results O
suggest O
that O
AKRs O
induction O
by O
PAHs O
in O
smokers' O
PBLs O
is O
associated O
with O
BMI; O
therefore O
, O
the O
role O
of O
adipose O
tissue O
accumulation O
in O
PAHs' O
effects O
needs O
further O
investigation O
. O

PAHs O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O
the O
effect O
of O
PAHs O
on O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
(PBLs) O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
tobacco O
smoke O
exposure O
, O
and O
AKR1A1*2 O
and O
AKR1C3*2 O
polymorphisms O
, O
on O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
messenger O
RNA O
(mRNA) O

PAHs O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
( O
PAHs O
 O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O

PAHs O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O

o-quinones O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
( O
o-quinones O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O

polycyclic O
aromatic O
hydrocarbons O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
